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ABSTRACT
This thesis focuses on the development of a new synthetic strategy towards
twelve-membered tetraaza macrocycles and the synthesis of new sulfhydryl
reactive linker moieties for the application in pseudocontact shift (PCS) NMR
spectroscopy.
The first part addresses the development of a new robust synthetic pro-
cedure for the selective synthesis of twelve-membered tetraaza macrocycles
using natural amino acids and derivatives as cheap chiral building blocks.
Cyclization of linear tetrapeptides was attempted but due to the preferred
trans configuration of the peptide bond only small amounts of the cyclic
tetrapeptide were obtained. Tetraalanine was reduced to tetraalaninol and the
cyclization of tetraalaninol in solution was attempted using a preorganized
bisaminal approach. This approach was unsuccessful and no product could
be isolated. A more flexible mixed amine / amide tetramer was synthesized
and successfully cyclized under modest dilution conditions forming a C2
symmetric twelve-membered bislactam. This reaction was highly efficient
and afforded various bislactams based on alanine, alanine / valine and alanine
/ serine in good yields. From these bislactams various valuable intermediates
for further tag synthesis are accessible as well as the final tetraaza macro-
cycles M4-cyclen, M2P2-cyclen and M3O1-cyclen. The newly developed
approach allows the synthesis of a variety of differently substituted twelve-
membered macrocycles.
The second part primarily focuses on the development of new sulfhydryl-
reactive linker moieties for site-selective protein tagging. The widely used
formation of a disulphide linkage has the inherent problem of being unstable
under reductive conditions as they are found in living cells, limiting the range
of application to buffered in-vitro applications. Pyridine phenyl sulfone based
tags were synthesized and in-cell NMR experiments were conducted with the
B1 domain of the streptococcal protein G (GB1). The structure of the protein
was successfully calculated with the Rosetta approach using only pseudo-
contact shifts and residual dipolar couplings (RDCs) obtained from in-cell
experiments in oocytes. We proved for the first time that accurate structures
of proteins inside cells can be generated solely from experimental PCSs and
RDCs within the Rosetta package. The conjugation speed was dramatically
increased for the fluorine substituted pyridine phenyl sulfone analogue de-
creasing the reaction time from 24 h at 40  C to six hours at 20-25  C. Further
enhancement was achieved using a pyridine thiazol allowing efficient tagging
in less than one hour at 20-25  C and pH 7.0.
The last part deals with various different applications of M8-DOTA in or-
der to solve structural or biological problems. Gd-M8-DOTA was selectively
coupled to the Pittsburgh compound B (PiB) for in-vivo magnetic resonance
imaging experiments. PiB strongly interacts with the amyloid plaques found
in Alzheimer’s disease and thus PiB-Gd-M8-DOTA allows detecting amyloid
plaques by MRI.
A second collaboration project addresses the problems found in the assign-
ment of a hexa-polyproline. Due to the repetitive nature of this peptide the
chemical shift dispersion was small. Increasing the chemical shift range found
in hexa-polyproline was the goal of the attempted conjugation of M8-DOTA
to the hexa-polyproline. We showed that M8-DOTA can not be coupled to
the N-terminal aniline moiety and a less sterically demanding amine linker is
required.
Prospective experiments were carried out on Eu-M8-DOTA and its closely
related derivatives, Eu-M4-DOTA and Eu-DOTA, in order to check for pos-
sible applications in Förster resonance energy transfer (FRET) spectroscopy.
All complexes were not luminescence under UV irradiation and a UV har-
vesting molecule was required. Eu-azaxanthon-M7-DOTA showed excellent
luminescence properties required for potential applications in FRET spec-
troscopy. Preliminary experiments with Tb-M7PyThiazol-DOTA showed
similar properties with a red shifted UV absorption maximum (from 250 nm
to 300 nm) indicating great potential for FRET spectroscopy.
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1
I NTRODUCT ION
1 . 1 METHODS IN STRUCTURAL B IOLOGY.
Understanding of biological process inside living organisms ultimately breaks
down to the understanding and accurate description of the molecules involved
and their interactions. Biological processes are based on highly specific in-
teractions between several biomolecules. In the field of structural biology,
a whole variety of different techniques is used to study interactions and to
solve structures of biomacromolecules like proteins and DNA/RNA. In the
early 1900s little to nothing was known about proteins and their structures.1
Technological advancement in mass spectrometry and the development of Ed-
man degradation2 allowed the determination of the protein sequence as a
first key step in understanding protein structures and functions. Nowadays
mass spectrometry can also provide valuable insights into the stoichiometry
and composition of proteins and their complexes, and the presence of small
molecules.3 Modern techniques like multiangle light scattering4 and small
angle scattering are used to provide information about the absolute molar
mass and the average size and shape of molecules in aqueous solutions. The
first breakthrough in achieving atomic resolution was already made in 1958
by Kendrew et al.5 with the determination of the first protein structure by X-
ray to a resolution of 6Å. Since then the vast majority of protein structures
deposited in the Protein Data Bank (PDB) were determined using X-ray crys-
tallography. Although the principles of nuclear magnetic resonance (NMR)
were discovered already in the 1930’s by Rabi et al.,6 it was not until 1982
when Wüthrich et al. showed that NMR spectroscopy can be used to determ-
ine protein structures in solution.7 It was only due to the fast development in
the field of NMR and the discovery of the Fourier transformation and multi-
dimensional NMR methods that such an undertaking was possible. Wüthrich
et al.7 used nuclear Overhauser enhancements,8 scalar couplings and amide
proton exchange rates to calculate the structure.9 In the early days NMR spec-
troscopy and X-ray crystallography were the only methods to obtain atomic
resolution structures of biomolecules. At the time of this writing (May 2018)
around 117’000 X-ray and 11’000 NMR protein structures were deposited
in the PDB database. Making X-ray still de facto the most convenient tool
to obtain accurate 3D structures of proteins. Nevertheless, NMR has proven
very useful in the many cases were the protein could not be crystallized or
highly dynamic regions were present. Due to the solid nature of X-ray crystal-
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lography, limits are reached if dynamics are involved and NMR spectroscopy
has been tremendously valuable to overcome these limits. Nowadays many
protein structures are solved using both X-ray and NMR methods. Structural
information in solids can also be obtained by means of electron microscopy.
This technique was developed roughly two decades later than X-ray crystallo-
graphy and by the 1960s electron microscopy had made significant improve-
ments in terms of resolution. De Rosier and Klug10 obtained the first three
dimensional electron microscopy structure of the T4 bacteriophage tail with
a resolution of 35Å, which was then further refined to 20Å.11 Although this
resolution was relatively low, Henderson and Unwin12 determined in 1975
the structure of bacteriorhodopsin to 7Å matching the resolution achieved
by the first X-ray structure of a protein. One drawback of both X-ray and
electron microscopy lies in the susceptibility of biomolecules towards strong
radiation.13 Damage-induced disorder leads to missing diffraction spots at
high resolutions. Cooling of protein crystals not only allowed the usage of
high energy synchrotron X-rays but also lied the foundation for cryo elec-
tron microscopy.14 Electron microscopy started as a crystallographic tool but
nowadays it is a single particle method that does not rely on crystals. Tradi-
tionally, cryo electron microscopy was limited to large macromolecules but
very recently it could be shown by Khoshouei15 and co-workers that high res-
olutions of 3.2Å can be achieved on smaller proteins like haemoglobin (64
kDa) which is anticipated to drop even further to proteins smaller than 10 kDa.
Cryo electron microscopy has been a revolution in the field of structural bio-
logy and allows not only the study of structures but also the observation of dy-
namic processes.16,17 The whole conformational space accessible by the pro-
tein can be present in a thermodynamic equilibrium prior to flash freezing and
are therefore measurable. This provides valuable information about flexible
regions within the protein structure. Dynamical processes is the area where
NMR spectroscopy can provide the most detailed information about conform-
ational changes and dynamics.18,19 However, NMR spectroscopy is limited to
relatively small proteins or parts thereof. Studying huge biomolecules with
NMR is extremely challenging20 and cryo electron microscopy is the way
to go for such systems. Nevertheless X-ray crystallography, cryo electron
microscopy and most standard NMR spectroscopy methods require samples
and experimental conditions vastly different to those found inside living cells.
The crowded intracellular environments in which proteins usually fulfil their
functions are not well represented. Huge efforts are made to develop new
biophysical methods that allow the study of biomolecules inside living cells.
High resolution methods like cryo electron microscopy and X-ray crystallo-
graphy are therefore simply excluded due to the requirement of vitrified or
crystalline samples and the usage of high-energy radiation. On the other hand
NMR spectroscopy can provide non-destructive atomic resolution informa-
tion of isotope-enriched NMR-active protein samples inside living cells.21,22
This offers the unique opportunity to study proteins under physiological con-
ditions, something which is up to now not possible with the other atomic
resolution methods. Newer methods like Förster resonance energy transfer
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spectroscopy23,24 and electron paramagnetic resonance spectroscopy25 have
proven to provide valuable information about relative distances.
1 . 2 PROTE IN NMR SPECTROSCOPY
1 . 2 . 1 Historical Background
Since the first protein structure has been solved by Wüthrich et al.,7,26,27
many more were solved and added to the PDB. Nowadays 8% of all pro-
tein structures deposited in the PDB are solved by NMR spectroscopy. It
can also be seen that the number of published structures solved by NMR
has stagnated. This is a direct consequence of the fact that once crystals
are obtained a structure can be solved quickly, while NMR structures usu-
ally require a lot more effort. Nevertheless, NMR can provide unique in-
formation that can hardly be obtained by other means. Compared with the
other two major contributors to three-dimensional structures (X-ray crystal-
lography and cryo electron microscopy) NMR spectroscopy requires larger
amounts of samples especially in the early days of NMR spectroscopy given
the low sensitivity of past devices. Initially protein structures were solved re-
lying entirely on two-dimensional homonuclear correlation experiments. In-
formation was extracted from correlations caused by scalar coupling or from
the through space distance-dependent nuclear Overhauser effect.28 It is clear
that such strategies could only be applied to relatively small proteins as lar-
ger proteins gave overly crowded proton spectra which were extremely diffi-
cult to interpret. The introduction of heteronuclear experiments significantly
simplified the problem due to the increased chemical shift dispersion and
the resulting reduced signal overlap. Unfortunately the natural abundance
of 13C and 15N is small with 1.1% and 0.37%, respectively.29 Various iso-
tope labelling schemes were developed and are now routinely applied in pro-
tein NMR spectroscopy. However, the development of triple resonance ex-
periments has pushed the field tremendously forward and with the steady in-
crease of magnetic field strength the range of proteins accessible by NMR in-
creased. Efficient backbone and sidechain assignments became possible and
allowed the assignments of proteins up to 30 kDa.30 The increased size of lar-
ger proteins causes the proteins to tumble more slowly which leads to larger
linewidths and, therefore, a lower signal-to-noise ratio. In severe cases the sig-
nal is broadened beyond detection disallowing the measurement of large pro-
teins by NMR spectroscopy. Deuterium labelling31 was used to increase relax-
ation times and to minimize spin-diffusion which leads to smaller linewidths
therefore making proteins accessible well beyond 30 kDa. Improvements in
NMR pulse sequence programming namely the invention of transverse relaxa-
tion optimized spectroscopy (TROSY)32 and cross relaxation-enhanced polar-
ization transfer (CRINEPT)33 enabled the community to study very large pro-
teins. Today, new superconducting magnets with field strength beyond 1GHz
are available and the introduction of cryogenic probeheads as well as sophist-
icated statistical approaches allow the efficient and fast measurement of large
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proteins and their complexes.34 Proteins in the one MDa range are nowadays
accessible by NMR spectroscopy.35 Knowledge of three-dimensional struc-
tures, binding modes, dynamics and interactions can be provided by NMR
spectroscopy and are extremely valuable for drug discovery. NMR allows the
detection of weak interactions which sometimes are to weak to be detected
by other biological assays like FRET.36,37
1 . 2 . 2 Resonance assignment
First thing needed for the determination of any three-dimensional structure
or any dynamics is the knowledge of the chemical shift of a particular spin.
Therefore, before any information can be obtained about relative orientations,
distances or angles, an assignment needs to be done. For well-behaved small
proteins with less than 80-100 amino acids, a homonuclear strategy can be
applied. Using TOCSY and COSY spectra for intra-residue correlation and
NOESY spectra for inter-residue correlation. NOESY experiments are gener-
ally optimized to detect only short distances at the cost of sensitivity as due to
the overall protein fold several protons can be quite close in space even if they
are largely separated in the protein sequence itself. For larger proteins this
approach is not sufficient any more as signal overlap and spectral crowding
increases with size. For larger proteins, the standard procedure for the reson-
ance backbone assignment involves recording HNCACB and HN(CO)CACB
spectra. These spectra correlate each NH group with the Ca and the Cb shifts
of the corresponding amino acid while providing a correlation with weaker
intensity to the preceding amino acid. Most triple resonance experiments use
1J and 2J couplings to establish connectivities between adjacent amino acids.
These experiments are often used in pairs like HNCO and HN(CA)CO which
help to correlate each NH group with the carbonyl group of the correspond-
ing and preceding amino acids. Similar results are obtained for the HNCA and
HN(CO)CA experiments which link the NH group with the Ca shifts (see Fig-
ure 1.1). In optimal cases those experiments allow a complete walk through
the peptide chain that only stops at prolines due to the missing NH. Neverthe-
less, many more three-dimensional as well as two-dimensional experiments
exist which allow the assignment of the complete backbone as well as the
side chains.19,38 For a complete assignment of all 1H, 13C, and 15N shifts in a
protein using magnetization transfers through internuclear J couplings, a total
of at least six NMR spectra is required. HNCACB, CBCA(CO)NH, (H)CCH-
TOCSY (aliphatic and aromatic regions) and H(C)CH-TOCSY (aliphatic and
aromatic regions). However, 13C- and 15N-edited NOESY-HSQC spectra are
extremely useful for the generation of 1H-1H distance restraints, providing
valuable input data for future structure calculations.38 Nowadays many soft-
ware tools exist that focus on automating the assignment as well as the re-
cording of the required experimental data such that resonance assignments of
small to medium sized proteins are routinely performed.39
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Figure 1.1: Backbone assignment using multidimensional NMR ex-
periments. Figure adapted from http://chem.rutgers.edu.
1 . 2 . 3 Protein structure determination
For protein structure determination usually a set of different geometrical
restraints is used. While distance restraints offer information about inter-
molecular distances, angle restraints are used to define relative orientation
between small units. On the other hand orientation restraints can be used to
calculate the relative orientation of large subunits with respect to one another.
Distance restraints
Distance restraints are most often obtained from 1H-1H NOE signals. The
NOE effect is the transfer of spin polarization from one set of spins to another
set of spins through a mechanism called cross-relaxation. In simple cases
were the molecule is considered a rigid body were only one rotational cor-
relation time exists for the whole molecule this effect is simply proportional
to r 6.40 Unfortunately, a protein is not rigid nor does it necessarily have only
one correlation time. Local mobility can cause part of the proteins to have con-
siderable different correlation times and thus introducing large errors into the
distance calibration. This is however not a big problem since NOEs are usu-
ally classified into three categories weak/medium/strong only. For structure
calculations these categories are simply transferred to 1.8-2.7Å, 1.8-3.3Å,
and 1.8-5.0Å, where 1.8Å corresponds to two times the van der Waals radius
of a hydrogen atom. The sloppy classification of NOE can be attributed to the
difficulty of accurately correlate an intensity to a distance because of various
competing and influencing mechanisms. The intensity does not only depend
on the interatomic distance but also on factors like spin diffusion and local
structural fluctuations due to conformational averaging. Because of this, gen-
erally a large set of NOEs (10-20 per residues) is required and in particular
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long-range NOE information is crucial for a successful structure calculation
by NOEs. Automated NOE assignment is usually performed in an iterative
fashion were an ambiguous NOE assignment is followed by a structure calcu-
lation which guides further NOE assignments.41 The recent development of
exact NOEs42 offers a new method to accurately convert NOE data to inter-
nuclear distances with average errors of around 0.07Å. Nevertheless, exact
NOEs and normal NOEs can routinely only be observed up to a distance of 5-
6Å. The extremely valuable long-range information can only be obtained by
other methods like paramagnetic relaxation enhancement (PRE) and pseudo-
contact shift (PCS).19,43
Angle restraints
Backbone dihedral angles f (N-Ca),y(Ca-C’),w(C’-N) and side-chain c(n)
can be determined by a variety of multi-dimensional NMR experiments. The
angles f , y and w define the secondary structure and the conformation of the
side-chain is defined by the c angles.43 According to Karplus equation,44 the
angle can be estimated from the corresponding 3J coupling, some of them can
be directly determined using three-dimensional experiments.43 The torsion
angles f and y are usually obtained using coupling constants while most
side-chain angles and the cis/trans peptide bond angles (w) are determined
by NOEs. Recording coupling constant experiments with sufficient precision
and intensity is difficult, because long evolution and refocusing periods are
needed. Fortunately apart from coupling constants and relaxation rates, also
chemical shifts are sensitive to torsion angles. It turned out that 1H, 13C and
15N chemical shifts are also susceptible to changes in dihedral angles espe-
cially Ha , Ca and CO shifts are strongly affected by the backbone angles f
and y . On the other hand 15N shifts are sensitive to the side-chain angles
of the preceding amino acids. It is relatively straight forward to measure
most chemical shifts and, therefore, various software package have been de-
veloped that allowed the prediction of torsion angles from chemical shifts and
sequence homology.45,46
Orientation restraints
Due to the relatively short ranged information obtained by NOEs it sometimes
still remains an unsolved question what the orientation of two secondary ele-
ments relative to each other is. In such cases additional information is required
which can be provided by the measurement of residual dipolar couplings. The
orientation of a bond vector in a protein can be determined relative to the prin-
cipal axis of the molecular alignment tensor. RDCs usually have large errors
but given a large data set the structure can also be solved using entirely RDCs.
Knowing how certain bonds are orientated relative to each other helps to solve
the overall orientation of flexible loops or secondary structure elements.47–49
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Structure calculation using Rosetta
The three-dimensional structure of a protein is directly related to its amino
acid sequences. Therefore it should be possible to calculate the structure of
a protein solely from its sequence. The Rosetta protein modelling suite is a
unified software package that allows protein structure prediction without any
additional experimental data relying solely on the statistics of the PDB.50,51
Nevertheless, experimental data can be added that drive the algorithm to-
wards a structure that best represents the experimentally obtained data. The
Rosetta approach uses short fragments of three and nine amino acids. For
each of these small segments Rosetta selects a few hundred fragments from
the crystallographic structural database that are similar in their sequence to
represent the conformational space that this segment is most likely to be
found in during folding. Rosetta then applies a Monte Carlo strategy to yield
native-like protein conformations with typical accuracies of 3-6Å (see Figure
1.2).
Figure 1.2: "Schematic representation of a typical process of comparative mod-
eling by homology. Initially, template proteins are identified. Then the sequence
of the target protein is aligned against the sequence of the protein templates, and
then a model is built and validated, obtaining in the end, the 3-D structure of
the target protein. If necessary, the final structure may undergo a refinement pro-
cess." Figure taken from (52).
Adding structural information from experimental NMR data can signi-
ficantly improve the quality of the final models. Protein NMR chemical
shifts are highly sensitive to the surrounding local structure. An extension to
Rosetta, CS-Rosetta was developed which uses chemical shifts obtained from
backbone assignments to optimize the selection of protein fragments from the
Protein Data Bank.53 In contrast to the previously selected fragments, these
fragments are not only similar in their sequence they are also more closely
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related to the native state as their chemical shifts match better. Extremely
valuable long-range pseudocontact shift informations obtained from a single
metal binding site were successfully incorporated in the Rosetta approach.
PCS-Rosetta can automatically calculate the anisotropy of the magnetic sus-
ceptibility tensor and the metal position from the experimental data during
structure calculations.54 It could be shown that proteins of up to 150 residues
could be accurately calculated from exclusively PCS data. The program suc-
cessfully discriminates correctly folded states from incorrectly folded ones.
While PCS-Rosetta allowed only the usage of one single paramagnetic center,
this approach was quickly extended to multiple paramagnetic centres. The
GPS-Rosetta approach uses multiple paramagnetic centres thus in a way oper-
ates like GPS satellites to pinpoint the location of spins.55 All components of
the anisotropy of the magnetic susceptibility tensors are simultaneously fitted
during the low-resolution backbone-only annealing of the Rosetta program.
1 . 3 in-cell PROTE IN NMR SPECTROSCOPY
With the huge variety of possible experiments and computation approaches,
structure determination of small to medium sized proteins has become
straightforward. The introduction of structural restraints obtained from
NMR spectroscopy has proven extremely useful. Nevertheless, most protein
samples are recorded in buffered aqueous solution that only poorly mimic
the natural environment of the protein. A completely different approach is
needed if one wants to study proteins and their interactions at their native,
intracellular location. In-vitro studies have increased our three-dimensional
knowledge of these proteins. Nevertheless they do not necessarily represent
the state of proteins inside a living cell.56 Various specific and non-specific
interactions with the crowded cellular environment can be crucial for the pro-
teins structure and function. In-cell NMR can address these changes as well
as post-translational protein modifications. The first in-cell NMR has been
described by Serber et al..57 Since then the term in-cell NMR has been used
for measurements inside living cells while in-vivo refers to measurements
in living organisms. Most of today’s in-cell NMR approaches exploit the
fact that most atomic nuclei (with the exception of hydrogen) are not NMR
active in their most abundant isotope. Isotope labelling is used as a selective
filter that renders the whole cellular background invisible to the spectrometer
due to the very low natural abundance. In essence the protein of interest is
expressed in growth media with isotopically enriched precursors. If bacteria
are grown in unlabelled medium first and only switched to labelled material
before the induction of recombinant protein expression the selective isotope
labelling is generally restricted to the protein of interest. This allows the dir-
ect measurement of intact bacteria cells without further purification. On the
other hand, proteins can also be purified from bacteria cells and then trans-
ferred to eukaryotic cells. For measurements in Xenopus laevis oocytes the
labelled proteins can be deposited by microinjection due to the conveniently
large size of the cell. These cells are collected and can then be measured
1.4 PARAMAGNET IC PROTE IN NMR SPECTROSCOPY 9
using established protein NMR experiments.21,56,58 Alternatively, the protein
can also be brought into cells by means of other methods like electroporation,
cell penetrating peptides59 and osmotic shock.
1 . 4 PARAMAGNET IC PROTE IN NMR SPECTROSCOPY
In paramagnetic systems, many different effects can be observed that provide
long-range structural information. Paramagnetic relaxation enhancement
(PRE), residual dipolar couplings (RDC) and pseudocontact shifts (PCS) are
commonly used for structural information (see Figure 1.3). Contact shifts
(CS), dipolar shift anisotropy (DSA), correlation between Dipole-Dipole
(DD) interactions and DSA (DD-DSA) and residual chemical shift aniso-
tropy (RACS) are not commonly used for structure determinations.60
Figure 1.3: "Restraints observed from paramagnetic NMR. Left panel:
Reduction in the peak intensity is observed for the resonances that are
close to paramagnetic centres due to paramagnetic relaxation (PRE).
With anisotropic paramagnetic centres, both PCS (middle panel) and
RDCs (right panel) are observed. Peaks with red and blue represent
resonances in diamagnetic and paramagnetic conditions, respectively."
Figure taken from (61).
1 . 4 . 1 Paramagnetic relaxation enhancement
Every paramagnetic center causes line broadening to the NMR spectrum due
to the paramagnetic enhancement of the transverse relaxation rates. The PRE
effect arises due to a dipole-dipole interaction and decreases similarly to the
NOE effect with a r 6 dependency.62–64 However, replacing one of the nuc-
lear spins by an electron spin the relaxation can be enhanced by a factor of
658 boosting the observable range up to 30-40Å. Although paramagnetic
relaxation enhancements can be observed with every paramagnetic center, ni-
troxide radicals, Mn2+ and Gd3+ are preferred. These paramagnetic centres
have an isotropic electron g-factor and thus do not give rise to any pseudocon-
tact shift. The PRE is measured by taking the difference in nuclear relaxation
rates between a paramagnetic and a diamagnetic sample. In practice most
PRE studies use a simplistic approach by taking the ratio of peak intensities
in the paramagnetic and diamagnetic sample. PREs are in general far less ac-
curate than NOEs nevertheless they have proven to be of great use in structure
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determination especially also in the context of the determination of sparsely
populated states of proteins and their complexes.63 Due to conformational
changes, a spin in a minor populated state can come relatively close to the
paramagnetic center and thus influences the PRE in such a way that a closer
apparent distance is obtained, which can be mathematically decomposed into
an ensemble of structures thus providing unique information especially about
sparsely populated states.63
1 . 4 . 2 Residual dipolar couplings
In NMR spectroscopy, dipolar couplings are useful for the characterizations
of protein structures as they depend on distance and orientation between two
spins as well as dynamics. The dipolar coupling is a through space effect
which arises from the interaction of any two magnetically active nuclei. How-
ever, Brownian motion averages dipolar couplings to zero under isotropic con-
ditions. It is only under anisotropic conditions that these dipolar couplings
are not averaged to zero and are thus observable as residual dipolar couplings.
The partial alignment of the proteins (roughly one in thousand) causes the
dipolar couplings which are generally in the range of kHz to be observable as
residual dipolar couplings of a few Hz. The RDC DAK between two spins A
and K depends on their distance and orientation,64
DAK =  (hB20gAgK/(240r3AKkbTp3)⇤
[Dcax(3cos
2Q 1)+ 1.5Dcrhsin2Qcos2F] (1.1)
where gA and gK are the gyromagnetic ratios of spin A and K, respectively,
rAK is the internuclear distance and, h is Planck’s constant, T the temperature,
kb the Boltzmann constant and Q and F are the polar angles. This equation
clearly reveals that RDCs do not depend on the distance from the spin to the
paramagnetic center.64 RDCs can only be recorded if the molecules Brownian
motion is not averaged over all three principle room directions. For this pur-
pose liquid crystals were introduce in 1963 by Saupe and Englert.65 However,
multiple dipolar couplings made the spectra extremely difficult to interpret. In
the early 1990s, bicells were introduced66 and since then extensively used for
the partial alignment of proteins in solution. Besides bicells also various other
alignment media like phage particles67 and strain-induced gels68 have been
developed. Most of this methods rely on steric hindrance to enforce a prefer-
ential orientation and require the addition of some sort of alignment media.69
On the other hand metal ions with an anisotropic c tensor cause a weak align-
ment in the direction of the magnetic B0 field. However, the introduction of a
paramagnetic metal often requires paramagnetic tagging of the protein with a
suitable tag.70
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1 . 4 . 3 Contact shift
The contact shift is an effect that arises through direct spin delocalization
and/or spin polarization. The contact shift can be described by the simplified
equation 1.2,
d c = A
h¯
geµbS(S+ 1)
3gIkbT
(1.2)
where A/h¯ is the contact coupling constant, µb is the Bohr magneton, kb
the Boltzmann constant, T the temperature, S the total spin quantum number
and ge is the electron g-factor. This equation only holds true for a single
electron in an orbital which is well separated from excited states and has an
isotropic electron g-factor. Most other cases are difficult to describe especially
in complexes with low symmetry. Due to the contact shift being mostly a
through bond effect it is often neglected for atoms more than four bond away
from the paramagnetic center. In fact, contact shifts are rich of structural
information and conformational arrangements. Nevertheless, this information
can hardly be derived into useful restraints for structure determination.71
1 . 4 . 4 Pseudocontact shift
The pseudocontact shift is an effect that arises due to a through-space dipole-
dipole interaction. The effect manifests itself in a chemical shift change ori-
ginating from the interaction of the spin with a paramagnetic center with an
anisotropic electron g-factor. For the point-dipole approximation and a rigid
molecule the PCS can be described by equation 1.3,
DdPCS = 1
12pr3
[Dcax(3cos2Q 1)+ 1.5Dcrhsin2Qcos2F] (1.3)
where DdPCS is the PCS usually reported in ppm, r is the distance of the
nuclear spin to the paramagnetic center, Dcax and Dcrh are the axial and
rhombic components of the anisotropy of the magnetic susceptibility tensor
c , and Q and F are the polar angles describing the relative position of the
nuclear spin.72 The magnetic susceptibility tensor c can be decomposed in
an isotropic ciso and and anisotropic component Dc . Only the anisotropic
part is of interest in terms of pseudocontact shifts. The anisotropy can be
decomposed into an axial (Dcax) and a rhombic (Dcrh) component according
to the equations 1.4 and 1.5.73
Dcax =czz  cxx+ cyy2 (1.4)
Dcrh =cxx cyy (1.5)
For future comparison of different c tensors, a convention was introduced.
The unique tensor representation (UTR) was established by Schmitz et
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al..74 The c tensor axes were labelled according to the following scheme:
|cz| > |cy| > |cx|. This convention ensures that the axial and rhombic com-
ponent will always have the same sign and that the rhombic component is
at most 2/3 of the axial component. Equation 1.3 can only be applied if the
coordinate frame of the molecule is aligned with the coordinate frame of the
tensor and the metal position is at the origin. In order to achieve this, tensor
parameters are usually reported with the metal coordinates in the molecular
frame and the three euler angles (a ,b ,g) describing the required rotations
to align both coordinate frames. The Euler angles in the UTR representation
adhere to the ZYZ’ convention and are reported between 0-180°. However,
special care needs to be taken if one compares tensors in the UTR, because
due to the symmetric nature of the tensor a rotation around 170° can be
equivalent to a rotation around 10°. It is also possible due to the definition of
the axial and rhombic components that two tensors have the same sign but
completely different euler angles resulting in an overall shift to the opposite
direction.72 Determination of the Dcax and Dcrh can be accomplished by
fitting pseudocontact shifts to a known structure. In total there are eight para-
meters that need to be determined Dcax and Dcrh, the three metal coordinates
x,y,z (for the translation of the structure coordinate frame to the tensor frame)
and the three Euler angles a ,b ,g (for the rotation of the structure coordinate
frame to align with the tensor frame). If at least eight shifts are known the
equation can be solved and the tensor can be determined. In practice many
more shift are required to get an accurate representation of the tensor due to
experimental errors. If the metal position is known the problem reduces to
five variables, which can be solved using five shifts. Pseudocontact shifts can
be observed over a very long range of up to 70Å. Large pseudocontact shifts
are only observed in close proximity to the metal center and can therefore be
loosely correlated to a distance, because the errors introduced by the angular
dependency are small. However, small to medium sized PCS can not be dir-
ectly correlated to a distance as it would be the case for NOEs or PREs due
to the angular dependency. The experimentally observable shift is the sum of
the diamagnetic shift, contact shift and the pseudocontact shift. In order to
calculate the pseudocontact shift a diamagnetic reference must be measured
to obtain the diamagnetic reference shift. Unfortunately contact shifts are not
easily separated from pseudocontact shifts and, therefore, only shifts from
nuclei significantly faraway (i.e. more than 4-5 bounds), where the contact
shift is negligibly small, are used. Pseudocontact shifts can be measured more
precisely than for example PREs and NOEs as the only relevant information
is the chemical shift difference and not the linewidths or intensities. Shift
differences can be measured very accurately to a precision of better than
0.01 ppm. Commonly used for performing PCS NMR spectroscopy is the
1H-15N HSQC experiment. From a completely assigned diamagnetic refer-
ence spectrum the shifted peaks can be identified in the paramagnetic 1H-15N
HSQC due to their characteristic shift on a 45° angle. Assigning a few easily
recognizable shifts allows the estimation of the tensor and thus finding new
additional shifts and their correct assignments. In principle, if three different
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magnetic susceptibility tensors of three metals were known (provided their
main directions differ by at least 10°) each individual nucleus can be located.
In practice, however, the uncertainties are too large such that usually four
different tensors are needed for a precise location, if no other restraints are
used.71,72
1 . 5 LANTHAN IDE CHELAT ING TAGS
A prerequisite for paramagnetic protein NMR spectroscopy is the introduc-
tion of a paramagnetic center. Most often paramagnetic lanthanides are used
in their plus three oxidation state. Some proteins contain a metal binding
pocket where the lanthanide can replace the naturally occurring metal. Never-
theless most proteins do not contain such binding sites and artificial methods
are required for selective protein labelling.
1 . 5 . 1 Lanthanide binding proteins
Many proteins have metal binding pockets, however, lanthanides have no rel-
evant function in nature and, therefore, no natural highly selective lanthanide
binding motifs have evolved. In contrast, the natural occurring Ca2+ Mg2+
and Mn2+ ions have highly selective binding motifs in proteins. In some
cases these metals can be substituted by a lanthanide.72 Ca is particularly
well suited as it is most similar to lanthanides in terms of ionic radius and
complexation chemistry. Metalloproteins containing the EF-hand motif have
been successfully substituted with Ln3+ to generate pseudocontact shifts. Cal-
bindin D9K selectively binds two Ca2+ ions. Bertini et al. replaced one cal-
cium ion with paramagnetic lanthanides and determined the Dc values (see
Figure 1.4). Up to date this is the most complete series of Dc values for
the whole lanthanide series except promethium which is radioactive.75 Al-
though replacing a naturally occurring metal with a lanthanide is convenient,
its binding is not very tight, structural changes may occur and the observable
pseudocontact shifts are small. Also this approach is only viable for proteins
containing a suitable metal binding motif which is roughly a third of all nat-
ural proteins.76
1 . 5 . 2 Lanthanide binding peptides
Inspired by nature’s EF-hand motif several lanthanide binding peptides (LBP)
were developed for the site-specific attachment of Ln3+ ions to the protein.
In principle this limits the application of this LBP to the N or C terminus
of the protein. Nevertheless it could also be shown that such LBP can be
engineered with a cysteine residue such that disulphide conjugation becomes
possible. If prior knowledge of the proteins three dimensional structure is
available the LBP can also be engineered into a flexible loop of the protein.
Peptide fusion offers in contrast to chemical reactions, a quantitative yield.
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Figure 1.4: "Paramagnetic properties of Ln3+ ions. Only paramagnetic and non
radioactive lanthanides are included. Representative isosurfaces are plotted for
PCSs by± 5 ppm using tensors reported by Bertini et al.Bertini et al. The radius
of the yellow sphere indicates the distance from the metal ion at which 1H NMR
signals of macromolecules with a rotational correlation time of 15 ns broaden
by 80Hz due to paramagnetic relaxation enhancement (PRE) at a magnetic field
strength of 18.8 T. For Eu3+, the estimate of the relaxation enhancement includes
a contribution from excited J manifolds." Tensor parameters were converted to
UTR. Figure adapted from (77).
However, isotopic labelling of the protein also labels the LBP and can thus
complicate the NMR spectra. It could be shown that 16-residue LBP are
sufficient to tightly bind the lanthanide ion with affinities reaching 50 nM.78
LBP synthesized with cysteines at different locations within the 16-residue
sequence allow fine tuning of the resulting c tensor relative to the protein.79
This feature is not easily accessible with most other lanthanide chelating tags
as their tagging mode can not be altered easily. Increased rigidity of the LBP
can be achieved by N- or C-terminal fusion and one carefully engineered
cysteines disulphide bridge between the LBP and the protein. Unfortunately
finding an optimal linkage to the target protein is challenging both on the C-
and N-terminus. Conjugation on a highly solvent exposed cysteine residue
is likely to yield a very flexible and mobile tag which results in very small
observable pseudocontact shifts.72
1 . 6 NON-PEPT ID IC SYNTHET IC LANTHAN IDE CHELAT ING TAGS
Most lanthanide chelating tags are conjugated to proteins taking advantage
of the nucleophilicity of sulphur. Targeting free cysteines with sulfhydryl re-
active probes has become the method of choice for selective couplings. Few
example also involve click-chemistry.72
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1 . 6 . 1 Sulfhydryl reactive functional groups used for tagging
The vast majority of the tags reported in literature are using disulphides,
pyridine-disulphides or thiosulfonate (see Scheme 1). All of these sulfhydryl-
reactive motifs form a mixed disulphide between the tag and the protein and
are therefore not stable under strongly reducing conditions as they are found
for example in living cells.72 Maleimides are regularly used in biological
assays for the fast and selective labelling of cysteines forming a very stable
thioether bond.80 However, in terms of PCS NMR spectroscopy, this linkage
is not preferred due to the formation of two diastereomers upon conjuga-
tion with the protein. More recent approaches involve the usage of vinyl
pyridines81,82 or pyridine phenyl sulfones83–85 to form a stable non-reducible
linkage. It could be shown that such conjugates are highly stable under
physiological conditions, nevertheless, the limited reactivity of these tags
enforced using a high pH and/or high temperature. Tagging under such harsh
conditions is not a problem for small and very stable proteins like ubqiuitin or
GB1. Most other proteins would suffer degradation under conditions largely
deviating from physiological values. Iodoacetamide and bromoacetamide
are used for the formation of thioether bonds between proteins and linkers
under much milder conditions.86,87 Nevertheless, tagging was relatively slow
if compared to standard disulphide bond formation and required generally
higher amounts of tag. Introducing non-natural amino acids into the protein
allows the usage of a copper catalysed azide-alkyne cycloaddition.88 Unfor-
tunately, the formed linkage is also rather long and it could be shown that
many proteins are sensitive to the presence of copper and precipitate out of
solution. Approaches dealing with the formation of thioether suffer from low
reactivity and/or increased linker size.72
1 . 6 . 2 Open chain molecules
EDTA-based tags
Initially lanthanide chelating tags were based on the EDTA scaffold. EDTA
is a universal high affinity hexadentate metal chelator.89 Protein conjugation
was achieved using pyridine-disulphides or thiosulfonate as activator (see
Scheme 2). Although EDTA itself is not chiral, metal complexes formed with
EDTA are chiral and two enantiomers are obtained.89 Conjugation with the
already chiral protein leads to two diastereoisomers which consequently res-
ults in peak doubling giving rise to two sets of signals in the NMR spectra.
This is clearly seen by PCS NMR spectroscopy as the two different tag en-
antiomers also have two different c tensors. It could be shown that the intro-
duction of a single stereogenic center to the EDTA tags can lead to only one
observable set of peaks.72,89
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Scheme 1: General reaction scheme for the covalent
attachment of lanthanide chelating tags to proteins. The
Lanthanide chelating tag is represented as R and no
further reaction conditions are stated.
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Scheme 2: Selection of thiol reactive open chain ligands for lanthanide chelat-
ing tags. Thiol reactive part is highlighted in red. Tags based on EDTA form
hexadentate complexes whereas DTPA forms octadentate and TAHA nonadent-
ate complexes.
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DTPA-based tags
Consequently by going from hexadentate to octadentate the binding affinity
for lanthanide(III) ions increased. Unfortunately the number of possible di-
astereoisomers increased to eight. Double attachment to the protein surface
was tried to increase the tags probability to adapt only a single conforma-
tion (see Scheme 2). This approach was unsuccessful as up to five different
set of signals were observed, however, shifts up to a distance of 40Å could
be obtained. On small proteins, decomposition of multiple sets of signals
might be possible, however, on medium to large sized proteins this becomes
infeasible.72,90
TAHA-based tags
A nonadentate TAHA-based tag was conjugated to cysteine mutants of ubi-
quitin and pseudocontact shifts were recorded for Tm3+ and Tb3+ loaded
tags (see Scheme 2). Only one set of signals was obtained for each sample
indicating the presence of only one diastereoisomer.91
1 . 6 . 3 DOTA-type ligand
DOTA in MRI applications
In magnetic resonance imaging (MRI) a variety of gadolinium based con-
trast agents are used as the quality of a MR image depends amongst other
factors on the increased relaxation rates caused by the PRE effect. Due to the
seven unpaired electrons Gd is strongly paramagnetic and has a very slow
electronic relaxation rate. However, free gadolinium is extremely toxic, be-
cause the ionic radius of Gd3+ (107.8 pm) is close to that of Ca2+ (114 pm).
Gadolinium blocks many voltage-gated calcium channels at nano- to micro-
molar concentrations. For potential application in humans, gadolinium must
be chelated in highly stable complexes to avoid intoxication of the patient.
Many MRI contrast agents are based on DTPA which has also been applied
for PCS NMR spectroscopy (see Figure 1.5). The development of Gd-DOTA
for MRI application showed the high stability of DOTA based gadolinium
tags. Gd-DOTA (Dotarem®) showed the highest Kd (25.6) of all marketed
MRI contrast agents.92,93 This property is highly favourable not only for MRI
application but also for PCS NMR spectroscopy. Recent studies have shown
that gadolinium based contrast agents are retained in the brain and especially
the linear contrast agents leak gadolinium which in some rare cases presum-
ably even harmed the patients.94
DOTA isomers
Tags based on the DOTA scaffold form highly stable and inert complexes
with lanthanide(III) ions. This is the result of the good match between the
size of the cavity formed by DOTA and the ionic radii of lanthanide(III)
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Figure 1.5: Structures of marketed gadolinium chelates used for magnetic reson-
ance imaging. Figure adapted from (92).
ions. Usually a lanthanide ion has eight to nine coordination sites and eight
are provided by the DOTA-ligand. The ninth coordination site can either
be empty or occupied by a small ligand like water. This largely depends on
the ionic radii of the lanthanide as DOTA complexes with small lanthanides
prefer eight coordination sites while the complexes with larger lanthanides
have enough space to accommodate a ninth coordination site. The lanthan-
ide(III) ion is sandwiched between two square planes. One plane is formed
by the four nitrogens of the cyclen base and one is formed by the four oxy-
gens of the carboxylic acid sidechains. Lanthanide DOTA complexes form
two isomers in solution, referred to as square antiprism (SAP) and twisted
square antiprism (TSAP) (see Figure 1.6). Each of these isomeric forms is
present as an enantiomeric pair giving rise to four different isomers. The in-
terconversion between isomers may occur by pendant arm rotation resulting
in a clockwise (L) or anticlockwise (D) conformation or by a ring flip from
llll to dddd . The SAP isomers are displayed by D(llll ) and L(dddd )
while the opposite configurations (D(dddd ) and L(llll )) form the TSAP
isomers. The interconversion between different isomers causes no problems
for isotropic paramagnetic effects, however, the measurement of pseudocon-
tact shift relies on the anisotropic component of the magnetic susceptibility
and thus is largely affected by motional averaging.95
DOTA in PCS NMR spectroscopy
DOTA-SSPy 7 was tested on calcium dependent cell adhesion protein
ECAD12 S87C and small PCS and a weak alignment was observed.96 The
motional averaging caused by the flexibility significantly reduced the PCSs
as well as the RDCs. A modified DOTA based tag (CLaNP-3 8) with two
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Figure 1.6: "Schematic representation of SAP and TSAP isomer
conformations for Ln-DOTA-type complexes." Figure taken
from (95).
attachment sites was tested to reduce flexibility (see Scheme 3).97 However,
in this case two attachment sites were not sufficient to select only one of
the four possible DOTA conformations and the observed PCS were small
and peak doubling was observed. Using two attachments sites instead of one
significantly reduces the tags mobility with respect to the protein surface.
However, it does not necessarily reduce the mobility inside the tag caused by
ring flipping motions or side arm rotations. The problem of peak doubling
was solved by the introduction of sterically more demanding side arms and
for tag 9 no evidence was found for peak doubling and larger Dc values
were obtained.98 This tag has an overall +3 charge as all donors are neutral.
The net charge of the tag was reduced to +1 by the installation of two nitro
phenolic groups instead of the pyridine N-oxides (tag 10).99 CLaNP-5 (tag
9) has become one of the most successful double-arm cyclen based tags and
is clearly superior to its single-arm pendant were one pyridine N-oxide is
replaced by an acetate.100 Favouring one conformer can also be induced by
chiral sidearms. Tag 11 is a close analogue of CLaNP-3 8 were the acetates
are substituted by isopropanol moieties and the thiosulfonate was replaced
by pyridine-disulphide.101 A more recent version of CLaNP-5 9, CLaNP-9
12, addresses the reduction stable problem by using alpha bromo acetam-
ides as sulfhydryl-reactive probes.86 The measured PCS are generally lower
than for CLaNP-5 9 which was mostly attributed to the increased linker size.
Unfortunately, the tags reactivity causes problems in synthesis, handling as
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well as tagging. All of these double-arm cyclen-based tags require two single
cysteine mutations separate by a specific distance that must be carefully
engineered. Nevertheless, if carefully planned very large PCS and a strong
alignment can be observed with these tags.
8 9 10
11 12
Scheme 3: Selection of double-arm- cyclen-based tags. The lanthanide is omit-
ted.
Initial results obtained for the single arm analogue of CLaNP-5 revealed
that the conformational and translational freedom is to large. Häussinger et
al. developed a single-arm cyclen-based tag with eight stereospecific methyl
groups (see Scheme 4).102 Using a four times methyl substituted cyclen
(4S-M4-cyclen) and lactic acid, a sterically more crowded and highly rigid
tag was obtained. This tag exists in two different forms (4R4S) and (8S)-
DOTA-M8. First experiments were reported using the 8S variant. It was
shown that the introduction of the eight methyl groups dramatically reduced
the conformational flexibility. Comparison with the non substituted DOTA
showed significantly larger c tensors. Initial experiments performed with
Dy3+ loaded (8S)-DOTA-M8 showed the presence of a second species. Opina
et al. showed that the second species arises from the slow conformational
equilibrium between a TSAP and SAP geometry.95 The ratio strongly correl-
ates with the size of the lanthanide. For lanthanum a ratio of 98:2 (L(dddd )
: D(dddd )) was found while for lutetium the opposite 3:97 was found. In
terms of DOTA conformers this corresponds to a SAP to TSAP switch al-
though strictly speaking this is not true for DOTA-M8 as both conformers are
twisted square antiprisms. The only major difference is the sense of ration
of the pendant arms. For intermediate lanthanides the ratio approaches in
extreme cases (holmium) almost 50:50. Surprisingly the (4R4S) variant of
DOTA-M8 was not studied by Opina et al. However, recent work performed
in our research group involving DFT calculations suggest a L(dddd (SAP)
geometry for the whole lanthanide series.
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If averaging motions are fast enough on the NMR time scale the PCS
are small but still only one set of signals is observed. The presence of a
second species can be avoided by introducing large chiral substituents to
the side arms. Tag 13, synthesized in both enantimoeric forms ((S,S,S) and
(R,R,R)) showed large tensor parameters and only a single set of paramag-
netic peaks.103 Single arm variants of 11, 14 and 15, showed also only one
set of paramagnetically shifted peaks. Introducing chiral and/or large chiral
side arms to cyclen based-tags suppresses slow conformational changes,
which would lead to peak doubling. However, fast averaging processes are
not necessarily removed. Ring flip motions are completely suppressed in the
DOTA-M8 tag as the methyl groups would need to adopt a very unfavourable
axial position.95
A reduction stable derivative of DOTA-M8, M8-CAM-I, was developed,
where the activator was replaced by a propyliodoacetamide. Tensor paramet-
ers obtained for these derivative were generally worse than for DOTA-M8
which was attributed to the increased linker length.87 In order to reduce the
linker length M7-Py-DOTA was developed.83 M7-Py-DOTA features the
same scaffold as DOTA-M8 with one pendant arm replaced by a sulfhydryl
reactive pyridine phenyl sulfone moiety. Two closely related analogues ofM7-
Py-DOTA were published shortly after, featuring the opposite chirality on the
pendant arms and cyclen as core.104 These tags offer a non-reducible covalent
linkage with the protein and are therefore suited for in-cellmeasurements. All
of these tags suffer from a relative low reactivity thus requiring harsh con-
ditions like increased pH or elevated temperatures. The M7-Py-DOTA tag
was developed in the (3R4S) configuration and displayed no second set of
peaks for thulium and terbium, although terbium showed a ration of 80:20
(L(dddd ) : D(dddd )) for the (8S)-DOTA-M8 tag.95
The vast majority of tags relies on one or two cysteines on the protein sur-
face. Introduction of unnatural amino acids allows the usage of chemistry not
relying on the high nucleophilicity of thiols. Para azido-L-phenylalanine can
selectively be introduced into the protein sequence and requires an alkyne in-
stalled on the tag for a copper catalysed azide-alkyne cycloaddition. Tags, 16
and 17, were specifically designed for this propose, but showed smaller PCS
than tag 13 due to the increased tether size.105 Also some proteins are sens-
itive to copper and precipitate out of solution. Designing a short and highly
reactive reduction stable tag remains challenging and further development is
needed.
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Scheme 4: Selection of single-arm- cyclen-based tags. The lanthanide is omitted.
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RESEARCH GOAL
Pseudocontact shift protein NMR spectroscopy relies on the principle of at-
taching a paramagnetic source on the surface of the protein or inside. A very
convenient source of paramagnetism are lanthanide 3+ ions. Today most PCS
NMR experiments were carried out using a lanthanide chelating tag which
is site-selectively conjugated to the protein surface. The most promising
lanthanide chelating tags are based on the DOTA framework. The DOTA
framework as well as the linkage are under constant development in order to
push the range of applications even further.
The Häussinger group focuses its research mainly on the development of
new high performing lanthanide chelating tags mostly based on M4-cyclen.
The literature known procedure for the synthesis of M4-cyclen106 has proven
to be extremely challenging to up-scale in industry and academia. Therefore,
a up-scalable and robust synthetic procedure to obtain M4-cyclen was needed.
The first aim of this thesis involved the development of a robust procedure for
the synthesis of M4-cyclen which should be highly flexible. The procedure
should allow the synthesis of selectively labelled compounds as well as the
synthesis of differently substituted twelve-membered tetraaza macrocycles.
The procedure should also allow the introduction of substituents with func-
tional groups on the macrocycle such that the installation of a sulfhydryl
reactive moiety on the base ring becomes possible.
The second part of the thesis aims to extend the applicability of pseudocon-
tact shift NMR spectroscopy to in-cell applications. Most PCS experiments
published in literature are conducted in buffered solution that mimic biolo-
gical environments. Under the reductive environments found inside living
cells the commonly used disulphide bridge is quickly cleaved. Therefore,
the second aim of the thesis was to develop a reduction stable linker moiety
which allows the determination of protein structures inside living cells using
PCS NMR spectroscopy.
Thirdly, not only proteins but also RNAs are important biological mo-
lecules and targeting these by PCS NMR spectroscopy is desirable but chal-
lenging. Therefore, we aimed for the development of a suitable tag for RNA
PCS NMR spectroscopy.

Part I
SYNTHES I S OF SUBST ITUTED
TWELVE -MEMBERED TETRAAZA
MACROCYCLES
This part of the thesis focuses on the development and ex-
ploration of new synthetic routes towards substituted twelve-
membered tetraaza macrocycles suitable as core building blocks
for DOTA based lanthanide chelating tags.

3
DEVELOPMENT OF A MULT IGRAM SCALE
SYNTHES I S FOR 4 ( S ) M4 -CYCLEN
3 . 1 RETROSYNTHET IC ANALYS I S AND CONS IDERAT IONS
The literature known procedure for the synthesis of 4(S)M4-cyclen utilizes
nucelophilic ring opening of the corresponding alanine-based aziridine.106
This method could so far not been up scaled. 4(S)M4-cyclen could be ob-
tained by simply reducing its cyclic tetraalanine precursor. Many cyclic tet-
rapeptides have biological activity and are therefore of great interest for both
academia and industry. Nevertheless a high yielding general approach to syn-
thesize cyclic tetrapeptides has not been reported so far.107 Many procedures
involve proline108 or unnaturally configured amino acids as turn inducing
amino acid. Some approaches apply click chemistry to form a triazol which
mimics a carboxylic amide.109 For our synthesis of 4(S)M4-cyclen we envi-
sioned three different approaches starting from enantiomerically pure alanine
derivatives. Method A in Scheme 5 utilizes a Head-to-Tail cyclization of
an alanine-based tetramer in solution or on solid phase support. Method B
and C (see Scheme 5) involve the formation of a preorganized open chain
intermediate. Either one or two sequential ring closing reactions close the
preorganized structure forming the twelve-membered macrocycle.
a
a
a
x = CO, CH2
x = CO, CH2
x = CO, CH2
22
22
22
Scheme 5: General strategies to synthesis 4(S)-M4 cyclen.
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3 . 2 HEAD-TO -TA IL SOL ID PHASE CYCL IZAT ION (METHODE A)
Cyclic tetrapeptides were synthesised using an polymer based approach.110
Cyclic tetraalanine was successfully synthesised in small scales (mg) by
Florian Lüttin during his master thesis within our group. He showed that a
polymer assisted Head-to-Tail cyclization is possible on an functionalized
polymer support (see Scheme 6).111 His findings were the starting point for
further investigations during this thesis. We investigated if this process could
be extended to larger quantities of up to multigram scale.
23
Scheme 6: Polymer based approach to facilitate Head-to-Tail cyclization. For
clarity the polymer is shown as a grey sphere.
3 . 2 . 1 Synthesis of N-Cbz-protected tetraalanine 30
The synthesis of N-Cbz-protected tetraalanine was adapted from the proced-
ure described by Florian Lüttin (see Scheme 7).
Starting from commercially available tert-butyl alanine 25 and N-Cbz-
alanine the dimer 24 was synthesised in high yields using HATU and DIPEA
in acetonitrile. On large scale this process was very time consuming as the
final product required purification by flash column chromatography. In or-
der to avoid purification by flash column chromatography HATU could be
exchanged to T3P offering an easier work-up due to the water soluble by-
products with, however, lower yields. Subsequent deprotection forming the
free amine 28 and the free acid 27 were carried out in excellent yields. A
second peptide coupling with HATU and DIPEA in acetonitrile formed the
fully protected tetramer 29. The product crystallized out of solution during
the reaction and was isolated by filtration in medium yield. The lower yield
was attributed to the high solubility of the product in acetonitrile. Neverthe-
less, the time consuming purification step was avoided and this method was
preferred on large scales. A solvent with a lower solubility for tetraalanine 29
could increase the yield. However, material cost are low and the reaction was
not further optimized. Final deprotection with trifluoroacetic acid yielded the
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Scheme 7: Synthesis of compound 30. Reaction conditions: i.) HATU, DIPEA,
MeCN, 20-25  C, 3.5 h; ii.) TFA / H2O, 20-25  C, 2 h; iii.) Pd/C, MeOH, 20-
25  C, 2 h; iv.) HATU, DIPEA, MeCN, 20-25  C, 2 h; v.) TFA / H2O, 20-25  C,
30min.
desired N-Cbz-protected tetramer 30 in quantitative yield.
3 . 2 . 2 Polystyrene functionalization
The first successful cyclization of tetraalanine on a small scale in our group
was performed using a nitrophenol functionalized polystyrene by Florian Lüt-
tin. During up scaling experiments we tested three different functionalized
polymers (see Scheme 8). Loading capacity as well as cost and reusability
were critical criteria. Each polymer consisted of a nitrophenol analogue cova-
lently bound to polystyrene.
n m
OHO2N
n m
OHO2N
O
n m
OHO2N
A B C
Scheme 8: Nitrophenol-based polymers A, B and C
30 DEVELOPMENT OF A MULT IGRAM SCALE SYNTHES I S FOR 4(S) M4 -
CYCLEN
Polymer A
We synthesised 4-(chloromethyl)-2-nitrophenol (31) by hydroxymethylation
of 2-nitrophenol followed by converting the hydroxyl group to chlorine using
hydrogen chloride gas in chloroform. Hydroxymethylation of 2-nitrophenol
had a very low yield and an alternative was searched. Using commercially
available 4-hydroxy-3-nitrobenzoic acid (32) and the procedure described by
Chen et al.112 we obtained 4-(hydroxymethyl)-2-nitrophenol (33) in better
yield by reducing the acid with borane tetrahydrofuran complex and boron
trifluoride diethyl etherate in tetrahydrofuran (see Scheme 9). The conversion
strongly depended on the amount of BH3 and BF3 used. We found that best
results were obtained using 4 eq. of BH3 ·THF and 1 eq. BF3 ·OEt2 (see entry
5 in Table 3.1) instead of 2 and 1.5 as described.
Table 3.1: Reaction condition screening for the reduction of 4-hydroxy-3-ni-
trobenzoic acid with borane tetrahydrofuran complex and boron trifluoride di-
ethyl etherate.
Entry eq. BH3 ·THF eq. BF3 ·OEt2 Conversion [%]
1 2 1 23
2 2 1 25
3 2 0 22 (solid precipitate)
4 3 1 71
5 4 1 100
All reactions were carried out in tetrahydrofuran at 20-25  C. Conversion was
determined by 1H-NMR.
Our first synthesis of 4-(chloromethyl)-2-nitrophenol (31) used an HCl
generator (H2SO4 and NaCl). However, during up scaling HCl gas from a
gas cylinder was used. Surprisingly the reaction did not take place. We found
that little traces of sulphuric acid and water present in the gas synthesised
with the HCl generator were responsible for catalysing the reaction. After
the intentional addition of sulphuric acid and water the reaction performed
equally well with HCl gas from a gas cylinder. Polystyrene was function-
alized by Friedel-Crafts alkylation using aluminium trichloride with a low
yield of 7.3%. The functionalization efficiency dropped significantly if less
precursor was used and we were not able to recycle the precursor. During the
reaction the unreacted precursor decomposed. The polymer functionalization
was determined by elemental analysis. A loading of 2.08mmol N/g polymer
was achieved. This indicated the presence of 2.08mmol of available coupling
sites per gram polymer. The steps needed to synthesise the precursor 31 and
the low yield during functionalization made this polymer very expensive for
up scaling.
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Scheme 9: Reaction conditions for the functionalization of polymer A: i.) BH3 /
BF3 · Et2O, THF, 20-25  C, 18 h; ii.) HCl (g), CH3Cl, 20-25  C, 18 h; iii.) AlCl3,
nitrobenzene, 65  C, 48 h.
Polymer B
Polymer B was developed to reduce up scaling costs. 4-(Hydroxymethyl)-
2-nitrophenol (32) was acetylated to protect the hydroxyl group during the
in-situ generation of the carboxylic acid chloride. In a one pot synthesis 34
was converted to the corresponding acyl chloride and subsequently reacted
with polystyrene and aluminium trichloride in nitrobenzene (see Scheme 10).
The acetyl group was cleaved off under basic conditions.
32 34
34
B
Scheme 10: Synthesis of polymer B. Reaction conditions: i.) acetyl chloride,
THF, 0-5  C - 20-25  C, 18 h; ii.) oxalyl chloride cat. DMF, nitrobenzene, 20-
25  C, 45min; iii.) AlCl3, nitrobenzene, 40  C, 18 h; iv.) aq. NaOH, 40  C, 4 h.
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A polymer loading of 1.06mmol N/g polymer was obtained. In comparison
to polymer A the functionalization extent is only 50%. However the overall
functionalization yield with respect to the nitro compound was increased by
a factor of ten. This polymer can be more easily scaled up due to its lower
cost and fewer reaction steps involved.
Polymer C
As a third approach, not involving the synthesis of any nitrophenol precursor,
direct nitration of commercially available phenol polymer-bound was tested.
The polymer was nitrated in nitric acid at 20-25  C without sulphuric acid to
avoid over nitration (see Scheme 11). The achieved polymer nitration was
0.75mmol N/g polymer. This labelling was lower than for polymer A and
B. The commercially available phenol polymer-bound has a functionaliza-
tion ranging between of 0.5-1.5 mmol /g. Roughly 50% of the polymer was
nitrated. The high cost of this polymer and the low yields during functional-
ization made this polymer unpractical to use for a large scale synthesis.
n m
OHO2N
n m
OH
i.)
~50 %
C
Scheme 11: Synthesis of Polymer C. Reaction conditions: i.) nitric acid 68%,
20-25  C, 5 h.
3 . 2 . 3 Functionalized polystyrene induced cyclization
Polymer A was used to screen for optimal polymer loading conditions. The
N-Cbz-protected tetramer 30 was coupled to the polymer using DCC, DIC
and HATU as coupling reagent. We found that HATU offered by far the
best coupling efficiency based on the weight increase of the polymer. DCC
was not suitable for this type of reaction as its by product were difficult to
separate from the polymer. DIC offers soluble by-products but coupling per-
formance was lower than for HATU. All three polymers were loaded with
N-Cbz-protected tetraalanine 30 using HATU and DIPEA in dimethylform-
amide. Polymer A and B performed equally well. Both polymers allowed
the loading of roughly half the available active sites (entry 1 and 2 Table
3.2). Polymer C showed a very low loading probably due to the unspecific
nitration. Polymer C was, therefore, skipped from further investigations.
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Table 3.2: Loading efficiency for the three different polymers using HATU and
DIPEA in dimethylformamide.
Entry Poly. Polymer functionalization [g 1] Polymer loading [g 1]
1 A 2.08mmol 0.91mmol 44%
2 B 1.06mmol 0.51mmol 48%
3 C 0.75mmol 0.03mmol 4%
All reactions were carried out at 20-25  C for 18 h.
Polymers A and B were treated with hydrogen bromide solution in acetic
acid. This procedure was used to remove the N-terminal protecting group and
afforded the free tetraalanine polymer bound as a hydrobromide salt. Extens-
ive washing of the polymer was required to remove impurities and acetic acid
from the polymer. The pH was increased to >9 with DIPEA in dimethylform-
amide to induce cyclization. The polymer was stirred at 20-25  C for 24 h.
Although we detected the formation of the desired compound by ESI-MS
it was not possible to isolate cyclic tetraalanine 23 in pure form after the
cyclization. Reduction of the crude material with lithium aluminium hydride
yielded 4(S)M4-cyclen in very low yields after purification by preparative
HPLC.
3 . 3 HEAD-TO -TA IL IN SOLUT ION CYCL IZAT ION
3 . 3 . 1 Cyclization of tetraalanine
It has been shown by Titlestad113 that activated tetrapeptide esters cyclize in
solution. Using TCP to form an active ester was already tested by Florian
Lüttin during his master thesis with little success. The yield was considerably
smaller than the one reported. During this study HATU was used to form
the active ester in-situ from tetraalanine 35. Tetraalanine 35 was obtained by
catalytic hydrogenation of the N-Cbz-protected tetraalanine in methanol (see
Scheme 12).
Cyclization was performed in dimethylformamide under moderate dilution
conditions (1 g L−1) and under pseudo dilution conditions with HATU and
DIPEA at 60  C. Small amounts of the cyclic tetrapeptide 23 were detected
in the crude material. Using HATU instead of TCP as active ester resulted
in an lower yield. The lower stability of the active ester at high temperature
presumably caused decomposition prior to cyclization. The highly rigid struc-
ture of the tetrapeptide 35 is unfavourable for a cyclization. For further up
scaling purposes this cyclization method was not considered.
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Scheme 12: Synthesis of compound 23. Reaction conditions: i.) Pd/C, H2, meth-
anol, 20-25  C, 2 h; ii.) HATU, DIPEA, DMF, 60  C, 24 h.
3 . 3 . 2 Cyclization of tetraalaninol (Method C)
In order to reduce the rigidity of the open chain tetramer, tetraalanine was
reduced to tetraalaninol. To force tetraalaninol into a conformation suitable
for cyclization it was treated with a 1,2-dicarbonyl compound forming a pre-
organized bisaminal (see Scheme 13). This step was necessary to block all
the amines within the chain from performing side reactions. Upon bisaminal
formation several different regio and diastereoisomers are possible. Some
of them are probably less favoured due to steric effects induced by the four
methyl groups.
35 36
37a 37b
38b38a
36
36
Scheme 13: Formation of bisaminal 37a, 37b and 38a, 38b. Reaction conditions:
i.) LiAlH4 in THF, reflux, 16 h; ii.) DCM, 20-25  C; iii.) DCM, 20-25  C.
Among the tested 1,2-dicarbonyl compounds glyoxal, 1,2-butandion and
1,2-cyclohexadion, only glyoxal formed an intermediate that was detected by
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ESI-MS. For the other 1,2-dicarbonyl compounds the steric hindrance was
to large or the intermediate stability was to low prohibiting the formation of
any bisaminal species. NMR analysis of the glyoxal intermediate showed the
presence of multiple different species. The protons of the aldehyde did not
favour the formation of a single species as their size is to small to cause any
significant steric repulsion with the methyl groups. To close the bisaminal
intermediate two strategies were tried. A Mitsunobu-type ring closing and the
transformation of the hydroxy group to a bromide leaving group by Appel
reaction. Both reaction could not be performed successfully. We found no
evidence for the presence of a closed bisaminal species by ESI-MS. This
strategy was infeasible because the bisaminal key intermediates could not
be purified and decomposed upon further reaction. Any attempts with two
dimeric subunits (Method B) resulted in a complex mixture and were not
further investigated.
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3 . 4 . 1 Retrosynthetic analysis and considerations
The results previously obtained clearly revealed that a highly rigid tetramer
like tetraalanine (35) is not suitable for the large scale synthesis of 4(S)M4-
cyclen 22. However a highly flexible molecule like tetraalaninol (36) is also
not suitable due to the lack of a functional group to close the ring. We con-
cluded that for the successful cyclization of a linear tetramer it would be
best to use an amide coupling. The reaction velocities obtained by HATU
mediated peptide bond formations are remarkably high. On the other hand
the linear precursor needs to be flexible enough to allow the formation of
an intermediate conformer with both ends in close proximity. Therefore, we
investigated the cyclization properties of compound 39, that can be closed by
peptide coupling (see Figure 3.1).
39
Figure 3.1: Proposed flexible tetramer cyclization.
Compound 39 contains only one rigid peptide bond in contrast to the three
present in tetraalanine 35. Protecting groups are required for the non-terminal
amine groups to avoid the formation of smaller sized cycles during the final
peptide coupling step. Scheme 14 shows a retrosynthetic analysis for the
4(S)M4-cyclen synthesis based on a flexible alanine-based tetramer.
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Scheme 14: Retrosynthetic analysis for the synthesis of 4(S)M4-cyclen using a
flexible tetramer 39.
We envisioned that the desired target compound 22 can be obtained by
reduction and deprotection of the bislactam 40. The bislactam 40 could be
synthesised by an intramolecular peptide bond formation under diluted con-
ditions. The synthesis of the required alanine-based tetramer 39 could be ac-
complished in a convergent fashion starting from the alanine-based dimer 44
which itself could by prepared from commercially available alanine derivat-
ives 43 and 42.
3 . 4 . 2 Synthesis of alanine-based tetramers
We planned to synthesise the dimer 45 by nucleophilic substitution of an activ-
ated N-terminal protected alaninol derivative (see Scheme 15 ). Although the
installation of a tosyl and mesyl leaving group on N-Boc-protected alaninol
46 was possible, the subsequent nucleophilic substitution with tert-butyl-
protected alanine 25 resulted in very low yields and mostly decomposed
starting materials. It turned out that nucleophilic substitutions with protected
alanine derivatives require high temperature and long reaction times. This
conditions decomposed the reactive tosyl 47 and mesyl 48 N-Boc-protected
alaninol. The synthesis of the more reactive triflate 49 was not possible.
Considering these findings, we proposed a new strategy to synthesise a
suitable alanine-based dimer by nucleophilic ring opening of nosyl-protected
methyl aziridine. Although initially we wanted to avoid the usage of highly
toxic aziridines this strategy produced the required alanine-based dimer (52)
in medium yield. A benzyl moiety was chosen as protecting group for the
secondary amine (52) as it does not severely restrict the flexibility. This pro-
tection step was required to prevent side reactions from occurring during
further chain elongation steps. The proposed fully protected alanine-based
dimer (53) was synthesised in three steps in an overall yield of 30%. The
overall yield was low, however, all the required steps were scalable and in-
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Scheme 15: Synthesis of compound 45. Reaction conditions: i.) Ts-Cl, DCM,
20-25  C, 18 h; ii.) Mes-Cl, DCM, 0-5  C, 3 h.
volved relative inexpensive starting materials.
54 55 52 53
Scheme 16: Synthesis of compound 53. Reaction conditions: i.) NsCl, MeCN,
0-5  C, 2 h; ii.) DIPEA, 20-25  C, 30min; iii.) tert-butyl alanine 25, THF, 60  C,
18 h; iv.) BnBr, K2CO3, MeCN, 50  C, 18 h.
For further chain elongation two independent deprotection steps were de-
veloped (see Scheme 17). Under aqueous acidic conditions the tert-butyl ester
was hydrolysed in excellent yield. The deprotection of the nosyl protecting
group was carried out using either thiophenol or dodecanethiol. Dodecan-
thiol was preferred as it is far less malodorous and toxic which was essential
especially considering further large scale experiments. Deprotection was com-
pleted overnight, however, work-up was difficult, because the dodecanethiol
adduct and the free amine 56 could only be separated by an acid-base ex-
traction. Different acids (formic acids, hydrochloric acid) as well as different
acid concentrations were tested. Nevertheless, the yields remained moderate
and best results were obtained by performing a quick extraction with 1 M
hydrochloric acid. We were surprised to find that further peptide coupling
of the free amine 56 and the free acid 57 did not yield the expected alanine-
based tetramer 58. We found that upon reaction of HATU with the free acid
57 an intramolecular reaction forming the six membered ring 59 took place.
This finding was unexpected and in combination with the generally rather
moderate yields obtained for the synthesis of the precursors we were forced
to search for an alternative way.
We realized that nucleophilic substitution of an activated alaninol derivat-
ive with alanine derivatives generally resulted in low yields. Therefore, we
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Scheme 17: Attempted synthesis of compound 58. Reaction conditions: i.) Do-
decanthiol, K2CO3, MeCN, 50  C, 18 h; ii.) aq. 4 M HCl, MeCN, 50  C, 6 h.
envisioned to synthesise the alanine-based dimer by reductive amination of
N-Cbz-protected alanine aldehyde 60 with tert-butyl-protected alanine 25.
Reductive aminations are known to be very fast and high yielding. Although
there are various methods available to selectively reduce a carboxylic ester to
an aldehyde we thought it would be easier to selectively oxidise the corres-
ponding amino alcohol (see Scheme 18).
Starting from commercially available L-alaninol (54), Cbz protection was
carried out in high yields using a biphasic system. Purification of the product
was done by crystallization. Several oxidation conditions, including DMP,
Swern-oxidation and IBX were tested. It was found that best results were
obtained using IBX as oxidizing agent. Initial reactions were carried out in
DMSO at 20-25  C, however, final separation of the aldehyde 60 from DMSO
and the IBX by-products was difficult. Inspired by the results obtained by
More and Finney,114 ethyl acetate as solvent was used at reflux. The yield was
low and decomposition occurred due to the long reaction time needed for full
conversion. We found that the addition of 2 eq. of DMSO per equivalent IBX
dramatically increased the reaction rate. This might be due to the increased
solubility of IBX in DMSO compared to ethyl acetate. Reductive amination
of aldehyde 60 with tert-butyl alanine 25 was carried out in dichloromethane.
The muchmilder reducing agent, sodium triacetoxyborohydride, was superior
to sodium borohydride. Using sodium borohydride partially deprotected the
tert-butyl ester. Benzyl protection of 62 was achieved using benzylbromide
in acetonitrile with potassium carbonate in good yields. The desired alanine-
based dimer 63was synthesised in four steps with an excellent overall yield of
72%. tert-Butyl deprotection was carried out in hydrochloric acid and yielded
the free acid 64 in quantitative yield. Hydrochloric acid deprotection was pre-
ferred over trifluoroacetic acid due to the undesired formation of a trifluoro-
acetate salt which caused lower yields on the subsequent peptide coupling re-
action. Cbz deprotection was difficult. Experiments performed with Pd/C and
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Scheme 18: Synthesis of compound 66. Reaction conditions: i.) Cbz-Cl, Na2CO3,
H2O / EtOAc, 20-25  C, 1 h; ii.) IBX, DMSO, EtOAc, reflux, 3.5 h; iii.) tert-butyl
alanine 25, NaBH(OAc)3, DCM, 16 h; iv.) BnBr, K2CO3, MeCN, 50  C, 16 h; v.)
Pd/BaSO2, H2, 1 bar, MeOH, 20-25  C, 2 h; vi.) conc. HCl in 1,4-dioxane, 40  C,
18 h; vii.) HATU, DIPEA, MeCN, 20-25  C, 40min; viii.) HBr in acetic acid,
40  C, 30min.
H2 in methanol revealed that the Cbz protecting group as well as the benzyl
protecting group got cleaved off. Screening of different solvents (methanol,
ethanol, isopropanol, ethyl acetate and tetrahydrofuran) resulted in longer re-
action times but no improvements in selectivity. Therefore, different deactiv-
ated catalysts were tested. Lindlar’s catalyst showed no reactivity. We were
pleased to see that Rosenmund’s catalyst did deprotect the Cbz protecting
group within 2 h in methanol while keeping the benzyl group mostly unaf-
fected. Subsequent peptide bond formation between the free acid 64 and the
free amine 56 afforded the linear fully protected alanine-based tetramer 65 in
69% yield. In order to form the bislactam 67 both terminal protecting groups
need to be cleaved off. Due to the low acidic stability of the tert-butyl group
as well as the low stability of the Cbz protecting group towards strong acids
both protecting groups were simultaneously removed using hydrogen brom-
ide solution in acetic acid. Although these procedure was highly convenient
and avoided a second hydrogenation, special care had to be taken in order to
remove acetic acid from the final product 66. Acetic acid was removed by a
repeated sequence of dissolving the product in a mixture of acetonitrile and
hydrochloric acid and evaporation to dryness. In addition extensive drying for
several days under vacuum at 40  C was required.
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3 . 4 . 3 Synthesis of alanine-based twelve-membered macrocycles
Formation of the bislactam was performed under moderate dilution (1 g L−1)
in acetonitrile and DIPEA using HATU as coupling reagent (see Scheme 19).
We were very surprised to find that this reaction is extremely fast and com-
pletion was achieved within five minutes. We found no evidence for the form-
ation of a 32-membered macrocycle or other polymers. The only by-product
detected was the N-acetylated alanine-based tetramer arising from an insuf-
ficient acetic acid removal. Starting from the fully protected alanine-based
tetramer 65, the deprotection and cyclization was done in an astonishing yield
of 81%. The final two steps, deprotection and reduction, could be performed
in any order. However, we observed that reduction prior to deprotection is
favourable. Isolation of dibenzyl-protected cyclen 68 after the reduction was
more efficient and required less solvent. We found that 4(S)M4-cyclen 22
adsorbs exceptionally strong to the lithium and aluminium salts arising from
the quenching of the reduction forming sparingly soluble aluminium cyclen
salts. Quantitative extraction of 4(S)M4-cyclen 22 from these salts required
extensive washing and was not always succesfull. Applying standard reduc-
tion conditions (lithium aluminium hydride in tetrahydrofuran) to reduce
the bislactam resulted in low yields and partial debenzylation was observed.
Using a trimethylsilyl mediated reduction with lithium aluminium hydride in
dichloromethane at 20-25  C afforded the dibenzyl protected 4(S)M4-cyclen
22 in high yields. This compound itself is a highly useful intermediated for
further lanthanide chelating tag synthesis because selective trans protection is
difficult to achieve starting from 4(S)M4-cyclen 22. Final deprotection of the
benzyl groups was achieved using the procedure described by Ranganathan
et al.106 for the tetrabenzylated 4(S)M4-cyclen or by catalytic hydrogenation
under high pressure. Although this reaction sequence was preferred due to
the above mentioned issues with the isolation of 4(S)M4-cyclen 22 from the
reduction and the formation of the valuable trans benzyl-protected 4(S)M4-
cyclen 68, performing the debenzylation first followed by the reduction was
possible and sometimes even higher overall yields were achieved. However,
the reduction of bislactam 67 to 4(S)M4-cyclen 22 was poorly reproducible.
Although the conversion was always comparable the isolated yield varied
between 25-90%. This poor reproducibility was not encounter in the reduc-
tion - debenzlyation sequence and, therefore, this sequence was considered
for up scaling. Overall the target compound 22 could be synthesised in 27%
overall yield. We also grew crystals of 4(S)M4-cyclen 22 suitable for X-ray
analysis (see Figure 3.2).
3 . 4 . 4 Development of a large scale synthesis for alanine-based tetramers
Up scaling of the first four steps (see Scheme 18) resulting in the fully pro-
tected dimer 63 was possible on multigram scales. The acidic deprotection
forming the free acid 70 could also be achieved in high yields on large scales.
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Scheme 19: Synthesis of compound 22. Reaction conditions: i.) HATU, DIPEA,
MeCN, 20-25  C, 20min; ii.) TMS-Cl, LiAlH4, DCM, 0-5  C to 20-25  C, 3 h;
iii.) ammonium formate, Pd(OH)2/C, EtOH, reflux, 16 h; iv.) Pd/C, H2, 45 bar,
acetic acid, 20-25  C, 16 h; v.) TMS-Cl, LiAlH4, DCM, 0-5  C to 20-25  C, 3 h.
Figure 3.2: X-Ray structure of compound 22⇤2H2O ⇤2HCl, the ellipsoids repres-
ent the 50% probability level. The bond lengths and angles are within normal
ranges.
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However, the deprotection of the Cbz protecting group using Rosenmund’s
catalyst was not scalable. Several small scale reactions showed a poor repro-
ducibility. We observed that only slight deviations from the optimal reaction
time lead to a large over deprotection. Several different solvents and temper-
atures were screened and the reaction progress monitored by ESI-MS and
NMR. It was not possible using an identical setup to obtain an identical re-
action time. This might be attributed to the inhomogeneous inactive catalyst
used. It was observed that the time required for the catalyst to turn active
(brown to black color change) was always slightly different varying a few
minutes. Addition of the substrate after catalyst activation was tried but no
reproducibility was observed. After extensive screening we found no condi-
tions for a selective hydrogenation on large scale. Therefore, an alternative
synthetic route towards the alanine-based tetramer 66 was needed. Neverthe-
less, the achieved high yields, during cyclization of the alanine-based tetramer
66 was remarkable an proved our initial strategy to be correct.
3 . 4 . 5 Alternative synthesis for alanine-based tetramers
Retrosynthetic analysis and considerations
Trying to avoid the Cbz deprotection step in the previous synthesis (see
Scheme 18). We envisioned the synthesis of the alanine-based tetramer 66
could be accomplished by two selective reductive aminations and a final
benzyl protection step (see Scheme 20). This alternative approach lacks the
convergent nature of the previous one. The synthesis of N-Cbz-alaninal (60)
as well as all reductive amination steps could be carried out accordingly. This
approach is based on the synthesis of the middle part 71 followed by the
extension on the C-terminus and the N-terminus. The introduction of the
benzyl group could be done on the late alanine-based tetramer stage. The
middle block of the alanine-based tetramer could be obtained by coupling N-
Cbz-alanine (72) with L-alaninol (54) followed by an oxidation of the alcohol
73. A second alternative would be the introduction of the protected aldehyde
74 followed by a selective deprotection.
Synthesis of alanine-based tetramer
Cbz-protected alaninal 60 was treated with trimethyl orthoformate forming
the dimethyl acetal 77 in high yield (see Scheme 21). The Cbz deprotection
was carried out using Pd/C and H2 in methanol with moderate yield. The
volatile nature of the free amine 74 caused the loss of product during work-
up. The final peptide coupling was successfully performed using T3P. The
liberation of the aldehyde 71 by acidic hydrolysis of the dimethyl acetal 78
was not possible. The acteal 78 was highly stable under most acidic condi-
tions and only got cleaved in pure trifluoroacetic acid forming the enol 79.
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Scheme 20: Retrosynthetic analysis for the alternative synthesis of the flexible
tetramer 66.
60 77
71
79
74 24
78
Scheme 21: Attempted synthesis of 71. Reaction conditions: i.) trimethyl ortho-
formate, MeOH, 20-25  C, 18 h; ii.) Pd/C, H2, 1 bar, MeOH, 20-25  C, 6 h; iii.)
T3P, DIPEA, EtOAc, 20-25  C, 18 h.
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Unable to deprotect the dimethyl acetal 78 under milder conditions, the re-
quired aldehyde 71 was synthesised by oxidation of the corresponding amino
alcohol 73 (see Scheme 22). Direct coupling of N-Cbz-alanine (72) with L-
alaninol (54) was possible using HATU and DIPEA in acetonitrile. However,
purification was very difficult and resulted in low yields. Using T3P did not
result in the formation of amino alcohol 73. A very convenient way, using so-
dium borohydride in tetrahydrofuran, methanol and water, to reduce dialanine
methylester 80 to the coresponding alcohol 73 was described by Heidelberg
and Martin.115 Dialanine methylester 80 was synthesised by a HATU medi-
ated peptide coupling in excellent yields but the cumbersome purification on
large scale rendered this reagent unattractive. On the other hand using T3P res-
ulted in lower yields but isolation of the pure product was achieved without
flash column chromatography using solely aqueous extractions to remove any
by-products. The dipetide 80 was reduced using the procedure described by
Heidelberg and Martin115 in 84%. Further oxidation was achieved in 92%
using an adapted procedure of the N-Cbz-alaninal (60) oxidation. Due to the
low solubility of the starting material in ethyl acetate, acetonitrile was used
instead. In acetonitrile the reaction could be performed without the addition
of DMSO. The procedure developed for the reductive amination was applied
for the formation of the Cbz-protected alanine-based trimer 81. Further de-
protection resulted in the alanine-based trimer 76 and reductive amination
yielded the protected alanine-based tetramer 82 in good yields. Final benzyl
protection was achieved using the same conditions already developed for the
fully protected alanine-based dimer 63. Using this second approach yielded
the fully protected alanine-based tetramer in 36% overall yield which was
slightly lower than the yield obtained for the first approach (40%). Neverthe-
less, no catalytic hydrogenation was needed.
Development of a large scale synthesis for alanine-based tetramers
The T3P mediated peptide coupling and the sodium borohydride reduction
were easily scaled up to multigram scales. The IBX oxidation performed
comparable to the large scale synthesis of N-Cbz-alaninal (60) and so did
the subsequent reductive amination. The Cbz deprotection, however, was
incomplete even after several hours under a hydrogen atmosphere. Addi-
tional Pd/C as well as applying high hydrogen pressure did not significantly
increase the conversion. Presumably small contaminations carried through
from the IBX oxidation deactivated the catalyst after a short period of time.
This impurity were most likely less pronounced in the small scale. In order
to use this procedure on larger scales the intermediate aldehyde 84 should be
purified by flash column chromatography prior to reductive amination. This
procedure was not suitable for large scale synthesis. Nevertheless, it allows
interesting opportunities for the synthesis of selectively labelled 13C marked
compounds. The formation of an alanine-based trimer followed by the last
reductive amination allows the introduction of a labelled compound at the
latest state possible. Purifying the alanine-based trimer 81 would ensure that
losses of expensive labelled material can be minimized. This strategy was
3.4 HEAD-TO -TA IL IN SOLUT ION CYCL IZAT ION OF FLEX IBLE
ALAN INE -BASED TETRAMERS
45
24 83 80 73
712581
76 60 75
65
Scheme 22: Synthesis of compound 65. Reaction conditions: i.) T3P, DIPEA,
EtOAc, 20-25  C, 18 h; ii.) NaBH4, H2O, MeOH, THF, 20-25  C, 18 h; iii.)
IBX, MeCN, 80  C, 4 h; iv.) NaBH(OAc)3, DCM, 20-25  C, 4 h; v.) Pd/C, H2,
1 bar, MeOH, 20-25  C, 6 h; vi.) NaBH(OAc)3, DCM, 20-25  C, 16 h; vii.) BnBr,
K2CO3, MeCN, 40  C, 18 h.
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successfully applied by Raphael Vogel during his master thesis within our
group to synthesise 4(S)M4-cyclen with one methyl group selectively 13C
labelled.116
3 . 4 . 6 Alternative protecting groups
Retrosynthetic analysis and considerations
Inspired by the findings presented by Kanai et al.117 we envisioned that repla-
cing the benzyl group with a fluoro benzyl group would increase the stability
and therefore a selective hydrogenation would be possible. The rest of the
synthesis could then be performed accordingly to the procedures already de-
veloped for the benzyl derivatives.
Synthesis of alanine-based tetramers
Starting from the alanine-based dimer 62 which was obtained as described
previously the introduction of the fluorobenzyl group was achieved in com-
parable yields using fluorobenzyl bromide instead of benzyl bromide (see
Scheme 23). The tert-butyl deprotection of 85 was performed as for its
benzyl analogue. The Cbz deprotection was surprisingly still time sensitive.
Deprotection reactions using Rosenmund’s catalyst were also badly repro-
ducible. In search for a better reproducible method transferhydrogenation
with ammonium formate, cyclohexene and 1,4-cyclohexadiene were tested.
This method allowed for a more specific control over the amount of reducing
agent. Various reaction screenings were performed and best conditions were
found using Pd/C and ammonium formate in ethanol at 50  C. Cyclohexene
and 1,4-cyclohexadiene did not react. We found that heating the reaction for
15min before the addition of substrate ensures the activation of the catalyst
and thus creating a more reproducible setting. It was key to slow down the
reaction to such a rate that careful monitoring by HPLC was possible. This
required the overreaction to be slow enough such that 10min prolonged re-
action time does not deprotect a significant amount of the desired product.
To minimize the risk of product loss due to overreaction the deprotection
was carried out in small batches of 7.5 g maximum. The peptide coupling
forming the alanine-based tetramer 86 was performed in moderate yield. The
free acid 87 and the free amine 88 could not be purified by flash column
chromatography or crystallization and were used without further purification.
This and small amounts of overdeprotection caused the yield to drop to 55%
after flash column chromatography of the alanine-based fully protected tetra-
mer 86. Final deprotection was carried out analogously to the deprotection of
the fully benzyl protected tetramer 89. Although the Cbz deprotection of the
alanine-based dimer 85 remained critical it was possible to synthesise large
quantities of the alanine-based tetramer 90.
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Scheme 23: Synthesis of compound 90. Reaction conditions: i.) Cbz-Cl, Na2CO3,
H2O / EtOAc, 20-25  C, 1 h; ii.) IBX, DMSO, EtOAc, reflux, 3.5 h; iii.) tert-butyl
alanine 25, NaBH(OAc)3, DCM, 16 h; iv.) FBnBr, K2CO3, MeCN, 45  C, 16 h;
v.) Pd/C, ammonium formate, EtOH, 50  C, 1 h; vi.) conc. HCl in 1,4-dioxane, 20-
25  C, 2 h; vii.) HATU, DIPEA, 20-25  C, 16 h; viii.) HBr in acetic acid, 40  C,
30min.
Synthesis of alanine-based twelve-membered macrocycles
For the cyclization the same conditions were applied as for the benzyl ana-
logue (see Scheme 24). We found that above a two litre scale reaction, mean-
ing two gram of the alanine-based tetramer in two litre of acetonitrile the
cyclization efficiency dropped significantly. This finding is most like attrib-
uted to the lower stirring efficiency in larger flasks. It turned out to be highly
critical that the alanine-based tetramer 90 was completely dissolved and ho-
mogeneously distributed before the addition of the coupling reagent. We also
found that slow addition of the coupling reagent is not favourable. Best results
were obtained by dissolving the alanine-based tetramer 90 in acetonitirile and
DIPEA followed by the addition of HATU in one portion. The same proced-
ure as for the reduction and the debenzylation of the dibenzylated bislactam
67 was applied. Surprisingly we found that the difluorobenzyl-protected
4(S)M4-cyclen 91 could not be deprotected by transferhydrogenation. Even
under high pressure using Pd/C and H2 in acetic acid at elevated temperat-
ures the protecting group could not be removed. However, it was possible
to remove the fluorobenzyl protecting groups from the difluorobenzylated
bislactam 92. This lead to the same inconveniences as described above for
the isolation of 4(S)M4-cyclen 22 after the reduction. The unavailability of
a trans protected 4(S)M4-cyclen derivative could be tolerated as it was not
the primary goal of this study. Nevertheless, we found that the benzyl protect-
ing group could be reinstalled after the deprotection allowing the usage of
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the already developed reduction - deprotection sequence. The slightly lower
yields during peptide coupling and the fluorobenzyl protecting reaction as
well as the additional two steps dropped the overall yield to 11%.
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Scheme 24: Synthesis of compound 22. Reaction conditions: i.) HATU, DIPEA,
MeCN, 20-25  C, 20min; ii.) TMS-Cl, LiAlH4, DCM, 0-5  C to 20-25  C, 3 h;
iii.) Pd/C, H2, 45 bar, acetic acid, 20-25  C, 16 h; iv.) TMS-Cl, LiAlH4, DCM, 0-
5  C to 20-25  C, 3 h; v.) BnBr, K2CO3, MeCN, 55  C, 16 h; vi.) Pd/C, H2, 45 bar,
acetic acid, 20-25  C, 16 h; vii.) TMS-Cl, LiAlH4, DCM, 0-5  C to 20-25  C, 3 h;
viii.) ammonium formate, Pd(OH)2/C, EtOH, reflux, 16 h.
Synthesis of mixed alanine-based twelve-membered macrocycles
Unfortunately the synthesis of the alanine-based tetramer 65 was not possible
on large scale due to the problems encountered in deprotecting the Cbz pro-
tecting group. However, large quantities of the alanine-based dimer 63 were
already prepared. Using the free amine 88 from the fluorobenzyl route and
the free acid 64 from the benzyl route the mixed fully protected alanine-based
tetramer 93 was synthesised (see Scheme 25). Following the same proced-
ures as for the other alanine-based tetramers 66 and 90 the mixed protected
bislactam 94 was synthesised. We found that the benzyl protecting group can
be selectively removed in the presence of the fluorobenzyl protecting group
using milder hydrogenation conditions. Replacing acetic acid with methanol
and using a hydrogen pressure of one bar the benzyl protecting group was
selectively removed. This could potentially be used for further selective modi-
fications. However, during this study there was no need for such an additional
functionalization. Therefore, complete deprotection was performed in acetic
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acid with Pd/C under high hydrogen pressure. After the deprotection of both
protecting groups the bislactam 69 was obtained which was further used as
described previously.
64 88 93
959469
Scheme 25: Synthesis of compound 69. Reaction conditions: i.) HATU, DIPEA,
MeCN, 20-25  C, 16 h; ii.) HBr in acetic acid, 40  C, 30min, 30min; iii.) HATU,
DIPEA, MeCN, 20-25  C, 20min; Pd/C, H2, 45 bar, acetic acid, 20-25  C, 16 h.

4
SYNTHES I S OF NEW SUBST ITUTED CYCLEN
DER IVAT IVES
Work described in this chapter has been partially performed in collaboration
with Fabienne Thommen during her master thesis within our group and is also
described in her master thesis.118 We investigated the scope and applicability
of the synthetic strategies developed for 4(S)M4-cyclen 22 in order to syn-
thesize a more rigid cyclen derivative. The larger substituents could have an
influence not only on the D / L ratio but also on the observed tensor paramet-
ers. The coordination geometry becomes more asymmetric and thus could
improve the observed PCSs.
4 . 1 SYNTHES I S OF 4(S) M2P2 -CYCLEN
4 . 1 . 1 Retrosynthetic analysis and considerations
Using the same procedure as described for the synthesis of 4(S)M4-cyclen 22
we envisioned that 4(S)M2P2-cyclen 96 could be made out of the bislactam
97 (see Scheme 26). The bislactam 97 could be synthesised from the linear
alanine / valine-based tetramer 98. Reductive amination of N-Cbz-alaninal 60
and tert-butyl valine 99 followed by a benzyl protection step would yield the
alanine / valine-based dimer 100. We encountered no problems during tert-
butyl deprotection steps in the 4(S)M4-cyclen synthesis. Similar conditions
could be applicable for the alanine / valine-based dimer 100. We proposed
that Cbz deprotection of the alanine / valine-based dimer 100 results in a
higher selectivity due to the higher steric hindrance caused by the isopropyl
group. This would avoid the introduction of the more stable fluorobenzyl pro-
tecting group. In principle it would also be possible to synthesise the amino
aldehyde of Cbz-valinol and performing a reductive amination with tert-butyl
alanine 25. However this would result in a dimer having the Cbz protecting
group close to the isopropyl group and the labile benzyl group would be next
to the alanine methyl group. We thought this configuration is potentially even
more problematic as the Cbz group is sterically more shielded and thus less
reactive.
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Scheme 26: Retrosynthetic analysis for the synthesis of 4(S)M2P2-cyclen 96.
4 . 1 . 2 Synthesis of alanine / valine -based tetramers
Starting from N-Cbz-alaninal 60 a reductive amination with tert-butyl valine
was performed in good yield (see Scheme 27). Subsequent benzyl protection
was slower and longer reaction times were needed to achieve a comparable
conversion. We attributed this to the larger steric hindrance induced by the
isopropyl substituent. We found that the selective tert-butyl deprotection
could be carried out analogously with comparable yield. We were delighted
to find that the Cbz deprotection could be carried out using Pd/BaSO4 and
H2 at 20-25  C. The benzyl protecting group was much more stable towards
catalytic hydrogenolysis and was mostly unaffected. Presumably the size
difference between methyl and isopropyl caused the higher selectivity. The
coupling of the free amine 101 and the free acid 102 was achieved using
HATU and DIPEA in acetonitrile. The final deprotection step was carried
out using hydrogen bromide solution in acetic acid. Although the findings
obtained for the Cbz deprotection of the alanine / valine based dimer 100
suggested that it would be possible to do this final deprotection in two steps
the one step procedure was preferred.
4 . 1 . 3 Synthesis of alanine / valine -based twelve-membered macrocycles
We were pleased to find that although the steric crowding of the alanine /
valine-based tetramer 105 is increased a cyclization took place (see Scheme
28). The HATU mediated cyclization of the alanine / valine-based tetramer
105 formed the bislactam 97 in good yields of up to 59% starting from the
fully protected alanine / valine-based tetramer 106. The yields were lower
than those obtained for the methyl analogue. The reduction of the protected
bislactam 97 to the trans dibenzylated 4(S)M2P2-cyclen 107 showed no
significant influence of the two isopropyl groups. The final transferhydrogen-
ation afforded 4(S)M2P2-cyclen 96 in excellent yields. The target compound
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Scheme 27: Synthesis of compound 98. Reaction conditions: i.) Cbz-Cl, Na2CO3,
H2O / EtOAc, 20-25  C, 1 h; ii.) IBX, DMSO, EtOAc, reflux, 3.5 h; iii.) tert-butyl
alanine 25, NaBH(OAc)3, DCM, 16 h; iv.) BnBr, K2CO3, MeCN, 65  C, 2 d; v.)
Pd/BaSO4, H2, 1 bar, MeOH, 20-25  C, 2 h; vi.) conc. HCl in 1,4-dioxane, 40  C,
16 h; vii.) HATU, DIPEA, MeCN, 20-25  C, 20min; viii.) HBr in acetic acid,
40  C, 30min.
could be synthesised in an overall yield of 23%. This is slightly less than
the yield we observed for the initial synthesis of 4(S)M4-cyclen 22 on small
scales, however, still larger than the overall yield obtained for the fluorobenzyl
based route. The lower yield predominantly originated from the lower yields
achieved during the cyclization. We also grew crystals of 4(S)M2P2-cyclen
96 suitable for X-ray analysis (see Figure 3.2).
4 . 2 SYNTHES I S OF 3(S) 1(R) M301 -CYCLEN
Driven by the success in synthesising 4(S)M2P2-cyclen 96 and 4(S)M4-
cyclen 22 we extended the scope of the methodology to an amino acid con-
taining a functional group on the side chain. Introducing a functional group
to one of the substituents would offer interesting possibilities for further
functionalization. It would allow the installation of a cysteine-reactive linker
moiety on the cyclen core which could offer a different tagging geometry.
There is so far no cyclen based lanthanide chelating tag known in literature
with a linker installed on the base cyclen ring.
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Scheme 28: Synthesis of compound 96. Reaction conditions: i.) HATU, DIPEA,
MeCN, 20-25  C, 20min; ii.) TMS-Cl, LiAlH4, DCM, 0-5  C to 20-25  C, 3 h;
iii.) ammonium formate, Pd/C, EtOH, reflux, 16 h.
Figure 4.1: X-Ray structure of compound 96, the ellipsoids represent the 50%
probability level. The bond lengths and angles are within normal ranges.
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4 . 2 . 1 Retrosynthetic analysis and considerations
In order to ensure that all substituents direct in the same direction we planned
to synthesise 3(S)1(R)M301-cyclen 108. Although on of the configurations
is (R) in the final product, topologically the starting materials can still be
based on the natural amino acids. The priority of the different substituents
changes during the course of the synthesis causing an initially (S) configured
substituent to be (R) configured in the final product.
The synthesis of the C2 symmetric 4(S)M2P2-cyclen 96 had lower yields
than the original 4(S)M4-cyclen 22 synthesis. We envisioned that one methyl
group could be replaced by a hydroxy methyl group if a protected serine
derivative is used (see Scheme 29). The synthesis of the alanine / serine-
based tetramer 109 could start from the already developed free acid 64 and
the free amine 110. For the synthesis of the free amine 110 the same pro-
cedure should be applicable as for the free amine 101 used for the synthesis
of 4(S)M2P2-cyclen 96. We proposed that the large steric bulkiness of the
hydroxy tert-butyl group has the same influence than the isopropyl group on
the selectivity of the hydrogenation. Deprotection of the hydroxy tert-butyl
group was anticipated during the final hydrogen bromide deprotection step.
However, acetylation of the free hydroxy group might occur under strongly
acidic conditions in acetic acid. Reduction of the protected bislactam 111
would also reduce the acetyl protecting group to the corresponding alcohol.
Final deprotection could be achieved using transferhydrogenation conditions.
108 111 112
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Scheme 29: Retrosynthetic analysis for the synthesis of 3(S)1(R)M301-cyclen
108.
56 SYNTHES I S OF NEW SUBST ITUTED CYCLEN DER IVAT IVES
4 . 2 . 2 Synthesis of alanine / serine -based tetramers
The synthesis of N-Cbz-alaninal 60 was performed as described previously.
The aldehyde 60 was further reacted with tert-butyl-protected serine 113
yielding the dimer 114 in excellent yield. The installation of the benzyl pro-
tecting group was more challenging due to the increased steric hindrance
and required longer reaction times. The subsequent Cbz deprotection worked
well showing that the increased size difference between the methyl group and
the hydroxy tert-butyl group is responsible for the better selectivity achieved
during hydrogenation. The free amine 110 and the free acid 115were coupled
in high yields resulting in the fully protected alanine / serine-based tetramer
116. Final acidic deprotection with hydrogen bromide in acetic acid afforded
the free alanine / serine-based tetramer 117. To our delight we observed that
the hydroxy tert-butyl group indeed got cleaved off and in-situ replaced by
an acetyl protecting group. This protecting group is less bulky and protects
the alcohol functionality from side reactions during the cyclization.
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Scheme 30: Synthesis of compound 112. Reaction conditions: i.) Cbz-Cl,
Na2CO3, H2O / EtOAc, 20-25  C, 1 h; ii.) IBX, DMSO, EtOAc, reflux, 3.5 h; iii.)
tert-butyl O-tert-butyl serine 113, NaBH(OAc)3, DCM, 16 h; iv.) BnBr, K2CO3,
MeCN, 65  C, 2 d; v.) Pd/BaSO4, H2, 1 bar,MeOH, 20-25  C, 24 h; vi.) conc. HCl
in 1,4-dioxane, 40  C, 16 h; vii.) HATU, DIPEA,MeCN, 20-25  C, 2 h; viii.) HBr
in acetic acid, 40  C, 30min.
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4 . 2 . 3 Synthesis of alanine / serine -based twelve-membered macrocycles
The cyclization of the free alanine / serine-based tetramer 117 was accom-
plished analogously to the already established protocol. We found that the
yields were lower than those observed for the other cyclizations. However,
after purification of the protected bislactam 111 the final reduction and depro-
tection step proceeded with comparable yields. As a convenient side effect
during the reduction of the protected bislactam 111 the acetyl protecting
group was removed as well. The desired macrocycle could be obtained in an
overall yield of 17%. The lower yield can be mostly attributed to the less
efficient cyclization compared to 4(S)M4-cyclen 22 and 4(S)M2P2-cyclen
96. We also grew crystals of 3(S)1(R)M301-cyclen 108 suitable for X-ray
analysis (see Figure 4.2).
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Scheme 31: Synthesis of compound 108. Reaction conditions: i.) HATU,DIPEA,
MeCN, 20-25  C, 1 h; ii.) TMS-Cl, LiAlH4, DCM, 0-5  C to 20-25  C, 24 h; iii.)
Pd/C, H2, 90 bar, 20-25  C, 17 h.
4 . 3 RACEMIZAT ION STUDY OF N - CBZ -ALAN INAL
During the synthesis of 4(S)M2P2-cyclen 96 we observed the presence of
multiple species in the proton NMR spectra of most linear precursors (e. g.
100 and 104) which were less pronounced for the 4(S)M4-cyclen 22 synthesis.
Initially we attributed these signals to the presence of different conformers.
Those signals were most clearly visible in the proton spectrum of the alanine
/ valine-based dimer 100. We assumed conformational dynamics as well as
cis-trans isomerization of the amide bond to be the reason for these signals.
We performed variable temperature NMR analysis of the fully protected alan-
ine / valine-based dimer 100 and we found evidence for a dynamical process
arising from the isomerization of the carbamate (see Figure 4.3).
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Figure 4.2: X-Ray structure of compound 108 ⇤H2O ⇤HCl, the ellipsoids repres-
ent the 50% probability level. The bond lengths and angles are within normal
ranges.
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Figure 4.3: Variable temperature 1H-NMR spectroscopy for 100: Spectra were
recorded in DMSO d6 from 298-378K. The region of the benzylic Cbz protons
is shown.
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Nevertheless, not all signals present in the room temperature proton NMR
spectrum could be explained by this dynamics. Therefore, we suspected the
other signals might arise from undesired diastereoisomers. The most likely
source of racemization was the oxidation of N-Cbz-alaninol 61 to N-Cbz-
alaninal 60. Amino aldehydes are known to be susceptible to racemization.119
For further clarification we synthesised the undesired diastereoisomer 120
from commercially available N-(D)-Cbz-protected alaninol 121 (see Scheme
32).
121 122 123
120
Scheme 32: Synthesis of compound 120. Reaction conditions: i.) IBX, DMSO,
EtOAc, reflux, 3.5 h; ii.) tert-butyl alanine 25, NaBH(OAc)3, DCM, 16 h; iii.)
BnBr, K2CO3, MeCN, 65  C, 18 h
Comparison of the proton NMR shifts for the non-benzylated alanine /
valine-based dimers 103 and 123 showed little to no difference. However for
the benzylated alanine / valine-based dimers 100 and 120 the difference was
clearly visible (see Figure 4.4). We found that during the IBX oxidation of
N-Cbz-alaninol 61 to N-Cbz-alaninal 60 racemization occurred. We further
investigated this issue and found that racemization occurs during the oxida-
tion step and not during the following work up. We determined the extend of
racemization to be around 10-15% in all experiments performed using the
IBX oxidation in ethyl acetate.
Close inspection of the NMR data obtained for the alanine-based dimers
and the alanine-based tetramers synthesised during the 4(S)M4-cyclen 22
synthesis also suggested the presence of undesired diastereoisomers. Al-
though, racemization occurred during the first oxidation step we found that
the percentage of undesired diastereoisomers gradually decreases. We found
that after the cyclization the undesired diastereoisomers were reduced to
less than 5% in the case of the 4(S)M4-cyclen 22 and 4(S)M2P2-cyclen
96 syntheses. We hypothesized that the ability to cyclize is decreased for
a compound having the wrong overall stereochemistry. The final products
were obtained with less than 2% of the undesired diastereoisomers. In the
case of 3(S)1(R)M301-cyclen 124 the undesired diastereoisomers were not
sufficiently removed during the subsequent reaction steps. Due to the lack of
a purification method for 3(S)1(R)M301-cyclen the final product contained
60 SYNTHES I S OF NEW SUBST ITUTED CYCLEN DER IVAT IVES
Figure 4.4: Comparison between the proton NMR spectrum for 120 (top) and
100 (bottom) in DMSO d6 at 298K.
roughly 5-10% of other diastereoisomers.
Surprisingly, we found that the (R)(S)alanine / valine-based dimer 120
was a highly crystalline solid which could be easily crystallized exceeding
an ee of 99%. On the other hand we did not find a crystallization method
for the desired (S)(S)alanine / valine-based dimer 100. The compound was
always obtained as an oil. We suspect that this behaviour is likely true for
most closely related dimers. This offers the possibility to enrich enantio-
meric excess after the fourth step using simple crystallization techniques.
Using a (R)(S)dimer would ultimately end in the formation of a macrocycle
with alternating stereochemistry. If such a compound could be cyclized and
further used to synthesise a functional tag was beyond the scope of this thesis.
5
CONCLUS ION & OUTLOOK
5 . 1 CONCLUS ION
A new synthesis for 4(S)M4-cyclen 22 was successfully developed starting
from commercially available alanine-based precursors. Inducing cyclization
on solid phase with tetraalanine was challenging and only successful in small
scales up to 20mg. Cyclization of tetraalanine in solution resulted in even
lower yields. The steric hindrance and the preferred trans configuration of the
peptide were the key reasons for the low obtained yields. This process was
not scalable to multigram scales due to the high cost of materials and the low
cyclization yield. Using the much more flexible tetraalaninol analogue was
unsuccessful as no method could be developed to selectively close the ring.
The three secondary amines needed protection and the C-terminal hydroxy
group could not be converted into a good leaving group that would allow
intramolecular ring closure. This findings were the key to the development of
a mixed alanine / alaninol tetramer which allowed an intramolecular peptide
bond formation in high yields under diluted conditions. The benzyl protected
alanine-based tetramer was the key intermediate that allowed high cyclization
yields.
The synthesis of this key intermediate proved to be challenging as two
different approaches developed on small scales failed in up scaling. The low
selectivity obtained during the Cbz deprotection of the alanine-based dimer
63 forced us to replace the benzyl group with the much more stable fluoroben-
zyl group. However, this introduced deprotection problems on the later stages.
The fluorobenzyl group offered higher stability towards the Cbz-deprotection
conditions, nevertheless, it was not completely inert and up scaling remained
challenging. Over the course of the development of the synthesis more than
two grams of the desired 4(S)M4-cyclen 22 were synthesised. The synthesis
of 4(S)M4-cyclen 22 initially developed by Ranganathan et al.106 is much
shorter and remains an alternative. The new developed approaches on the
other hand do not rely on a random cyclization and can therefore be used
for the rational synthesis of various differently substituted twelve-membered
tetraaza macrocycles. The synthesis was successfully adopted to synthesise
4(S)M2P2-cyclen 96 and 3(S)1(R)M301-cyclen 124. The larger substituents
reduced the yield obtained during the formation of the bislactam. In principal
most natural amino acids could be used, however, special attention has to be
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paid on the stability of the intermediate amino aldehyde especially towards
racemization. Also the strongly acidic conditions used to deprotect the fully
protected tetramers are problematic for acid labile substituents. Due to the
general strategy of forming a bislactam any substituent carrying a reducible
functional group (carboxylic acid, carboxylic amide, etc.) will suffer trans-
formation during the reduction step.
5 . 2 OUTLOOK
One critical step during the synthesis of 4(S)M4-cyclen 22 is the formation
of the free amine 56. Further investigation towards an alternative protecting
scheme should be taken. Although the fluorobenzyl protecting group dramat-
ically reduces the problem, avoiding it is preferred. The introduction of a
third orthogonal protecting group would be advisable. The synthesis for the
free acid 64 could still be done using the Cbz protected alanine-based dimer
63. The convergent nature of the first approach would be lost, however, the
obtained fully protected alanine-based tetramer would be identical. Further
optimization should also address the oxidation of the amino alcohol 61 to the
amino aldehyde 60. A oxidation procedure without racemization is definitely
desirable. Although, the undesired diastereomers were removed during the
later steps they significantly reduce the overall yield. Optimization of the re-
action conditions are still desirable as most of the linear precursor turned out
to be non crystalline and therefore no crystallization can be performed. Flash
column chromatography on large scale is expensive and time consuming and
thus should be avoided as much as possible.
Part II
SYNTHES I S OF REDUCT IVLY STABLE L INKERS
FOR PCS NMR SPECTROSCOPY
This chapter deals with the development and application of new
reductivly stable lanthanide chelating tags for PCS NMR spec-
troscopy.

6
SYNTHES I S AND APPL ICAT ION OF M7PY-DOTA
Part of this work was conducted in collaboration with Dr. Francois-Xavier
Theillet and Dr. Philipp Selenko and has been published.83
6 . 1 RETROSYNTHET IC ANALYS I S AND CONS IDERAT IONS
To address the inherent problem of the instability of the disulfide bond to-
wards strongly reductive environments as they are encountered in cells we
suggested the formation of a thioether linkage. Results published by Yang et
al.84 showed that the formation of a thioether is possible via a nucleophilic
aromatic substitution on a pyridine phenyl sulfone moiety. Work previously
conducted in our group by Dr. Heiko Gsellinger, published in his doctoral
thesis,120 showed that introducing an aliphatic cysteine reactive functional
group like an alpha bromo keton or an alpha beta unsaturated keton is very dif-
ficult. We envisioned that introducing a pyridine phenyl sulfone could solve
several problems encountered during the synthesis of alpha bromo ketons due
to the higher stability towards acidic hydrolysis and simpler reaction steps.
We proposed that one of the coordinating lactic acid side arms in the ori-
ginal M8-SSPy-DOTA102 tag could be replaced by the pyridine moiety (see
Scheme 33). Taking advantage of not only forming a shorter linker but also
of introducing a different donor atom. The proposed synthesis for the new
linker starts from bromo methyl pyridine 125 and thiophenol 126 followed by
an oxidation to the sulfone 127. Free radical bromination should deliver the
desired alpha bromo methyl pyridine 128 which could undergo nucleophilic
substitution with three times lactic acid tert-butyl ester (LacOtBu) alkylated
M4-cyclen 129. Final acidic hydrolysis and metallations could form the de-
sired tags 130.
6 . 2 SYNTHES I S OF LN -M7PYSO2PH -DOTA
Three times LacOtBu alkylated M4-cyclen 129 was synthesized using three
equivalents of the triflate of LacOtBu in a mixture of acetonitrile / dichloro-
methane (1:1) as solvent. We found that using pure dichloromethane results
in incomplete alkylation and the majority of the product was two times
alkylated. Using pure acetonitrile on the other hand resulted in a mixture
with significant overalkylation. We found that starting the reaction with di-
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Scheme 33: Retrosynthetic analysis for the synthesis of Ln-M7PySO2Phe-
DOTA 130.
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chloromethane and adding acetonitrile after two to three hours is optimal and
minimizes the formation of the fourfold alkylated product. Separation of the
formed products was achieved using preparative HPLC. To reduce expens-
ive material losses the one and two times alkylated products were reused in
future reactions. Methyl pyridine phenyl sulfone 127 was synthesized from
methyl bromo pyridine 125 and thiophenol 126 immediately followed by an
oxidation of the thioether to the sulfone 127 (see Scheme 34). Free radical
bromination was performed using NBS and AIBN in tetrachloromethane. We
found that using less toxic solvents like acetonitrile and dichloromethane
resulted in low yields and complex mixtures. The monobrominated product
128 was separated from the dibrominated product by flash column chroma-
tography and was immediately used afterwards. We were delighted to find
that the alpha bromo pyridine 128 was highly reactive towards nucleophilic
substitution on the already sterically very crowded three times alkylated
M4-cyclen 129. Subsequent acidic hydrolysis was achieved using aqueous
hydrochloric acid and final metallation was performed using four equivalents
of the corresponding lanthanide 3+ salt.
6 . 3 TAGG ING OF GB1 MUTANTS
We prepared diamagnetic Lu-M7Py-DOTA 132, and paramagnetic Tm-M7Py-
DOTA 133 and Tb-M7Py-DOTA 134 complexes, which we coupled to the
streptococcal protein G B1 domain (GB1) via cysteine residues. We used
site-directed mutagenesis to prepare three different mutants of GB1, E19C,
K28C and E42C. Initial tagging reactions at 20-25  C in 50mM phosphate
buffer, 0.5mM TCEP at pH 7.0 showed no conversion. Adjusting the pH to
7.6 increased reaction rates but no full conversion was observed within 24 h.
Due to the high thermal stability of the GB1 protein tagging was performed at
45  C and was >95% completed after 24 h. GB1 concentrations were adjusted
to 300 µM and a four-fold excess of M7Py-DOTA loaded with Lu, Tm, or Tb
was used. Although tagging was possible for all mutants of GB1 the high
temperatures required for tagging are not suitable for more labile proteins.
Nevertheless, tagging in presence of TCEP clearly demonstrated the stability
of the thioether bond towards reduction. TCEP is a much strong reducing
agent than glutathione which is present in cells and, therefore, no cleavage of
the tag should occur inside a cell. Tagging in the presence of TCEP offered
two major advantages over the standard procedure applied for tagging with
M8-SSPy-DOTA. First, protein dimerization was hindered in the presence of
TCEP and second, the removal of TCEP prior to tagging was not required as
it would be for M8-SSPy-DOTA. A simple buffer exchange from high TCEP
concentrations to minimal TCEP concentrations was sufficient.
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Scheme 34: Synthesis of tags 132-135. Reaction Conditions: i.) K2CO3, DMF,
90  C, 22 h; ii.) NaOCl, acetic acid, 20-25  C, 16 h; iii.) NBS, AIBN, CCl4, reflux,
10 h; iv.) K2CO3, MeCN, 20-25  C, 18 h; v.) MeCN, aq. HCl 1 M, 80  C, 4 h; vi.)
Ln3+, aq. NH4OAc 100mM, 80  C, 18 h.
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6 . 4 IN -V ITRO AND IN -CELL NMR ANALYS I S
For GB1 samples we recorded 2D 1H-15N HSQC spectra at 600 MHz which
showed large pseudocontact shifts of up to 6 ppm (see Figures 6.1, 6.2 and
6.3). We also detected strong cross peak splitting in 2D 1H-15N IPAP-HSQC
spectra due to the partial alignment of the GB1 within the magnetic field. This
resulted in residual dipolar couplings reaching 25Hz. We found that samples
tagged with Tm-M7Py-DOTA showed the largest pseudocontact shifts.
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Figure 6.1: In-vitro PCS by metal-loaded DOTA-M7Py. Superposition of full 2D 1H-
15N HSQC spectra of GB1-E19C coupled to diamagnetic Lu-M7Py-DOTA (black)
and paramagnetic Tm-M7Py-DOTA (red/blue) at 600MHz and 293K. Water signal
removed for clarity.
For further in-cell NMR experiments only the Tm and Lu loaded proteins
were used. Using microinjection we injected GB1 carrying either paramag-
netic (Tm) or diamagentic (Lu) M7Py-DOTA into Xenopus laevis oocytes
for in-cell NMR measurements. We recorded 2D 1H-15N HSQC spectra at
effective NMR concentrations of ~25 µM (intracellular GB1 concentrations
~50 µM). The PCSs we obtained were virtually indistinguishable from the
respective in-vitro samples with an overall RMSD of 0.04 ppm, indicating
that the structure of the protein is in-cell similar to the structure of the protein
in-vitro. This was expected as GB1 is known to be a very stable protein that
does not change conformation inside cells.121 The measured RDCs were also
comparable to the one obtained in-vitro. Because the intracellular viscosity
is higher than the viscosity in-vitro, a faster T2 relaxation was observed.
This lead to overall broader lines and larger errors especially for the RDC
measurements. Free lanthanide ions are highly toxic and we did not detect
any sample degradation or leakage of the metal for up to 24 h. This clearly
showed the excellent stability of this tag inside living Xenopus laevis oocytes.
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Figure 6.2: In-vitro PCS by metal-loaded M7Py-DOTA. Superposition of full 2D 1H-
15N HSQC spectra of GB1-K28C coupled to diamagnetic Lu-M7Py-DOTA (black)
and paramagnetic Tm-M7Py-DOTA (red/blue) at 600MHz and 293K. Water signal
removed for clarity.
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Figure 6.3: In-vitro PCS by metal-loaded DOTA-M7Py. Superposition of full 2D 1H-
15N HSQC spectra of GB1-E42C coupled to diamagnetic Lu-M7Py-DOTA (black)
and paramagnetic Tm-M7Py-DOTA (red/blue) at 600MHz and 293K. Water signal
removed for clarity.
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We determined magnetic susceptibility tensor parameters for both in-cell and
in-vitro measurements using the program Numbat.74 We chose the atomic
coordinates of the Cb of the corresponding cysteine residue as starting co-
ordinates for the metal position in the minimization. The position was then
further refined in an iterative fashion. Table 6.1, 6.2 and 6.3 show the calcu-
lated magnetic susceptibility tensor parameters. We found that Tm and Tb
have opposite signs in their magnetic susceptibility tensor parameters which
results in an overall trend of shifting towards the opposite direction. This can
be best seen in Figure 6.4 where all tensor isosurfaces have opposite colors
going from Tb to Tm.
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E42C
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K28C
Figure 6.4: Tensor isosurfaces of the three GB1 mutants E19C, K28C and E42C. Tb-
M7Py-DOTA left and Tm- M7Py-DOTA right. The red isosurfaces indicate a shift of
-8 ppm (inner) and -4 ppm (outer). The blue isosurfaces indicate the corresponding
positive shift.
72 SYNTHES I S AND APPL ICAT ION OF M7PY-DOTA
Table 6.1: In-vitro and in-cell PCS tensor parameters for GB1 K28C
fitted against the GB1 X-ray structure (PDB code: 2QMT).
in-vitro in-cell
Tb, 50 PCS Tm, 62 PCS Tm, 62 PCS
Dcax / 10 32m3 38.5 (1.3) -31.9 (0.8) -32.9 (0.9)
Dc rh / 10 32m3 22.8 (0.9) -18.2 (0.5) -17.8 (0.6)
x / Å 9.8 (0.2) 9.8 (0.2) 9.8 (0.2)
y / Å 12.3 (0.1) 12.3 (0.1) 12.1 (0.1)
z / Å 31.5 (0.1) 31.5 (0.1) 31.6 (0.1)
a / ° 108.1 (0.8) 96.3 (0.5) 96.9 (0.5)
b / ° 41.4 (0.7) 48.4 (0.5) 46.9 (0.4)
g / ° 156.09 (1.4) 172.6 (0.9) 171.3 (0.9)
Tensor parameters (errors) were calculated in Numbat74 from the indic-
ated number of selected PCS. All tensor parameters are reported in the
UTR. The following amino acids were excluded from the fit because of
too close proximity (<15Å) to the final lanthanide position: K10, T11,
L12, E19, V21, A23, A24, T25, A26, Q32, G38, D40, T53.
Table 6.2: In-vitro and in-cell PCS tensor parameters for GB1 E19C
fitted against the GB1 X-ray structure (PDB code: 2QMT).
in-vitro in-cell
Tb, 76 PCS Tm, 74 PCS Tm, 60 PCS
Dcax / 10 32m3 -13.9 (1.7) 31.4 (2.2) 27.3 (2.1)
Dc rh / 10 32m3 -7.0 (0.8) 7.1 (2.8) 3.6 (0.9)
x / Å -3.5 (0.3) -3.5 (0.8) -4.8 (0.3)
y / Å 30.5 (0.3) 30.5 (0.6) 30.5 (0.3)
z / Å 21.7 (0.3) 21.7 (0.9) 22.0 (0.3)
a / ° 148.3 (1.9) 148.6 (6.2) 155.1 (1.8)
b / ° 103.4 (1.1) 115.9 (6.0) 106.3 (1.1)
g / ° 65.5 (10.0) 5.6 (5.3) 126.3 (9.9)
Tensor parameters (errors) were calculated in Numbat74 from the indic-
ated number of selected PCS. All tensor parameters are reported in the
UTR. The following amino acids were excluded from the fit because
of too close proximity (<15Å) to the final lanthanide position: L5, T16,
D22, A48, T49, T51, F52.
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Table 6.3: In-vitro and in-cell PCS tensor parameters for GB1 E42C
fitted against the GB1 X-ray structure (PDB code: 2QMT).
in-vitro in-cell
Tb, 76 PCS Tm, 74 PCS Tm, 60 PCS
Dcax / 10 32m3 25.5 (1.6) -34.8 (2.0) -32.9 (4.6)
Dc rh / 10 32m3 10.9 (0.8) -22.5 (1.4) -21.9 (3.1)
x / Å 16.5 (0.2) 16.5 (0.3) 16.0 (0.3)
y / Å 12.8 (0.1) 12.8 (0.1) 12.8 (0.1)
z / Å 10.7 (0.2) 10.7 (0.2) 10.4 (0.1)
a / ° 80.4 (0.3) 62.0 (0.3) 63.1 (2.6)
b / ° 96.4 (0.3) 104.1 (0.4) 105.5 (6.7)
g / ° 120.2 (0.1) 100.4 (0.1) 101.7 (1.7)
Tensor parameters (errors) were calculated in Numbat74 from the indic-
ated number of selected PCS. All tensor parameters are reported in the
UTR. The following amino acids were excluded from the fit because of
too close proximity (<15Å) to the final lanthanide position: N8, N35,
D36, G41, Y45, D46, D47, A48, F52, T53, V54, T55.
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6 . 5 ROSETTA STRUCTURE CALCULAT ION
We used our in-cell PCS and RDC data as input for a structure calculation
within GPS-Rosetta. GPS-Rosetta includes PCS restraints from multiple
paramagnetic centers and uses them as distance and angle restraints in its
calculation routines. We generated the 3- and 9-residue fragments of known
protein structures with the Robetta protein sequence server. We excluded
all homologous of the GB1 sequences. Using these fragments, we gener-
ated 10000 GB1 structures, out of which we collected the 100 lowest-energy
structures and compared their conformations to experimentally determined
GB1 structures from X-ray crystallography (PDB code: 2QMT) and solution
NMR (PDB code: 1GB1, 2PLP). Using Rosetta’s ab-initio approach without
any additional experimental data we found poor convergence of individual
structures, with a median backbone Ca RMSD of 1.85Å (see Figure 6.5).
We added a PCS-based weighting function and recalculated 10000 GB1 struc-
tures. We used 72, 86, and 96 PCS constraints from the E19C, K28C, and
E42C GB1 mutants, respectively. The convergence of GB1 structures was
substantially improved. For this PCS-based approach we found an average
Ca RMSD of the 100 lowest-energy models was 0.98Å and 0.64Å between
the closest model and the crystal structure (PDB code: 2QMT) (see Figure
6.6). We calculated another 10000 GB1 structures using PCS and RDC data.
The convergence we obtained was similar to the one without RDC data. We
found an average Ca RMSD of 1.04Å for the 100 lowest-energy structures,
0.64Å for the closest model and the X-ray structure (PDB code: 2QMT) (see
Figure 6.7).
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Figure 6.5: Ab initio GB1 structures without using experimental restraints. (a) Scat-
ter plots depict Rosetta energy scores and Ca RMSDs of 10’000 GB1 structures
compared to the GB1 X-ray structure (2QMT). (b) A superposition of the ten low-
est energy structures. GB1 models with L1 conformations corresponding to the one
of the GB1 X-ray structure are shown in red, deviating L1 conformers are coloured
orange.
We inspected the 10 lowest energy structures of each set and found a
remarkable difference between the structures obtained with PCS data and
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Figure 6.6: GB1 structures with PCS input data. (a) Scatter plots depict Rosetta
energy scores and Ca RMSDs of 10’000 GB1 structures compared to the GB1 X-
ray structure (2QMT). (b) A superposition of the ten lowest energy structures. GB1
models with L1 conformations corresponding to the one of the GB1 X-ray structure
are shown in red, deviating L1 conformers are coloured orange.
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Figure 6.7: GB1 structures with PCS and RDC input data. (a) Scatter plots depict
Rosetta energy scores and Ca RMSDs of 10’000 GB1 structures compared to the
GB1 X-ray structure (2QMT). (b) A superposition of the ten lowest energy structures.
GB1 models with L1 conformations corresponding to the one of the GB1 X-ray
structure are shown in red, deviating L1 conformers are coloured orange.
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the ones we obtained with PCS and RDC data. In both ensembles loop L1
(residues N8 to E15), which connects strands b1 and b2 of GB1, displayed
two distinct conformations. One conformation was identical to the X-ray
structure with an average Ca RMSD of 1.1Å, and the other conformation
had a kink and a larger Ca deviation and average RMSD of 1.6Å. We found
only 3 out of ten structures adopted the X-ray loop L1 conformation in PCS
alone generated structures. In the case of PCS and RDC data five out of ten
adopted the X-ray conformation. Previous solution NMR data indicated that
loop L1 is highly flexible and the in-vitro solution conformation is similar
to the conformation obtained in X-ray crystallography. Although it was ex-
pected that GB1 adopts the same conformation in-cell and in-vitro we were
delighted to see that PCS and RDC data from single 2D in-cell NMR experi-
ments are sufficient to determine protein structures within GPS-Rosetta.
6 . 6 FLUOR INATED LEAV ING GROUPS
6 . 6 . 1 Retrosynthetic analysis and considerations
To counteract the low reactivity exhibited by our M7PySO2Phe-DOTA com-
plexes we envisioned to synthesize complexes with fluorinated leaving groups
(see Scheme 35). Although the nature of the leaving group only plays a minor
role in nucleophilic aromatic substitution reactions its nature is not entirely
irrelevant. An increased acidity of the leaving group could enhance the re-
activity. We proposed three different leaving groups based on fluorinated
thiophenols 136, 137 and 138. Upon nucleophilic substitution, oxidation and
bromination the alpha bromo pyridines 139, 140 and 141 could be obtained.
The procedures already developed for the synthesis of M7PySO2Phe-DOTA
could be adapted for the synthesis of the corresponding complexes.
6 . 6 . 2 Synthesis of fluorinated derivatives of DOTA-M7PySO2Ph
The synthesis of the mono-CF3 substituted analogue of M7PySO2Phe-DOTA
started from bromo methyl pyridine 125 (see Scheme 36). A nucleophilc
aromatic substitution with thiophenol 136 in acetonitrile and potassium car-
bonate yielded the intermediate thioether after 18 h at 65  C. The immediate
oxidation of the thioether with bleach was unsuccessful as only the formation
of the intermediate sulfoxide was detected. The increased electronegativity
resulted in an lower oxidation tendency. We isolated the crude intermediate
and oxidized it with sodium tungstate and hydrogen peroxide in methanol
at 20-25  C. We found that this oxidizing conditions are superior and no
formation of the N-oxide was detected. Using stronger oxidizing agents
like hydrogen peroxide in acetone resulted in the formation of the sulfone
N-oxide. Finally a free radical bromination of the sulfone 142 yielded the
alpha bromo pyridine 139. Subsequent alkylation of triply alkylated M4-
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Scheme 35: Retrosynthetic analysis for three fluorine substituted analogues (139,
140, 141) of 128.
cyclen 129, deprotection and metallation yielded Tm and Lu complexes of
M7PySO2-para-CF3-Ph-DOTA 145 and 146.
Similar conditions were applied for the synthesis of 3,5-bis-CF3 substi-
tuted analogue of M7PySO2Ph-DOTA . The nucleophilc substitution of
bromo methyl pyridine 125 with thiophenol 137 yielded the intermediate
thioether which was oxidized using the optimized conditions described pre-
viously. Free radical bromination of the sulfone 143 yielded the alpha bromo
pyridine 140. Subsequent alkylation of three times alkylated M4-cyclen 129,
deprotection and metallation yielded Tm and Lu complexes of M7PySO2-bis-
CF3-Ph-DOTA 149 and 150.
The synthesis of a penta fluoro substituted pyridine sulfone 144 was not
possible. We tried several oxidizing conditions including bleach, hydrogen
peroxide / acetone and sodium tungstate / hydrogen peroxide. It was only pos-
sible to oxidize the sulphur once forming the sulfoxide. Harsher conditions
yielded the sulfoxide N-oxide. We found that the increased electronegativity
of the thiophenols influence both the aromatic substitution and the oxidation
leading to lower yields in the case of para-CF3 and 3,5-bis-CF3 substitution.
6 . 6 . 3 Tagging of GB1 E42C
We applied the same conditions as for our initial tagging experiments for Tm
and Lu loadedM7PySO2Ph-DOTA. Tagging was performed using GB1 E42C
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125 136 142 139
147139129
148146 Ln = Lu145 Ln = Tm
Scheme 36: Synthesis of tags 146 and 145. Reaction Conditions: i.) K2CO3,
DMF, 65  C, 18 h; ii.) Na2WO4, H2O2, 20-25  C, 18 h; iii.) NBS, AIBN, CCl4,
reflux, 18 h; iv.) K2CO3, MeCN, 20-25  C, 18 h; v.) MeCN, aq. HCl 1 M, 80  C,
4 h; vi.) Ln3+, aq. NH4OAc 100mM, 80  C, 18 h.
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Scheme 37: Synthesis of tags 150 and 149. Reaction Conditions: i.) K2CO3,
DMF, 80  C, 18 h; ii.) Na2WO4, H2O2, 20-25  C, 18 h; iii.) NBS, AIBN, CCl4,
reflux, 18 h; iv.) K2CO3, MeCN, 20-25  C, 18 h; v.) MeCN, aq. HCl 1 M, 80  C,
4 h; vi.) Ln3+, aq. NH4OAc 100mM, 80  C, 18 h.
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at 20-25  C in 50mM phosphate buffer, 0.5mM TCEP at pH 7.0. The protein
concentration was adjusted to 300 µM and a fourfold excess of Tm-M7PySO2-
para-CF3-Ph-DOTA 145 and Tm-M7PySO2-3,5-bis-CF3-Ph-DOTA 149 was
used. We observed no changes in reaction rates for these two fluorinated tags
in comparison to the non fluorinated tag indicating that the stronger acidity of
the leaving group has only a minor or no influence on the overall reaction rate.
7
SYNTHES I S AND APPL ICAT ION OF M7PY-DOTA
DER IVAT IVES
7 . 1 RETROSYNTHET IC ANALYS I S AND CONS IDERAT IONS
Driven by the finding for the fluorinated leaving groups we envisioned that
a significant gain in reaction rate should be obtained by stabilizing the in-
termediate Meisenheimer complex.122 Nucleophilc aromatic substitution
largely depend on the stability of the intermediate Meisenheimer complex
(see Scheme 38).
130 153
Scheme 38: Formation of the intermediate Meisenheimer complex 153.
The incoming nucleophile brings in a negative charge. Thus, stabilizing
this negative charge within the aromatic system is favourable and enhances
reactivity. In nucleophilic aromatic substitution with pyridines the 2 and
4 position are susceptible to substitution due to their ability to delocalize
the electron pair towards the nitrogen. In order to increase the tendency to
undergo nucleophilic aromatic substitutions the electron density of the pyrid-
ine has to be reduced. This causes the pyridine ring to more likely accept
an incoming electron pair. We envisioned that substituting a hydrogen in
the 5 position with a fluorine would significantly increase the reactivity. The
desired alpha bromo pyridine sulfone 154 could be synthesized from the com-
mercially available 5-fluoro-4-bromo-2-methyl pyridine 155 (see Scheme 39).
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154 156 126 155
Scheme 39: Retrosynthetic analysis for the synthesis of the fluorinated alpha
bromo pyridine 154.
7 . 2 SYNTHES I S OF M7FPYSO2PH
The fluoro pyridine phenyl sulfone 156 was synthesized by nucleophilic
aromatic substitution of fluoro bromo methyl pyridine 155 and thiophenol
(126) followed by the oxidation of the intermediate thioether (see Scheme
40). The rate of the nucleophilic aromatic substitution was enhanced due to
the increased electrophilicity of the fluorinated pyridine. Compound 156 was
found to be not stable at 20-25  C. After several days the compound turned
blue. The blue minor impurities could be easily separated by flash column
chromatography. A free radical bromination of the fluoro pyridine phenyl
sulfone 156 yielded the alpha bromo compound 154 in low yields. Due to
the costly starting material 157 the reaction was stopped early in order to re-
duce the amount of dibrominated by-products. The starting material could be
recovered using flash column chromatography. Further nucleophilic substitu-
tion, deprotection and metallation showed no significant differences in terms
of yields in comparison to the previously shown complexes. We synthesized
Tm-M7FPySO2Ph-DOTA 158 and Lu-M7FPySO2Ph-DOTA 159. Most of
the time we observed lower yields for the Tm metallation in comparison
to Lu3+. We attributed this behaviour to the presumably stronger catalytic
activity of Tm3+. The excess of lanthanide ions in solution was reduced from
4 equivalents to 1.2. Although this reduction did slightly increase the overall
yield, the yield for Tm was still lower than for Lu and sometimes incomplete
conversion was detected. We also studied the temperature required for metall-
ation and we found that at 20-25  C and below 50  C no formation of the
complex is detected. Therefore, we decided to reduce the excess to two-fold
in order to ensure complete conversion and we kept the temperature at 80  C
for 18 h as described by Häussinger et al..102
7 . 3 TAGG ING OF UB IQU IT IN S57C
The protein ubiquitin S57C was expressed by PD Dr. Daniel Häussinger
according to the procedure reported by Sass et al..123 We tagged ubiquitin
S57C at 20-25  C in 10mM phosphate buffer, 2.0mM TCEP at pH 7.0. Ubi-
quitin S57C concentrations were adjusted to 150 µM and a four-fold excess of
M7FPy-DOTA loaded with Lu and Tm was used. The reaction progress was
monitored using LC-ESI-MS. We found that 80% of the protein was tagged
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Scheme 40: Synthesis of tags 159 and 158. Reaction Conditions: i.) K2CO3,
DMF, 70  C, 1 h; ii.) Na2WO4, H2O2, 20-25  C, 48 h; iii.) NBS, AIBN, CCl4,
reflux, 6 h; iv.) K2CO3, MeCN, 20-25  C, 18 h; v.) MeCN, aq. HCl 1 M, 65  C,
2 h; vi.) Ln3+, aq. NH4OAc 100mM, 80  C, 18 h.
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within 3 h. To ensure compleation of the tagging reaction the tagging was
prolonged for additional 16 h until ESI-MS showed full conversion. Upon
closer inspection of the ESI-MS spectra we found that the tag slowely de-
composes due to the reaction with TCEP. Therefore, we performed the same
tagging reactions without TCEP. Finally, we recorded 1H-15N HSQC spectra
and found in the paramagentic Tm spectrum two sets of signals. One set
belonged to the desired paramagnetically shifted species while the other set
has almost identical shifts as the untagged protein. If tagging was performed
without TCEP the second species was around 30%, in the presence of TCEP
the second species was only around 15%. We concluded that the untagged
species is most likely dimerized protein. However, the exact percentage could
not be estimated well, since the tagged protein experienced strong PRE ef-
fects due to paramagnetic metal. On the other hand the untagged species did
not experience this effect and therefore could be overestimated. Nevertheless
from this experiments it was clear that tagging without TCEP results in a
larger amount of apparently untagged protein. It has been reported in liter-
ature that benzenesulfinic acid can induce the formation of thiolsulphonate
derivatives which are susceptible towards nucleophilic substitution forming
disulfides.124 Upon successful tagging one equivalent of benzenesulfinic acid
is released for each tagged protein, but also one equivalent of benzenesulfinic
acid is released per molecule of tag destroyed by TCEP. This self induced pro-
tein dimerization could explain the special reaction kinetics observed for the
tagging reaction. This could explain why we observed 80% conversion after
3 h but still needed an additional 16 h in order to not dectect any monomeric
ubiquitin by ESI-MS. For future tagging reactions we reduced the amount
of TCEP from 2.0mM to 450 µM and increased the amount of tag from a
four-fold excess to a six-fold excess. This conditions reduced the amount of
untagged species from 15% to less then 10%.
7 . 4 IN -V ITRO NMR ANALYS I S
For ubiquitin S57C samples we recorded 2D 1H-15N HSQC spectra at 600
MHz which showed large pseudocontact shifts of up to -10 ppm. We found
that samples tagged with Tm-M7FPy-DOTA 158 showed predominantly
negative PCS shifts and only a few positive PCS shifts (see Figure 7.1).
We determined magnetic susceptibility tensor parameters using the program
Numbat74 (see Table 7.1 see Figure 7.2). We chose the atomic coordinates
of the Cb of the corresponding cysteine residue as starting values for the
minimizations. The position was then further refined in an iterative fashion.
Figure 7.2 shows the tensors orientation with respect to the protein. Inspec-
tion of the relative orientation revealed that mostly the "belt" of the tensor is
pointing towards the protein and the axial component is pointing away from
the protein. This arrangement is less favourable because the tensor’s axial
component is in general larger.
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Scheme 41: Tagging reaction, formation of TCEP adduct 163 and dimerization
of ubiqutin catalysed by benzensulfinic acid.
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Figure 7.1: In-vitro PCS by metal-loaded MF7Py-DOTA. Superposition of full 2D
1H-15N HSQC spectra of ubiquitin S57C coupled to diamagnetic Lu-M7FPy-DOTA
(black) and paramagnetic Tm-M7FPy-DOTA (red) at 600MHz and 298K. Water
signal removed for clarity.
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Table 7.1: In-vitro PCS tensor parameters for ubiquitin S57C fitted
against the ubiquitin X-ray structure (PDB code: 1UBI).
Tm, 80 PCS
Dcax / 10 32m3 17.8 (1.5)
Dc rh / 10 32m3 9.8 (1.0)
x / Å 20.7 (0.5)
y / Å 11.4 (0.4)
z / Å 12.7 (0.5)
a / ° 2.8 (8.3)
b / ° 154.3 (7.0)
g / ° 27.0 (6.4)
Tensor parameters (errors) were calculated in Numbat74 from the indic-
ated number of selected PCS. All tensors are represented in the UTR.
Only amino acids residing in a stable secondary structure (2-7, 12-16,
23-34, 38-40, 41-45, 48-49, 56-59 and 66-71) were used if present in
the spectra.
Figure 7.2: Tensor representation of Tm-M7FPy-
DOTA tagged to ubiquitin S57C. The red isosurfaces
indicate a shift of -3 ppm (inner) and -1 ppm (outer).
The blue isosurfaces indicate the corresponding posit-
ive shift.
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7 . 5 . 1 Retrosynthetic analysis and considerations
To address the major problems arising from the release of benzenesulfinic
acid we envisioned the synthesis of non aromatic leaving groups. The comer-
cially available spin label tag MTSL releases methylsulfinic acid upon con-
jugation and is widly applied and no product dimerization has been reported
due to the release of methylsulfinic acid.125 The introduction of a sulfonamide
(compound 164) would produce SO2 and NH3 upon successful nucleophilic
aromatic substitution. On the other hand the introduction of a methylsulfone
(compound 165) would release methylsulfinic acid which quickly hydrolyses
to SO2 and methanol. Both compounds would avoid the formation of ben-
zenesulfinic acid and most likely avoid dimerization. Due to the harsh condi-
tions required for the free radical bromination of the methyl pyridine precurs-
ors we proposedmodification of the final phenyl sulfone tag 162. Primary sulf-
onamides can be easily prepared under aqueous conditions using hydroxylam-
ine-O-sulfonic acid.126 The methylsulfone could be introduced by alkylation
of the free thiol 166 with methyliodid followed by an oxidation. For further
testing reaction we planned to prepare only Tm-based complexes and no Lu-
based complexes as only Tm offers measurable PCS shifts.
164 167
166165
162
Scheme 42: Retrosynthetic analysis for the synthesis of sulfonamide-based tags
164 or methylsulfone-based tags 165.
7 . 5 . 2 Synthesis of M7FPySO2NH2 DOTA and M7FPySO2Me DOTA
We tried the direct substitution of Tm-M7FPySO2Ph-DOTA 158 with sodium
sulfide. The result we obtained was unsatisfying as most of the starting ma-
terial decomposed and only little product was produced. We obtained similar
results for the direct substitution with sodium sulfite. Neither the free thiol nor
the sulfinic acid could be produced directly. However, we were very pleased
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to find that 2-(trimethylsilyl)ethanethiol quantitatively reacts at 20-25  C in
the presence of K2CO3 in acetonitrile (see Scheme 43). This rather special
protecting group for a thiol can be selectively cleaved in the presence of tet-
rabutylammonium fluoride. It was also possible to oxidize the thioether 168
forming the sulfoxide 169. Treatment of the sulfoxide 169 with tetrabutylam-
monium fluoride released the sulfinic acid which was in-situ transformed to
the sulfonamide 170. The alkylation of the free thiol 171 with methyliodide
was performed quantitatively and the following oxidation was achieved in
moderate yield (see Scheme 44). We could prepare two close analogues of
Tm-M7FPySO2Phe-DOTA bearing a sulfonamide and a methyl sulfone. We
found that once a metal is introduced into the tag its stability greatly increases
and various modifications could be performed under mild conditions. This
strategy requires a few more steps but is definitely preferable due to the stabil-
ity of the pyridine phenyl sulfone 156 under acidic and free radical conditions.
158
171
172 173
171168
Scheme 43: Synthesis of tag 168. Reaction Conditions: i.) HSC2H4Si(CH3)3,
K2CO3, MeCN, 20-25  C, 2 h; ii.) TBAF 1 M in THF, MeCN, 20-25  C, 30min;
iii.) CH3I, K2CO3, MeCN, 20-25  C, 2 h; iv.) Na2WO4, H2O2, MeOH, 20-25  C,
18 h.
168
169 170
Scheme 44: Synthesis of tag 170. Reaction Conditions: i.) Na2WO4, H2O2,
MeOH, 20-25  C, 18 h; ii.) TBAF 1 M in THF, MeCN, 20-25  C, 30min; iii.)
NaOAc, hydroxylamine-O-sulfonic acid, H2O, 20-25  C, 6 h
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7 . 5 . 3 Tagging of ubiquitin S57C
We tagged ubiquitin S57C at 20-25  C in 10mM phosphate buffer, 0.45mM
TCEP at pH 7.0. Ubiquitin S57C concentrations were adjusted to 150 µM and
a six-fold excess of Tm-M7FPySO2NH2-DOTA 170 and Tm-M7FPySO2Me-
DOTA 173 was used. We found that Tm-M7FPySO2NH2-DOTA 170 did not
react within 24 h and a conversion of approximately 10%was achieved within
24 h for Tm-M7FPySO2Me-DOTA 173. Although our experiments with the
fluorinated leaving groups indicated that the leaving group plays a minor role
in the overall reaction kinetics we found that only phenyl sulfone pyridines
offer a high enough reactivity for useful protein tagging reactions.
7 . 6 DETERMINAT ION OF INTR INS IC MAGNET IC SUSCEPT IB I L -
I TY TENSORS
This section of the thesis summarizes the key findings of the study of the in-
trinsic magnetic susceptibility tensors of Ln-M7FPySO2Phe-DOTA tags. The
results presented here are obtained in collaboration with Raphael Vogel dur-
ing his master thesis in our group and are described in more detail in his
thesis.116
7 . 6 . 1 Pseudocontact shift tensor fitting
For a full determination of magnetic susceptibility tensor parameters a de-
tailed knowledge of the position and the corresponding shift is required. Due
to the large PRE effect exhibited by paramagnetic lanthanides the measure-
ment of 2D NMR spectra is severely limited and in some cases impossible.
Therefore, a precise assignment of a shift to a position becomes impossible
in severe cases. We used a selectively 13C methyl labelled M4-cyclen to syn-
thesize Ln-M7FPySO2Phe-DOTA tags. The synthesis of singly labelled M4-
cyclen was performed using the dimer to trimer to tetramer strategy described
previously. In the target lanthanide complexes all cyclen methyl groups are
25% labelled. This is due to the statistical distribution obtained by the al-
kylation of the singly labelled M4-cyclen. This allowed the identification
of the corresponding methyl proton shift in the 1D proton spectrum of the
early lanthanide from Ce-Eu and Yb due to their characteristic 1JCH splitting.
However, for the late lanthanide the linewidths were too broad to observe
any doublet splitting. Measuring 1D carbon spectra allowed us to identify
the four methyl carbon shifts. However, we found that those carbon shifts as
well as the fluorine shift from the linker are heavily influenced by the contact
shifts and therefore could not be used for the tensor determination. The car-
bon shifts were broadened due to the PRE and the coupling to the protons.
Decoupling became very inefficient for most shifted signals due to the small
decoupling bandwidth. For example if the proton chemical shift range is 1400
ppm we would require a decoupling bandwidth of 840 kHz on a 600MHz
spectrometer (1400 ppm x 600MHz). Even using a very broad decoupling
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scheme like GARP with a figure of merit of 4.8 this would still correspond
to a decoupler field strength of 175 kHz. At this field strength the 90° pulse
would be around 1 µs. Typical high power proton pulse lengths are in the or-
der of 10 µs. A shorter pulse would require more power and thus damage the
probehead. Therefore it is not possible to decouple the whole proton chemical
shift range in strongly paramagnetic samples (see Figure 7.3).
840 kHz at 600 MHz
~7 kHz Waltz-16 decoupling 
1H (ppm)
1H (ppm)
Figure 7.3: Proton spectrum of Dy-M7FPy-DOTA116 and decoupling bandwidth at
600MHz for the routinely applied Waltz-16 decoupling sequence.
However, this circumstance could be used to our advantage as a series of
selectively 1H decoupled 1D carbon spectra allowed us to identify pairs of
carbon and proton shifts. If the decoupler offset matches the frequency of the
connected protons the signal becomes sharper as the signal is only broadened
by PRE and not broadened by the coupling with the protons (see Figure 7.4).
Therefore, four proton signals could be assigned to four possible positions.
Furthermore, for the early lanthanides it was possible to record 2D COSY
spectra which allowed the assignment of individual spin systems. In the case
of the weakly paramagnetic lanthanides Sm and Eu we were able to record
in addition 2D HSQC HMBC and ROESY spectra. In this cases the tensors
could be determined precisely because all proton shifts could be assigned.
The atomic coordinates were taken from a DFT optimized structure of the
corresponding lanthanide tag. For Ce to Nd it was only possible to record
COSY spectra. In this case we could only assign different spin systems but
no exact positions.
In the cases were only individual spin systems could be assigned but no
exact assignment, a combinatorial approach was used to find the best solu-
tion. For, however, the late lanthanides no individual spin systems could be
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Figure 7.4: Selectively decoupled 13C spectra of Tb-DOTA-M7FPy.116 The 1H de-
coupler offset has been set to the following proton frequencies: 8.3 ppm (orange),
-68.5 ppm (black), -45.3 ppm (violet), -29.6 ppm (green) and - 25.6 ppm (red). The
blue spectra with no decoupling was taken as a reference. The red spectra shows the
effect of decoupling at a wrong frequency.
identified as it was not possible to measure COSY spectra. For these difficult
cases information gained from the early lanthanides could be used. It was
found that certain group of protons always shifted in the same direction and
are always found on either the low or high field end of the spectrum. Us-
ing this information and the proton shifts from the cyclen methyl protons a
combinatorial approach was applied to find the assignment with the best fit.
We found several possible solutions with an r2 value of >0.999. Therefore,
the correct assignment could not be deduced. However, the distribution of the
fitted tensor parameters allowed us to obtain an estimate of the true size of the
tensor (see Table 7.2 and 7.3). We found that this numbers are much larger
than the tensor parameters we obtained for both GB1 and ubiquitin S57C
samples. To further confirm this finding we investigated the tags performance
on the protein ubiquitin S57C and we found that approximately 80% of the
tensors potential is lost. This percentage is roughly constant for all lanthanide
complexes of M7FPy-DOTA.
These findings clearly showed that although our previously developed tags
have very large intrinsic tensors most of the PCS effect is lost and not trans-
ferred onto the protein. The reason for this extreme loss of performance is the
relative movement of the tag with respect to the protein surface. Our pyridine-
based tags have already a very short and rigid linker and it is highly doubt-
able whether this could actually be shortened further. These tags offer only
one rotatable bond formed between the protein and the pyridine ring. There-
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Table 7.2: Tensor parameters calculated for the early lanthanide Ln-
M7FPySO2Phe-DOTA tags (top) and conjugated to ubiquitin S58C (bot-
tom).
Ce Pr Nd Sm Eu
Dcax 3.5 10.4 4.6 -0.83 4.5
Dc rh 2.1 2.7 2.1 -0.27 2.6
Dcax -0.99 2.4 1.1 -0.76 -1
Dc rh -0.65 1.5 0.59 -0.46 -0.66
All tensor parameters are reported in the UTR. Axial and rhombic com-
ponents are given in 10 32m3.
Table 7.3: Tensor parameters calculated for the late lanthanide Ln-
M7FPySO2Phe-DOTA tags (top) and conjugated to ubiquitin S58C (bottom).
Tb Dy Ho Er Tm Yb
Dcax 58 (-7.4) 93 (10) 38 (4.6) 29 (2.2) 83 (0.8) 23 (1.9)
Dc rh 32 (9.0) 32 (16) 19 (6.4) 14 (2.9) 22 (4.6) 8.7 (1.6)
Dcax -12 -21 6.6 5.1 -16 -2.7
Dc rh -7.5 -12 4.2 0.52 -9 -1.7
All tensor parameters are reported in the UTR. Axial and rhombic components
are given in 10 32m3.
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fore, the rotation around this bond is presumably responsible for the great loss
of performance. Translational motions are far less likely to cause large aver-
aging effects as most often no crossing of the tensors node planes occurs. On
the other hand rotation around the linkage can cause crossing of node planes
going from positive to negative values thus having a large influence on the
observed shifts. Inside the tag the four base nitrogens and the metal form a
square pyramid. The tensors z-axis is only slightly tilted away from the axis
created by the center of the base square and the tip. Therefore, rotation around
the protein pyridine thioether bond caused a significant reduction of especially
the axial component of the tensor. On the other hand if a tensor could be cre-
ated where the z-axis of the tensor and the thioether bond are perfectly aligned
then a rotation around this bond would only average the rhombic component
of the tensor. Future study should focus on restricting the tensors mobility and
reducing the losses caused by rotational motions. Increasing the tags intrinsic
tensor parameters is still desirable but considering the loss of almost 80% of
the potential makes this approach less efficient.
7 . 7 DECREAS ING ELECTRON DENS ITY OF THE COORD INAT ING
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7 . 7 . 1 Retrosynthetic analysis and considerations
We thought one alternative way to circumvent the protein dimerization would
be to enhance the tagging reaction rate. Changing the leaving group was
unsuccessful therefore a change of the pyridine ring was needed. One way
the reduce the electron density of the pyridine ring even further would be
to replace the fluorine group with a nitro group. Unfortunately, the required
nitro bromo methyl pyridine was not readily commercially accessible. There-
fore, we envisioned to synthesize the compound 174 by nitration of hydroxy
methyl pyridine 175 and a subsequent hydroxy to bromine transformation
(see Scheme 45). This would install the nitro group on the 3 position and not
on the 5 position of the coordinating pyridine ring. However, as long as the
electron withdrawing group is ortho to the leaving group the stabilizing effect
should take place. With the nitro bromo methyl pyridine 174 in hand we
could apply the same procedure as for all previously shown pyridine phenyl
sulfones.
176 174 177 175
Scheme 45: Retrosynthetic analysis for the synthesis of the nitrated alpha bromo
pyridine phenyl sulfone 176.
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7 . 7 . 2 Synthesis of NO2PySO2Phe
The nitration of hydroxy methyl pyridine 175 was challenging and did only
proceed if fuming nitric acid was used. We were surprised that upon heating
of the reaction mixture not only the desired mononitrated species was formed.
We also observed significant formation of the dinitro compound which is
rather unusual for a deactivated pyridine ring. Surprisingly upon prolonged
heating also the methyl group got oxidized and decarboxylated yielding 3,
5-dinitropyridin-4-ol as the only product. Finally, best results were obtained
by nitrating methyl hydroxy pyridine 175 at 0-5  C to 20-25  C for 3 h. The
product precipitated out of solution after the reaction mixture was poured
on ice. The hydroxy nitro methyl pyridine 177 was then further reacted with
phosphoroxy bromide forming the nitro bromo methyl pyridine 174 in very
low yield after purification by flash column chromatography. The nucelo-
philic aromatic substitution with thiophenol was accomplished in quantitat-
ive yield. We already noticed during the oxidation of the fluorinated leaving
groups that removing electron density from both rings severely hinders the
oxidation of the thioether to the sulfone. First, we oxidized the thioether 178
with sodium tungstate and hydrogen peroxide at 20-25  C for 24 h and found
conversions of only 20%. However, upon heating of the reaction mixture
significant amount of the overoxidized by-product (N-oxide sulfoxide) was
detected. We found that best results were obtained by oxidizing the start-
ing material at 20-25  C for an extended period of time. After conversion
of 50-60% was reached the reaction started to slow down dramatically and
the product was recovered by preparative HPLC. With the compound 179 in
hand we tested its reactivity and benchmarked it against the fluoro analogue
156. We were delighted to see that the nitro compound 179 reacts several
order of magnitude faster with our model compound (N-acetyl cysteine) than
the fluoro compound 156. Unfortunately we were not able to perform a free
radical bromination with the compound 179. It was, therfore, not possible to
synthesize the alpha bromo 3-nitro pyridine 4-phenyl sulfone 176. However,
it was possible to synthesize the methyl thioether 180 and perform a free
radical bromination to yield the alpha bromo nitro pyridine methyl sulfide
181. We chose to perform the free radical bromination before the oxidation
to avoid having a too deactivated aromatic system. Compound 181 was then
further reacted with three times tert-butyllactic acid alkylated M4-cyclen 129.
To our great surprise we found that a nucleophilic substitution did occur on
the nitro position and not on the bromo position. It turned out that the nitro
position is more reactive. Although, the initial results were promising we
were not able to synthesize a nitro analogue of Ln-M7FPySO2Ph-DOTA.
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175 177 174 178
179180
181 176
Scheme 46: Synthesis of nitro based linkers 179 and 181. Reaction Conditions:
i.) HNO3 90%, H2SO4, 0-5  C - 20-25  C, 3 h; ii.) POBr3, toluene, reflux, 18 h;
iii.) thiophenol, K2CO3, DMF, 80  C, 70min; iv.) Na2WO4, H2O2, MeOH, 20-
25  C, 72  C; v.) NaSCH3, K2CO3, DMF, 70  C, 18 h, NBS, AIBN, CCl4, reflux,
6 h
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SYNTHES I S AND APPL ICAT ION OF
M7PYTH IAZOL -DOTA
8 . 1 RETROSYNTHET IC ANALYS I S AND CONS IDERAT IONS
Toda et al. showed that certain activated hetroaromatic systems like tetrazole,
oxadiazole, triazole and benzothiazole are suceptible towards nucleophilic
substitutions.127 Some derivatives achieved similar kinetics than maleimides
for the conjugation to cysteines. For our tag design we envisioned to syn-
thesize a methyl substituted benzothiazol analogue, because this molecule
is relatively short and rigid. However, for coordination with the lanthanide
a coordinating atom is required. Therefore, we planned to replace carbon
seven by a nitrogen atom generating a pyridinethiazol (see Scheme 47). A
pyridinethiazol should be even more reactive than their corresponding ben-
zothiazol counterparts due to the enhanced delocalization of electron density
towards the nitrogen. The target molecule, alpha bromo pyridinethiazol 182,
could be synthesized by forming the intermediate pyridinethiazol via a nuc-
leophilic aromatic substitution of 6-methyl 3-amino 2-bromo pyridine 183
and potassium ethylxanthate (184). A subsequent alkylation and oxidation
followed by a free radical bromination would produce the required alpha
bromo pyridinethiazol 182.
8 . 2 SYNTHES I S OF M7PYTH IAZOL -DOTA
Starting from commercially available amino bromo methyl pyridine 183 we
synthesized the pyridinethiazol 186 in excellent yield. Nucleophilic substi-
tution with iodomethane was high yielding and after purification by flash
column chromatography the methylated intermediate 187 was obtained. We
found that our standard oxidizing procedure (sodium tungstate and hydrogen
peroxide) offered a very low conversion. We applied mCPBA in dichloro-
methane instead and obtained full conversion within one hour. This finding
was remarkable and might have also been applicable to the more difficult
cases obtained earlier. Free radical bromination was carried out and similar
yields were obtained. The alkylation with threefold alkylated M4-cyclen 129
progressed similarly and the yields were comparable. However upon aqueous
acidic deprotection we found that hydrolysis of the methyl sulfone took place.
Therefore, the yield dropped dramatically to 41% for the deprotection step.
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Scheme 47: Retrosynthetic analysis for the synthesis of Ln-M7PyThiazol-DOTA
185.
The metallation with Ln3+ in aqueous ammonium acetate at 80  C was espe-
cially low yielding for Tm whereas Lu performed only slightly worse than
for the pyridine based analogues. In this case we also observed hydrolysis
during the metallation step. Further study revealed that the target compounds
188 and 189 are not stable in pure water at elevated temperatures. However
the thioether compound 187 was very stable and did not hydrolyse under
these conditions. Therefore for future synthesis of different lanthanide tags
an adopted procedure was used.
In order to avoid the large losses caused by the hydrolysis we performed a
free radical bromination on the thioether 187. The yield for this reaction was
significantly lower, however, due to the availability of the inexpensive starting
materials this route was further used. Alkylation of the three times alkylated
M4-cyclen 129 was performed with similar yields. We found that the yield
for the deprotection step was increased by a factor of two. We were delighted
to see that metallations with Tb, Dy and Sm were higher yielding and the
final oxidation worked smoothly in good yields. This approach offered an
increased overall yield and was therefore definitely preferred although an
additional reaction step was required.
8 . 3 TAGG ING OF UB IQU IT IN S57C AND K48C
Two different ubiqutin mutants S57C and K48C were tagged at 20-25  C in
10mM phosphate buffer, 0.45mM TCEP at pH 7.0. We adjusted the protein
concentrations to 150 µM and a fourfold excess of M7FPy-DOTA loaded
with Lu, Tm, Dy, and Tb was used. The tagging progress was monitored by
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Scheme 48: Synthesis of tags 188 and 189. Reaction Conditions: i.) potassium
ethyl xanthogenate, DMF, 130  C, 18 h; ii.) CH3I, K2CO3, MeCN, acetone, 20-
25  C, 2 h; iii.) mCPBA, DCM, 0-5  C - 20-25  C, 1 h; iv.) NBS, AIBN, CCl4,
reflux, 2.4 h; v.) K2CO3, MeCN, 20-25  C, 18 h; vi.) MeCN, aq. HCl 1 M, 65  C,
2 h; vii.) Ln3+, aq. NH4OAc 100mM, 80  C, 18 h.
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195196 Ln = Tb197 Ln = Dy
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199 Ln = Tb
200 Ln = Dy
201 Ln = Sm
Scheme 49: Synthesis of tags 199 - 201. Reaction Conditions: i.) NBS, AIBN,
CCl4, reflux, 4 h; ii.) K2CO3, MeCN, 20-25  C, 18 h; iii.) MeCN, aq. HCl 1 M,
65  C, 2 h; iv.) Ln3+, aq. NH4OAc 100mM, 80  C, 18 h; v.) mCPBA, DCM, 0-
5  C - 20-25  C, 18 h.
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LC-ESI-MS. We were delighted to find that upon addition of the tag within
less than five minutes a conversion of more than 80% and within 15 minutes
greater than 95% was reached (see Figure 8.1).
Figure 8.1: Reaction kinetics measured by LC-ESI-MS for M7FPySO2Phe-
DOTA and M7PySO2MeThiazol-DOTA in 10mM phosphate buffer pH 7.0
at 20-25  C. Protein concentrations were adjusted to 150 µM.
To ensure completion of tagging the reaction was prolonged for additional
four hours. We knew from the synthesis of the tag that hydrolysis of the tag
might occur in aqueous conditions. We found no evidence for the hydrolysed
tag, however, we detected the degradation product formed by the tag upon
reaction with TCEP. The M7PyThiazol-DOTA as well as the M7FPy-DOTA
type tags are more reactive than M7Py-DOTA type tags and thus do react with
TCEP. We also incubated ubiquitin S57C samples with M7Pythiazol-DOTA
for two days and found that under the applied conditions only cysteines are
reactive enough to conjugate to the tag. For example lysine or serine residues
did not react with the tag. M7PyThiazol-type tags do release methylsulfinic
acid upon conjugation which quickly hydrolyses to SO2 and methanol. There-
fore, no dimerization due to the formation of benzenesulfinic acid should
occur. Upon close inspection of the paramagnetic 1H-15N HSQC spectra we
found a second unshifted species. We compared the integrals in the 2D HSQC
spectra and found that the amount of this species varied between (10-20%)
going from Tm to Dy. This difference in intensity could be attributed to the
difference in PRE strength. In order to get a better estimate of the percentage
of untagged protein we tagged ubiquitin S57C with Sm-M7PyThiazol-DOTA.
Sm has only a weak PRE and therefore the intensity should be affect to a
lower extent. Unfortunately most signals also did not shift because Sm has in
general only a very small tensor. We found three shifted signals and compared
their intensities and found that greater 95% of the protein was tagged which
is in agreement with the LC-ESI-MS measurement. We tried to push the reac-
tion to 100% by retagging an already tagged sample. We found no significant
difference in comparison to the only once tagged samples. The nature of the
102 SYNTHES I S AND APPL ICAT ION OF M7PYTH IAZOL -DOTA
untagged species remains unclear. We speculate that to a small degree the
cysteine free thiol gets chemically modified (i.e. oxidation or methylation)
and is no longer capable of performing a nucleophilic aromatic substitution.
Nevertheless tagging efficiencies of greater 95% are perfectly acceptable for
PCS NMR spectroscopy. We could only detect the second species due to the
relative small size of ubiquitin. In NMR data obtained from larger proteins
this second species will most likely disappear in the noise due to the limited
signal-to-noise.
8 . 4 IN -V ITRO NMR ANALYS I S
We recorded 2D 1H-15N HSQC spectra at 600 MHz for both mutants tagged
with Lu, Tm, Dy and Tb loaded M7PyThiazol-DOTA. In the case of ubiquitin
S57C we found that Tm-M7PyThiazol-DOTA 189 almost exclusively offers
positive shifts while Dy-M7PyThiazol-DOTA 200 and Tb-M7PyThiazol-
DOTA 199 offer predominately negative shifts. On the other hand for the
K48C mutant we observed mixed positive and negative shifts for all three
paramagnetic lanthanides. In general we found that terbium and dysprosium
both shift in the same direction with dysprosium being stronger while thulium
shifts to the opposite. For both mutants we obtained large measurable pseudo-
contact shifts reaching up to ten ppm (see Figure 8.2, 8.3, 8.4 and 8.5). We
also detected strong cross-peak splitting in 2D 1H-15N IPAP-HSQC spectra
due to paramagnetic alignment of ubiquitin and resulting RDC effects (amp-
litudes reaching 30 Hz at 298K, 600MHz).
We determined magnetic susceptibility tensor parameters for both mutants
using the program Numbat74 (see Table 8.1 and 8.2). The tensor are repres-
ented in Figure 8.6 and 8.7. The alignment of the tensors main axes with the
protein remains constant. The observed tensor for thulium is tilted by 90° in
comparison to terbium and dysprosium resulting in shifts going the opposite
direction. We found that tensor parameters for terbium are smaller than for
dysprosium however their overall shape looks similar. The ratio between the
axial and rhombic component of the magnetic susceptibility tensor describes
the overall shape of the tensor. In the case of thulium the ratio is very large
resulting in an tensor with an overall shape similar to a dz2 orbital whereas the
ratio is small for terbium resulting in an overall shape similar to a dxy orbital.
We found that the tensor parameters for the Tm-M7PyThiazol-DOTA are
twice as large as for Tm-M7FPy-DOTA. This fact shows the great potential
of the pyridine thiazol based tags as they only loose roughly 50% of their
intrinsic tensor if measured on the protein if compared to tensor parameters
obtained for the free Tm-M7FPySO2Phe-DOTA 158.
Upon closer inspection of the two coordination geometries for M7FPy-
DOTA and M7PyThiazol-DOTA type tags we concluded that the gain in
performance can not simply be explained by the rigidity or the absolute dis-
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Figure 8.2: In-vitro PCS effects by metal-loaded M7PyThiazol-DOTA. Superposi-
tion of full 2D 1H-15N HSQC spectra of ubiquitin S57C coupled to diamagnetic
Lu-M7PyThiazol-DOTA (black) and paramagnetic Tm-M7PyThiazol-DOTA (red),
Tb-M7PyThiazol-DOTA (blue) and Dy-M7PyThiazol-DOTA (orange) at 600MHz
and 298K. Water signal removed for clarity.
Figure 8.3: Correlation graphs between PCSs calculated from the X-ray structure
1UBI and the experimental in-vitro PCSs obtained for Tm-M7PyThiazol-DOTA
(red), Tb-M7PyThiazol-DOTA (blue) and Dy-M7PyThiazol-DOTA (orange) at 600
MHz and 298K on ubiquitin S57C. Hollow markers indicate PCSs not used during
the fit displayed in Table 8.1.
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Figure 8.4: In-vitro PCS effects by metal-loaded M7PyThiazol-DOTA. Superposi-
tion of full 2D 1H-15N HSQC spectra of ubiquitin K48C coupled to diamagnetic
Lu-M7PyThiazol-DOTA (black) and paramagnetic Tm-M7PyThiazol-DOTA (red),
Tb-M7PyThiazol-DOTA (blue) and Dy-M7PyThiazol-DOTA (orange) at 600MHz
and 298K. Water signal removed for clarity.
Figure 8.5: Correlation graphs between PCSs calculated from the X-ray structure
1UBI and the experimental in-vitro PCSs obtained for Tm-M7PyThiazol-DOTA
(red), Tb-M7PyThiazol-DOTA (blue) and Dy-M7PyThiazol-DOTA (orange) at 600
MHz and 298K on ubiquitin K48C. Hollow markers indicate PCSs not used during
the fit displayed in Table 8.2.
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Table 8.1: In-vitro PCS tensor parameters for ubiqutin S57C fitted
against the ubiqutin X-ray structure (PDB code: 1UBI).
Tm, 74 PCS Dy, 66 PCS Tb, 72 PCS
Dcax / 10 32m3 35.4 (0.6) 41.9 (0.8) 30.8 (1.1)
Dc rh / 10 32m3 11.3 (0.7) 26.1 (0.5) 19.6 (0.7)
x / Å 20.5 (0.2) 20.5 (0.2) 20.5 (0.2)
y / Å 15.1 (0.1) 15.1 (0.1) 15.1 (0.1)
z / Å 6.3 (0.2) 6.3 (0.2) 6.3 (0.2)
a / ° 50.3 (1.6) 145.9 (1.3) 146.5 (0.9)
b / ° 44.0 (0.9) 84.3 (1.1) 84.5 (1.3)
g / ° 17.9 (3.0) 138.4 (2.6) 132.0 (4.1)
Tensor parameters (errors) were calculated in Numbat74 from the indic-
ated number of selected PCS. All tensors are represented in the unique
tensor representation UTR. Only amino acids residing in a stable second-
ary structure (2-7, 12-16, 23-34, 38-40, 41-45, 48-49, 56-59 and 66-71)
were used if present in the spectra.
(a) Tm (b) Dy (c) Tb
Figure 8.6: Tensor representation of Tm, Dy and Tb-M7PyThiazol-DOTA tagged to
ubiquitin S57C. The red isosurfaces indicate a shift of -3 ppm (inner) and -1 ppm
(outer). The blue isosurfaces indicate the corresponding positive shift.
(a) Tm (b) Dy (c) Tb
Figure 8.7: Tensor representation of Tm, Dy and Tb-M7PyThiazol-DOTA tagged to
ubiquitin K48C. The red isosurfaces indicate a shift of -3 ppm (inner) and -1 ppm
(outer). The blue isosurfaces indicate the corresponding positive shift.
106 SYNTHES I S AND APPL ICAT ION OF M7PYTH IAZOL -DOTA
Table 8.2: In-vitro PCS tensor parameters for ubiqutin K48C fitted
against the ubiqutin X-ray structure (PDB code: 1UBI).
Tm, 70 PCS Dy, 70 PCS Tb, 72 PCS
Dcax / 10 32m3 47.4 (1.7) 58.0 (2.0) 36.0 (1.3)
Dc rh / 10 32m3 8.3 (1.3) 24.6 (1.0) 21.8 (0.9)
x / Å 19.0 (0.2) 19.0 (0.1) 19.0 (0.1)
y / Å 18.6 (0.2) 18.6 (0.1) 18.6 (0.1)
z / Å 22.8 (0.1) 22.8 (0.1) 22.8 (0.1)
a / ° 88.3 (0.5) 8.5 (0.5) 7.1 (0.4)
b / ° 81.5 (1.1) 71.2 (0.8) 70.7 (1.1)
g / ° 143.9 (2.1) 178.2 (2.5) 5.0 (1.1)
Tensor parameters (errors) were calculated in Numbat74 from the indic-
ated number of selected PCS. All tensors are represented in the unique
tensor representation UTR. Only amino acids residing in a stable second-
ary structure (2-7, 12-16, 23-34, 38-40, 41-45, 48-49, 56-59 and 66-71)
were used if present in the spectra.
tance from the metal to the protein. The rigidity is in both cases very similar
as there is only on rotatable bond between the tag and the cysteine. In ad-
dition the relative distance from the metal center to the attachment point is
almost identical (5.4Å to 5.6Å). Therefore we hypothesize that the differ-
ence most likely originates from the different axis of rotation with respect
to the protein (see Figure 8.8). The alignment of the tensors principle z-axis
with the rotatable bond axis is much better for M7PyThiazol-DOTA than
for M7FPy-DOTA. This presumably causes smaller averaging effects of the
tensors anisotropy especially for the axial component. A rotation around the
linkage cases larger averaging effects for M7FPy-DOTA than for M7PyThia-
zol-DOTA due to the higher probability of crossing a node plane of the tensor.
In ideal cases the rotation occurs around the tensors principle z-axis causing
only averaging effects to the rhombic component of the anisotropy tensor.
8 . 4 . 1 Determination of the absolute configuration for M7PyThiazol
The configuration of the basal 4(S)-M4-cyclen is locked in (dddd ) configur-
ation as there is no possibility to form a (llll ) tag because the four methyl
group on the base ring would need to adopt a sterically very unfavourable
axial position. However, for the side arms two configurations are possible:
D counter-clockwise and L clockwise. Both configurations are possible for
(8S)-M8-DOTA tags and their relative percentage varies with the size of the
lanthanide having a 27/73 ratio for Dy.95 During our tagging experiments we
observed no second set of shifted signals for Dy-M7PyThiazol-DOTA. Fur-
ther investigations of the Lu-M7PyThiazol-DOTA and Sm-M7PyThiazol by
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Figure 8.8: Different attachments sites for M7FPy-DOTA andM7PyThiazol-
DOTA.
NMR clearly showed that both complexes adopt the L configuration. There-
fore we concluded that all complexes between Sm and Lu and most likely
the whole lanthanide series adopts a L configuration with the M7PyThiazol-
DOTA ligand. In addition we fitted the magnetic susceptibility tensor for
the Sm-M7PyThiazol-SO2Me-DOTA and found a correlation coefficient of
0.905 for the D and 0.987 for the L configuration. In addition in NOESY
spectra we only observe NOEs between the side arm methyls and one of
the methyls from the base ring (see Figure 8.9). If the structure would be D
configured we would expect to either observe none or two NOEs between
the side arm methyls and the base ring methyls, because both distances are
almost identical, whereas in the L case one group of methyls is significantly
closer than the other resulting in one observed NOE.
Λ δδδδ Δ δδδδ
Figure 8.9: Possible conformations for M7PyThiazol-DOTA calculated us-
ing DFT.
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9 . 1 CONCLUS ION
It could be shown that nucleophilic aromatic substitution is suitable for pro-
tein tagging reactions. Our first attempt, the pyridine phenyl sulfone based
tag, was successfully applied to tag GB1 and recording in-cell pseudocontact
shifts. The structure of GB1 could be calculated using the Rosetta approach
with the addition of pseudocontact shifts and residual dipolar couplings. The
initial reaction rate was slow and tagging required high temperature for pro-
longed time. We demonstrated that increasing the acidity of the leaving group
has a negligible influence on the overall reaction rate. However, the introduc-
tion of an electron withdrawing group on the coordinating pyridine ring, nitro
or fluorine, increased the reactivity of the linker towards nucleophilic dis-
placement by thiols significantly. The fluoropyridine phenyl sulfone could be
successfully installed on the DOTA framework forming the M7-FPy-DOTA
tag. The reactivity of this tag was significantly improved, and the conjugation
proceeded at room temperature within six hour. The complex kinetics we
observed were primarily due to the formation of benzenesulfinc acid which
catalysed protein dimerization. A sulfonamide as well as aliphatic sulfones
were tested as leaving groups but they showed significantly lower reaction
rates. Although our initial experiments with the fluorine substituted phenyls
as leaving groups clearly demonstrated that an increase in acidity does not
speed up the reaction it was still crucial for the leaving group to be of aromatic
nature. The problem could be avoided using the much more reactive pyridine
thiazol which is highly reactive towards nucleophilic aromatic substitution
especially in the two position. The pyridine thiazol allowed us to use methyl-
sulfinic acid as leaving group, which relatively quickly hydrolyses in aqueous
solution. The tagging reaction with M7-PyThiazol-DOTA is extremely fast at
room temperature under physiological conditions offering a complete tagging
(>95%) within less than one hour. M7FPy-DOTA and M7PyThiazol-DOTA
were both tested on ubiquitin mutants and it could be shown that pyridine
thiazol based tags are far superior to the relatively similar fluoro pyridine
tags not only in reaction speed but also with respect to the size of observable
pseudocontact shifts.
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9 . 2 OUTLOOK
Future experiments should focus on the development of pyridine thiazol
based tags as they are highly reactive and provide large tensor parameters. In
future experiments it should be investigated what the nature of the second
species present in all ubiquitin samples is. Applications to larger proteins
should show whether this is a significant issue or not, as small concentrations
of untagged protein usually disappear in the background noise. Up to now it
remains an open question if tagging would also be possible at lower temper-
atures (5  C). In general, we showed that tagging at pH 7.00 does not cause
tagging of unwanted residues like serine or lysine, however, the highest pH
possible without tagging unwanted amino acid residues has not been determ-
ined. Our prospective experiments with the M7-azaxanthon-DOTA (see Part
III) showed that DOTA based tags potentially could be used for FRET ex-
periments, if a UV harvesting antenna is installed. Future experiments could
reveal if pyridine thiazol or fluoro pyridine -based DOTA tags are suitable
for FRET, as some of the complexes (especially Tb and Eu) are highly lu-
minescent under UV light irradiation at 366 nm (see Appendix for UV/VIS
absorption and emission spectra of Tb-M7PyThiazol-DOTA).
Part III
M I SCELLANEOUS
This part of the thesis focuses on smaller side-projects involving
the usage of lanthanide chelating tags.
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10 . 1 PROSPECT IVE INVEST IGAT IONS OF DOTA-TYPE COM-
PLEXES FOR FRET ANALYS I S .
Apart from being excellent shift reagents, lanthanide complexes can also
serve as valuable probes for FRET spectroscopy. Luminescent lanthanide
complexes have unique spectroscopic properties. They are a result of trans-
itions within the 4f-orbitals. These transitions are symmetry forbidden elec-
tronically induced dipole transitions. This leads to very narrow and well
separated emissions bands and extremely long excited-state lifetimes of up
to milliseconds. Most lanthanide ions have a very low extinction coefficient
in aqueous solutions due to the very efficient quenching with coordinating
water molecules. However many chelating ligands have been developed to
shield the lanthanide ion from solvent influences. The emission bands for
terbium and europium lie in the visible range and therefore, they are used
most often. Nevertheless, dysprosium, samarium and thulium also emit in
the visible range but with lower intensity. Considering the strength of the
measurable pseudocontact shifts terbium should be preferred for a combina-
tion tag, i.e. suitable for both applications simultaneously.128,129 However our
initial experiments focused on europium which is more common for FRET
applications than terbium. Europium also exhibits smaller PREs and thus is
better suited for NMR analysis.
1 0 . 1 . 1 Synthesis and photoluminescence study of Eu-DOTA, Eu-M4-
DOTA and Eu-DOTA
In order to test the photophysical properties of our M8-SSPy-DOTA tag we
synthesized the model compound 202 and its lesser rigidified analogues 203
and 204 (see Scheme 50). The synthesis of Eu-M8-DOTA 202 started from
M4-cyclen 22 while the other two ligands 205 and 206 were commercially
available and used as obtained. We performed metallation using europium
triflate in aqueous ammonium acetate at 80  C for 18 h. The yields were sig-
nificantly higher for the less substituted ligands presumably due to the lower
steric hindrance during the metallation step. We studied the photophysical
properties of these three complexes and found no visible luminescence on
irradiation with UV light at 254 nm and 366 nm. All these complexes lack a
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functional group which could act as UV-light harvesting antenna.
22 207 208
208 202
203205
206 204
Scheme 50: Synthesis of Eu-complexes 202, 203 and 204. Reaction Conditions:
i.) K2CO3, MeCN, 20-25  C, 6 h; ii.) TFA, water, MW: 120  C, 30min; iii.) / iv.)
/ v.) Eu3+, aq. NH4OAc 100mM, 80  C, 18 h
1 0 . 1 . 2 Synthesis and photoluminescence study of Eu-Azaxanthon-M7-
DOTA
It has been shown on DOTA-based tags that the installation of an azax-
anthon leads to emissive lanthanide complexes.130,131 We synthesized Eu-M7-
azaxanthon-DOTA 209 for further photophysical studies. The azaxanthon 210
was prepared from commercially available 6-methyl-2-chloronicotinic acid
(211) and methyl-4-hydroxybenzoate (212) followed by an intramolecular
condensation (see Scheme 51). The free radical bromination of compound
210 was very slow and a reaction time of four days was required to achieve
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a conversion of 70%. The desired monobromide 213 was isolated by flash
column chromatography and reacted with the three times alkylatedM4-cyclen
129. Subsequent deprotection and metallation yielded the desired europium
complex 209.
211 212 214 210
213129215
216 209
Scheme 51: Synthesis of compound 209. Reaction Conditions: i.) NaOMe, neat,
125  C, 24 h; ii.) polyphosphoric acid, 120  C, 18 h; iii.) NBS,AIBN,CCl4, reflux,
4 d; iv.) K2CO3, MeCN, 20-25  C, 18 h; v.) TFA, 20-25  C, 7 h; vi.) Eu3+, aq.
NH4OAc 100mM, 80  C, 18 h
We measured UV/Vis absorption and emission spectra of Eu-Azaxanthon-
M7-DOTA 209 (see Figure A.6) and we found that the complex absorbs in
the UV range with maxima at 248 nm, 289 nm and 334 nm. Very typical for
europium complex we found one very strong and narrow emission band at
614 nm corresponding to the 5D0 ! 7F2 transition. This preliminary res-
ults clearly indicate that M7-DOTA-based tags could potentially be used for
FRET analysis if and only if they are conjugated to a UV harvesting antenna
molecule.
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Figure 10.1: UV/Vis absorption and emission spectrum of Eu-
Azaxanthon-M7-DOTA 209 measured in acetonitrile at 20-25
 C. lex=250 nm.
1 0 . 2 CONJUGAT ION OF M8-DOTA TO SMALL MOLECULES
1 0 . 2 . 1 Conjugation of M8-DOTA to polyproline
This section describes a collaboration project with Dr. Marc-Olivier Ebert
from the ETH Zurich. The Ebert group was interested in studies of a polypro-
line hexamer. Due to the relative small chemical shift range an assignment is
difficult to obtain. We therefore envisioned that conjugation of a M8-DOTA
paramagnetic tag to the N-terminus via an amide bond should greatly in-
crease the observable chemical shift range. We received the Fmoc-protected
polyproline 217 polymer bound. Starting from the Fmoc-protected polypro-
line polymer bound we first performed a deprotection step with piperidine
in dimethylformamide following standard solid phase synthesis procedure
(see Scheme 52). After deprotection we performed a HATU mediated peptide
coupling with the free acid 218 of M8-DOTA. To our surprise we detected
no conjugation to the polyproline. We found that during this reaction the free
acid side-arm got cleaved off forming compound 129. Further investigations
showed that it was possible to conjugate Cbz-alanine 24 to polyproline and
it was also possible to conjugate tert-butyl alanine 25 to the free acid 218 of
M8-DOTA. Therefore, we conclude that only the combination of the anilin
219 and the free acid 218 of M8-DOTA was problematic. Future experiments
should be conducted with a terminal alanine or glycine on the polyproline
side.
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Scheme 52: Reaction Conditions: i.) Piperidine, DMF, 20-25  C, 30min.
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1 0 . 2 . 2 Conjugation of M8-DOTA to Pittsburgh compound B
This section describes a collaboration project with Dr. Carlos Geraldes from
the university of Coimbra. Their research focused on the Pittsburgh com-
pound B (PiB) which has been used as amyloid affinity probe for the in-vivo
positron emission tomography detection of amyloid beta deposits in the brain
caused by Alzheimer’s disease.132,133 The key idea was to produce a M8-
DOTA-PiB conjugate which efficiently binds to Gd3+ or Ga3+ and has a
positive logP in order to be able to cross the blood-brain barrier. Our study
focused on the conjugation of M8-DOTA to PiB and the formation of a Gd3+
complex. We received samples of the free amine with a C6 and C10 linker.
We coupled the free amine 221 with the C6 linker to the free acid 218 of
M8-DOTA and deprotected the tert-butyl groups with hydrogen bromide
solution in acetic acid. The free ligand 222 was not soluble in water and the
metallation was conducted in dimethylformamide (see Scheme 53). The final
product was purified by preparative HPLC and sent back for further studies.
We also tried the same procedure for the C10 analogue but all yields were
significantly lower and the final metallation step failed.
218 221 222
223
Scheme 53: Synthesis of compound 223. Reaction Conditions: i.) HATU,
DIPEA, MeCN, 20-25  C, 1 h; ii.) HBr in AcOH, 40  C, 20min.
10.3 PROSPECT IVE INVEST IGAT IONS FOR A DOTA-TYPE TAG SU ITABLE
FOR PCS NMR SPECTROSCOPY ON RNA
119
10 . 3 PROSPECT IVE INVEST IGAT IONS FOR A DOTA-TYPE TAG
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Generating pseudocontact shifts on a DNA or RNA most often requires con-
jugation of the tag to the backbone. Wu et al.134 showed that DOTA-type
tags can be conjugated to a phosphorothioate group. If this group resides in
between the backbone two diastereomers are formed. Avoiding the formation
of two diastereomers would only be possible upon conjugation of the tag to
a terminal phosphorothioate group. However, attaching a tag at the end will
most likely result in a very flexible and highly mobile tag which generates
only little PCS.
1 0 . 3 . 1 Design and Synthesis of a p-p stacking linker
We envisioned that a biphenyl linker could provide additional non-covalent
interactions to stabilize the tag in one specific location (see Figure 10.2). We
proposed that such a tag could be easily synthesized by reaction of Ln-M7FPy-
DOTA with an excess of 4,40-Bis(mercaptomethyl)biphenyl followed by the
activation with 2,20-Dithiodipyridine.
π–π stacking
Ln-M7FPy-DOTA
Figure 10.2: Representation of the envisioned interaction between the bi-
phenyl linker and the last base pair.
We first synthesized the paramagnetic Tm-M7-FPy-S-Biphenyl-SSPy-
DOTA 224 starting from Tm-M7FPy-DOTA 158. The phenyl sulfone was
substituted and the intermediate product was purified by preparative HPLC
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and further activated with 2,20-Dithiodipyridine in an overall yield of 24%
(see Scheme 54). The yields were low, especially for the nucleophilic aro-
matic substitution. Although we used a large excess of the thiol, the dimerized
compound could still be detected. Nevertheless, the tag could be synthesized
and the identity was confirmed by HR-ESI-MS. Further experiments should
reveal its potential for PCS NMR spectroscopy of DNA and or RNA.
158 224
Scheme 54: Synthesis of compound 224. Reaction Conditions: i.) 4,40-Bis(mer-
captomethyl)biphenyl, K2CO3, MeCN, 2 h, 20-25  C; ii.) 2,20-Dithiodipyridine,
AcOH, MeOH, 2 h, 20-25  C.
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METHODS AND MATER IALS
REAGENTS
All chemicals were used as purchased without further purification if not stated
otherwise.
NMR SPECTROSCOPY
All NMR experiments were performed at 298K if not stated otherwise.
Small molecules
NMR 250MHz, 400MHz and 500MHz experiments were performed on a
Bruker Avance III NMR spectrometer equipped with a direct observe 5mm
BBFO smart probe. NMR 600MHz experiments were either recorded on a
Bruker Avance III NMR spectrometer equipped with a direct observe 5mm
BBFO smart probe or on a Bruker Avance III HDNMR spectromete equipped
with a cryogenic 5mm four-channel QCI probe (H/C/N/F). NMR samples
were purified by preparative HPLC and stabilized with trifluoroacetic acid if
needed.
Protein Samples
GB1 protein NMR samples were recorded in 20mM phosphate buffer pH
7.00. All ubiquitin samples were recorded in 10mM phosphate buffer pH
6.00. All spectra were either recorded on a Bruker Avance III NMR spec-
trometer equipped with a direct observe 5mm BBFO smart probe or on a
Bruker Avance III HD NMR spectrometer equipped with a cryogenic 5mm
four-channel QCI probe (H/C/N/F).
MS SPECTROSCOPY
Small organic molecules were measured on a Bruker Daltonics Esquire 3000
plus spectrometer using concentrations between 1-10 µgmL−1 in methanol or
acetonitrile with 0.1% trifluoroacetic acid or using the direct injection mode
124 METHODS AND MATER IALS
of the analytic HPLC-ESI-MS.
HR-ESI-MS spectra were measured on a Bruker MaXis 4G HiRes ESI Mass
Spectrometer using concentrations between 1-10 µgmL−1 in methanol or acet-
onitrile with 0.1% trifluoroacetic acid.
HPLC -ES I -MS
A Shimadzu LC 20 System equipped with a Shimadzu Fraction Collector
(FRC-10A) and a Shimadzu LSMS-2020 was used. Oven temperature was
set to 40  C.
Analytical method
• Column: ReprosilPur120 ODS-3 3 µm 150x3mm
• Solvent A: Water + 0.1% TFA
• Solvent B: 90% Acetonitrile + 10% water + 0.085% TFA.
• Flow rate: 1.0 ml/min
• UV Detector: set to 254 and 280 nm
• Gradient: 2 minutes at 5% B followed by a gradient over 4min from
5% B to 100% B. These conditions were kept for 8min followed by
a gradient from 100% B to 5% B over 1min. These conditions were
kept constant for another 7min.
• ESI-MS: positive mode 100-1500 m/z.
Preparative method
• Column: Reprosil-Pur 120 ODS-3 5 µm 30x20mm
• Solvent A: Water + 0.1% TFA
• Solvent B: 90% Acetonitrile + 10% water + 0.085% TFA.
• Flow rate: 10.0 ml/min
• UV Detector: set to 254 and 280 nm
• Gradient: 2 minutes at 5% B followed by a gradient over 7min from
5% B to 100% B. These conditions were kept for 7min followed by
a gradient from 100% B to 5% B over 1min. These conditions were
kept constant for another 2min.
• ESI-MS: positive mode 100-1500 m/z.
• Fraction Collector sample volume: 5-10mL
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HPLC
A Waters Prep LC 4000 System equipped with a Waters 2487 Dual Absorb-
ance Detector and a Waters 740 Data Module was used.
Preparative method
• Column: Reprosil-Pur 120 ODS-3 5 µm 30x20mm
• Solvent A: Water + 0.1% TFA
• Solvent B: 90% Acetonitrile + 10% water + 0.085% TFA.
• Flow rate: 10.0 ml/min
• UV Detector: set to 254 and 280 nm
• Gradient: 2 minutes at 10% B followed by a gradient over 20min from
10% B to 50% B. These conditions were kept for 3min followed by a
gradient from 50% B to 100% B over 10min. These conditions were
kept constant for another 10min before the column was equilibrated to
the starting conditions.
• Fraction Collector sample volume: 10-20mL
UV-V I S SPECTROSCOPY
UV-VIS spectra were recorded on an Agilent Technologies UV-Visible 8453
spectrophotometer in HPLC-grade solvents.
PHOTOLUMINESCENCE
The photoluminescence measurements were performed on a Shimadzu RF-
5301PC spectrofluorophotometer or on a Fluorolog Horiba Jobin Yvon spec-
trofluorophotometer.
PROTE IN TAGG ING
All protein samples were incubated for 1-18 h in a 10mM phosphate buffer
pH 7.00 with 2mM TCEP. The buffer was exchanged by means of serial
ultrafiltration (3x) in 10mM phosphate buffer, 0.45mM TCEP at pH 7.0
(Amicon Ultra-4, MWCO 3 kDa, Millipore). Protein tagging reactions were
carried out in 10mM phosphate buffer pH 7.00 at 20-25  C for 2-24 h. The
protein concentration was adjusted to 100-150 µM and a 4-6 fold excess of
tag was used. Protein samples were shaken in a Thermo-Shaker Grant-bio.
GB1 protein samples were tagged in 50mM phosphate buffer pH 7.6, 0.5mM
TCEP at 40-45  C and protein concentrations were adjusted to 300 µM.
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DFT CALCULAT IONS
DFT calculations were performed at sciCORE (http://scicore.unibas.ch/)
scientific computing core facility at University of Basel. All lanthanide
containing complexes were geometry optimized using ORCA135,136 the
SARC2137 basis set, BP86 functional and the zeroth order regular approx-
imation (ZORA).
CENTR I FUGAT ION
Centrifugation steps were carried out using a Hettich Universal 320 R centri-
fuge at 7380 rpm (6750 g).
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tert -BUTYL ( (BENZYLOXY)CARBONYL) -L -ALANYL -L -ALAN IN -
ATE (26 ) .
N-Benzyloxycarbonyl-L-alanine (12.3 g, 55.1mmol, 1.0 eq.) and HATU
(23.0 g, 60.6mmol, 1.1 eq.) were suspended in acetonitrile (100mL). N-ethyl
diisopropylamine (7.85 g, 60.6mmol, 1.1 eq.) was added and the mixture
turned to a yellow solution. A solution of L-alanine tert-butyl ester hydro-
chloride (10.0 g, 55.1mmol, 1.0 eq.) and N-ethyl diisopropylamine (7.85 g,
60.6mmol, 1.1 eq.) in acetonitrile (100mL) was added while maintaining the
temperature between 20-25  C. The yellow solution was stirred for 3.5 h and
then evaporated to dryness yielding a dark yellow oil. This oil was dissolved
in ethyl acetate (200mL) and extracted with aqueous citric acid (10%, 4x
50mL), aqueous saturated sodium hydrogen carbonate (2x 50mL) and brine
(50mL). The organic layer was dried with sodium sulphate and evaporated
to dryness yielding a yellow oil (33.5 g). The yellow oil was purified by flash
column chromatography (SiO2, ethyl acetate) yielding a yellowish oil. The
oil was dried under high vacuum yielding a white foam (18.9 g, 54.0mmol,
97.9%).
HR-ESI-MS: calcd. for [26+Na]+ C18H26N2NaO5 m/z= 373.1734, found
m/z= 373.1733.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 8.15 (d, 3JHH = 7.1Hz, 1
H, H5), 7.40 (d, 3JHH = 7.6Hz, 1H, H1), 7.38-7.28 (m, 5H, H14, H15, H16),
5.02 (d, 2JHH = 12.9Hz, 1H, H12a), 4.99 (d, 2JHH = 12.9Hz, 1H, H12b),
4.11 (dq, 3JHH = 7.1Hz, 3JHH = 7.3Hz, 1H, H6), 4.08 (dq, 3JHH = 7.6Hz,
3JHH = 7.3Hz, 1H, H2), 1.38 (s, 9H, H10), 1.24 (d, 3JHH = 7.3Hz, 3H, H8),
1.21 (d, 3JHH = 7.3Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 172.32 (1C, C3),
171.68 (1C, C7), 155.60 (1C, C11), 137.06 (1C, C13), 128.32 (2C, C15),
127.75 (1C, C16), 127.69 (2C, C14), 80.26 (1C, C9), 65.27 (1C, C12), 49.58
(1C, C2), 48.25 (1C, C6), 27.57 (3C, C10), 18.21 (1C, C4), 16.89 (1C, C8).
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( (BENZYLOXY)CARBONYL) -L -ALANYL -L -ALAN INE (27 ) .
tert-Butyl ((benzyloxy)carbonyl)-L-alanyl-L-alaninate (26) (19.3 g,
55.1mmol, 1.0 eq.) was dissolved in dichloromethane (100mL), tri-
fluoroacetic acid (40mL) and water (4mL) at 0-5  C. The reaction mixture
was warmed up to 20-25  C and stirred for 2 h before filtered through celite.
The filtrate was evaporated to dryness yielding a yellowish oil. The oil was
dissolved in ethyl acetate (100mL) and extracted with aqueous saturated
sodium hydrogen carbonate (1x 100mL, 2x 50.0mL). The combined
aqueous layers were acidified with aqueous hydrochloric acid (37%) and
extracted with ethyl acetate (3x 80.0mL). The combined organic layers were
dried with sodium sulphate and evaporated to dryness yielding a yellowish
oil. The oil was dried under high vacuum yielding an off-white solid (15.3 g,
52.0mmol, 94.3%).
HR-ESI-MS: calcd. for [27+Na]+ C14H18N2NaO5 m/z= 317.1108, found
m/z= 317.1107.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 8.12 (d, 3JHH = 7.3Hz,
1H, H5), 7.40 (d, 3JHH = 7.8Hz, 1H, H1), 7.39-7.25 (m, 5H, H12, H13,
H14), 5.03 (d, 2JHH = 12.5Hz, 1H, H10a), 4.99 (d, 2JHH = 12.5Hz, 1
H, H10b), 4.19 (dq, 3JHH = 7.8Hz, 3JHH = 7.4Hz, 1H, H2), 4.07 (dq,
3JHH = 7.3Hz, 3JHH = 7.2Hz, 1H, H6), 1.27 (d, 3JHH = 7.4Hz, 3H, H4),
1.20 (d, 3JHH = 7.2Hz, 3H, H8).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 174.49 (1C, C7),
172.75 (1C, C3), 156.07 (1C, C9), 137.52 (1C, C11), 128.80 (2C, C13),
128.24 (1C, C14), 128.18 (2C, C12), 65.77 (2C, C10, C6), 47.85 (1C, C2),
18.62 (1C, C8), 17.62 (1C, C4).
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tert -BUTYL L -ALANYLL -ALAN INATE (28 ) .
tert-Butyl ((benzyloxy)carbonyl)-L-alanyl-L-alaninate (26) (51.3 g, 146mmol,
1.0 eq.) was dissolved in methanol (300mL). Palladium on activated charcoal
(moistened with water, 10% Pd basis, 15 g) was added and the mixture was
stirred at 20-25  C under 1.0 bar of hydrogen for 2 h. The suspension was
filtered through celite, washed with methanol (50.0mL) and evaporated to
dryness yielding a yellowish oil (29.4 g, 136mmol, 93.1%).
HR-ESI-MS: calcd. for [28+H]+ C10H21N2O3 m/z= 217.1547, found m/z=
217.1548.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 8.05 (d, 3JHH = 7.1Hz, 1H,
H5), 4.12 (dq, 3JHH = 7.1Hz, 3JHH = 7.3Hz, 1H, H6), 3.26 (q, 3JHH = 6.8Hz,
1H, H2), 1.98 (bs, 2H, H1), 1.39 (s, 9H, H10), 1.25 (d, 3JHH = 7.3Hz, 3H,
H8), 1.12 (d, 3JHH = 6.8Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 175.49 (1C, C3),
171.82 (1C, C7), 80.39 (1C, C9), 49.85 (1C, C2), 47.95 (1C, C6), 27.89 (3C,
C10), 21.57 (1C, C4), 17.31 (1C, C8).
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tert -BUTYL ( (BENZYLOXY)CARBONYL) -L -ALANYL -L -ALANYL -
L -ALANYL -L -ALAN INATE (29 ) .
((Benzyloxy)carbonyl)-L-alanyl-L-alanine (27) (40.0 g, 136mmol, 1.0 eq.)
was suspended in acetonitrile (450mL) and N-ethyl diisopropylamine
(27mL). To this suspension dimethylformamide (18.0 g) was added forming
a clear solution. To this solution HATU (51.7 g, 163mmol, 1.2 eq.) was added.
The solution turned yellow immediately and was further stirred for 5min. A
solution of tert-butyl L-alanylL-alaninate (28) (29.4 g, 136mmol, 1.0 eq.) in
acetonitrile (100mL) was added while maintaining the temperature between
20-25  C. The resulting suspension was stirred for 2 h at 20-25  C before the
product was filtered off and washed with acetonitrile (100mL) and diethyl
ether (200mL). The product was dried and recrystallized from acetonitrile
yielding an off-white solid (31.0 g, 62.9mmol, 46.3%).
HR-ESI-MS: calcd. for [29+H]+ C24H37N4O7 m/z= 493.2657, found m/z=
493.2656.
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1H-NMR (500.13MHz, 298K, DMSO d6): d = 8.14 (d, 3JHH = 7.0Hz,
1H, H13), 7.96 (d, 3JHH = 7.4Hz, 1H, H5), 7.87 (d, 3JHH = 7.5Hz, 1H,
H9), 7.48 (d, 3JHH = 7.5Hz, 1H, H1), 7.38-7.26 (m, 5H, H20, H21, H22),
5.03 (d, 2JHH = 12.9Hz, 1H, H18a), 5.00 (d, 2JHH = 12.9Hz, 1H, H18b),
4.28 (dq, 3JHH = 7.5Hz, 3JHH = 7.4Hz, 1H, H10), 4.26 (dq, 3JHH = 7.4Hz,
3JHH = 7.5Hz, 1H, H6), 4.09 (dq, 3JHH = 7.0Hz, 3JHH = 7.4Hz, 1H, H14),
4.04 (dq, 3JHH = 7.5Hz, 3JHH = 7.3Hz, 1H, H2), 1.38 (s, 9H, H24), 1.24
(d, 3JHH = 7.4Hz, 3H, H16), 1.21 (d, 3JHH = 7.4Hz, 3H, H12), 1.20 (d,
3JHH = 7.5Hz, 3H, H8), 1.20 (d, 3JHH = 7.5Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 171.06 (1C, C3),
170.69 (1C, C11), 170.48 (1C, C7), 170.46 (1C, C15), 154.65 (1C, C17),
135.88 (1C, C19), 127.20 (2C, C21), 126.62 (1C, C22), 126.54 (2C, C20),
79.16 (1C, C23), 64.2 (1C, C18), 48.84 (1C, C2), 47.12 (1C, C14), 46.84 (1
C, C6), 46.42 (1C, C10), 26.43 (3C, C24), 17.22 (1C, C12), 16.98 (1C, C8),
16.91 (1C, C4), 15.71 (1C, C16).
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( (BENZYLOXY)CARBONYL) -L -ALANYL -L -ALANYL -L -ALANYL -
L -ALAN INE (30 ) .
tert-Butyl ((benzyloxy)carbonyl)-L-alanyl-L-alanyl-L-alanyl-L-alaninate (29)
(3.00 g, 6.09mmol, 1.0 eq.) was dissolved in trifluoroacetic acid (4.50mL)
and water (450 µL). The solution was stirred at 20-25  C for 30min. The
reaction mixture was evaporated to dryness yielding a white waxy solid
(2.65 g, 6.07mmol, 99.7%).
HR-ESI-MS: calcd. for [30+Na]+ C20H28N4NaO7 m/z= 459.1850, found
m/z= 459.1848.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 8.09 (d, 3JHH = 7.1Hz,
1H, H13), 7.97 (d, 3JHH = 7.5Hz, 1H, H5), 7.87 (d, 3JHH = 7.5Hz, 1H,
H9), 7.46 (d, 3JHH = 7.5Hz, 1H, H1), 7.40-7.27 (m, 5H, H20, H21, H22),
5.03 (d, 2JHH = 12.9Hz, 1H, H18a), 5.00 (d, 2JHH = 12.9Hz, 1H, H18b),
4.28 (dq, 3JHH = 7.5Hz, 3JHH = 7.2Hz, 1H, H10), 4.26 (dq, 3JHH = 7.5Hz,
3JHH = 7.2Hz, 1H, H6), 4.18 (dq, 3JHH = 7.1Hz, 3JHH = 7.2Hz, 1H, H14),
4.05 (dq, 3JHH = 7.5Hz, 3JHH = 7.2Hz, 1H, H2), 1.26 (d, 3JHH = 7.2Hz, 3
H, H16), 1.20 (d, 3JHH = 7.2Hz, 3H, H12), 1.20 (d, 3JHH = 7.2Hz, 3H, H8),
1.20 (d, 3JHH = 7.2Hz, 3H, H4).
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13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 173.83 (1C, C15),
172.14 (1C, C3), 171.67 (1C, C11), 171.53 (1C, C7), 155.58 (1C, C17),
136.90 (1C, C19), 128.21 (2C, C21), 127.67 (1C, C22), 127.57 (2C, C20),
65.24 (1C, C18), 49.87 (1C, C2), 47.87 (1C, C6), 47.58 (1C, C10), 47.29 (1
C, C14), 18.12 (1C, C8), 18.00 (1C, C4), 17.96 (1C, C12), 17.02 (1C, C16).
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L -ALANYL -L -ALANYL -L -ALANYL -L -ALAN INE (35 ) .
((Benzyloxy)carbonyl)-L-alanyl-L-alanyl-L-alanyl-L-alanine (30) (1.50 g,
3.44mmol, 1.0 eq.) was dissolved in methanol (15mL). Palladium on
activated charcoal (moistened with water, 10% Pd basis, 150mg) was added
and the mixture was stirred at 20-25  C under 1.0 bar of hydrogen for 2 h. The
suspension was filtered through celite, washed with methanol (10mL) and
evaporated to dryness yielding a white solid (950mg, 3.14mmol, 91.3%).
HR-ESI-MS: calcd. for [35+H]+ C12H23N4O5 m/z= 303.1663, found m/z=
303.1664.
1H-NMR (600.13MHz, 298K, D2O): d = 8.59 (d, 3JHH = 5.2Hz, 1H,
H5), 8.41 (d, 3JHH = 6.0Hz, 1H, H9), 8.10 (d, 3JHH = 6.8Hz, 1H, H13),
4.34 (dq, 3JHH = 5.2Hz, 3JHH = 7.2Hz, 1H, H6), 4.29 (dq, 3JHH = 6.0Hz,
3JHH = 7.1Hz, 1H, H10), 4.20 (dq, 3JHH = 6.8Hz, 3JHH = 7.3Hz, 1H,
H14), 4.08 (q, 3JHH = 7.3Hz, 1H, H2), 1.53 (d, 3JHH = 7.3Hz, 3H, H4),
1.41 (d, 3JHH = 7.2Hz, 3H, H8), 1.37 (d, 3JHH = 7.1Hz, 3H, H12), 1.36 (d,
3JHH = 7.3Hz, 3H, H16).
13C{H}-NMR (from HMBC, 150.95MHz, 298K, D2O): d = 178.54 (1C,
C15), 174.26 (1C, C7), 173.82 (1C, C11), 170.52 (1C, C3), 50.25 (1C, C14),
49.61 (2C, C6, C10), 49.02 (1C, C2), 17.02 (1C, C16), 16.58 (1C, C4), 16.53
(2C, C8, C12).
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4 -(HYDROXYMETHYL ) -2 -N I TROPHENOL (33 ) .
4-Hydroxy-3-nitro-benzoic acid (8.20 g, 43.9mmol, 1.0 eq.) was dissolved
in dry tetrahydrofuran (100mL) at 20-25  C under argon atmosphere. Boron
trifluoride diethyl etherate (48%, 13.0 g, 43.9mmol, 1.0 eq.) was added
followed by the addition of borane-tetrahydrofuran complex (1 M, 154mL,
154mmol, 3.5 eq.) over 15min. The solution was stirred for 18 h and then
carefully quenched with methanol (20.0mL) and water (10.0mL). The
solution was evaporated to dryness under reduced pressure and the remaining
crude oil was dissolved in water (350mL) and ethyl acetate (150mL).
The layers were separated and the aqueous layer was extracted with ethyl
acetate (3x 200mL). The combined organic layers were extracted with brine
(100mL), dried over sodium sulphate and evaporated to dryness yielding
a yellow crude product. This crude product was purified by flash column
chromatography (SiO2, hexane / ethyl acetate (1:1)) yielding a yellow
crystalline solid (10.8 g, 63.8mmol, 72.7%).
HR-ESI-MS: calcd. for [33+Na]+ C7H7NNaO4 m/z= 192.0267, found m/z=
192.0266.
1H-NMR (500.13MHz, 298K, CDCl3): d = 10.59 (s, 1H, H7), 8.12 (d,
4JHH = 2.1Hz, 1H, H5), 7.61 (dd, 3JHH = 8.6Hz, 4JHH = 2.1Hz, 1H, H1),
7.17 (d, 3JHH = 8.6Hz, 1H, H2), 4.70 (s, 2H, H8).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 154.65 (1C, C3), 136.37 (1
C, C1), 133.34 (1C, C4), 133.24 (1C, C6), 123.16 (1C, C5), 120.26 (1C, C2),
63.73 (1C, C8).
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4 -(CHLOROMETHYL ) -2 -N I TROPHENOL (31 ) .
4-(Hydroxymethyl)-2-nitrophenol (33) (4.30 g, 25.4mmol, 1.0 eq.) was
suspended chloroform (100mL) wetted with aqueous hydrochloric acid
(37%, 1mL). The suspension was saturated with hydrogen chloride gas.
Sulphuric acid (98%, cat.) was added and the reaction mixture was left
stirring under an hydrogen chloride atmosphere for 18 h. The aqueous layer
was separated and the organic layer was evaporated to dryness. The crude
product was crystallized from methyl tert-butyl ether / hexane yielding a
EXPER IMENTAL PART 133
yellow solid (2.09 g, 11.2mmol, 43.9%).
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.14 (d, 4JHH = 2.2Hz, 1H, H5),
7.63 (dd, 3JHH = 8.7Hz, 4JHH = 2.2Hz, 1H, H1), 7.18 (d, 3JHH = 8.7Hz, 1H,
H2), 4.57 (s, 2H, H8).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 155.16 (1C, C3), 137.89 (1
C, C1), 133.35 (1C, C4), 130.08 (1C, C6), 125.03 (1C, C5), 120.85 (1C, C2),
44.68 (1C, C8).
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4 -ACETOXY -3 -N ITROBENZO IC AC ID (34 ) .
4-Hydroxy-3-nitro-benzoic acid (15.0 g, 81.9mmol, 1.0 eq.) and N-ethyl
diisopropylamine (31.8 g, 246mmol, 3.0 eq.) were suspended in tetrahydro-
furan (150mL). The suspension was cooled to 0-5  C and a solution of acetyl
chloride (9.64 g, 123mmol, 1.5 eq.) in tetrahydrofuran (20.0mL) was added
dropwise. The reaction was allowed to warm up to 20-25  C and was left
stirring for 18 h. The reaction mixture was evaporated to dryness and the
crude product was dissolved in ethyl acetate (100mL) and water (100mL).
The layers were separated and the organic layer was extracted with aqueous
saturated sodium hydrogen carbonate (2x 100mL). The combined aqueous
layers were acidified with hydrochloric acid (37%) and extracted with ethyl
acetate (2x 100mL). The organic layers were dried with sodium sulphate
and evaporated to dryness yielding a yellow solid (10.5 g, 46.6mmol, 85.4%).
HR-ESI-MS: calcd. for [34+Na]+ C9H7NNaO6 m/z= 248.0166, found m/z=
248.0169.
1H-NMR (500.13MHz, 298K, CDCl3): d = 10.70 (bs, 1H, H8), 8.82 (d,
3JHH = 2.1Hz, 1H, H5), 8.38 (dd, 3JHH = 8.5Hz, 4JHH = 2.1Hz, 1H, H1),
7.39 (d, 3JHH = 8.5Hz, 1H, H2), 2.41 (s, 3H, H10).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 169.38 (1C, C7), 168.17 (1
C, C9), 148.26 (1C, C3), 141.93 (1C, C4), 136.12 (1C, C1), 128.08 (1C, C6),
128.07 (1C, C5), 125.99 (1C, C2), 20.93 (1C, C10).
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POLYMER FUNCT IONAL IZAT ION
Polymer A 225
Poly(styrene-divinylbenzene) (2% cross-linked, 200-400 mesh, 3.00 g) and
4-(chloromethyl)-2-nitrophenol (31) (1.80 g, 115mmol, 1.0 eq.) were suspen-
ded in nitrobenzol (60mL) and heated to 65  C. A solution of aluminium
trichloride (15.3 g, 115mmol, 12 eq.) in nitrobenzol (60mL) was added. The
mixture was stirred for 48 h at 65  C. The reaction mixture was filtered and
the polymer was washed with chloroform (100mL), water (100mL), hydro-
chloric acid (1 M, 100mL), 1,4-dioxane (100mL) and methanol (100mL).
The solid was dried yielding a black powder (4.06 g, 2.08mmol N/g).
EA: found C 79.38%, H 6.35%, N 2.88%.
Polymer B 226
4-Acetoxy-3-nitrobenzoic acid (34) (5.70 g, 25.3mmol, 1.0 eq.) was dis-
solved in nitrobenzol (150). Oxalylchloride (7.71 g, 60.7mmol, 2.4 eq.) and
dimethylformamide (cat.) was added. The reaction mixture was stirred at
20-25  C for 45min. Then aluminium trichloride (6.75 g, 50.6mmol, 2.0 eq.)
was added. After 10min poly(styrene-divinylbenzene) (2% cross-linked,
200-400 mesh, 15.0 g) was added and the reaction was heated to 40  C
for 18 h. The reaction mixture was filtered and the polymer was washed
with acetone (100mL), methanol (100mL) and diethyl ether (100mL). The
yellow polymer was dried and suspended in methanol (40mL) and aqueous
sodium hydroxide (4 M, 40mL). The suspension was stirred at 40  C for 4 h.
The polymer was filtered off and washed with methanol (100mL). The solid
was dried yielding an orange powder (18.8 g, 1.06mmol N/g).
EA: found C 81.10%, H 6.80%, N 1.78%.
Polymer C 227
Phenol, polymer-bound (1% cross-linked, 100-200 mesh, extent of labeling:
0.5-1.5mmol g−1, 3.00 g) was suspended in nitric acid (68%, 100mL). The
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suspension was stirred at 20-25  C for 5 h. Then the polymer was filtered
off and washed with water (50mL), dimethylformamide (50mL), ethanol
(50mL), acetone (50mL), diethyl ether (50mL). The solid was dried yielding
an orange powder (3.14 g, 750 µmol N/g).
EA: found C 88.49%, H 7.52%, N 0.57%.
POLYMER LOAD ING
Polymer 225 or 226 (1.00 g) was suspended in dimethylformamide
(15.0mL) and N-ethyl diisopropylamine (600 µL, 3.45mmol, 3.0 eq.). To this
suspension HATU (451mg, 1.15mmol, 1.0 eq.) and ((benzyloxy)carbonyl)-
-L-alanyl-L-alanyl-L-alanyl-L-alanine (30) (500mg, 1.15mmol, 1.0 eq.) was
added. The suspension was stirred at 20-25  C for 18 h. Then the polymer
was filtered off and washed with dimethylformamide (50mL), ethanol
(50mL), acetone (50mL) and diethyl ether (50mL). The polymer was dried
under vacuum. Polymer loading: for Polymer A 225 (400mg), Polymer B
226 (190mg).
GENERAL PROCEDURE : POLYMER DEPROTECT ION AND CYL IZA -
T ION
Loaded polymer (1-2 g) was suspended in hydrobromic acid solution (48%,
5.00mL ) and stirred for 1 h at 20-25  C. Then the polymer was washed
with acetic acid (50mL), dimethylformamide (50mL), ethanol (50mL) and
diethyl ether (50mL). The polymer was further suspended in dimethylform-
amide (10mL) and N-ethyl diisopropylamine (5.0mL) was added. After 18 h
at 20-25  C the polymer was filtered off and washed with dimethylformamide
(5.0mL). The filtrate was evaporated yielding the crude product from the
cyclization.
(S) -2 -( ( (S) -2 -( ( (S) -2 -( ( (S) -2 -AM INOPROPYL )AMINO)PRO-
PYL )AMINO)PROPYL )AMINO)PROPAN -1 -OL (36 ) .
L-Alanyl-L-alanyl-L-alanyl-L-alanine (35) (250mg, 827 µmol, 1.0 eq.) was
suspended in tetrahydrofuran (10mL) and lithium aluminium hydride solu-
tion (2 M in tetrahydrofuran, 8.3mL, 16.5mmol, 20 eq.) was added and the
suspension was refluxed for 8 h. The reaction mixture was cooled to 20-25  C
and stirred for 16 h. The reaction was quenched with aqueous potassium
hydroxide (2 M, 2.0mL) and ethyl acetate (10.0mL). The suspension
was diluted with tetrahydrofuran (10mL) and ethyl acetate (10mL). The
suspension was dried with sodium sulphate. The suspension was filtered and
washed with ethyl acetate (50mL). The solvent was removed under reduced
pressure yielding a colorless oil (140mg, 568 µmol, 68.7%). The product
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was used without further purification.
HR-ESI-MS: calcd. for [36+H]+ C12H31N4O m/z= 247.2492, found m/z=
247.2496.
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(S) -2 -( ( tert -BUTOXYCARBONYL)AMINO)PROPYL 4 -METHYL -
BENZENESULFONATE (47 ) .
tert-Butyl (S)-(1-hydroxypropan-2-yl)carbamate (1.00 g, 5.71mmol, 1.0 eq.)
was dissolved in dichloromethane (20mL) and cooled to 0-5  C. 4-Methyl-
benzol-1-sulfonylchlorid (1.63 g, 8.57mmol, 1.5 eq.) was added and the
reaction was warmed up to 20-25  C. The solution was stirred at 20-25  C
for 18 h. The solution was extracted with water (20mL), aqueous saturated
sodium hydrogen carbonate (20mL) and water (20mL). The organic layer
was dried over sodium sulphate and evaporated to dryness. The crude oil was
purified by (SiO2, ethyl acetate / cyclohexane (3:7)) yielding a white solid
(1.33 g, 4.04mmol, 70.7%).
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.72 (d, 3JHH = 8.3Hz, 2H, H6),
7.40 (d, 3JHH = 8.3Hz, 2H, H7), 4.57 (d, 3JHH = 8.8Hz, 1H, H1), 4.05-4.00
(m, 1H, H3a), 3.93 (dd, 2JHH = 9.9Hz, 3JHH = 4.2Hz, 1H, H3b), 3.92-3.84
(m, 1H, H2), 2.45 (s, 3H, H9), 1.40 (s, 9H, H12), 1.35 (d, 3JHH = 7.2Hz, 3H,
H4).
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(S) -2 -( ( tert -BUTOXYCARBONYL)AMINO)PROPYL METHANES -
ULFONATE (50 ) .
tert-Butyl (S)-(1-hydroxypropan-2-yl)carbamate (200mg, 1.14mmol,
1.0 eq.) was dissolved in dichloromethane (5.0mL) and cooled to 0-5  C.
Methanesulfonyl chloride (157mg, 1.37mmol, 1.2 eq.) was added and
the reaction was stirred at 0-5  C for 3 h. The solution was extracted with
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water (3x 5.0mL). The organic layer was dried over sodium sulphate and
evaporated to dryness yielding a white solid (280mg, 1.11mmol, 97.0%).
1H-NMR (600.13MHz, 298K, CDCl3): d = 4.57 (bs, 1H, H1), 4.26-4.20 (m,
1H, H3a), 4.14 (dd, 2JHH = 10.1Hz, 3JHH = 4.3Hz, 1H, H3b), 4.00-3.91 (m,
1H, H2), 3.03 (s, 3H, H5), 1.44 (s, 9H, H8), 1.23 (d, 3JHH = 6.9Hz, 3H, H4).
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(S) -2 -METHYL -1 -( ( 4 -N I TROPHENYL )SULFONYL )AZ IR ID INE
(55 ) .
L-Alaninol (6.00 g, 79.9mmol, 1.0 eq.) was dissolved in pyridine (25.3 g,
320mmol, 4.0 eq.). This solution was added to a slurry of 4-nitrobenzene
sulfonyl chloride (41.6 g, 188mmol, 2.3 eq.) in acetonitrile (50mL) at 0-5  C.
The reaction mixture was stirred at 0-5  C for 2 h. Ethyl acetate (150mL) and
water (75mL) were added and the mixture was stirred for another 10min. The
aqueous layer was removed and the organic layer was washed with aqueous
citric acid (1mM, 2x 50mL) and water (40mL). The organic solution was
cooled to 10  C and N-ethyl diisopropylamine (21.1mL, 128mmol, 1.6 eq.)
was added. The reaction was stirred at 20-25  C for 30min. The lower layer
was removed and the organic layer was extracted with aqueous citric acid
(1 M, 2x 50mL) and water (2x 40mL). The organic layer was dried with
sodium sulphate and concentrated under reduced pressure to approximately
50mL. Isopropanol (50mL) was added and more ethyl acetate was removed
under reduced pressure. The resulting slurry was cooled to 0-5  C. The
suspension was filtered and the filter cake was washed with cold isopropanol
(10mL). The product was dried under vacuum at 20-25  C yielding a yellow
solid (12.1 g, 49.9mmol, 62.5%).
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.40-8.36 (m, 2H, H6), 8.17-8.12
(m, 2H, H5), 2.97 (ddd, 3JHH = 7.0Hz, 3JHH = 5.6Hz, 3JHH = 4.7Hz, 1H,
H2), 2.72 (d, 3JHH = 7.0Hz, 1H, H3a), 2.12 (d, 3JHH = 4.7Hz, 1H, H3b), 1.29
(d, 3JHH = 5.6Hz, 3H, H1).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 150.72 (1C, C7), 144.43 (1
C, C4), 129.21 (2C, C5), 124.41 (2C, C6), 36.95 (1C, C2), 35.61 (1C, C3),
16.88 (1C, C1).
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tert -BUTYL ((S) -2 -( ( 4 -N I TROPHENYL )SULFONAMIDO)PRO-
PYL ) -L -ALAN INATE (52 ) .
(S)-2-Methyl-1-((4-nitrophenyl)sulfonyl)aziridine (55) (6.20 g, 25.6mmol,
1.0 eq.), tert-butyl L-alaninate (5.58 g, 38.4mmol, 1.5 eq.) and N-ethyl diisop-
ropylamine (6.35mL, 38.4mmol, 1.5 eq.) were dissolved in tetrahydrofuran
(60mL) and stirred at 60  C for 18 h. The reaction mixture was evaporated to
dryness and the crude product was purified by flash column chromatography
(SiO2, ethyl acetate / cyclohexane / triethylamine (50:50:1)) yielding a yellow
solid (7.48 g, 19.3mmol, 75.4%).
HR-ESI-MS: calcd. for [52+H]+ C16H26N3O6S m/z= 388.1537, found m/z=
388.1542.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.36-8.32 (m, 2H, H11),
8.10-8.06 (m, 2H, H10), 5.77 (bs, 1H, H1), 3.20 (ddq, 3JHH = 7.7Hz,
3JHH = 4.2Hz, 3JHH = Hz, 1H, H2), 3.08 (q, 3JHH = 7.0Hz, 1H, H6), 2.64
(dd, 2JHH = 12.2Hz, 3JHH = 4.2Hz, 1H, H3a), 2.31 (dd, 2JHH = 12.2Hz,
3JHH = 7.7Hz, 1H, H3b), 1.44 (s, 9H, H14), 1.19 (d, 3JHH = 7.0Hz, 3H, H8),
1.14 (d, 3JHH = 6.5Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 174.75 (1C, C7), 150.06 (1
C, C12), 146.72 (1C, C9), 128.58 (2C, C11), 124.37 (2C, C10), 81.59 (1C,
C13), 57.27 (1C, C6), 52.36 (1C, C3), 50.10 (1C, C2), 28.17 (3C, C14), 19.57
(1C, C4), 19.22 (1C, C8).
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tert -BUTYL N -BENZYL -N - ( (S) -2 -( ( 4 -N I TROPHENYL )SULFON-
AMIDO)PROPYL ) -L -ALAN INATE (53 ) .
tert-Butyl ((S)-2-((4-nitrophenyl)sulfonamido)propyl)-L-alaninate (52)
(6.40 g, 16.5mmol, 1.0 eq.) and potassium carbonate (4.56 g, 33.0mmol,
2.0 eq.) were suspended in acetonitrile. To this suspension benzyl bromide
(7.06 g, 41.3mmol, 2.5 eq.) was added and the mixture was stirred at 50  C
for 18 h. Excess benzyl bromide was quenched with triethylamine (5.0mL).
The suspension was filtered and the filtrate was evaporated to dryness. The
crude oil was purified by flash column chromatography (SiO2, ethyl acetate
/ cyclohexane / triethylamine (30:70:1)) yielding a yellowish waxy solid
(5.08 g, 10.6mmol, 64.5%).
HR-ESI-MS: calcd. for [53+H]+ C23H32N3O6S m/z= 478.2006, found m/z=
478.2009.
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.20-8.17 (m, 2H, H11), 8.02-
7.98 (m, 2H, H10), 7.35-7.25 (m, 3H, H18, H19), 7.13-7.06 (m, 2H, H17), 3.49
(d, 2JHH = 14.5Hz, 1H, H15a), 3.45 (d, 2JHH = 14.5Hz, 1H, H15b), 3.35-3.30
(m, 1H, H2), 3.34 (q, 3JHH = 7.0Hz, 1H, H6), 2.51 (dd, 2JHH = 13.7Hz,
3JHH = 4.2Hz, 1H, H3a), 2.42 (dd, 2JHH = 13.7Hz, 3JHH = 10.2Hz, 1H, H3b),
1.51 (s, 9H, H14), 1.18 (d, 3JHH = 6.3Hz, 3H, H4), 1.14 (d, 3JHH = 7.0Hz, 3
H, H8).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 173.37 (1C, C7), 149.75 (1
C, C12), 146.71 (1C, C9), 138.07 (1C, C16), 128.68 (2C, C18), 128.22 (2C,
C11), 128.00 (2C, C17), 127.50 (1C, C19), 124.11 (2C, C10), 81.93 (1C, C13),
57.65 (1C, C6), 55.61 (1C, C3), 54.93 (1C, C15), 47.77 (1C, C2), 28.16 (3C,
C14), 19.80 (1C, C4), 10.29 (1C, C8).
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tert -BUTYL N - ( (S) -2 -AM INOPROPYL ) -N -BENZYL -L -ALAN IN -
ATE (56 ) .
Method A
tert-Butyl N-benzyl-N-((S)-2-((4-nitrophenyl)sulfonamido)propyl)-L-alan-
inate (53) (2.50 g, 5.23mmol, 1.0 eq.), dodecanthiol (2.5mL, 10.5mmol,
2.0 eq.) and potassium carbonate were suspended in acetonitrile (20mL). The
suspension was heated to 50  C for 18 h. The mixture was cooled to 20-25  C
filtered and evaporated to dryness. The crude product was dissolved in ethyl
acetate. The organic solution was extracted with hydrochloric acid (1 M,
3x 20mL). The combined aqueous layers were extracted with ethyl acetate
(3x 20mL). The pH of the aqueous layer was adjusted to 14 with aqueous
sodium hydroxide (40%). The product was extracted with ethyl acetate (3x
20mL). The combined organic layers were dried with sodium sulphate and
evaporated to dryness yielding a yellowish oil (1.14 g, 3.89mmol, 74.5%).
Method B
tert-Butyl N-benzyl-N-((S)-2 (((benzyloxy)carbonyl)amino)propyl)-L-alan-
inate (63) (751mg, 1.76mmol, 1.0 eq.) was dissolved in methanol (5.0mL).
Palladium on barium sulphate (60.0mg, 5% Pd/BaSO4) was added and
the reaction flask was flushed with nitrogen. Then hydrogen was bubbled
through the solution for 5min and the reaction mixture was left stirring under
1 bar hydrogen at 20-25  C for 2 h. The suspension was filtered through
celite and washed with methanol (3 x 5.0mL). The filtrate was evaporated to
dryness yielding a yellowish oil (480mg, 1.64mmol, 93.3%).
HR-ESI-MS: calcd. for [56+H]+ C17H29N2O2 m/z= 293.2224, found m/z=
293.2228.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.36-7.33 (m, 2H, H13), 7.32-
7.28 (m, 2H, H14), 7.25-7.21 (m, 1H, H15), 3.76 (d, 2JHH = 14.8Hz, 1H,
H11a), 3.73 (d, 2JHH = 14.8Hz, 1H, H11b), 3.40 (q, 3JHH = 7.1Hz, 1H, H6),
2.84 (ddq, 3JHH = 8.5Hz, 3JHH = 5.1Hz, 3JHH = 6.3Hz, 1H, H2), 2.57
(dd, 2JHH = 13.2Hz, 3JHH = 5.1Hz, 1H, H3a), 2.33 (dd, 2JHH = 13.2Hz,
3JHH = 8.5Hz, 1H, H3b), 1.48 (s, 9H, H10), 1.23 (d, 3JHH = 7.1Hz, 3H, H8),
0.98 (d, 3JHH = 6.3Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 173.18 (1C, C7), 140.41 (1
C, C12), 128.46 (2C, C13), 128.27 (2C, C14), 126.91 (1C, C15), 80.71 (1C,
C9), 60.89 (1C, C11), 59.71 (1C, C6), 56.11 (1C, C3), 45.26 (1C, C2), 28.28
(3C, C10), 21.16 (1C, C4), 13.75 (1C, C8).
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N -BENZYL -N - ( (S) -2 -( ( 4 -N I TROPHENYL )SULFONAMIDO)PRO-
PYL ) -L -ALAN INE (57 ) .
tert-Butyl N-benzyl-N-((S)-2-((4-nitrophenyl)sulfonamido)propyl)-L-alanin-
ate (53) (2.50 g, 5.23mmol, 1.0 eq.) was dissolved in acetonitrile (40mL)
and hydrochloric acid (4 M, 40mL). The solution was stirred at 50  C and
stirred for 6 h. The reaction mixture was evaporated to dryness yielding the
title compound as hydrochloride salt (2.31 g, 5.04mmol, 96.5%).
HR-ESI-MS: calcd. for [57+H]+ C19H24N3O6S m/z= 422.1380, found m/z=
422.1386.
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.38-8.33 (m, 2H, H11), 8.22-
8.18 (m, 2H,H10), 7.36-7.26 (m, 5H,H15, H16, H17), 4.42 (ddq, 3JHH = 3.2Hz,
3JHH = 2.4Hz, 3JHH = 6.2Hz, 1H, H2), 4.04 (d, 2JHH = 13.5Hz, 1H, H13a),
3.15 (d, 2JHH = 13.5Hz, 1H, H13b), 3.04 (q, 3JHH = 6.8Hz, 1H, H6), 2.81
(dd, 2JHH = 12.4Hz, 3JHH = 2.4Hz, 1H, H3a), 2.50 (dd, 2JHH = 12.4Hz,
3JHH = 3.2Hz, 1H, H3b), 1.52 (d, 3JHH = 6.2Hz, 3H, H4), 1.47 (d,
3JHH = 6.8Hz, 3H, H8).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 170.89 (1C, C7), 150.69 (1
C, C12), 144.92 (1C, C9), 137.28 (1C, C14), 130.34 (2C, C10), 128.86 (2C,
C16), 128.67 (2C, C15), 127.75 (1C, C17), 124.02 (2C, C11), 62.89 (1C, C6),
58.35 (1C, C13), 54.35 (1C, C3), 53.06 (1C, C2), 21.32 (1C, C4), 17.18 (1C,
C8).
3NH
1
2
4
7
O
N 5
6
8
OH
9
10
11
12
N+
O
-O
S
O
O
13
14
17
16
15
57
142 EXPER IMENTAL PART
tert -BUTYL ((S) -2 -AM INOPROPYL ) -L -ALAN INATE (228 ) .
Method A
tert-Butyl ((S)-2-((4-nitrophenyl)sulfonamido)propyl)-L-alaninate (52) (2.00
g, 5.16mmol, 1.0 eq.) was dissolved in acetonitrile (20mL). Then potassium
carbonate (1.07 g, 7.74mmol, 1.5 eq.) and dodecanthiol (2.5mL, 10.3mmol,
2.0 eq.) were added and the reaction mixture was stirred at 60  C for 18 h. The
mixture was filtered and evaporated to dryness. The residue was taken up in
ethyl acetate (30mL) and extracted with aqueous formic acid (1 M, 3x 30mL).
The combined aqueous layers were extracted with ethyl acetate (20mL). The
pH of the aqueous layer was adjusted to 14 with aqueous sodium hydroxide (4
M). The product was extracted with ethyl acetate (3x 20mL). The combined
organic layers were dried with sodium sulphate and evaporated to dryness
yielding a yellowish oil (540mg, 2.67mmol, 51.7%).
Method B
tert-Butyl ((S)-2-(((benzyloxy)carbonyl)amino)propyl)-L-alaninate (62)
(600mg, 1.78mmol, 1.0 eq.) was dissolved in methanol (10mL) and palla-
dium on activated charcoal (moistened with water, 10% Pd basis, 60.0mg)
was added. The suspension was hydrogenated at 1.0 bar hydrogen for 4 h.
The reaction mixture was filtered over celite and the solvent was removed
under reduced pressure yielding a yellowish oil (355mg, 1.76mmol, 98.6%).
HR-ESI-MS: calcd. for [228+H]+ C10H23N2O2 m/z= 203.1754, found m/z=
203.1753.
1H-NMR (500.13MHz, 298K, CDCl3): d = 3.16 (q, 3JHH = 7.0Hz, 1H,
H6), 2.91 (ddq, 3JHH = 8.4Hz, 3JHH = 4.3Hz, 3JHH = 6.4Hz, 1H, H2), 2.63
(dd, 2JHH = 11.3Hz, 3JHH = 4.3Hz, 1H, H3a), 2.19 (dd, 2JHH = 11.3Hz,
3JHH = 8.4Hz, 1H, H3b), 1.46 (s, 9H, H10), 1.24 (d, 3JHH = 7.0Hz, 3H, H8),
1.04 (d, 3JHH = 6.4Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 175.58 (1C, C7), 80.96 (1
C, C9), 57.91 (1C, C6), 56.76 (1C, C3), 47.23 (1C, C2), 28.23 (3C, C10),
21.67 (1C, C4), 19.42 (1C, C8).
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( (S) -2 -AM INOPROPYL ) -L -ALAN INE (229 ) .
tert-Butyl ((S)-2-aminopropyl)-L-alaninate (228) (50.0mg, 258 µmol, 1.0 eq.)
was dissolved in hydrochloric acid (1 M, 10.0mL) and stirred at 45  C
for 30min. The solvent was evaporated yielding the title compound as
hydrochloride salt (55.3mg, 252 µmol, 97.8%).
HR-ESI-MS: calcd. for [229+H]+ C6H15N2O2 m/z= 147.1128, found m/z=
147.1127.
1H-NMR (600.13MHz, 298K, D2O): d = 4.11 (q, 3JHH = 7.2Hz, 1H, H6),
3.81 (ddq, 3JHH = 6.4Hz, 3JHH = 6.2Hz, 3JHH = 6.8Hz, 1H, H2), 3.44
(dd, 2JHH = 13.4Hz, 3JHH = 6.2Hz, 1H, H3a), 3.36 (dd, 2JHH = 13.4Hz,
3JHH = 6.4Hz, 1H, H3b), 1.60 (d, 3JHH = 7.2Hz, 3H, H8), 1.45 (d,
3JHH = 6.8Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, D2O): d = 172.03 (1C, C7), 56.92 (1C,
C6), 48.31 (1C, C3), 44.58 (1C, C2), 16.06 (1C, C4), 14.25 (1C, C8).
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( (S) -2 -( ( 4 -N I TROPHENYL )SULFONAMIDO)PROPYL ) -L -ALAN-
INE (230 ) .
tert-Butyl ((S)-2-((4-nitrophenyl)sulfonamido)propyl)-L-alaninate (52)
(1.00 g, 2.58mmol, 1.0 eq.) was dissolved in hydrogen chloride solution
(conc. in 1,4-dioxane, 10mL) and stirred at 45  C for 1 h. The solvent
was evaporated yielding the title compound as hydrochloride salt (930mg,
2.53mmol, 98.0%).
HR-ESI-MS: calcd. for [230+H]+ C12H18N3O6S m/z= 332.0911, found
m/z= 332.0913.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 8.46-8.41 (m, 2H,
H11), 8.16-8.11 (m, 2H, H10), 8.52 (d, 3JHH = 8.0Hz, 1H, H1), 3.99 (q,
3JHH = 7.2Hz, 1H, H6), 3.77-3.67 (m, 1H, H2), 3.01-2.88 (m, 2H, H3), 1.45
(d, 3JHH = 7.2Hz, 3H, H8), 0.96 (d, 3JHH = 6.7Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 170.62 (1C, C7),
149.66 (1C, C12), 146.83 (1C, C9), 128.16 (2C, C11), 124.72 (2C, C10),
54.72 (1C, C6), 49.65 (1C, C3), 46.60 (1C, C2), 18.53 (1C, C4), 13.82 (1C,
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C8).
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BEN ZYL (S) - ( 1 -HYDROXYPROPAN -2 -YL )CARBAMATE (61 ) .
Sodium carbonate (245 g, 2.32mol, 3.1 eq.) was dissolved in water (500mL).
A solution of (S)-alaninol (57.0 g, 759mmol, 1.0 eq.) in ethyl acetate
(180mL) was added at 20-25  C. The biphasic mixture was stirred vigorously
and benzyl chloroformate (133 g, 782mmol, 1.03 eq.) was added at 20-25  C.
After addition the biphasic mixture was further stirred for 1 h before diluted
with water (500mL) and ethyl acetate ( 600mL). The clear layers were
separated and the aqueous layer was extracted with ethyl acetate (250mL).
The combined organic layers were extracted with water (250mL), dried
over sodium sulphate and evaporated to dryness. The crude product was
recrystallized from ethyl acetate / cyclohexane yielding a white solid (149 g,
711mmol, 93.8%).
HR-ESI-MS: calcd. for [61+Na]+ C11H15NNaO3 m/z= 232.0944, found
m/z= 232.0944.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.41-7.28 (m, 5H, H9,H10,H11),
5.10 (d, 2JHH = 12.1Hz, 1H, H7a), 5.07 (d, 2JHH = 12.1Hz, 1H, H7b), 5.06 (bs,
1H, H5), 3.82 (ddd, 3JHH = 6.8Hz, 3JHH = 5.6Hz, 3JHH = 2.4Hz, 1H, H3),
3.63 (dd, 2JHH = 10.2Hz, 3JHH = 2.4Hz, 1H, H2a), 3.50 (dd, 2JHH = 10.2Hz,
3JHH = 5.6Hz, 1H, H2b), 2.73 (bs, 1H, H1), 1.15 (d, 3JHH = 6.8Hz, 3H, H4).
13C{H}-NMR (150.9MHz, 298K, CDCl3): d = 156.70 (1C, C6), 136.46 (1
C, C8), 128.64 (2C, C10), 128.27 (1C, C11), 128.23 (2C, C9), 66.93 (1C, C7),
66.83 (1C, C2), 49.05 (1C, C3), 17.32 (1C, C4).
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BEN ZYL (S) - ( 1 -OXOPROPAN -2 -YL )CARBAMATE (60 ) .
(S)-(1-Hydroxypropan-2-yl)carbamate (61) (45.0 g, 215mmol, 1.0 eq.),
2-iodoxybenzoic acid (IBX) (90.3 g, 322mmol, 1.5 eq.) were suspended in
ethyl acetate (450mL). The suspension was heated to reflux. At reflux di-
methyl sulfoxide (46mL, 645mmol, 3.0 eq.) was added. The suspension was
further refluxed for 3.5 h before cooled down to 0-5  C. The suspension was
filtered and washed with ethyl acetate (150mL). The filtrate was extracted
with aqueous saturated sodium hydrogen carbonate (450mL), water (450mL)
and brine (300mL). The organic layer was dried with sodium sulphate and
evaporated to dryness yielding a colourless oil (41.5 g, 200mmol, 93.1%).
HR-ESI-MS: calcd. for [60+H]+ C11H14NO3 m/z= 208.0968, found m/z=
208.0967.
1H-NMR (250.13MHz, 298K, CD3CN): d = 9.51 (d, 3JHH = 0.5Hz, 1H, H1),
7.54-7.11 (m, 5H, H8,H9,H10), 5.10 (s, 2H, H6), 4.08 (qdd, 3JHH = 7.4Hz,
3JHH = 7.0Hz, 3JHH = 0.5Hz, 1H, H2), 1.27 (d, 3JHH = 7.4Hz, 3H, H3).
13C{H}-NMR (125.8MHz, 298K, CDCl3): d = 198.97 (1C, C1), 155.82 (1
C, C5), 136.15 (1C, C7), 128.59 (2C, C9), 128.29 (1C, C10), 128.17 (2C,
C8), 67.09 (1C, C6), 55.93 (1C, C2), 14.86 (1C, C3).
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BEN ZYL (R) - ( 1 -OXOPROPAN -2 -YL )CARBAMATE (122 ) .
(R)-(1-Hydroxypropan-2-yl)carbamate (1.06 g, 5.07mmol, 1.0 eq.), 2-iod-
oxybenzoic acid (IBX) (3.27 g, 11.7mmol, 2.3 eq.) were suspended in ethyl
acetate (20mL). The suspension was heated to reflux. At reflux dimethyl
sulfoxide (1.7mL, 23.3mmol, 4.6 eq.) was added. The suspension was
further refluxed for 3.5 h before cooled down to 0-5  C. The suspension was
filtered and washed with ethyl acetate (10mL). The filtrate was extracted
with aqueous saturated sodium hydrogen carbonate (20mL), water (20mL)
and brine (20mL). The organic layer was dried with sodium sulphate and
evaporated to dryness yielding a colourless oil (1.04 g, 5.07mol, 99.0%).
1H-NMR (250.13MHz, 298K, CD3CN): d = 9.51 (d, 3JHH = 0.5Hz, 1H, H1),
7.54-7.11 (m, 5H, H8,H9,H10), 5.10 (s, 2H, H6), 4.08 (qdd, 3JHH = 7.4Hz,
3JHH = 7.0Hz, 3JHH = 0.5Hz, 1H, H2), 1.27 (d, 3JHH = 7.4Hz, 3H, H3).
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13C{H}-NMR (125.8MHz, 298K, CDCl3): d = 198.97 (1C, C1), 155.82 (1
C, C5), 136.15 (1C, C7), 128.59 (2C, C9), 128.29 (1C, C10), 128.17 (2C,
C8), 67.09 (1C, C6), 55.93 (1C, C2), 14.86 (1C, C3).
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tert -BUTYL ((S) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO)PROP -
YL ) -L -ALAN INATE (62 ) .
Benzyl (S)-(1-oxopropan-2-yl)carbamate (60) (41.4 g, 200mmol, 1.0 eq.)
was dissolved in dichloromethane (600mL). To this solution L-alanine tert-
butyl ester (30.6 g, 200mmol, 1.0 eq.) was added. The solution was stirred at
20-25  C for 5min followed by the addition of sodium triacetoxyborohydride
(141 g, 600mmol, 3.0 eq.). The reaction mixture was stirred at 20-25  C
for 16 h. The excess of sodium triacetoxyborohydride was quenched with
aqueous saturated sodium hydrogen carbonate (450mL) and the pH adjusted
to >9 by addition of triethylamine (100mL). The two layers were separated
and the organic layer was washed with water (250mL) and dried with sodium
sulphate. The organic layer was evaporated to dryness yielding a colourless
oil that slowly crystallised forming a white solid (66.0 g, 196mmol, 98.1%).
HR-ESI-MS: calcd. for [62+H]+ C18H29N2O4 m/z= 337.2122, found m/z=
337.2121.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.38-7.33 (m, 3H,
H15,H16), 7.32-7.28 (m, 2H, H14), 7.09 (d, 3JHH = 8.1Hz, 1H, H1), 5.01 (d,
2JHH = 12.8Hz, 1H, H12a), 4.98 (d, 2JHH = 12.8Hz, 1H, H12b), 3.54 (dddq,
3JHH = 8.1Hz, 3JHH = 6.3Hz, 3JHH = 6.2Hz, 3JHH = 6.6Hz, 1H, H2), 3.09 (q,
3JHH = 6.9Hz, 1H, H6), 2.47 (dd, 2JHH = 11.5Hz, 3JHH = 6.2Hz, 1H, H3a),
2.40 (dd, 2JHH = 11.5Hz, 3JHH = 6.3Hz, 1H, H3b), 1.86 (bs, 1H, H5), 1.40
(s, 9H, H10), 1.11 (d, 3JHH = 6.9Hz, 3H, H8), 1.03 (d, 3JHH = 6.6Hz, 3H, H4).
13C{H}-NMR (150.9MHz, 298K, DMSO d6): d = 174.46 (1C, C7), 155.53
(1C, C11), 137.25 (1C, C13), 128.31 (2C, C15), 127.72 (3C, C14, C16), 79.91
(1C, C9), 65.03 (1C, C12), 56.67 (1C, C6), 52.18 (1C, C3), 46.61 (1C, C2),
27.69 (3C, C10), 18.66 (1C, C8), 18.58 (1C, C4).
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( (S) -2 -( ( (BENZYLOXY)CARBONYL)AMINO)PROPYL ) -L -ALAN-
INE (231 ) .
tert-Butyl ((S)-2-(((benzyloxy)carbonyl)amino)propyl)-L-alaninate (62)
(600mg, 1.78mmol, 1.0 eq.) was dissolved in methanol (10mL) and hydro-
chloric acid (1 M, 10mL). The solution was stirred at 40  C before it was
evaporated to dryness yielding a off-white solid (550mg, 1.74mmol, 97.5%).
HR-ESI-MS: calcd. for [231+H]+ C14H21N2O4 m/z= 281.1496, found m/z=
281.1499.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 7.45-7.28 (m, 5H, H12,H13,
H14), 5.07 (d, 2JHH = 12.3Hz, 1H, H10a), 5.02 (d, 2JHH = 12.3Hz, 1H, H10b),
4.01 (q, 3JHH = 7.2Hz, 1H, H2), 3.93 (ddq, 3JHH = 8.7Hz, 3JHH = 5.1Hz,
3JHH = 6.2Hz, 1H, H6), 3.02 (dd, 2JHH = 12.8Hz, 3JHH = 8.7Hz, 1H, H7a),
2.96 (dd, 2JHH = 12.8Hz, 3JHH = 5.1Hz, 1H, H7b), 1.46 (d, 3JHH = 7.2Hz, 3
H, H4), 1.14 (d, 3JHH = 6.2Hz, 3H, H8).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 170.79 (1C, C3),
155.65 (1C, C9), 136.85 (1C, C11), 128.39 (2C, C13), 127.89 (2C, C12),
127.85 (1C, C14), 65.55 (1C, C10), 54.80 (1C, C2), 49.44 (1C, C7), 44.05 (1
C, C6), 18.64 (1C, C8), 13.99 (1C, C4).
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TERT -BUTYL N -BEN ZYL -N - ( ( S ) -2 ( ( (BEN ZYLOXY)CARBONYL ) -
AM INO)PROPYL ) -L -ALAN INATE (63 ) .
tert-Butyl ((S)-2-(((benzyloxy)carbonyl)amino)propyl)-L-alaninate (62)
(23.7 g, 70.4mmol, 1.0 eq.) was dissolved in acetonitrile (200mL) and
potassium carbonate (10.7 g, 77.4mmol, 1.1 eq.) was added. To this sus-
pension benzyl bromide (12.6 g, 73.9mmol, 1.05 eq.) was added and the
reaction mixture was stirred at 50  C for 16 h. Excess of benzyl bromide
was quenched with triethylamine (15mL). The reaction mixture was then
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cooled to 20-25  C filtered and evaporated to dryness yielding a crude yellow
oil. The crude product was purified by flash column chromatography (SiO2,
ethyl acetate / cyclohexane (7:3)) yielding a yellowish oil (25.3 g, 59.3mmol,
84.2%).
HR-ESI-MS: calcd. for [63+H]+ C25H35N2O4 m/z= 427.2591, found m/z=
427.2596.
1H-NMR (600.13MHz, 298K, CD3CN): d = 7.41-7.17 (m, 10H, H14,
H15, H16, H19, H20, H21), 5.81 (bs, 1H, H1), 5.06 (d, 2JHH = 12.6Hz, 1
H, H12a), 5.01 (d, 2JHH = 12.6Hz, 1H, H12b), 3.76 (d, 2JHH = 14.2Hz, 1
H, H17a), 3.71 (d, 2JHH = 14.2Hz, 1H, H17b), 3.59 (m, 1H, H2), 3.28 (q,
3JHH = 7.1Hz, 1H, H6), 2.58 (dd, 2JHH = 13.4Hz, 3JHH = 8.1Hz, 1H, H3a),
2.52 (dd, 2JHH = 13.4Hz, 3JHH = 6.3Hz, 1H, H3b), 1.44 (s, 9H, H10), 1.17
(d, 3JHH = 7.1Hz, 3H, H8), 1.09 (d, 3JHH = 6.3Hz, 3H, H4).
13C{H}-NMR (100.61MHz, 298K, CD3CN): d = 174.05 (1C, C7), 156.97 (1
C, C11), 141.08 (1C, C18), 138.59 (1C, C13), 129.50 (Carom.), 129.40 (Carom.),
129.19 (Carom.), 128.76 (2C, C19), 128.66 (2C, C14), 127.87 (Carom.), 81.57
(1C, C9), 66.52 (1C, C12), 59.00 (1C, C6), 56.55 (1C, C3), 56.55 (1C, C17),
46.64 (1C, C2), 28.37 (3C, C10), 19.25 (1C, C4), 13.88 (1C, C8).
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N -BEN ZYL -N - ( (S) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO) -
PROPYL ) -L -ALAN INE (64 ) .
tert-Butyl N-benzyl-N-((S)-2-(((benzyloxy) carbonyl)amino)propyl)-L-alan-
inate (63) (4.01 g, 9.40mmol, 1.0 eq.) was dissolved in hydrogen chloride
solution (conc. in 1,4-dioxane, 30.0mL). The reaction mixture was heated to
40  C and stirred for 18 h. The solution was evaporated to dryness yielding
the title compound as a hydrochloride salt (3.81 g, 9.36mmol, quant.). The
product was used in the next step without additional purification.
HR-ESI-MS: calcd. for [64+H]+ C21H27N2O4 m/z= 371.1965, found m/z=
371.1970.
EXPER IMENTAL PART 149
1H-NMR (500.13MHz, 298K, CD3CN): d = 7.58-7.31 (m, 10H, H13,
H14, H15, H18, H19, H20), 5.08 (d, 2JHH = 12.2Hz, 1H, H11a), 5.05 (d,
2JHH = 12.2Hz, 1H, H11b), 4.66 (d, 2JHH = 12.9Hz, 1H, H16a), 4.17-4.06
(m, 1H, H2), 4.07 (q, 3JHH = 7.2Hz, 1H, H6), 3.96 (d, 2JHH = 12.9Hz,
1H, H16b), 3.22 (dd, 2JHH = 13.6Hz, 3JHH = 1.8Hz, 1H, H3a), 3.10 (dd,
2JHH = 13.6Hz, 3JHH = 10.4Hz, 1H, H3b), 1.55 (d, 3JHH = 7.2Hz, 3H, H8),
1.16 (d, 3JHH = 6.9Hz, 3H, H4).
13C{H}-NMR (125.75MHz, 298K, CD3CN): d = 171.12 (1C, C7), 159.86
(1C, C10), 137.40 (1C, C12), 131.47 (1C, C17), 131.07 (2C, C18), 131.03
(Carom.), 130.42 (Carom.), 129.54 (Carom.), 129.17 (Carom.), 128.97 (2C, C13),
68.13 (1C, C11), 61.08 (1C, C6), 59.53 (1C, C3), 56.69 (1C, C16), 44.69 (1
C, C2), 18.05 (1C, C4), 9.64 (1C, C8).
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tert -BUTYL (5S ,8S ,11S ,14S ) -7 ,13 -D I BENZYL -5 ,8 ,11 ,14 -TET -
RAMETHYL -3 ,9 -D I OXO -1 -PHENYL -2 -OXA -4 ,7 ,10 ,13 -TET RA-
AZA PEN TADECAN -15 -OATE (65 ) .
Method A
tert-Butyl ((S)-2-((S)-2-(((S)-2-(((benzyloxy)carbonyl)amino)propyl)amino)-
propanamido)propyl)-L-alaninate (75) (410mg, 882 µmol, 1.0 eq.) was
dissolved in acetonitrile (20mL). Benzyl bromide (462mg, 2.65mmol,
3.0 eq.) and potassium carbonate (366mg, 2.65mmol, 3.0 eq.) were added
and the suspension was stirred at 40  C for 18 h. The suspension was filtered
and evaporated to dryness. The crude oil was purified by flash column
chromatography (SiO2, ethyl acetate) yielding a yellowish oil (511mg,
792 µmol, 89.8%).
Method B
tert-butyl N-((S)-2-aminopropyl)-N-benzyl-L-alaninate (56) (380mg,
1.30mmol, 1.0 eq.), N-benzyl-N-((S)-2-(((benzyloxy)carbonyl)amino)prop-
yl)-L-alanine (64) trifluoroacetate salt (630mg, 1.30mmol, 1.0 eq.) and
N-ethyl diisopropylamine (430 µL, 2.60mmol, 2.0 eq.) were dissolved in
acetonitrile (10mL). HATU (519mg, 1.37mmol, 1.1 eq.) was added. The
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reaction mixture was stirred at 20-25  C for 16 h. The solvent was removed
under vacuum and the crude oil was dissolved in ethyl acetate (10mL) and
extracted with water (2x 5.0mL) and brine (2.0mL). The organic layer was
dried with sodium sulphate and evaporated to dryness. The resulting oil was
purified by flash column chromatography (SiO2, ethyl acetate / cyclohexane
(5:5)) yielding a white solid (580 g, 899 µmol, 69.2%).
HR-ESI-MS: calcd. for [65+H]+ C38H53N4O5 m/z= 645.4010, found m/z=
645.4009.
1H-NMR (500.13MHz, 298K, CDCl3): d = 7.40-7.14 (m, 15H, H19, H20,
H21, H24, H25, H26, H32, H33, H34), 5.12 (d, 2JHH = 12.2Hz, 1H, H30a), 4.94
(d, 2JHH = 12.2Hz, 1H, H30b), 4.70 (d, 3JHH = 7.8Hz, 1H, H1), 3.99 (ddq,
3JHH = 7.8Hz, 3JHH = 6.1Hz, 3JHH = 6.5Hz, 1H, H10), 3.87-3.80 (m, 1H,
H2), 3.85 (d, 2JHH = 14.1Hz, 1H, H22a), 3.72 (d, 2JHH = 14.1Hz, 1H, H22b),
3.72 (d, 2JHH = 13.4Hz, 1H, H17a), 3.38 (d, 2JHH = 13.4Hz, 1H, H17b),
3.36 (q, 3JHH = 6.9Hz, 1H, H6), 3.28 (q, 3JHH = 6.9Hz, 1H, H14), 2.67
(dd, 2JHH = 13.5Hz, 3JHH = 6.1Hz, 1H, H11a), 2.59 (dd, 2JHH = 13.5Hz,
3JHH = 7.8Hz, 1H, H11b), 2.48 (dd, 2JHH = 13.3Hz, 3JHH = 3.6Hz, 1H,
H3a), 2.28 (dd, 2JHH = 13.3Hz, 3JHH = 9.3Hz, 1H, H3b), 1.44 (s, 9H, H28),
1.19 (d, 3JHH = 6.9Hz, 3H, H8), 1.17 (d, 3JHH = 6.5Hz, 3H, H12), 1.16 (d,
3JHH = 7.0Hz, 3H, H16), 1.05 (d, 3JHH = 6.6Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 173.41 (1C, C15), 172.98
(1C, C7), 156.45 (1C, C29), 140.06 (1C, C23), 139.23 (1C, C18), 136.71 (1
C, C31), 129.09 (2C, C19), 128.63 (Carom.), 128.59 (2C, C24), 128.44 (Carom.),
128.28 (Carom.), 128.24 (2C, C32), 128.13 (Carom.), 127.28 (Carom.), 126.92
(Carom.), 80.89 (1C, C27), 66.63 (1C, C30), 58.47 (1C, C6), 57.77 (1C, C14),
56.48 (1C, C3), 56.36 (1C, C22), 55.70 (1C, C11), 54.88 (1C, C17), 45.19 (1
C, C2), 44.30 (1C, C10), 28.28 (3C, C28), 19.50 (1C, C4), 19.17 (1C, C12),
15.29 (1C, C16), 8.31 (1C, C8).
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N - ( (S) -2 - ( (S) -2 - ( ( (S) -2 -AM INO PROPYL ) (BEN ZYL )
AMINO)PROPANAMIDO)PROPYL ) -N -BEN ZYL -L -ALAN INE (66 ) .
tert-Butyl (5S,8S,11S,14S)-7,13-dibenzyl-5,8,11,14-tetramethyl-3,9-dioxo-1-
phenyl-2-oxa-4,7,10,13-tetraazapentadecan-15-oate (65) (1.73 g, 2.68mmol,
1.0 eq.) was dissolved in hydrobromic acid solution (16% wt. in acetic acid,
15.0mL) and stirred at 40  C for 30min. The solvent was removed under
reduced pressure yielding a brownish oil. This oil was further suspended
in acetonitrile (15mL) and hydrochloric acid (37%, 5.0mL). This mixture
was again evaporated to dryness. The procedure was repeated three times
to remove residual acetic acid from the product. Finally, the product was
dissolved in methanol (15.0mL) and evaporated to dryness, yielding a light
brown foam. This foam was extensively dried under high vacuum at 40  C for
2 d. The product (1.89 g) is obtained as a mixture of HCl and HBr salt with
minimal acetate content and was further used without additional purification.
HR-ESI-MS: calcd. for [66+H]+ C26H39N4O3 m/z= 455.3017, found m/z=
455.3022.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 9.96 (bs, 1H, H27), 8.64 (bs,
2H, H1), 7.51-7.40 (m, 2H, Harom.), 7.35-7.22 (m, 5H, Harom.), 7.21-7.11 (m,
3H, Harom.), 3.67 (d, 2JHH = 14.5Hz, 1H, H22a), 3.62 (d, 2JHH = 14.5Hz,
1H, H22b), 3.61 (m, 1H, H10), 3.44 (q, 3JHH = 6.9Hz, 1H, H6), 3.47 (d,
2JHH = 14.1Hz, 1H, H17a), 3.42 (d, 2JHH = 14.2Hz, 1H, H17b ), 3.32-3.24
(m, 1H, H2), 2.99 (q, 3JHH = 7.3Hz, 1H, H14), 2.77 (dd, 2JHH = 13.8Hz,
3JHH = 11.5Hz, 1H, H11a), 2.54 (dd, 2JHH = 13.6Hz, 3JHH = 8.6Hz, 1
H, H3a), 2.39-2.31 (m, 2H, H11b, H3b), 1.10 (d, 3JHH = 6.9Hz, 3H, H8),
1.08 (d, 3JHH = 7.0Hz, 3H, H16), 1.00 (d, 3JHH = 6.5Hz, 3H, H4), 0.98 (d,
3JHH = 6.2Hz, 3H, H12).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 177.43 (1C, C15),
171.50 (1C, C7), 140.74 (1C, C23), 138.50 (1C, C18), 129.01 (Carom.), 128.15
(Carom.), 128.11 (Carom.), 127.95 (Carom.), 126.87 (Carom.), 126.42 (Carom.),
59.12 (1C, C14), 57.44 (1C, C6), 55.87 (1C, C22), 55.03 (1C, C11), 53.63 (1
C, C17), 53.46 (1C, C3), 44.61 (1C, C10), 43.31 (1C, C2), 18.29 (1C, C12),
17.37 (1C, C4), 10.8 (1C, C8), 10.19 (1C, C16).
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(3S ,6S ,9S ,12S ) -4 ,10 -D IBEN ZYL -3 ,6 ,9 ,12 -TET RA -METHYL -1 ,
4 ,7 ,10 -TET RAAZACYCLODODECANE -2 ,8 -D I ONE (67 ) .
Method A
(3S,6S,9S,12S)-3,6,9,12-tetramethyl-1,4,7,10-tetraazacyclododecane-2,8-di-
one (69) (660mg, 2.57mmol, 1.0 eq.) was dissolved in acetonitrile (5.0mL)
and potassium carbonate (1.42 g, 10.3mmol, 4.0 eq.) was added. To this
suspension benzyl bromide (987mg, 5.65mmol, 2.2 eq.) was added and the
reaction mixture was heated to 55  C for 16 h. Excess benzyl bromide was
quenched with triethylamine (2.0mL). The reaction mixture was then cooled
to 20-25  C, filtered and evaporated to dryness yielding a crude yellow oil.
The crude product was purified by flash column chromatography (SiO2, ethyl
acetate / triethylamine (100:1)) yielding a white solid (890mg, 2.04mmol,
79.3%).
Method B
N-((S)-2-((S)-2-(((S)-2-aminopropyl)(benzyl)amino)propanamido)prop-
yl)-N-benzyl-L-alanine (66) (1.89 g, 2.68mmol, 1.0 eq.) and N-ethyl
diisopropylamine (2.2mL, 13.4mmol, 5.0 eq.) were dissolved in acetonitrile
(1.8 L). HATU (1.26 g, 3.22mmol, 1.2 eq. ) was added and the solution was
stirred at 20-25  C for 20min. The solvent was removed under vacuum. The
crude product was combined and purified by flash column chromatography
(SiO2, ethyl acetate / cyclohexane (7:3)) yielding a white solid (950mg,
2.18mmol, 81.2% yield calculated over 2 steps starting from 65).
HR-ESI-MS: calcd. for [67+H]+ C26H37N4O2 m/z= 437.2911, found m/z=
437.2917.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.73 (d, 3JHH = 4.8Hz,
2H, H5), 7.45-7.42 (m, 4H, H11), 7.33-7.25 (m, 6H, H12,H13), 3.90 (d,
2JHH = 13.3Hz, 2H, H9a), 3.57 (d, 2JHH = 13.3Hz, 2H, H9b), 3.34 (dddq,
3JHH = 10.8Hz, 3JHH = 4.8Hz, 3JHH = 2.8Hz, 3JHH = 6.6Hz, 2H, H6),
3.20 (q, 3JHH = 7.0Hz, 2H, H2), 2.77 (dd, 2JHH = 13.4Hz, 3JHH = 10.8Hz,
2H, H7a), 2.29 (dd, 2JHH = 13.4Hz, 3JHH = 2.8Hz, 2H, H7b), 1.15 (d,
3JHH = 6.6Hz, 6H, H8), 1.05 (d, 3JHH = 7.0Hz, 6H, H4).
13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 172.14 (2C, C3),
139.20 (2C, C10), 129.05 (4C, C11), 128.18 (4C, C12), 127.11 (2C, C13),
59.65 (2C, C2), 56.87 (2C, C9), 55.14 (2C, C7), 44.08 (2C, C6), 17.71 (2C,
C8), 8.54 (2C, C4).
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( 2S ,5S ,8S ,11S ) -1 ,7 -D IBEN ZYL -2 ,5 ,8 ,11 -TET RA -METHYL -1 ,4 ,
7 ,10 -TET RAAZACYCLODODECANE (68 ) .
(3S,6S,9S,12S)-4,10-dibenzyl-3,6,9,12-tetramethyl-1,4,7,10-tetraazacyclo-
dodecane-2,8-dione (67) (1.90 g, 4.35mmol, 1.0 eq.) was dissolved in
dichloromethane (50mL) and cooled to 0-5  C. Trimethylsilyl chloride
(2.60 g, 23.9mmol, 5.5 eq.) was slowly added. After completion, the reaction
mixture was stirred at 0-5  C for 30min followed by the addition of lithium
aluminium hydride (6.1mL, 2 M in tetrahydrofuran, 12.2mmol, 2.8 eq.). The
reaction mixture was allowed to warm to 20-25  C and was further stirred
for 3 h. The reaction mixture was cooled to 0-5  C and saturated aqueous
sodium hydrogen carbonate (5.0mL) was slowly added. To the resulting
suspension sodium sulphate (5.00 g) was added. The suspension was filtered
and evaporated to dryness yielding a white solid (1.65 g, 4.04mmol, 92.8%).
HR-ESI-MS: calcd. for [68+H]+ C26H41N4 m/z= 409.3326, found m/z=
409.3330.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.40-7.34 (m, 8H, H11,H12),
7.29-7.26 (m, 2H, H13), 3.81 (d, 2JHH = 12.8Hz, 2H, H9a), 3.13-3.02 (bs, 2
H, H6), 2.98 (d, 2JHH = 12.8Hz, 2H, H9b), 2.94 (bs, 2H, H5), 2.88-2.76 (m,
4H, H2,H7a), 2.45 (d, 2JHH = 11.8Hz, 2H, H3a), 2.40 (dd, 2JHH = 13.4Hz,
3JHH = 13.1Hz, 2H, H7b), 2.25 (dd, 2JHH = 11.8Hz, 3JHH = 11.8Hz, 2H,
H3b), 0.91 (d, 3JHH = 6.5Hz, 6H, H8), 0.87 (d, 3JHH = 5.5Hz, 6H, H4).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 139.97 (2C, C10), 129.41
(4C, C12), 128.50 (4C, C11), 127.30 (2C, C13), 56.62 (2C, C3), 51.72 (2C,
C9), 50.04 (2C, C6), 47.83 (2C, C7), 46.47 (2C, C2), 18.71 (2C, C4), 10.20
(2C, C8).
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( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET RAMETHYL -1 ,4 ,7 ,10 -TET RA-
AZACYCLODODECANE (22 ) .
Method A
(2S,5S,8S,11S)-1,7-dibenzyl-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclodo-
decane (68) (1.50 g, 3.67mmol, 1.0 eq.), palladium hydroxide on carbon (20
wt % loading, 750mg) and ammonium formate (5.00 g, 79.3mmol, 10 eq.)
were suspended in ethanol (50mL) and heated to reflux. The suspension was
refluxed for 16 h, cooled to 20-25  C, filtered over celite and evaporated to
dryness. The crude product was washed with cold acetone (1.0mL). The title
compound was obtained as a white solid (650mg, 2.85mmol 77.6%).
Method B
(3S,6S,9S,12S)-3,6,9,12-tetramethyl-1,4,7,10-tetraazacyclododecane-2,8-
dione 69 (430mg, 1.68mmol, 1.0 eq.) was dissolved in dichloromethane
(10mL) and cooled to 0-5  C. Trimethylsilyl chloride (1.10 g, 10.1mmol,
6.0 eq.) was slowly added. After completion, the reaction mixture was stirred
at 0-5  C for 30min followed by the addition of lithium aluminium hydride
(2 M in tetrahydrofuran, 8.4mL, 16.8mmol, 10 eq.). The reaction mixture
was allowed to warm to 20-25  C and was further stirred for 3 h. The reaction
mixture was cooled to 0-5  C and saturated aqueous sodium hydrogen
carbonate (5.0mL) was slowly added. To the resulting suspension sodium
sulphate (5.00 g) was added. The suspension was filtered and the filter cake
was washed with dichloromethane (5x 50mL). The filtrate was evaporated to
dryness yielding a white solid (350mg, 1.53mmol, 91.2%).
ESI-MS: calcd. for [22+H]+ C12H29N4 m/z= 229.23, found m/z= 229.15.
1H-NMR (500.13MHz, 298K, CDCl3): d = 2.70-2.60 (m, 8H, H2, H3eq),
2.38 (dd, 2JHH = 13.4Hz, 3JHH = 10.6Hz, 4H, H3ax), 2.01 (bs, 4H, H1), 0.95
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(d, 3JHH = 6.1Hz, 12H, H4).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 52.32 (4C, C2), 47.67 (4C,
C3), 18.42 (4C, C4).
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BENZYL (S) - ( 1 ,1 -D IMETHOXYPROPAN -2 -YL )CARBAMATE (77 ) .
Benzyl (S)-(1-oxopropan-2-yl)carbamate (60) (2.00 g, 9.65mmol, 1.0 eq.)
and trimethyl orthoformate (1.54 g, 14.5mmol, 1.5 eq.) were dissolved
in methanol (10mL) and stirred at 20-25  C for 18 h. The solution was
evaporated to dryness yielding a yellowish solid (2.38 g, 9.40mmol, 97.4%).
HR-ESI-MS: calcd. for [77+Na]+ C13H19NNaO4 m/z= 276.1206, found
m/z= 276.1211.
1H-NMR (600.13MHz, 298K, CD3CN): d = 7.39-7.30 (m, 5H, H10, H11,
H12), 5.51 (bs, 1H, H6), 5.05 (s, 2H, H8), 4.16 (d, 3JHH = 4.6Hz, 1H, H3),
3.76 (qd, 3JHH = 6.8Hz, 3JHH = 4.6Hz, 1H, H4), 3.35 (s, 3H, H2/1), 3.34 (s,
3H, H1/2), 1.05 (d, 3JHH = 6.8Hz, 3H, H5).
13C{H}-NMR (150.95MHz, 298K, CD3CN): d = 156.77 (1C, C7), 138.43
(1C, C9), 129.38 (2C, C11), 128.77 (1C, C12), 128.59 (2C, C10), 107.21 (1
C, C3), 66.68 (1C, C8), 56.08 (1C, C2/1), 55.50 (1C, C1/2), 49.35 (1C, C4),
15.65 (1C, C5).
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(S) -1 ,1 -D IMETHOXYPROPAN -2 -AMINE (74 ) .
Benzyl (S)-(1,1-dimethoxypropan-2-yl)carbamate (77) (2.38 g, 9.40mmol,
1.0 eq.) was dissolved in methanol (100mL). Palladium on activated charcoal
(moistened with water, 10% Pd basis, 200mg) was added and the mixture
was stirred at 20-25  C under 1.0 bar of hydrogen for 6 h. The suspension was
filtered through celite and evaporated to dryness yielding a yellowish liquid
(790mg, 6.63mmol, 70.5%).
1H-NMR (600.13MHz, 298K, CD3CN): d = 3.92 (d, 3JHH = 6.1Hz, 1H,
H3), 2.86 (qd, 3JHH = 6.6Hz, 3JHH = 6.1Hz, 1H, H4), 3.35 (s, 3H, H2/1),
3.33 (s, 3H, H1/2), 1.05 (d, 3JHH = 6.8Hz, 3H, H5).
13C{H}-NMR (150.95MHz, 298K, CD3CN): d = 110.20 (1C, C3), 55.12 (1
C, C2/1), 55.10 (1C, C1/2), 49.17 (1C, C4), 18.13 (1C, C5).
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BENZYL ((S) -1 -( ( (S) -1 ,1 -D IMETHOXYPROPAN -2 -YL )AMINO) -
1 -OXOPROPAN -2 -YL )CARBAMATE (78 ) .
N-Carbobenzyloxy-L-alanine (656mg, 2.94mmol, 1.0 eq.) and (S)-1,1-di-
methoxypropan-2-amine (350mg, 2.94mmol, 1.0 eq.) was dissolved in ethyl
acetate (10mL). Propylphosphonic anhydride solution (50 wt. % in ethyl
acetate, 2.6mL, 4.41mmol, 1.5 eq.) and N,N-diisopropylethylamine (1.0mL,
5.88mmol, 2.0 eq.) were added and the solution was stirred at 20-25  C
for 18 h. The solution was extracted with hydrochloric acid (1 M, 20.0mL),
aqueous saturated sodium hydrogen carbonate (20.0mL) and brine (20.0mL).
The organic layer was evaporated to dryness yielding a white solid (810mg,
2.50mmol, 84.9%).
HR-ESI-MS: calcd. for [78+Na]+ C16H24N2NaO5 m/z= 347.1577, found
m/z= 347.1584.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.39-7.30 (m, 5H, H14, H15,
H16), 6.00 (d, 3JHH = 6.4Hz, 1H, H5), 5.31 (d, 3JHH = 5.1Hz, 1H, H1),
5.12 (d, 2JHH = 12.9Hz, 1H, H12a), 5.09 (d, 2JHH = 12.9Hz, 1H, H12b),
4.25-4.10 (m, 3H, H2, H6, H7), 3.42 (s, 3H, H9/10), 3.40 (s, 3H, H10/9), 1.38
(d, 3JHH = 7.10Hz, 3H, H3), 1.11 (d, 3JHH = 6.4Hz, 3H, H8).
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13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 171.79 (1C, C4), 155.97 (1
C, C11), 136.37 (1C, C13), 128.71 (2C, C15), 128.37 (1C, C16), 128.23 (2C,
C14), 106.10 (1C, C7), 67.12 (1C, C12), 56.17 (1C, C10/9), 55.91 (1C, C9/10),
50.82 (1C, C2), 46.67 (1C, C6), 19.02 (1C, C3), 14.87 (1C, C8).
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METHYL ( (BENZYLOXY)CARBONYL) -L -ALANYL -L -ALAN INATE
(80 ) .
N-Carbobenzyloxy-L-alanine (68.3 g, 306mmol, 1.0 eq.), L-alanine methyl
ester hydrochloride (42.7 g, 306mmol, 1.0 eq.) and N,N-diisopropylethylam-
ine (177mL, 1.07mol, 3.5 eq.) were suspended in ethyl acetate (500mL).
Propylphosphonic anhydride solution (50 wt. % in ethyl acetate, 214 g,
337mmol, 1.1 eq.) was added and the mixture was stirred at 20-25  C for
18 h. The mixture was diluted with hydrochloric acid (2 M, 500mL) and
the layers were separated. The aqueous layer was extracted with ethyl
acetate (200mL). The combined organic layers were extracted with aqueous
saturated sodium hydrogen carbonate (500mL) and brine (300mL). The
organic layer was dried with sodium sulphate and evaporated to dryness
yielding a white solid (79.5 g, 258mmol, 84.3%).
HR-ESI-MS: calcd. for [80+Na]+ C15H20N2NaO5 m/z= 331.1264, found
m/z= 331.1265.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.37-7.28 (m, 5H, H13, H14,
H15), 6.65 (d, 3JHH = 4.3Hz, 1H, H5), 5.43 (d, 3JHH = 6.2Hz, 1H, H1),
5.10 (s, 2H, H11), 4.54 (qd, 3JHH = 7.2Hz, 3JHH = 4.3Hz, 1H, H6), 4.25
(qd, 3JHH = 7.2Hz, 3JHH = 6.2Hz, 1H, H2), 3.73 (s, 3H, H9), 1.380 (d,
3JHH = 7.2Hz, 3H, H8), 1.379 (s, 3JHH = 7.2Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 173.32 (1C, C7), 171.96
(1C, C3), 155.94 (1C, C10), 136.31 (1C, C12), 128.67 (2C, C14), 128.32 (1
C, C15), 128.19 (2C, C13), 67.13 (1C, C11), 52.63 (1C, C9), 50.51 (1C, C2),
48.18 (1C, C6), 18.78 (1C, C4), 18.37 (1C, C8).
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BENZYL ((S) -1 -( ( (S) -1 -HYDROXYPROPAN -2 -YL )AMINO) -1 -OX-
OPROPAN -2 -YL )CARBAMATE (73 ) .
Methyl ((benzyloxy)carbonyl)-L-alanyl-L-alaninate (80) (20.0 g, 64.9mmol,
1.0 eq.) was dissolved in tetrahydrofuran (60mL) and methanol (60mL)
and cooled to 0-5  C. A solution of sodium borohydride (15.3 g, 389mmol,
6.0 eq.) in methanol / water 8:2 (225mL) was added dropwise and the
mixture was allowed to warm up to 20-25  C and was left stirring for 18 h.
The pH was adjusted to 7 with hydrochloric acid (4 M). Volatile organic
solvents were removed on the rotary evaporator. The white suspension was
diluted with ethyl acetate (200mL). The two layers were separated and the
aqueous layer was extracted with ethyl acetate (100mL). The combined
organic layers were extracted with aqueous saturated sodium hydrogen
carbonate (200mL) and water (100mL). The organic layer was dried with
sodium sulphate and evaporated to dryness yielding a white solid (15.3 g,
54.6mmol, 84.1%).
HR-ESI-MS: calcd. for [73+Na]+ C14H20N2NaO4 m/z= 303.1315, found
m/z= 303.1317.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.39-7.30 (m, 5H, H13, H14,
H15), 6.17 (bs, 1H, H1), 5.25 (bs, 1H, H6), 5.11 (s, 2H, H11), 4.18 (qd,
3JHH = 6.8Hz, 3JHH = 6.2Hz, 1H, H7), 4.07-3.98 (m, 1H, H2), 3.73 (bs, 1
H, H3a), 3.53-3.45 (m, 1H, H3b), 1.38 (d, 3JHH = 6.8Hz, 3H, H9), 1.14 (d,
3JHH = 6.9Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 172.71 (1C, C8), 156.16 (1
C, C10), 136.19 (1C, C12), 128.74 (2C, C14), 128.44 (1C, C15), 128.32 (2C,
C13), 67.35 (1C, C11), 66.82 (1C, C3), 50.98 (1C, C7), 47.94 (1C, C2), 18.54
(1C, C9), 16.97 (1C, C4).
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BENZYL ((S) -1 -OXO -1 -( ( (S) -1 -OXOPROPAN -2 -YL )AMINO)PRO-
PAN -2 -YL )CARBAMATE (71 ) .
Benzyl ((S)-1-(((S)-1-hydroxypropan-2-yl)amino)-1-oxopropan-2-yl)carba-
mate (73 (12.2 g, 43.5mmol, 1.0 eq.) was dissolved in acetonitrile (200mL).
2-Iodoxybenzoic acid (30.5 g, 109mmol, 2.5 eq.) was added and the suspen-
sion was stirred at 80  C for 2 h. The reaction mixture was cooled to 20-25  C
and diluted with ethyl acetate (600mL). The suspension was filtered and
the filtrate was evaporated to dryness. The residue was redissolved in ethtyl
acetate (100mL) and extracted with aqueous saturated sodium hydrogen
carbonate (100mL) and water (100mL). The organic layer was dried with
sodium sulphate and evaporated to dryness yielding a yellowish oil that
slowly crystallized yielding a yellowish solid (11.2 g, 40.2mmol, 92.5%).
HR-ESI-MS: calcd. for [71+H]+ C14H19N2O4 m/z= 279.1339, found m/z=
279.1334.
1H-NMR (600.13MHz, 298K, CDCl3): d = 9.53 (s, 1H, H3), 7.39-7.30 (m,
5H, H12, H13, H14), 6.57 (bs, 1H, H1), 5.24 (bs, 1H, H5), 5.12 (s, 2H, H10),
4.47 (dq, 3JHH = 7.0Hz, 3JHH = 6.6Hz, 1H, H2), 4.32-4.23 (m, 1H, H6), 1.41
(d, 3JHH = 7.0Hz, 3H, H8), 1.35 (d, 3JHH = 6.6Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 198.69 (1C, C3), 172.29
(1C, C7), 155.94 (1C, C9), 136.21 (1C, C11), 128.73 (2C, C13), 128.46 (1
C, C14), 128.30 (2C, C12), 67.33 (1C, C10), 54.71 (1C, C2), 50.61 (1C, C7),
18.60 (1C, C8), 14.60 (1C, C4).
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tert -BUTYL ((S) -2 -( (S) -2 -( ( (BENZYLOXY)CARBONYL)AMINO) -
PROPANAMIDO)PROPYL ) -L -ALAN INATE (81 ) .
Benzyl ((S)-1-oxo-1-(((S)-1-oxopropan-2-yl)amino)propan-2-yl)carbamate
(71) (11.2 g, 40.2mmol, 1.0 eq.) was dissolved in dichloromethane (200mL)
and tert-butyl L-alaninate (5.84 g, 40.2mmol) was added. The solution was
stirred at 20-25  C for 5min followed by the addition of sodium triacetoxy-
borohydride (21.3 g, 101mmol, 2.5 eq.). The suspension was stirred at
20-25  C for 4 h. The reaction mixture was extracted with aqueous saturated
sodium hydrogen carbonate (100mL) and water (100mL). The organic
layer was dried with sodium sulphate and evaporated to dryness yielding a
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yellowish oil. The oil was purified by flash column chromatography (SiO2,
ethyl acetate) yielding a colorless oil (14.2 g, 34.8mmol, 86.7%).
HR-ESI-MS: calcd. for [81+H]+ C21H34N3O5 m/z= 408.2493, found m/z=
408.2500.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.38-7.28 (m, 5H, H18, H19,
H20), 6.43 (bs, 1H, H5), 5.44 (bs, 1H, H9), 5.09 (s, 2H, H16), 4.25-4.16 (m,
1H, H10), 3.95-3.86 (m, 1H, H6), 3.20 (q, 3JHH = 6.9Hz, 1H, H2), 2.63
(dd, 2JHH = 10.9Hz, 3JHH = 3.3Hz, 1H, H7a), 2.53 (dd, 2JHH = 10.9Hz,
3JHH = 4.3Hz, 1H, H7b), 1.45 (s, 9H, H14), 1.38 (d, 3JHH = 7.0Hz, 3H, H12),
1.23 (d, 3JHH = 7.2Hz, 3H, H4), 1.14 (d, 3JHH = 6.9Hz, 3H, H8).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 175.09 (1C, C3), 171.81 (1
C, C11), 155.95 (1C, C15), 136.48 (1C, C17), 128.67 (2C, C19), 128.30 (1C,
C20), 128.20 (2C, C18), 81.23 (1C, C13), 67.02 (1C, C16), 57.38 (1C, C2),
50.77 (1C, C10), 52.00 (1C, C7), 45.75 (1C, C6), 28.22 (3C, C14), 19.26 (1
C, C12), 18.56 (1C, C8), 13.09 (1C, C4).
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tert -BUTYL ((S) -2 -( (S) -2 -AM INOPROPANAMIDO)PROPYL ) -L -
ALAN INATE (76 ) .
tert-Butyl ((S)-2-((S)-2-(((benzyloxy)carbonyl)amino)propanamido)propyl)-
-L-alaninate (81) (9.54 g, 23.4mmol, 1.0 eq.) was dissolved in methanol
(250mL). Palladium on activated charcoal (moistened with water, 10% Pd
basis, 500mg) was added and the mixture was stirred at 20-25  C under
1.0 bar of hydrogen for 6 h. The suspension was filtered through celite and
evaporated to dryness yielding a yellowish oil (6.28 g, 23.0mmol, 98.2%).
HR-ESI-MS: calcd. for [76+H]+ C13H28N3O3 m/z= 274.2125, found m/z=
274.2130.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.2 (bs, 1H, H5), 4.00-3.90
(m, 1H, H6), 3.47 (q, 3JHH = 7.0Hz, 1H, H10), 3.20 (q, 3JHH = 6.9Hz,
1H, H2), 2.64 (dd, 2JHH = 11.90Hz, 3JHH = 5.5Hz, 1H, H7a), 2.54 (dd,
2JHH = 11.90Hz, 3JHH = 3.3Hz, 1H, H7b), 1.45 (s, 9H, H14), 1.31 (d,
3JHH = 6.9Hz, 3H, H12), 1.24 (d, 3JHH = 7.0Hz, 3H, H4), 1.16 (3J=6.,
(3JHH = 6.7Hz, 3H, H8).
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13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 175.35 (1C, C11), 175.02
(1C, C3), 80.96 (1C, C13), 57.31 (1C, C2), 52.43 (1C, C7), 50.89 (1C, C10),
44.89 (1C, C6), 28.09 (3C, C14), 21.78 (1C, C12), 18.93 (1C, C4), 18.68 (1
C, C8).
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TERT -BUTYL ((S) -2 -( (S) -2 -( ( (S) -2 -( ( (BENZYLOXY)CAR-
BONYL )AMINO)PROPYL )AMINO)PROPANAMIDO)PROPYL ) -L -
ALAN INATE (75 ) .
tert-Butyl ((S)-2-((S)-2-aminopropanamido)propyl)-L-alaninate (76)
(331mg, 1.21mmol, 1.0 eq.) and benzyl (S)-(1-oxopropan-2-yl)carbamate
(60) (251mg, 1.21mmol, 1.0 eq.) were dissolved in dichloromethane (20mL).
The solution was stirred at 20-25  C for 5min followed by the addition of
sodium triacetoxyborohydride (769mg, 3.63mmol, 3.0 eq.). The reaction
mixture was stirred at 20-25  C for 16 h. The excess of sodium triacetoxyboro-
hydride was quenched with aqueous saturated sodium hydrogencarbonate
(20.0mL) and the pH adjusted to >9 by addition of triethylamine (2.0mL).
The two layers were separated and the organic layer was washed with water
(20mL) and dried with sodium sulphate. The organic layer was evaporated
to dryness yielding a colourless oil (410mg, 882 µmol, 72.9%).
HR-ESI-MS: calcd. for [75+H]+ C24H41N4O5 m/z= 465.3071, found m/z=
465.3076.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.38-7.26 (m, 5H, H20, H21,
H22), 5.47 (d, 3JHH = 6.7Hz, 1H, H13), 5.08 (s, 2H, H18), 4.00-3.92 (m, 1
H, H6), 3.76-3.73 (m, 1H, H14), 3.15 (q, 3JHH = 7.0Hz, 1H, H2), 3.07 (q,
3JHH = 6.9Hz, 1H, H10), 2.77 (dd, 2JHH = 12.9Hz, 3JHH = 7.1Hz, 1H, H15a),
2.67 (dd, 2JHH = 11.7Hz, 3JHH = 4.7Hz, 1H, H7a), 2.59 (dd, 2JHH = 12.9Hz,
3JHH = 5.0Hz, 1H, H15b), 2.45 (dd, 2JHH = 11.7Hz, 3JHH = 5.1Hz, 1H, H7b),
1.43 (s, 9H, H24), 1.26 (d, 3JHH = 7.0Hz, 3H, H12), 1.19 (d, 3JHH = 7.0Hz,
3H, H16), 1.19 (d, 3JHH = 7.0Hz, 3H, H4), 1.11 (d, 3JHH = 6.7Hz, 3H, H8).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 174.90 (1C, C3), 174.65 (1
C, C11), 156.00 (1C, C17), 136.61 (1C, C19), 128.53 (2C, C21), 128.19 (1C,
C22), 128.12 (2C, C20), 81.00 (1C, C23), 66.57 (1C, C18), 59.12 (1C, C10),
57.14 (1C, C2), 53.92 (1C, C15), 52.36 (1C, C7), 47.23 (1C, C14), 44.75 (1
C, C6), 28.08 (3C, C24), 20.10 (1C, C12), 18.85 (1C, C16), 18.85 (1C, C4),
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18.84 (1C, C8).
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tert -BUTYL N - ( (S) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO) -
PROPYL ) -N - ( 4 -FLUOROBEN ZYL ) -L -ALAN INATE (85 )
tert-Butyl ((S)-2-(((benzyloxy)carbonyl)amino)propyl)-L-alaninate (62)
(65.0 g, 189mmol, 1.0 eq.) was dissolved in acetonitrile (200mL) and po-
tassium carbonate (53.3 g, 386mmol, 2.0 eq.) was added. To this suspension
1-(bromomethyl)-4-fluorobenzene (43.8 g, 232mmol, 1.2 eq.) was added and
the reaction mixture was stirred at 45  C for 16 h. Excess of 1-(bromomethyl)-
-4-fluorobenzene was quenched with triethylamine (50.0mL). The reaction
mixture was cooled to 20-25  C filtered and evaporated to dryness yielding a
crude oil. The crude product was purified by flash column chromatography
(SiO2, ethyl acetate / cyclohexane (7:3)) yielding a yellowish oil (78.3 g,
176mmol, 91.3%).
HR-ESI-MS: calcd. for [85+H]+ C25H34FN2O4 m/z= 445.2497, found m/z=
445.2498.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.37-7.28 (m, 7H, H14,
H15, H16, H19), 7.11 (dd, 3JHH = 8.8Hz, 3JHH = 8.8Hz, 2H, H20), 7.05
(d, 3JHH = 8.0Hz, 1H, H1), 5.02 (d, 2JHH = 12.6Hz, 1H, H12a), 4.97 (d,
2JHH = 12.6Hz, 1H, H12b), 3.80 (d, 2JHH = 14.3Hz, 1H, H17a), 3.64 (d,
2JHH = 14.3Hz, 1H, H17b), 3.54 (dddq, 3JHH = 8.7Hz, 3JHH = 8.0Hz,
3JHH = 5.8Hz, 3JHH = 6.7Hz, 1H, H2), 3.20 (q, 3JHH = 7.1Hz, 1H, H6),
2.52 (dd, 2JHH = 13.1Hz, 3JHH = 5.8Hz, 1H, H3a), 2.48 (dd, 2JHH = 13.1Hz,
3JHH = 8.7Hz, 1H, H3b), 1.42 (s, 9H, H10), 1.10 (d, 3JHH = 7.1Hz, 3H, H8),
1.02 (d, 3JHH = 6.7Hz, 3H, H4).
13C{H}-NMR (150.9MHz, 298K, DMSO d6): d = 172.13 (1C, C7), 161.18
(d, 1JCF = 242.1Hz, 1C, C21), 155.48 (1C, C11), 137.29 (1C, C13), 135.89
(d, 4JCF = 2.9Hz, 1C, C18), 130.05 (d, 3JCF = 8.0Hz, 2C, C19), 128.30 (2
C, C15), 127.72 (1C, C16), 127.68 (2C, C14), 114.86 (d, 2JCF = 21.1Hz, 2C,
C20), 80.25 (1C, C9), 65.02 (1C, C12), 57.28 (1C, C6), 55.58 (1C, C3), 55.05
(1C, C17), 45.47 (1C, C2), 27.89 (3C, C10), 18.58 (1C, C4), 15.58 (1C, C8).
19F{H}-NMR (564.6MHz, 298K, DMSO d6): d = −114.86 (1 F, F21).
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tert -BUTYL N - ( (S) -2 -AM INO PROPYL ) -N - ( 4 -FLUOROBEN ZYL ) -
L -ALAN INATE (88 ) .
Ammonium formate (8.50 g, 135mmol, 8.0 eq.) was dissolved in ethanol
(485mL) and palladium on activated charcoal (moistened with water, 10%
Pd basis, 750mg) was added. The reaction mixture was then heated to 50  C
for 15min (H2 evolution!) followed by the addition of tert-butyl N-((S)-2--
(((benzyloxy)carbonyl)amino)propyl)-N-(4-fluorobenzyl)-L-alaninate (85)
(7.50 g, 16.9mmol, 1.0 eq.) dissolved in ethanol (15.0mL). The reaction
progress was carefully monitored by LC/MS. The reaction was stopped
once the starting material was consumed completely (approximately after
1 h). The hot suspension was then immediately filtered through celite and
triethylamine (20.0mL) was added. The solution was evaporated to dryness
yielding a yellowish oil (4.80 g, 15.4mmol, 91.5%) that was used without
further purification.
HR-ESI-MS: calcd. for [88+H]+ C17H28FN2O2 m/z= 311.2129, found m/z=
311.2128.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.37-7.32 (m, 2H, H13),
7.16-7.11 (m, 2H, H14), 3.70 (d, 2JHH = 14.3Hz, 1H, H11a), 3.62 (d,
2JHH = 14.3Hz, 1H, H11b), 3.25 (q, 3JHH = 7.0Hz, 1H, H6), 2.75 (ddq,
3JHH = 7.0Hz, 3JHH = 6.5Hz, 3JHH = Hz, 1H, H2), 2.36 (dd, 2JHH = 12.8Hz,
3JHH = 7.0Hz, 1H, H3a), 2.26 (dd, 2JHH = 12.8Hz, 3JHH = 6.5Hz, 1H, H3b),
1.44 (s, 9H, H10), 1.11 (d, 3JHH = 7.0Hz, 3H, H8), 0.87 (d, 3JHH = 6.3Hz, 3
H, H4).
13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 172.21 (1C, C7),
161.14 (d, 1JCF = 242.0Hz, 1C, C15), 136.35 (d, 4JCF = 2.9Hz, 1C, C12),
130.02 (d, 3JCF = 8.0Hz, 2C, C13), 114.86 (d, 2JCF = 21.1Hz, 2C, C14),
80.05 (1C, C9), 59.72 (1C, C3), 57.96 (1C, C6), 54.77 (1C, C11), 44.70 (1C,
C2), 27.88 (3C, C10), 21.48 (1C, C4), 14.08 (1C, C8).
19F{H}-NMR (564.6MHz, 298K, DMSO d6): d = −116.31 (1 F, F15).
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N -((S) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO)PROPYL ) -N - ( 4 -
FLUOROBEN ZYL ) -L -ALAN INE (87 ) .
tert-Butyl N-((S)-2-(((benzyloxy)carbonyl)amino)propyl)-N-(4-fluoroben-
zyl)-L-alaninate (85) (33.0 g, 74.2mmol, 1.0 eq.) was dissolved in hydrogen
chloride solution (4 M in 1,4-dioxane) and stirred at 20-25  C. The reaction
progress was monitored by LC/MS and once the starting material was
consumed (approximately 12 h) the solution was evaporated to dryness. The
crude oil was then dissolved in dichloromethane (100mL) and triethylamine
(30mL) was added. The organic layer was extracted with water (2x 100mL),
dried with sodium sulphate and evaporated to dryness yielding the title
compound as a triethylammonium salt (35.4 g. 72.3mmol, 97.4%). The
off-white foam was used in the next step without further purification.
HR-ESI-MS: calcd. for [87+H]+ C21H26FN2O4 m/z= 389.1871, found m/z=
389.1866.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 12.35 (bs, 1H, H9), 7.38-
7.26 (m, 7H, H13,H14,H15,H18), 7.09 (d, 3JHH = 8.0Hz, 1H, H1), 7.11-7.03 (m,
2H, H19), 5.01 (d, 2JHH = 12.5Hz, 1H, H11a), 4.98 (d, 2JHH = 12.5Hz, 1H,
H11b), 3.76 (d, 2JHH = 14.4Hz, 1H, H16a), 3.66 (d, 2JHH = 14.4Hz, 1H, H16b),
3.52 (dddq, 3JHH = 8.0Hz, 3JHH = 8.0Hz, 3JHH = 6.1Hz, 3JHH = 6.6Hz, 1H,
H2), 3.29 (q, 3JHH = 7.1Hz, 1H, H6), 2.56 (dd, 2JHH = 13.2Hz, 3JHH = 6.1Hz,
1H, H3a), 2.47 (dd, 2JHH = 13.2Hz, 1H, H3b), 1.16 (d, 3JHH = 7.1Hz, 3H,
H8), 1.01 (d, 3JHH = 6.6Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 174.64 (1C, C7),
161.16 (d, 1JCF = 242.1Hz, 1C, C20), 155.61 (1C, C10), 137.27 (1C, C12),
136.09 (1C, C17), 130.02 (d, 3JCF = 8.0Hz, 2C, C18), 128.33 (2C, C14),
127.73 (3C, C13,C15), 114.83 (d, 2JCF = 21.1Hz, 2C, C19), 65.07 (1C, C11),
56.96 (1C, C6), 55.93 (1C, C3), 55.00 (1C, C16), 45.57 (1C, C2), 18.59 (1C,
C4), 15.25 (1C, C8).
19F{H}-NMR (564.6MHz, 298K, DMSO d6): d = −116.26 (1 F, F20).
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tert -BUTYL (5S ,8S ,11S ,14S ) -7 ,13 -B I S (4 -FLUOROBEN ZYL ) -5 ,
8 ,11 ,14 -TET RAMETHYL -3 ,9 -D I OXO -1 -PHENYL -2 -OXA -4 ,7 ,10 ,
13 -TET RAAZA PENTADECAN -15 -OATE (86 ) .
tert-Butyl N-(((S))-2-aminopropyl)-N-(4-fluorobenzyl)-L-alaninate (88)
(18.0 g, 58.0mmol, 1.0 eq.), N-((S)-2-(((benzyloxy)carbonyl)amino)propyl)-
N-(4-fluorobenzyl)-L-alanine (87) triethylammonium salt (28.4 g, 58.0mmol,
1.0 eq.) and N-ethyl diisopropylamine (19.2mL, 116mmol, 2.0 eq.) were
dissolved in acetonitrile (300mL) and HATU (22.1 g, 58.0mmol, 1.0 eq.)
was added. The reaction mixture was stirred at 20-25  C for 16 h. The solvent
was removed under vacuum and the crude oil was dissolved in ethyl acetate
(300mL) and extracted with water (2x 100mL) and brine (50.0mL). The
organic layer was dried with sodium sulphate and evaporated to dryness. The
crude oil was first plugged through a short silica gel column (100 g SiO2). The
fractions containing the product were combined and evaporated to dryness.
The resulting oil was further purified by flash column chromatography (SiO2,
ethyl acetate / cyclohexane (3:7)) yielding a white foam (21.9 g, 32.1mmol,
55.4%).
HR-ESI-MS: calcd. for [86+H]+ C38H51F2N4O5 m/z= 681.3822, found
m/z= 681.3826.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.58 (d, 3JHH = 8.2Hz, 1
H, H9), 7.40-7.25 (m, 9H, H34,H33,H32,H24,H19), 7.12-7.06 (m, 2H, H25),
7.04-6.97 (m, 2H, H20), 5.05 (d, 2JHH = 12.5Hz, 1H, H30a), 4.98 (d,
2JHH = 12.5Hz, 1H, H30b), 3.86-3.77 (m, 1H, H10), 3.81 (d, 2JHH = 14.3Hz,
1H, H22a), 3.64 (m, 1H, H2), 3.62 (d, 2JHH = 14.3Hz, 1H, H22b), 3.50
(d, 2JHH = 14.4Hz, 1H, H17a), 3.45 (d, 2JHH = 14.4Hz, 1H, H17b), 3.29
(q, 3JHH = 6.9Hz, 1H, H6), 3.21 (q, 3JHH = 6.6Hz, 1H, H14), 2.57-2.51
(m, 2H, H11), 2.46 (dd, 2JHH = 13.3Hz, 3JHH = 4.8Hz, 1H, H3a), 2.28
(dd, 2JHH = 13.3Hz, 3JHH = 8.2Hz, 1H, H3b), 1.41 (s, 9H, H28), 1.10
(d, 3JHH = 7.2Hz, 3H, H16), 1.08 (d, 3JHH = 6.9Hz, 3H, H8), 1.04 (d,
3JHH = 6.6Hz, 3H, H12), 0.96 (d, 3JHH = 6.7Hz, 3H, H4).
13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 172.14 (1C, C15),
171.86 (1C, C7), 161.15 (d, 1JCF = 242.1Hz, 1C, C26), 161.13 (d,
1JCF = 242.1Hz, 1C, C21), 156.06 (1C, C29), 137.10 (1C, C31), 135.97
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(d, 4JCF = Hz, 1C, C23), 135.88 (d, 4JCF = 2.3Hz, 1C, C18), 130.17 (d,
3JCF = Hz, 2C, C19), 129.97 (d, 3JCF = Hz, 2C, C24), 128.34 (2C, C33),
127.84 (1C, C34), 127.80 (2C, C32), 114.84 (d, 2JCF = 21.1Hz, 2C, C25),
114.69 (d, 2JCF = Hz, 2C, C20), 80.23 (1C, C27), 65.15 (1C, C30), 57.57 (1
C, C6), 57.34 (1C, C14), 56.54 (1C, C3), 55.51 (1C, C11), 55.00 (1C, C22),
53.78 (1C, C17), 44.98 (1C, C2), 43.32 (1C, C10), 27.88 (3C, C28), 18.68 (2
C, C12,C4), 15.86 (1C, C16), 10.63 (1C, C8).
19F{H}-NMR (564.6MHz, 298K, DMSO d6): d = −116.20 (1 F, F26),
−116.37 (1 F, F21).
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N - ( (S) -2 - ( (S) -2 - ( ( (S) -2 -AM INO PROPYL ) (4 -FLUOROBEN ZYL )
AMINO)PROPANAMIDO)PROPYL ) -N - ( 4 -FLUOROBEN ZYL ) -L -AL -
AN INE (90 ) .
tert-Butyl (5S,8S,11S,14S)-7,13-bis(4-fluorobenzyl)-5,8,11,14-tetramethyl-3,
9-dioxo-1-phenyl-2-oxa-4,7,10,13-tetraazapentadecan-15-oate (86) (21.0 g,
30.8mmol, 1.0 eq.) was dissolved in hydrogen bromide solution (16% wt.
in acetic acid, 100mL) and stirred at 40  C for 30min. The solvent was
removed under reduced pressure yielding a brownish oil. This oil was further
suspended in acetonitrile (100mL) and aqueous hydrochloric acid (37%,
5.0mL). This mixture was again evaporated to dryness. This procedure
was repeated three times to remove residual acetic acid from the product.
Finally, the product was dissolved in methanol (100mL) and evaporated to
dryness, yielding a brownish foam. This foam was extensively dried under
high vacuum at 40  C for 5 d. The product (21.3 g) is obtained as a mixture of
HCl and HBr salt with minimal acetate content and was further used without
additional purification.
HR-ESI-MS: calcd. for [90+H]+ C26H36F2N4O3 m/z= 491.2828, found
m/z= 491.2831.
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1H-NMR (600.13MHz, 298K, DMSO d6): d = 10.13 (s, 1H, H27), 8.60 (bs,
3H, H1), 7.53-7.48 (m, 2H, H19), 7.32-7.24 (m, 2H, H24), 7.10-7.05 (m, 2
H, H20), 7.01-6.94 (m, 2H, H25), 3.61 (d, 2JHH = 14.9Hz, 1H, H22a), 3.59
(d, 2JHH = 14.9Hz, 1H, H22b), 3.53 (m, 1H, H10), 3.47 (q, 3JHH = 6.8Hz,
1H, H6), 3.40 (s, 2H, H17), 3.30 (m, 1H, H2), 2.94 (q, 3JHH = 7.0Hz, 1
H, H14), 2.73 (dd, 2JHH = 13.3Hz, 3JHH = 11.7Hz, 1H, H11a ), 2.46 (dd,
2JHH = 13.6Hz, 3JHH = 9.0Hz, 1H, H3a), 2.39-2.32 (m, 2H, H3b,H11b),
1.09 (d, 3JHH = 6.8Hz, 3H, H8), 1.06 (d, 3JHH = 7.1Hz, 3H, H16), 1.00 (d,
3JHH = 6.6Hz, 3H, H4), 0.95 (d, 3JHH = 6.2Hz, 3H, H12).
13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 177.48 (1C, C15),
171.50 (1C, C7), 161.29 (d, 1JCF = 242.1Hz, 1C, C21), 160.92 (d,
1JCF = 242.1Hz, 1C, C26), 136.99 (d, 4JCF = 2.8Hz, 1C, C23), 134.79
(1C, C18), 130.82 (d, 3JCF = 7.6Hz, 2C, C19), 129.73 (d, 3JCF = 7.9Hz, 2C,
C24), 114.81 (d, 2JCF = 20.9Hz, 2C, C20), 114.59 ((2JCF = 30.0Hz, 2C, C25),
59.42 (1C, C14), 57.39 (1C, C6), 55.03 (1C, C22), 54.87 (1C, C11), 53.49 (1
C, C3), 52.78 (1C, C17), 44.67 (1C, C10), 43.16 (1C, C2), 18.27 (1C, C12),
17.39 (1C, C4), 10.04 (1C, C16), 9.63 (1C, C8).
19F{H}-NMR (564.6MHz, 298K, DMSO d6): d = −116.21 (1 F, F21),
−116.76 (1 F, F26).
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( 3S ,6S ,9S ,12S ) -4 ,10 -B I S (4 -FLUOROBEN ZYL ) -3 ,6 ,9 ,12 -TET -
RAMETHYL -1 ,4 ,7 ,10 -TET RAAZA -CYCLODODECANE -2 ,8 -D I -
ONE (92 ) .
A total of 21.3 g of N-((S)-2-((S)-2-(((S)-2-aminopropyl)(4-fluoro benzyl)-
amino)propanamido)propyl)-N-(4-fluorobenzyl)-L-alanine (90) salt was
cyclized in several portions of max. 2.00 g. N-((S)-2-((S)-2-(((S)-2-amino-
propyl)(4-fluorobenzyl) amino) propanamido) propyl)-N-(4-fluorobenzyl)-
L-alanine (90) salt (2.00 g, 4.08mmol, 1.0 eq.) and N-ethyl diisopropylamine
(3.4mL, 20.4mmol, 5 eq.) were dissolved in acetonitrile (2.0 L). HATU
(1.55 g, 4.08mmol, 1.0 eq.) was added and the solution was stirred at 20-
25  C for 20min. The solvent was removed under vacuum. The crude product
from all batches was combined and purified by flash column chromatography
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(SiO2, ethyl acetate / cyclohexane (7:3)) yielding a white solid (10.4 g,
22.0mmol, 68.5% yield calculated over 2 steps starting from 86).
HR-ESI-MS: calcd. for [92+H]+ C26H35F2N4O2 m/z= 473.2723, found
m/z= 473.2720.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.71 (d, 3JHH = 4.9Hz,
2H, H5), 7.44 (dd, 3JHH = 8.4Hz, 4JHF = 6.0Hz, 4H, H11), 7.09 (dd,
3JHH = 8.4Hz, 3JHF = 8.8Hz, 4H, H12), 3.86 (d, 2JHH = 13.4Hz, 2H, H9a),
3.57 (d, 2JHH = 13.4Hz, 2H, H9b), 3.35 (dddq, 3JHH = 10.8Hz, 3JHH = 4.9Hz,
3JHH = 2.8Hz, 2H, H6), 3.20 (q, 2H, H2), 2.75 (dd, 2JHH = 13.4Hz,
3JHH = 10.8Hz, 2H, H7a), 2.29 (dd, 2JHH = 13.4Hz, 3JHH = 2.8Hz, 2H,
H7b), 1.14 (d, 3JHH = 6.5Hz, 6H, H8), 1.04 (d, 3JHH = 7.0Hz, 6H, H4).
13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 172.12 (2C, C3),
161.33 (d, 1JCF = 242.7Hz, 2C, C13), 135.34 (2C, C10), 130.97 (d,
3JCF = 7.8Hz, 4C, C11), 114.81 (d, 2JCF = 21.0Hz, 4C, C12), 59.66 (2C,
C2), 55.92 (2C, C9), 54.94 (2C, C7), 43.96 (2C, C6), 17.69 (2C, C8), 8.73 (2
C, C4).
19F{H}-NMR (564.6MHz, 298K, DMSO d6): d = −115.65 (1 F, F13).
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( 2S ,5S ,8S ,11S ) -1 ,7 -B I S (4 -FLUOROBENZYL ) -2 ,5 ,8 ,11 -TETRA-
METHYL -1 ,4 ,7 ,10 -TETRAAZACYCLODODECANE (91 ) .
(3S,6S,9S,12S)-4,10-Bis(4-fluorobenzyl)-3,6,9,12-tetramethyl-1,4,7,10-tetra-
aza-cyclododecane-2,8-dione (92) (120mg, 254 µmol, 1.0 eq.) was dissolved
in dichloromethane (5.0mL) and cooled to 0-5  C. Trimethylsilyl chloride
(152mg, 1.40mmol, 5.5 eq.) was slowly added. After completion, the
reaction mixture was stirred at 0-5  C for 30min followed by the addition
of a lithium aluminium hydride solution (2.5mL, 2 M in tetrahydrofuran,
5.08mmol, 20.0 eq.). The reaction mixture was allowed to warm to 20-25  C
and was further stirred for 3 h. The reaction mixture was cooled to 0-5  C
and saturated aqueous sodium hydrogen carbonate (2.0mL) was slowly
EXPER IMENTAL PART 169
added. To the resulting suspension sodium sulphate (4.00 g) was added. The
suspension was filtered and evaporated to dryness yielding a white solid
(103mg, 232 µmol, 91.2%).
HR-ESI-MS: calcd. for [91+H]+ C26H39F2N4 m/z= 445.3137, found m/z=
445.3146.
1H-NMR (500.13MHz, 298K, CDCl3): d = 7.31-7.28 (m, 4H, H11), 7.06-
7.00 (m, 4H, H12), 3.75 (d, 2JHH = 13.0Hz, 2H, H9a), 3.11-3.00 (m, 2H,
H2), 2.97 (bs, 2H, H9b), 2.90-2.74 (m, 4H, H3a, H6), 2.49-2.34 (m, 4H,
H3b, H7a), 2.27-2.11 (m, 2H, H7b), 0.91 (d, 3JHH = 6.4Hz, 6H, H8), 0.89 (d,
3JHH = 6.0Hz, 6H, H4).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 162.19 (d, 1JCF = 245.6Hz,
2C, C13), 135.58 (d, 4JCF = 1.5Hz, 2C, C10), 130.68 (d, 3JCF = 7.9Hz, 4C,
C11), 115.39 (d, 2JCF = 21.5Hz, 4C, C12), 56.59 (2C, C7), 51.01 (2C, C9),
50.17 (2C, C2), 47.91 (2C, C3), 46.58 (2C, C6), 18.78 (2C, C4), 10.24 (2C,
C8).
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( 3S ,6S ,9S ,12S ) -3 ,6 ,9 ,12 -TET RAMETHYL -1 ,4 ,7 ,10 -TET RA-
AZACYCLODODECANE -2 ,8 -D I ONE (69 ) .
Method A
(3S,6S,9S,12S)-4,10-Bis(4-fluorobenzyl)-3,6,9,12-tetramethyl-1,4,7,10-tetra-
azacyclododecane-2,8-dione (92) (2.50 g, 5.29mmol, 1.0 eq.) was dissolved
in acetic acid (40mL) and trifluoroacetic acid (2.0mL). Palladium on
charcoal (moistened with water, 10% Pd basis, 200mg) was added and the
suspension was hydrogenated at 45 bar for 16 h. The suspension was filtered
through celite and the solvent was removed under reduced pressure. The
residue was dissolved in dichloromethane (5.0mL) and aqueous sodium
hydroxide (2 M, 5.0mL). The layers were separated and the organic layer
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was washed with aqueous sodium hydroxide (2 M, 5.0mL). The organic
layer was dried with sodium sulphate and evaporated to dryness yielding the
title compound as a white solid (1.14 g, 4.45mmol, 84.1%).
Method B
(3S,6S,9S,12S)-4-Benzyl-10-(4-fluorobenzyl)-3,6,9,12-tetramethyl-1,4,7,
10-tetraazacyclododecane-2,8-dione (94) (3.69 g, 8.12mmol, 1.0 eq.) was
dissolved in acetic acid (50.0mL) and trifluoroacetic acid (2.0mL). Palla-
dium on charcoal (moistened with water, 10% Pd basis, 350mg) was added
and the suspension was hydrogenated at 45 bar for 16 h. The suspension was
filtered through celite and the solvent was removed under reduced pressure.
The residue was dissolved in dichloromethane (10.0mL) and aqueous
sodium hydroxide (2 M, 10.0mL). The layers were separated and the organic
layer was washed with aqueous sodium hydroxide (2 M, 10.0mL). The
organic layer was dried with sodium sulphate and evaporated to dryness
yielding the title compound as a white solid (1.85 g, 7.22mmol, 88.9%).
Method C
(3S,6S,9S,12S)-4,10-Dibenzyl-3,6,9,12-tetra-methyl-1,4,7,10-tetraazacy-
clododecane-2,8-dione (67) (50.0mg, 115 µmol, 1.0 eq.) was dissolved in
methanol (5.00mL). Palladium on charcoal (moistened with water, 10% Pd
basis, 50.0mg) was added and the suspension was hydrogenated at 1 bar for
16 h. The suspension was filtered through celite and the solvent was removed
under reduced pressure yielding the title compound as a white solid (25.0mg,
97.5 µmol, 84.8%).
HR-ESI-MS: calcd. for [69+H]+ C12H25N4O2 m/z= 257.1972, found m/z=
257.1975.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.78 (d, 3JHH = 9.1Hz, 2H,
H5), 3.79 (dddq, 3JHH = 9.1Hz, 3JHH = 3.4Hz, 3JHH = 3.0Hz, 3JHH = 6.9Hz,
2H, H6), 2.88 (q, 3JHH = 6.9Hz, 2H, H2), 2.79 (ddd, 2JHH = 12.5Hz,
3JHH = 6.1Hz, 3JHH = 3.0Hz, 2H, H7a), 2.40 (dd, 3JHH = 10.3Hz,
3JHH = 6.1Hz, 2H, H1), 2.05 (ddd, 2JHH = 12.5Hz, 3JHH = 10.3Hz,
3JHH = 3.4Hz, 2H, H7b), 1.17 (d, 3JHH = 6.9Hz, 6H, H4), 1.02 (d,
3JHH = 6.9Hz, 6H, H8).
13C{H}-NMR (150.95MHz, 298K, DMSO d6): d = 173.76 (2C, C3), 59.41
(2C, C2), 52.62 (2C, C7), 42.64 (2C, C6), 19.21 (2C, C4), 17.74 (2C, C8).
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tert -BUTYL (5S ,8S ,11S ,14S ) -7 -BENZYL -13 -(4 -FLUOROBENZ -
YL ) -5 ,8 ,11 ,14 -TET RAMETHYL -3 ,9 -D I OXO -1 -PHENYL -2 -OXA -
4 ,7 ,10 ,13 -TET RAAZA PEN TADECAN -15 -OATE (93 ) .
tert-Butyl N-(((S))-2-aminopropyl)-N-(4-fluorobenzyl)-L-alaninate (88)
(7.36 g, 23.7mmol, 1.0 eq.), N-benzyl-N-((S)-2-(((benzyloxy)carbonyl)-
amino)propyl)-L-alanine (64) triethylammonium salt (10.3 g, 21.9mmol,
0.9 eq.) and N-ethyl diisopropylamine (7.8mL, 47.4mmol, 2.0 eq.) were
dissolved in acetonitrile (100mL). HATU (9.01 g, 23.7mmol, 1.0 eq.) was
added. The reaction mixture was stirred at 20-25  C for 16 h. The solvent
was removed under vacuum and the crude oil was dissolved in ethyl acetate
(100mL) and extracted with water (2x 50mL) and brine (20.0mL). The
organic layer was dried with sodium sulphate and evaporated to dryness. The
crude oil was first plugged through a short silica gel column (150 g SiO2). The
fractions containing the product were combined and evaporated to dryness.
The resulting oil was further purified by flash column chromatography (SiO2,
ethyl acetate / cyclohexane (3:7)) yielding a white solid (7.66 g, 11.6mmol,
48.8%).
HR-ESI-MS: calcd. for [93+H]+ C38H52FN4O5 m/z= 663.3916, found m/z=
663.3905.
1H-NMR (500.13MHz, 298K, CDCl3): d = 7.38-7.19 (m, 12H, H19, H20,
H21, H24, H32, H33, H34), 6.94-6.89 (m, 2H, H25), 5.14 (d, 2JHH = 12.3Hz, 1
H, H30a), 4.99 (d, 2JHH = 12.3Hz, 1H, H30b), 4.61 (d, 3JHH = 8.0Hz, 1H, H1),
3.98 (ddq, 3JHH = 8.0Hz, 3JHH = 6.1Hz, 3JHH = 7.0Hz, 1H, H10), 3.90-3.83
(m, 1H, H2), 3.82 (d, 2JHH = 14.3Hz, 1H, H22a), 3.71 (d, 2JHH = 13.4Hz, 1
H, H17a), 3.68 (d, 2JHH = 14.3Hz, 1H, H22b), 3.38 (q, 3JHH = 6.9Hz, 1H, H6),
3.37 (d, 2JHH = 13.4Hz, 1H, H17b), 3.25 (q, 3JHH = 7.2Hz, 1H, H14), 2.66
(dd, 2JHH = 13.7Hz, 3JHH = 6.1Hz, 1H, H11a), 2.59 (dd, 2JHH = 13.7Hz,
3JHH = 6.1Hz, 1H, H11b), 2.49 (dd, 2JHH = 13.5Hz, 3JHH = 3.3Hz, 1H,
H3a), 2.26 (dd, 2JHH = 13.5Hz, 3JHH = 10.6Hz, 1H, H3b), 1.45 (s, 9H, H28),
1.21 (d, 3JHH = 6.9Hz, 3H, H8), 1.17 (d, 3JHH = 7.0Hz, 3H, H12), 1.16 (d,
3JHH = 7.2Hz, 3H, H16), 1.05 (d, 3JHH = 6.8Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 173.27 (1C, C15), 172.95
(1C, C7), 161.95 (1C, C26), 156.47 (1C, C29), 139.24 (1C, C18), 136.63 (1
C, C31), 135.74 (1C, C23), 130.07 (2C, C24), 129.10 (2C, C19), 128.64 (2
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C, C33), 128.46 (2C, C20), 128.24 (1C, C34), 128.21 (2C, C32), 127.31 (1C,
C21), 115.06 (2C, C25), 80.97 (1C, C27), 66.65 (1C, C30), 58.45 (1C, C6),
57.72 (1C, C14), 56.61 (1C, C3), 55.78 (1C, C11), 55.68 (1C, C22), 54.81 (1
C, C17), 45.20 (1C, C2), 44.33 (1C, C10), 28.42 (3C, C28), 19.51 (1C, C4),
19.17 (1C, C12), 15.5 (1C, C16), 8.12 (1C, C8).
19F{H}-NMR (564.76MHz, 298K, CDCl3): d = −116.22 (1 F, F26).
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N - ( (S) -2 -( (S) -2 -( ( (S) -2 -AM INOPROPYL ) (BENZYL )AMINO) -
PROPANAMIDO)PROPYL ) -N - ( 4 -FLUOROBENZYL ) -L -ALAN INE
(95 ) .
tert-Butyl (5S,8S,11S,14S)-7-benzyl-13-(4-fluorobenzyl)-5,8,11,14-tetra-
methyl-3,9-dioxo-1-phenyl-2-oxa-4,7,10,13-tetraazapentadecan-15-oate (93)
(7.66 g, 11.6mmol, 1.0 eq.) was dissolved in hydrogen bromide solution
(16% wt. in acetic acid, 40mL) and stirred at 40  C for 30min. The solvent
was removed under reduced pressure yielding a brownish oil. This oil
was further suspended in acetonitrile (50mL) and aqueous hydrochloric
acid (37%, 2.0mL). This mixture was again evaporated to dryness. This
procedure was repeated three times to remove residual acetic acid from
the product. Finally, the product was dissolved in methanol (30.0mL) and
evaporated to dryness, yielding a yellowish foam. This foam was extensively
dried under high vacuum at 40  C for 5 d. The product (7.91 g) is obtained
as a mixture of HCl and HBr salt with minimal acetate content and was used
without further purification.
HR-ESI-MS: calcd. for [95+H]+ C26H38FN4O3 m/z= 473.2922, found m/z=
473.2930.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 7.46-7.40 (m, 2H, H25),
7.20-7.14 (m, 2H, H24), 7.36-7.23 (m, 5H, H19, H20, H21), 4.06-3.88 (m, 3H,
H22, H10), 3.65-3.58 (m, 1H, H6), 3.65 (bs, 2H, H17), 3.30 (q, 3JHH = 6.8Hz,
1H, H14), 3.23-3.13 (m, 1H, H2), 2.77 (bs, 2H, H11), 2.64 (d, 3JHH = 6.9Hz,
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2H, H3), 1.30 (d, 3JHH = 6.9Hz, 3H, H8), 1.12 (d, 3JHH = 6.8Hz, 3H, H16),
1.11 (d, 3JHH = 6.8Hz, 3H, H4), 1.06 (d, 3JHH = 6.7Hz, 3H, H12).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 173.64 (1C, C15),
173.05 (1C, C7), 161.77 (1C, C26), 138.78 (1C, C18), 131.18 (1C, C23),
128.58 (2C, C20), 128.32 (2C, C19), 127.16 (1C, C21), 117.42 (2C, C24),
115.27 (2C, C25), 57.70 (1C, C6), 57.56 (1C, C14), 56.44 (1C, C11), 55.60
(1C, C17), 54.74 (1C, C22), 53.85 (1C, C3), 45.16 (1C, C2), 43.10 (1C, C10),
18.27 (1C, C12), 16.44 (1C, C4), 13.26 (1C, C8), 12.52 (1C, C16).
19F{H}-NMR (564.76MHz, 298K, DMSO d6): d = −114.44 (1 F, F26).
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( 3S ,6S ,9S ,12S ) -4 -BENZYL -10 -(4 -FLUOROBENZYL ) -3 ,6 ,9 ,12 -
TETRAMETHYL -1 ,4 ,7 ,10 -TETRAAZACYCLODODECANE -2 ,8 -D I -
ONE (94 ) .
A total of 7.91 g of N-((S)-2-((S)-2-(((S)-2-aminopropyl)(benzyl)amino)-
propanamido)propyl)-N-(4-fluorobenzyl)-L-alanine (95) salt was cyclized
in several portions of max. 2.00 g. N-((S)-2-((S)-2-(((S)-2-Aminopropyl)-
(benzyl)amino)propanamido)propyl)-N-(4-fluorobenzyl)-L-alanine (95)
salt (2.00 g, 4.24mmol, 1.0 eq.) and N-ethyl diisopropylamine (2.74mL,
21.2mmol, 5.0 eq.) were dissolved in acetonitrile (2.0 L). HATU (1.61 g,
4.24mmol, 1.0 eq.) was added and the solution was stirred at 20-25  C for
20min. The solvent was removed under vacuum. The crude product from all
batches was combined and purified by flash column chromatography (SiO2,
ethyl acetate / cyclohexane (7:3)) yielding a white solid (3.69 g, 8.12mmol,
70.0% yield calculated over 2 steps starting from 93).
HR-ESI-MS: calcd. for [94+H]+ C26H36FN4O2 m/z= 455.2817, found m/z=
455.2826.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 7.72 (d, 3JHH = 4.7Hz, 1
H, H13), 7.70 (d, 3JHH = 4.6Hz, 1H, H5), 7.47-7.43 (m, 2H, H19), 7.43-7.40
(m, 2H, H25), 7.32-7.27 (m, 3H, H26, H24), 7.11-7.06 (m, 2H, H20), 3.89
(d, 2JHH = 13.2Hz, 1H, H22a), 3.85 (d, 2JHH = 13.3Hz, 1H, H17a), 3.57 (d,
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2JHH = 13.3Hz, 1H, H17b), 3.56 (d, 2JHH = 13.3Hz, 1H, H22b), 3.40-3.32
(m, 1H, H6), 3.36-3.28 (m, 1H, H14), 3.21 (q, 3JHH = 7.0Hz, 1H, H2), 3.20
(q, 3JHH = 7.0Hz, 1H, H10), 2.81-2.71 (m, 2H, H7a, H15a), 2.32-2.26 (m, 2
H, H7b, H15b), 1.15 (d, 3JHH = 6.7Hz, 3H, H8), 1.14 (d, 3JHH = 6.6Hz, 3H,
H16), 1.05 (d, 3JHH = 7.0Hz, 3H, H4), 1.04 (d, 3JHH = 7.0Hz, 3H, H12).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 172.18 (1C, C3),
172.06 (1C, C11), 161.32 (1C, C21), 139.15 (1C, C23), 135.37 (1C, C18),
130.93 (2C, C19), 129.06 (2C, C25), 128.14 (2C, C24), 127.12 (1C, C26),
114.78 (2C, C20), 59.69 (1C, C2), 59.60 (1C, C10), 56.75 (1C, C22), 56.04
(1C, C17), 55.05 (1C, C15), 55.04 (1C, C7), 44.10 (1C, C6), 43.96 (1C, C14),
17.69 (1C, C16), 17.66 (1C, C8), 8.65 (1C, C4), 8.55 (1C, C12).
19F{H}-NMR (564.76MHz, 298K, CDCl3): d = −115.64 (1 F, F21).
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tert -BUTYL ((S) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO)PROP -
YL ) -L -VAL INATE (103 ) .
Benzyl (S)-(1-oxopropan-2-yl)carbamate (60) (12.6 g, 60.8mmol, 1.0 eq.)
was dissolved in dichloromethane (120mL). To this solution L-valine tert-
butyl ester (10.7 g, 62.0mmol, 1.0 eq.) was added. The solution was stirred at
20-25  C for 5min followed by the addition of sodium triacetoxyborohydride
(52.3 g, 246mmol, 4.1 eq.). The reaction mixture was stirred at 20-25  C
for 16 h. The excess of sodium triacetoxyborohydride was quenched with
aqueous saturated sodium hydrogen carbonate (150mL) and the pH adjusted
to >9 by addition of triethylamine (20.0mL). The two layers were separated
and the organic layer was washed with aqueous saturated sodium hydrogen
carbonate (2x 100mL), water (50.0mL) and dried with sodium sulphate. The
organic layer was evaporated to dryness and the crude oil was purified by
flash column chromatography (SiO2, cyclohexane / ethyl acetate / triethylam-
ine (70:30:1)) yielding a yellowish oil (19.4 g, 53.2mmol, 87.5%).
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HR-ESI-MS: calcd. for [103+H]+ C20H33N2O4 m/z= 365.2435, found m/z=
365.2439.
1H-NMR (400.13MHz, 298K, CD3CN): d = 7.41-7.25 (m, 5H, H14,H15,H16),
5.56 (bs, 1H, H1), 5.06 (d, 2JHH = 13.4Hz, 1H, H12a), 5.02 (d, 2JHH = 13.4Hz,
1H, H12b), 3.61 (qdd, 3JHH = 6.6Hz, 3JHH = 6.4Hz, 3JHH = 5.8Hz, 1H, H2),
2.76 (d, 3JHH = 6.3Hz, 1H, H6), 2.62 (dd, 2JHH = 11.9Hz, 3JHH = 5.8Hz, 1
H, H3a), 2.37 (dd, 2JHH = 11.9Hz, 1H, H3b), 1.81 (dqq, 3JHH = 6.3Hz,
3JHH = 6.8Hz, 3JHH = 6.8Hz, 1H, H8), 1.44 (s, 9H, H18), 1.17 (d,
3JHH = 6.6Hz, 3H, H4), 0.91 (d, 3JHH = 6.8Hz, 3H, H9/10), 0.90 (d,
3JHH = 6.8Hz, 3H, H9/10)).
13C{H}-NMR (100.61MHz, 298K, CD3CN): d = 171.15 (1C, C7), 156.88
(1C, C11), 138.54 (1C, C13), 129.41 (2C, C15), 128.77 (1C, C16), 128.66 (2
C, C14), 81.36 (1C, C17), 69.20 (1C, C6), 66.59 (1C, C12), 54.20 (1C, C3),
48.32 (1C, C2), 32.42 (1C, C8), 28.35 (3C, C18), 19.66 (1C, C9/10), 19.02 (1
C, C4), 18.94 (1C, C9/10).
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tert -BUTYL ((R) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO)PROP -
YL ) -L -VAL INATE (123 ) .
Benzyl (R)-(1-oxopropan-2-yl)carbamate (122) (1.05 g, 5.07mmol, 1.0 eq.)
was dissolved in dichloromethane (20mL). To this solution L-valine tert-butyl
ester (878mg, 5.07mmol, 1.0 eq.) was added. The solution was stirred at
20-25  C for 5min followed by the addition of sodium triacetoxyborohydride
(4.30 g, 20.3mmol, 4.1 eq.). The reaction mixture was stirred at 20-25  C for
16 h. The excess of sodium triacetoxyborohydride was quenched with aque-
ous saturated sodium hydrogen carbonate (20mL) and the pH adjusted to
>9 by the addition of triethylamine (3.0mL). The two layers were separated
and the organic layer was washed with aqueous saturated sodium hydrogen
carbonate (2x 20mL), water (20mL) and dried with sodium sulphate. The
organic layer was evaporated to dryness yielding a colorless oil (1.79 g,
4.91mmol, 96.9%).
1H-NMR (400.13MHz, 298K, CDCl3): d = 7.40-7.26 (m, 5H, H14,H15,H16),
5.24 (bs, 1H, H1), 5.10 (s, 2H, H12), 3.78 (qdd, 3JHH = 6.5Hz, 3JHH = 6.0Hz,
3JHH = 4.4Hz, 1H, H2), 2.77 (d, 3JHH = 6.1Hz, 1H, H6), 2.65 (dd,
2JHH = 12.4Hz, 3JHH = 6.0Hz, 1H, H3a), 2.44 (dd, 2JHH = 12.4Hz,
3JHH = 4.4Hz, 1H, H3b), 1.85 (dqq, 3JHH = 6.1Hz, 3JHH = 6.7Hz,
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3JHH = 6.7Hz, 1H, H8), 1.46 (s, 9H, H18), 1.15 (d, 3JHH = 6.5Hz, 3H,
H4), 0.92 (d, 3JHH = 6.7Hz, 3H, H9/10), 0.90 (d, 3JHH = 6.7Hz, 3H, H9/10)).
13C{H}-NMR (100.61MHz, 298K, CDCl3): d = 174.51 (1C, C7), 156.14
(1C, C11), 136.89 (1C, C13), 128.59 (2C, C15), 128.15 (1C, C16), 128.11 (2
C, C14), 81.15 (1C, C17), 67.91 (1C, C6), 66.53 (1C, C12), 53.16 (1C, C3),
46.60 (1C, C2), 31.84 (1C, C8), 28.29 (3C, C18), 19.49 (1C, C9/10), 19.04 (1
C, C4), 18.61 (1C, C9/10).
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tert -BUTYL N -BEN ZYL -N - ( (S) -2 -( ( (BEN ZYLOXY)CARBONYL )
AMINO)PROPYL ) -L -VAL INATE (100 ) .
tert-Butyl ((S)-2-(((benzyloxy)carbonyl)amino)propyl)-L-valinate (103)
(19.4 g, 53.2mmol, 1.0 eq.) was dissolved in acetonitrile (200mL) and
potassium carbonate (8.09 g, 58.5mmol, 1.1 eq.) was added. To this sus-
pension benzyl bromide (9.50mL, 79.8mmol, 1.5 eq.) was added over a
period of 5min. The reaction mixture was heated to 65  C and stirred for 2 d
under an argon atmosphere. Excess of benzyl bromide was quenched with
triethylamine (30.0mL). The suspension was stirred at 50  C for 30min and
an additional 30min at 20-25  C. The reaction mixture was filtered, washed
with acetonitrile (50.0mL) and evaporated to dryness. The crude oil was
purified by flash column chromatography (SiO2, cyclohexane / ethyl acetate
/ triethylamine (80:20:1)) yielding a colorless oil (21.0 g, 46.2mmol, 86.9%).
HR-ESI-MS: calcd. for [100+H]+ C27H39N2O4 m/z= 455.2904, found m/z=
455.2908.
1H-NMR (400.13MHz, 298K, CD3CN): d = 7.36-7.15 (m, 10H, H19,
H20, H21, H14, H15, H16), 5.47 (bs, 1H, H1), 5.02 (d, 2JHH = 12.5Hz, 1H,
H12a), 4.96 (d, 2JHH = 12.5Hz, 1H, H12b), 3.96 (d, 2JHH = 14.0Hz, 1H,
H17a), 3.72 (ddq, 3JHH = 8.8Hz, 3JHH = 5.5Hz, 3JHH = 6.2Hz, 1H,H2),
3.41 (d, 2JHH = 14.0Hz, 1H, H17b), 2.63 (d, 3JHH = 10.8Hz, 1H, H6), 2.57
(dd, 2JHH = 13.0Hz, 3JHH = 8.8Hz, 1H, H3a), 2.49 (dd, 2JHH = 13.0Hz,
3JHH = 5.5Hz, 1H, H3b), 1.97 (ddq, 3JHH = 10.8Hz, 3JHH = 6.5Hz,
3JHH = 6.5Hz, 1H, H8), 1.47 (s, 9H, H23), 1.08 (d, 3JHH = 6.6Hz, 3H, H4),
0.95 (d, 3JHH = 6.5Hz, 3H, H9/10), 0.81 (d, 3JHH = 6.5Hz, 3H, H9/10).
13C{H}-NMR (100.61MHz, 298K, CD3CN): d = 172.07 (1C, C7), 156.65
(1C, C11), 140.84 (1C, C18), 138.47 (1C, C13), 129.92 (2C, C20), 129.36 (1
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C, C21), 129.05 (2C, C19), 128.74 (2C, C15), 128.64 (1C, C16), 127.82 (2
C, C14), 81.68 (1C, C22), 71.04 (1C, C6), 66.56 (1C, C12), 56.96 (1C, C3),
56.71 (1C, C17), 46.77 (1C, C2), 28.55 (3C, C23), 28.27 (1C, C8), 20.11 (1
C, C9/10), 20.10 (1C, C9/10), 19.41 (1C, C4).
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tert -BUTYL N -BEN ZYL -N - ( (R) -2 -( ( (BEN ZYLOXY)CARBONYL )
AMINO)PROPYL ) -L -VAL INATE (120 ) .
tert-Butyl ((R)-2-(((benzyloxy)carbonyl)amino)propyl)-L-valinate (123)
(1.20 g, 3.29mmol, 1.0 eq.) was dissolved in acetonitrile (20mL) and po-
tassium carbonate (1.36 g, 9.87mmol, 3.0 eq.) was added. To this suspension
benzyl bromide (1.4mL, 8.23mmol, 2.5 eq.) was added over a period
of 1min. The reaction mixture was heated to 65  C and stirred for 18 h
under an argon atmosphere. Excess of benzyl bromide was quenched with
triethylamine (1.0mL). The suspension was stirred at 50  C for 30min and
an additional 30min at 20-25  C. The reaction mixture was filtered, washed
with acetonitrile (10mL) and evaporated to dryness yielding a white solid.
The solid was recrystallized from ethyl acetate / cyclohexane yielding a
white solid (960mg, 2.11mmol, 64.2%).
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.38-7.18 (m, 10H, H19, H20,
H21, H14, H15, H16), 6.95 (d, 3JHH = 8.9Hz, 1H, H1), 5.09 (d, 2JHH = 12.6Hz,
1H, H12a), 4.96 (d, 2JHH = 12.6Hz, 1H, H12b), 3.95 (d, 2JHH = 13.6Hz, 1H,
H17a), 3.82 (ddq, 3JHH = 10.1Hz, 3JHH = 3.9Hz, 3JHH = 6.8Hz, 1H, H2), 3.32
(d, 2JHH = 13.6Hz, 1H, H17b), 2.74 (dd, 2JHH = 13.6Hz, 3JHH = 10.1Hz,
1H, H3a), 2.52 (d, 3JHH = 10.8Hz, 1H, H6), 2.19 (dd, 2JHH = 13.6Hz,
3JHH = 3.9Hz, 1H, H3b), 1.88 (ddq, 3JHH = 10.8Hz, 3JHH = 6.4Hz,
3JHH = 6.4Hz, 1H, H8), 1.45 (s, 9H, H23), 1.02 (d, 3JHH = 6.8Hz, 3H, H4),
0.73 (d, 3JHH = 6.4Hz, 3H, H9/10), 0.67 (d, 3JHH = 6.4Hz, 3H, H9/10).
13C{H}-NMR (150.92MHz, 298K, CDCl3): d = 170.45 (1C, C7), 155.62
(1C, C11), 139.17 (1C, C18), 137.42 (1C, C13), 128.91 (2C, C20), 128.24 (1
C, C21), 127.87 (2C, C19), 127.63 (2C, C15), 127.62 (1C, C16), 126.27 (2
C, C14), 80.17 (1C, C22), 68.42 (1C, C6), 64.93 (1C, C12), 56.41 (1C, C3),
55.47 (1C, C17), 44.38 (1C, C2), 28.02 (3C, C23), 26.53 (1C, C8), 19.52 (1
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C, C9/10), 19.30 (1C, C9/10), 19.12 (1C, C4).
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tert -BUTYL N - ( (S) -2 -AM INO PROPYL ) -N -BEN ZYL -L -VAL INATE
(101 ) .
tert-Butyl N-benzyl-N-((S)-2-(((benzyloxy) carbonyl) amino) propyl)-L-val-
inate (100) (10.7 g, 23.5mmol, 1.0 eq.) was dissolved in meth|anol (100mL).
Palladium on barium sulphate (1.80 g, 5% Pd/BaSO4) was added and the
reaction flask was flushed with nitrogen. Then hydrogen was bubbled through
the solution for 5min and the reaction mixture was left stirring under 1 bar
hydrogen at 20-25  C for 3 h. The suspension was filtered through celite and
washed with methanol (3 x 50mL). The filtrate was evaporated to dryness
yielding a yellowish oil (6.82 g, 21.3mmol, 90.6%).
HR-ESI-MS: calcd. for [101+H]+ C19H33N2O2 m/z= 321.2537, found m/z=
321.2539.
1H-NMR (400.13MHz, 298K, DMSO d6): d = 7.40-7.16 (m, 5H, H13, H14,
H15), 3.93 (d, 2JHH = 14.1Hz, 1H, H11a), 3.35 (d, 2JHH = 14.1Hz, 1H, H11b),
3.27 (bs, 2H, H1), 2.96 (m, 1H, H2), 2.60 (d, 3JHH = 10.8Hz, 1H, H6), 2.42
(dd, 2JHH = 13.1Hz, 3JHH = 8.9Hz, 1H, H3a), 2.35 (dd, 2JHH = 13.1Hz, 1
H, H3b), 1.93 (dqq, 3JHH = 10.8Hz, 3JHH = 6.6Hz, 3JHH = 6.5Hz, 1H, H8),
1.47 (s, 9H, H17), 0.97 (d, 3JHH = 6.3Hz, 3H, H4), 0.90 (d, 3JHH = 6.6Hz, 3
H, H9/10), 0.76 (d, 3JHH = 6.6Hz, 3H, H9/10).
13C{H}-NMR (100.61MHz, 298K, DMSO d6): d = 170.32 (1C, C7),
139.56 (1C, C12), 128.64 (2C, C14), 128.12 (2C, C13), 126.87 (1C, C15),
80.33 (1C, C16), 69.76 (1C, C6), 58.57 (1C, C3), 55.44 (1C, C11), 44.80 (1
C, C2), 28.01 (3C, C17), 26.81 (1C, C8), 20.87 (1C, C4), 19.58 (1C, C9/10),
19.42 (1C, C9/10).
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N -BEN ZYL -N - ( ( S ) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO)PROP -
YL ) -L -VAL INE (102 ) .
tert-Butyl N-benzyl-N-((S)-2-(((benzyloxy) carbonyl)amino)propyl)-L-val-
inate (100) (5.77 g, 12.7mmol, 1.0 eq.) was dissolved in hydrogen chloride
solution (conc. in 1,4-dioxane, 50mL) and heated to 40  C for 16 h. The
reaction mixture was evaporated to dryness yielding the title compound as a
hydrochloride salt (5.41 g, 12.4mmol, 98.0%). The product was used in the
next step without further purification.
HR-ESI-MS: calcd. for [102+H]+ C23H31N2O4 m/z= 399.2278, found m/z=
399.2283.
1H-NMR (400.13MHz, 298K, CD3CN): d = 7.46-6.90 (m, 10H, H14, H15,
H16, H18, H19, H20), 5.57 (d, 3JHH = 8.1Hz, 1H, H1), 5.05 (d, 2JHH = 12.6Hz,
1H, H12a), 4.92 (d, 2JHH = 12.6Hz, 1H, H12b), 4.08 (d, 2JHH = 14.6Hz, 1
H, H17a), 3.91 (m, 1H, H2), 3.21 (d, (2JHH = 14.6Hz, 1H, H17b), 2.79 (d,
3JHH = 10.6Hz, 1H, H6), 2.64 (dd, 2JHH = 12.1Hz, 3JHH = 3.6Hz, 1H,
H3a), 2.12-1.97 (m, 2H, H3b, H8), 1.03 (d, 3JHH = 6.5Hz, 3H, H4), 0.96 (d,
3JHH = 6.6Hz, 3H, H9/10), 0.90 (d, 3JHH = 6.4Hz, 3H, H9/10).
13C{H}-NMR (100.61MHz, 298K, CD3CN): d = 177.55 (1C, C7), 156.37
(1C, C11), 141.25 (1C, C18), 136.52 (1C, C13), 128.43 (1C, Carom.), 128.10
(1C, Carom.), 127.61 (3C, Carom.), 125.98 (1C, Carom.), 71.86 (1C, C6), 65.94
(1C, C12), 55.99 (1C, C3), 53.55 (1C, C17), 44.19 (1C, C2), 26.83 (1C, C8),
19.81 (1C, C9/10), 18.93 (1C, C9/10), 16.88 (1C, C4).
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tert -BUTYL (5S ,8S ,11S ,14S ) -7 ,13 -D IBEN ZYL -8 ,14 -D I I SO -
PROPYL -5 ,11 -D IMETHYL -3 ,9 -D I OXO -1 -PHENYL -2 -OXA -4 ,7 ,
10 ,13 -TET RAAZA PEN TADECAN -15 -OATE (104 ) .
N-benzyl-N-((S)-2-(((benzyloxy)carbonyl)amino)propyl)-L-valine hydro-
chloride (102) (5.00 g, 11.5mmol, 1.0 eq.), tert-butyl N-((S)-2-aminoprop-
yl)-N-benzyl-L-valinate (101) (3.64 g, 11.4mmol, 1.01 eq.) and N-ethyl
diisopropylamine (6.0mL, 36.3mmol, 3.2 eq.) were dissolved in acetonitrile
(70mL). To this solution HATU (4.93 g, 13.0mmol, 1.1 eq.) was added. After
40min, additional HATU (1.06 g, 2.79mmol, 0.2 eq.) was added and the
solution was stirred for another 2 h. The solvent was removed under reduced
pressure and the crude oil was purified by flash column chromatography
(SiO2, pentane / methyl tert-butyl ether / triethylamine (70:30:1)) yielding a
colorless oil (6.05 g, 8.63mmol, 75.7%).
HR-ESI-MS: calcd. for [104+H]+ C42H61N4O5 m/z= 701.4636, found m/z=
701.4640.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 7.44-7.21 (m, 15H, H25,
H26, H27, H31, H32, H33, H36, H37, H38), 5.00 (d, 2JHH = 12.9Hz, 1H,
H29a), 4.98 (d, 2JHH = 12.9Hz, 1H, H29b), 4.09 (m, 1H, H12), 4.02 (d,
2JHH = 14.0Hz, 1H, H23a), 4.00 (d, 2JHH = 13.7Hz, 1H, H34a), 3.60 (bs,
1H, H2), 3.48 (bs, 1H, H34b), 3.41 (d, 2JHH = 14.0Hz, 1H, H23b), 2.79
(bs, 1H, H6), 2.72 (d, 3JHH = 10.4Hz, 1H, H16), 2.65-2.59 (m, 1H, H3a),
2.57-2.51 (m, 1H, H3b), 2.54-2.48 (m, 2H, H13), 2.06 (m, 1H, H8), 1.97
(dqq, 3JHH = 10.4Hz, 3JHH = 6.5Hz, 3JHH = 6.5Hz, 1H, H18), 1.46 (s, 9H,
H22), 1.08 (d, 3JHH = 6.7Hz, 3H, H14), 0.99 (d, 3JHH = 6.7Hz, 3H, H10/9),
0.96 (d, 3JHH = 6.7Hz, 3H, H4), 0.94 (d, 3JHH = 6.5Hz, 3H, H19/20), 0.82 (d,
3JHH = 6.5Hz, 3H, H9/10), 0.815 (d, 3JHH = 6.5Hz, 3H, H20/19).
13C{H}-NMR (from HMBC/HMQC, 600.13MHz, 298K, DMSO d6): d
= 169.45 (1C, C17), 155.00 (1C, C28), 138.59 (1C, C24), 136.37 (1C, C30),
127.48 (2C, C25), 126.8 (2C, C31), 79.86 (1C, C21), 69.82 (1C, C6), 69.05
(1C, C16), 64.7 (1 C, C29), 56.18 (1C, C3), 55.43 (1C, C13), 55.02 (1C, C34),
54.65 (1C, C23), 44.83 (1C, C2), 42.40 (1C, C12), 27.49 (3C, C22), 26.22 (1
C, C18), 26.08 (1C, C8), 19.26 (1C, C9/10), 18.92 (1C, C19/20), 18.89 (1C,
C9/10), 18.86 (1C, C19/20), 18.42 (1C, C14), 17.97 (1C, C4).
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N -((S) -2 -( (S) -2 -( ( (S) -2 -AM INO PROPYL ) (BEN ZYL )AMINO) -3 -
METHYLBUTANAMIDO)PROPYL ) -N -BEN ZYL -L -VAL INE (98 ) .
tert-Butyl (5S,8S,11S,14S)-7,13-dibenzyl-8,14-diisopropyl-5,11-dimethyl-3,
9-dioxo-1-phenyl-2-oxa-4,7,10,13-tetraazapenta-decan-15-oate (104) (8.55 g,
12.2mmol, 1.0 eq.) was dissolved in acetic acid (60mL) and hydrogen
bromide solution (33 wt.% in acetic acid, 60mL) was added. The solution
was stirred at 40  C for 30min and evaporated to dryness. This oil was further
suspended in acetonitrile (20mL) and hydrochloric acid (37%, 1.0mL). This
mixture was again evaporated to dryness. This procedure was repeated three
times to remove residual acetic acid from the product. Finally, methanol
(20mL) was added and the solvent was removed under reduced pressure
yielding a yellowish foam. This foam was extensively dried under high
vacuum at 40  C for 2 d. The product (9.04 g) is obtained as a mixture of
HCl and HBr salt with minimal acetate content and was used without further
purification.
HR-ESI-MS: calcd. for [98+H]+ C30H47N4O3 m/z= 511.3643, found m/z=
511.3650.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 7.81-7.71 (m, 3H, H11, H1),
7.39 (7.2, 10H, H24, H25, H26, H29, H30, H31), 4.10-4.03 (m, 1H, H12), 3.98
(d, 2JHH = 14.0Hz, 1H, H22a), 3.91 (d, 2JHH = 14.6Hz, 1H, H27a), 3.40 (d,
2JHH = 14.6Hz, 1H, H27b), 3.35 (d, 2JHH = 14.0Hz, 1H, H22b), 3.28-3.17
(m, 1H, H2), 2.70 (d, 3JHH = 10.8Hz, 1H, H16), 2.67-2.57 (m, 2H, H3), 2.59
(d, 3JHH = 10.8Hz, 1H, H6), 2.49-2.39 (m, 2H, H13), 2.02-1.96 (m, 2H, H18,
H8), 1.11 (d, 3JHH = 6.6Hz, 3H, H14), 1.06 (d, 3JHH = 6.5Hz, 3H, H4), 0.97
(d, 3JHH = 6.5Hz, 3H, H9/10), 0.95 (d, 3JHH = 6.5Hz, 3H, H19/20), 0.82 (d,
3JHH = 6.5Hz, 3H, H19/20), 0.78 (d, 3JHH = 6.5Hz, 3H, H9/10).
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13C{H}-NMR (125.75MHz, 298K, DMSO d6): d = 172.19 (1C, C17),
169.39 (1C, C7), 139.86 (1C, C28, C23), 128.78 (2C, C24), 128.39 (2C, C29),
128.26 (2C, C25), 128.17 (2C, C30), 126.94 (1C, C31), 126.88 (1C, C26),
69.82 (1C, C6), 68.74 (1C, C16), 55.58 (1C, C27), 55.47 (1C, C13), 55.06 (1
C, C22), 53.68 (1C, C3), 44.92 (1C, C2), 42.66 (1C, C12), 26.70 (1C, C8),
26.62 (1C, C18), 19.83 (2C, C19/20, C9/10), 19.75 (1C, C9/10), 19.55 (1C,
C19/20), 19.21 (1C, C14), 16.66 (1C, C4).
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( 3S ,6S ,9S ,12S ) -4 ,10 -D IBEN ZYL -3 ,9 -D I I SO PROPYL -6 ,12 -D I -
ME THYL -1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -2 ,8 -D I ONE
(97 ) .
A total of 9.03 g of N-((S)-2-((S)-2-(((S)-2-aminopropyl)(benzyl)amino)-
-3-methylbutanamido)propyl)-N-benzyl-L-valine (98) salt was cyclized in
several portions of max. 2.0 g. N-((S)-2-((S)-2-(((S)-2-aminopropyl)(ben-
zyl)amino)-3-methylbutanamido)propyl)-N-benzyl-L-valine (98) salt (2.00 g,
4.08mmol, 1.0 eq.) and N-ethyl diisopropylamine (3.4mL, 20.4mmol, 5 eq.)
were dissolved in acetonitrile (2.0 L). HATU (1.55 g, 4.08mmol, 1.0 eq.)
was added and the solution was stirred at 20-25  C for 20min. The solvent
was removed under vacuum. The crude products from all batches were
combined and purified by flash column chromatography (SiO2, ethyl acetate
/ cyclohexane / triethylamine (90:10:1)) yielding a yellowish solid (3.54 g,
7.18mmol, 58.9% yield calculated over 2 steps starting from 104).
HR-ESI-MS: calcd. for [97+H]+ C30H45N4O2 m/z= 493.3537, found m/z=
493.3539.
1H-NMR (600.13MHz, 298K, CDCl3): d = 7.37-7.23 (m, 10H, H14, H15,
H16), 3.98 (d, 2JHH = 14.2Hz, 2H, H12a), 3.90 (d, 2JHH = 14.2Hz, 2H, H12b),
3.74-3.64 (m, 2H, H8), 3.20 (dd, 2JHH = 13.7Hz, 3JHH = 11.3Hz, 2H, H10a),
2.96 (d, 3JHH = 8.1Hz, 2H, H2), 2.72 (dd, 2JHH = 13.7Hz, 3JHH = 3.1Hz, 2
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H, H10b), 2.16 (dqq, 3JHH = 8.1Hz, 3JHH = 6.7Hz, 3JHH = 6.7Hz, 2H, H4),
1.19 (d, 3JHH = 6.6Hz, 6H, H9), 1.02 (d, 3JHH = 6.7Hz, 6H, H5/6), 0.90 (d,
3JHH = 6.7Hz, 6H, H5/6).
13C{H}-NMR (150.9MHz, 298K, CDCl3): d = 173.85 (2C, C3), 139.25 (2
C, C13), 129.18 (4C, C15), 128.69 (4C, C14), 127.53 (2C, C16), 71.77 (2C,
C2), 58.46 (2C, C12), 54.08 (2C, C10), 45.04 (2C, C8), 28.06 (2C, C4), 22.20
(2C, C5/6), 20.06 (2C, C5/6), 18.44 (2C, C9).
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( 2S ,5S ,8S ,11S ) -1 ,7 -D IBEN ZYL -2 ,8 -D I I SO PROPYL -5 ,11 -D I -
METHYL -1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE (107 ) .
(3S,6S,9S,12S)-4,10-Dibenzyl-3,9-diisopropyl-6,12-dimethyl-1,4,7,10-tetra-
azacyclododecane-2,8-dione (97) (1.49 g, 3.02mmol, 1.0 eq.) was dissolved
in dichloromethane (50mL) and was cooled to 0-5  C. Trimethylchlorosilane
(2.2mL, 17.5mmol, 5.8 eq.) was added and the solution was stirred for 1 h
at 0-5  C. A suspension of lithium aluminium hydride (490mg, 12.9mmol,
4.3 eq.) in tetrahydrofuran (10mL) was prepared under inert conditions and
added dropwise to the reaction mixture at 0-5  C. After 3 h the excess of
lithium aluminium hydride was quenched with aqueous potassium hydroxide
(1 M, 2.0mL). The suspension was dried over sodium sulphate, filtered and
the filter cake was washed with dichloromethane (5 x 20mL). The filtrate
was evaporated to dryness and was purified by flash column chromatography
(SiO2, ethyl acetate / triethylamine (100:1)) yielding a white solid (1.29 g,
2.77mmol, 91.9%).
HR-ESI-MS: calcd. for [107+H]+ C30H49N4 m/z= 465.3952, found m/z=
465.3958.
1H-NMR (500.13MHz, 298K, CDCl3): d = 7.5-7.1 (m, 10H, H14, H15, H16),
4.03 (d, 2JHH = 11.5Hz, 2H, H12a), 3.16 (d, 2JHH = 11.5Hz, 2H, H12b),
2.86-2.74 (m, 4H, H3a, H8), 2.65-2.59 (m, 4H, H10a, H2), 2.53 (bs, 2H, H3b),
2.34-2.25 (m, 2H, H10b), 2.20-2.03 (m, 2H, H4), 1.00 (d, 3JHH = 6.6Hz, 6H,
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H5/6), 0.92 (d, 3JHH = 6.7Hz, 6H, H5/6), 0.87 (bs, 6H, H9).
13C{H}-NMR (125.75MHz, 298K, CDCl3): d = 140.30 (2C, C13), 129.24
(2C, C15), 128.49 (2C, C14), 127.30 (2C, C16), 59.22 (2C, C2), 56.62 (2C,
C10), 53.15 (2C, C12), 45.74 (2C, C8), 41.46 (2C, C3), 24.43 (2C, C4), 24.18
(2C, C5/6), 19.34 (2C, C5/6), 18.82 (2C, C9).
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( 2S ,5S ,8S ,11S ) -2 ,8 -D I I SO PROPYL -5 ,11 -D IMETHYL -1 ,4 ,7 ,10 -
TET RAAZACYCLODODECANE (96 ) .
(2S,5S,8S,11S)-1,7-Dibenzyl-2,8-diisopropyl-5,11-dimethyl-1,4,7,10-tetra-
azacyclododecane (107) (197mg, 423 µmol, 1.0 eq.) was dissolved in ethanol
(30mL) and ethyl acetate (3.0mL). Palladium on activated charcoal (101mg,
10% Pd) and ammonium formate (612mg, 9.71mmol, 23.0 eq.) were added
and the resulting suspension was refluxed for 16 h. The suspension was
cooled to 20-25  C, filtered through celite and washed with methanol (3 x
20mL). The solvent was removed under reduced pressure yielding a white
solid (118mg, 415 µmol, 98.2%).
HR-ESI-MS: calcd. for [96+H]+ C16H37N4 m/z= 285.3013, found m/z=
285.3013.
1H-NMR (500.13MHz, 298K, CDCl3): d = 2.70 (dd, 2JHH = 13.1Hz,
3JHH = 2.8Hz, 2H, H10a), 2.64 (dd, 2JHH = 13.0Hz, 3JHH = 1.9Hz, 2H, H3a),
2.64-2.59 (m, 2H, H8), 2.46-2.35 (m, 6H, H3b, H10b, H2), 1.94-1.86 (m, 2H,
H4), 0.94 (d, 3JHH = 7.0Hz, 6H, H5/6), 0.91 (d, 3JHH = 6.3Hz, 6H, H9), 0.85
(d, 3JHH = 7.0Hz, 6H, H5/6).
13C{H}-NMR (125.75MHz, 298K, CDCl3): d = 57.13 (2C, C2), 52.60 (2
C, C10), 47.64 (2C, C8), 44.98 (2C, C3), 28.13 (2C, C4), 20.29 (2C, C5/6),
18.16 (2C, C9), 16.62 (2C, C5/6).
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tert -BUTYL N - ( (S) -2 -( ( (BEN ZYLOXY)CARBONYL )AMINO) -
PROPYL ) -O - ( tert -BUTYL ) -L -SER INATE (114 ) .
Benzyl (S)-(1-oxopropan-2-yl)carbamate (60) (2.60 g, 12.5mmol, 1.1 eq.)
was dissolved in dichloromethane (20mL). To this solution tert-butyl
O-(tert-butyl)-L-serinate (2.52 g, 12.5mmol, 1.0 eq.) was added. The solu-
tion was stirred at 20-25  C for 5min followed by the addition of sodium
triacetoxyborohydride (10.9 g, 51.4mmol, 4.4 eq.). The reaction mixture was
stirred at 20-25  C for 16 h. The excess of sodium triacetoxyborohydride was
quenched with aqueous saturated sodium hydrogen carbonate (50.0mL) and
the pH adjusted to >9 by the addition of triethylamine (5.0mL). The two
layers were separated and the organic layer was washed with water (30mL)
and dried with sodium sulphate. The organic layer was evaporated to dryness
yielding a yellowish oil (4.61 g, 11.3mmol, 97.3%).
HR-ESI-MS: calcd. for [114+H]+ C22H37N2O5 m/z= 409.2697, found m/z=
409.2700.
1H-NMR (500.13MHz, 298K, CDCl3): d = 7.40-7.27 (m, 5H, H14, H15, H16),
5.23 (bs, 1H, H1), 5.08 (s, 2H, H12), 3.73 (qdd, 3JHH = 6.7Hz, 3JHH = 5.7Hz,
3JHH = 5.2Hz, 1H, H2), 3.52 (dd, 2JHH = 8.3Hz, 3JHH = 5.4Hz, 1H, H8a),
3.49 (dd, 2JHH = 8.3Hz, 3JHH = 4.7Hz, 1H, H8b), 3.24 (dd, 3JHH = 5.4Hz,
3JHH = 4.7Hz, 1H, H6), 2.75 (dd, 2JHH = 12.6Hz, 3JHH = 5.2Hz, 1H, H3a),
2.53 (dd, 2JHH = 12.6Hz, 3JHH = 5.7Hz, 1H, H3b), 1.45 (s, 9H, H10), 1.17
(d, 3JHH = 6.7Hz, 3H, H4), 1.15 (s, 9H, H18).
13C{H}-NMR (100.61MHz, 298K, CDCl3): d = 172.52 (1C, C7), 156.46
(1C, C11), 136.88 (1C, C13), 128.57 (2C, C15), 128.17 (2C, C14), 128.08 (1
C, C16), 81.19 (1C, C9), 73.13 (1C, C17), 66.53 (1C, C12), 62.99 (1C, C8),
62.70 (1C, C6), 52.73 (1C, C3), 47.33 (1C, C2), 28.25 (3C, C10), 27.51 (3C,
C18), 18.99 (1C, C4).
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tert -BUTYL N -BEN ZYL -N - ( (S) -2 -( ( (BEN ZYLOXY)CARBONYL )
AMINO)PROPYL ) -O - ( tert -BUTYL ) - L -SER INATE (118 ) .
tert-Butyl N-((S)-2-(((benzyloxy)carbonyl)amino)propyl)-O-(tert-butyl)-L-
serinate (114) (3.58 g, 8.76mmol, 1.0 eq.) and potassium carbonate (1.37 g,
9.91mmol, 1.1 eq.) were suspended in acetonitrile (35mL). Over a period of
2min benzyl bromide (1.3mL, 10.9mmol, 1.2 eq.) was added. The reaction
mixture was heated to 40  C and stirred for 18 h under an argon atmosphere.
The excess of benzyl bromide was quenched with triethylamine (10mL). The
suspension was heated to 50  C and stirred for 40min followed by cooling to
20-25  C. The reaction mixture was filtered and the filter cake was washed
with acetonitrile (20mL). The filtrate was evaporated to dryness and the
crude oil was purified by flash column chromatography (SiO2, cyclohexane
/ ethyl acetate / triethylamine (80:20:1)) yielding a colorless oil (2.99 g,
5.99mmol, 68.4%).
HR-ESI-MS: calcd. for [118+H]+ C29H43N2O5 m/z= 499.3166, found m/z=
499.3173.
1H-NMR (500.13MHz, 298K, CDCl3): d = 7.41-7.17 (m, 10H, H14, H15, H16,
H19, H20, H21), 5.79 (bs, 1H, H1), 5.11 (d, 2JHH = 12.3Hz, 1H, H12a), 5.06
(d, 2JHH = 12.3Hz, 1H, H12b), 3.89 (d, 2JHH = 14.4Hz, 1H, H17a), 3.83 (d,
2JHH = 14.4Hz, 1H, H17b), 3.73-3.64 (m, 1H, H2), 3.64 (dd, 2JHH = 9.4Hz,
3JHH = 5.6Hz, 1H, H8a), 3.57 (dd, 2JHH = 9.4Hz, 3JHH = 7.1Hz, 1H, H8b),
3.39 (dd, 3JHH = 7.1Hz, 3JHH = 5.6Hz, 1H, H6), 2.82 (dd, 2JHH = 13.3Hz,
3JHH = 4.9Hz, 1H, H3a), 2.73 (dd, 2JHH = 13.3Hz, 3JHH = 7.1Hz, 1H, H3b),
1.46 (s, 9H, H24), 1.16 (d, 3JHH = 7.6Hz, 3H, H4), 1.15 (s, 9H, H10).
13C{H}-NMR (125.76MHz, 298K, CDCl3): d = 171.22 (1C, C7), 156.34
(1C, C11), 139.69 (1C, C18), 137.04 (1C, C13), 128.59 (2C, C19), 128.38 (2
C, C20), 128.22 (2C, C15), 128.01 (2C, C14), 127.82 (1C, C21), 126.92 (1
C, C16), 81.18 (1C, C23), 73.24 (1C, C9), 66.18 (1C, C12), 63.59 (1C, C6),
60.32 (1C, C8), 57.03 (1C, C17), 56.49 (1C, C3), 46.11 (1C, C2), 28.22 (3C,
C24), 27.34 (3C, C10), 19.28 (1C, C4).
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tert -BUTYL N - ( (S) -2 -AM INO PROPYL ) -N -BEN ZYL -O - ( tert -BUT -
YL ) -L -SER INATE (110 ) .
tert-Butyl N-benzyl -N-((S)-2-(((benzyloxy)carbonyl)amino)propyl)-O--
(tert-butyl)-L-serinate (118) (2.99 g, 6.00mmol, 1.0 eq.), was dissolved in
methanol (30mL). Palladium (50mg, 5% Pd / BaSO4) was added and
the reaction flask was flushed with nitrogen. Then hydrogen was bubbled
through the solution for 5min and the reaction mixture was left stirring under
1 bar hydrogen at 20-25  C for 24 h. The suspension was filtered through
celite and washed with methanol (3x 50mL). The filtrate was evaporated to
dryness yielding a yellowish oil (2.02 g, 5.53mmol, 92.4%).
HR-ESI-MS: calcd. for [110+H]+ C17H37N2O3 m/z= 365.2799, found m/z=
365.2803.
1H-NMR (500.13MHz, 298K, CD3CN): d = 7.38-7.25 (m, 5H, H15, H16,
H17), 3.90 (d, 2JHH = 13.8Hz, 1H, H13a), 3.76 (d, 2JHH = 13.8Hz, 1H, H13b),
3.63 (dd, 2JHH = 10.5Hz, 3JHH = 5.1Hz, 1H, H8a), 3.55 (dd, 2JHH = 10.5Hz,
3JHH = 9.4Hz, 1H, H8b), 3.42-3.34 (m, 1H, H2), 3.37 (dd, 3JHH = 5.1Hz,
3JHH = 4.2Hz, 1H, H6), 2.95 (dd, 2JHH = 14.3Hz, 3JHH = 3.4Hz, 1H, H3a),
2.73 (dd, 2JHH = 14.3Hz, 3JHH = 11.7Hz, 1H, H3b), 1.48 (s, 9H, H10), 1.21
(d, 3JHH = 6.6Hz, 3H, H4), 1.15 (s, 9H, H12).
13C{H}-NMR (125.76MHz, 298K, CD3CN): d = 171.17 (1C, C7), 139.83
(1C, C14), 130.03 (2C, C16), 129.45 (2C, C15), 128.33 (1C, C17), 82.63 (1C,
C9), 75.25 (1C, C11), 63.36 (1C, C6), 60.02 (1C, C8), 57.32 (1C, C13), 54.53
(1C, C3), 47.57 (1C, C2), 28.43 (3C, C10), 27.57 (3C, C12), 15.77 (1C, C4).
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tert -BUTYL (5S ,8S ,11S ,14S ) -7 ,13 -D IBEN ZYL -14 -( tert -BUT -
OXYMETHYL ) -5 ,8 ,11 -TR IMETHYL -3 ,9 -D I OXO -1 -PHENYL -2 -
OXA -4 ,7 ,10 ,13 -TET RAAZA PEN TADECAN -15 -OATE (116 ) .
N-benzyl-N-((S)-2-(((benzyloxy) carbonyl)amino)propyl)-L-alanine hydro-
chloride (2.16 g, 5.32mmol, 1.0 eq.), tert-butyl N-((S)-2-aminopropyl)-N-
benzyl-O-(tert-butyl)-L-serinate (1.94 g, 5.32mmol, 1.0 eq.) and N-ethyl
diisopropylamine (2.7mL, 16.4mmol, 3.1 eq.) were dissolved in acetonitrile
(30mL). To this solution HATU (2.45 g, 6.44mmol, 1.2 eq.) was added. The
reaction mixture was stirred for 2 h. The solvent was removed under reduced
pressure and the crude oil was purified by flash column chromatography
(SiO2, ethyl acetate / cyclohexane / triethylamine (70:30:1)) yielding a
yellowish oil (3.35 g, 4.67mmol, 87.8%).
HR-ESI-MS: calcd. for [116+H]+ C42H61N4O6 m/z= 717.4586, found m/z=
717.4588.
1H-NMR (500.13MHz, 298K, CDCl3): d = 7.40-7.12 (m, 15H, H19, H20,
H21, H24, H25, H26, H32, H33, H34), 5.10 (d, 2JHH = 12.6Hz, 1H, H30a),
4.92 (d, 2JHH = 12.6Hz, 1H, H30b), 4.75 (d, 3JHH = 6.8Hz, 1H, H1), 4.02
(ddq, 3JHH = 7.2Hz, 3JHH = 6.9Hz, 3JHH = 6.5Hz, 1H, H10), 3.92 (d,
2JHH = 14.7Hz, 1H, H22a), 3.83-3.78 (m, 1H, H2), 3.76 (d, 2JHH = 14.7Hz,
1H, H22b), 3.71 (d, 2JHH = 13.7Hz, 1H, H17a), 3.64 (dd, 2JHH = 8.6Hz,
3JHH = 5.4Hz, 1H, H16a), 3.51 (dd, 2JHH = 8.6Hz, 3JHH = 5.7Hz, 1
H, H16b), 3.40 (d, 2JHH = 13.7Hz, 1H, H17b), 3.35 (dd, 3JHH = 5.7Hz,
3JHH = 5.4Hz, 1H, H14), 2.79 (dd, 2JHH = 13.3Hz, 3JHH = 6.9Hz, 1H, H11a),
2.75 (dd, 2JHH = 13.3Hz, 3JHH = 7.2Hz, 1H, H11b), 2.50 (dd, 2JHH = 13.5Hz,
3JHH = 3.7Hz, 1H, H3a), 2.32 (dd, 2JHH = 13.5Hz, 3JHH = 10.5Hz, 1H, H3b),
1.44 (s, 9H, H28), 1.21 (d, 3JHH = 6.9Hz, 3H, H8), 1.17 (d, 3JHH = 6.5Hz, 3
H, H12), 1.13 (s, 9H, H36), 1.05 (d, 3JHH = 7.3Hz, 3H, H4).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 173.03 (1C, C7), 171.42 (1
C, C15), 156.45 (1C, C29), 140.20 (1C, C23), 139.37 (1C, C18), 136.84 (1C,
C31), 129.05 (2C, C19), 128.68 (2C, C24), 128.58 (Carom.), 128.43 (Carom.),
128.28 (Carom.), 128.23 (2C, C32), 128.14 (Carom.), 127.22 (Carom.), 126.85
(Carom.), 80.95 (1C, C27), 72.99 (1C, C35), 66.62 (1C, C30), 63.13 (1C, C14),
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58.54 (1C, C6), 57.24 (1C, C22), 57.08 (1C, C11), 56.42 (1C, C3), 54.99 (2
C, C16, C17), 45.25 (1C, C2), 44.68 (1C, C10), 28.41 (3C, C28), 27.51 (3C,
C36), 19.50 (1C, C4), 19.18 (1C, C12), 8.63 (1C, C8).
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O -ACETYL -N - ( (S) -2 -( (S) -2 -( ( (S) -2 -AM INO PROPYL ) (BEN ZYL )
AMINO)PROPANAMIDO)PROPYL ) -N -BEN ZYL -L -SER INE (112 ) .
tert-Butyl (5S,8S,11S,14S)-7,13-dibenzyl-14-(tert-butoxymethyl)-5,8,11-tri-
methyl-3,9-dioxo-1-phenyl-2-oxa-4,7,10,13-tetra-azapentadecan-15-oate
(116) (1.04 g, 1.45mmol, 1.0 eq.) was dissolved in acetic acid (10.0mL) and
hydrogen bromide solution (33 wt.% in acetic acid, 10mL). The solution was
stirred at 40  C for 30min and evaporated to dryness. This oil was further
suspended in acetonitrile (10mL) and hydrochloric acid (37%, 500 µL). This
mixture was again evaporated to dryness. This procedure was repeated three
times to remove residual acetic acid from the product. Finally, methanol
(10mL) was added and the solvent was removed under reduced pressure
yielding a brown foam. The foam was extensively dried under high vacuum
at 40  C for 2 d. The product (1.12 g) is obtained as a mixture of HCl and HBr
salt with minimal acetate content and was used without further purification.
HR-ESI-MS: calcd. for [112+H]+ C28H41N4O5 m/z= 513.3071, found m/z=
513.3071.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 7.40-7.21 (m, 10H, H19, H20,
H21, H24, H25, H26), 4.23 (dd, 2JHH = 11.5Hz, 3JHH = 5.7Hz, 1H, H16a), 4.11
(dd, 2JHH = 11.5Hz, 3JHH = 7.8Hz, 1H, H16b), 3.92-3.82 (m, 1H, H10), 3.87
(d, 2JHH = 14.1Hz, 1H, H22a), 3.72 (d, 2JHH = 14.1Hz, 1H, H22b), 3.68-3.63
(m, 2H, H17), 3.50 (dd, 3JHH = 7.8Hz, 3JHH = 5.7Hz, 1H, H14), 3.28 (q,
3JHH = 7.0Hz, 1H, H6), 3.22-3.13 (m, 1H, H2), 2.69-2.59 (m, 2H, H3), 2.63
(dd, 2JHH = 12.5Hz, 3JHH = 4.9Hz, 1H, H11a), 2.46 (dd, 2JHH = 12.5Hz,
3JHH = 9.2Hz, 1H, H11b), 1.97 (s, 3H, H28), 1.13 (d, 3JHH = 7.0Hz, 3H, H8),
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1.10 (d, 3JHH = 6.5Hz, 3H, H4), 1.02 (d, 3JHH = 6.6Hz, 3H, H12).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 172.49 (1C, C7),
171.55 (1C, C15), 170.02 (1C, C27), 139.29 (1C, C23), 138.85 (1C, C18),
128.35 (Carom.), 128.47 (Carom.), 128.31 (Carom.), 128.15 (Carom.), 127.15
(Carom.), 127.00 (Carom.), 62.09 (1C, C16), 60.41 (1C, C14), 57.57 (1C, C6),
56.03 (1C, C11), 55.87 (1C, C22), 55.70 (1C, C17), 53.82 (1C, C3), 45.26 (1
C, C2), 43.27 (1C, C10), 20.01 (1C, C28), 18.28 (1C, C12), 16.45 (1C, C4),
12.76 (1C, C8).
3
H2N
1 2
4
7
O
N
5
6
8
11
N
H
9
10
12 15
O
N13
1416
OH17
18
22
23
21 20 19
24
25
26
O
27
O 28
112
2 -( ( 2S ,5S ,8S ,11S ) -1 ,7 -D IBEN ZYL -5 ,8 ,11 -TR IMETHYL -3 ,9 -
D I OXO -1 ,4 ,7 ,10 -TET RAAZACYCLODODECAN -2 -YL )ETHYL
ACETATE (111 ) .
O-Acetyl-N-((S)-2-((S)-2-(((S)-2-aminopropyl)(benzyl)amino)propan-
amido)propyl)-N-benzyl-L-serine (112) salt (1.07 g, 1.40mmol, 1.0 eq.) and
N-ethyl diisopropylamine (1.4mL, 8.60mmol, 6.1 eq.) were dissolved in
acetonitrile (1.0 L). Then HATU (900mg, 2.37mmol, 1.7 eq.) was added
to the solution. After 1 h the solvent was removed under reduced pressure
and the crude oil was purified by flash column chromatography (SiO2, ethyl
acetate / triethylamine (100:1)) yielding a yellowish solid (318mg, 643 µmol,
44.8% yield calculated over 2 steps starting from 116).
HR-ESI-MS: calcd. for [111+H]+ C28H39N4O4 m/z= 495.2966, found m/z=
495.2971.
1H-NMR (400.13MHz, 298K, DMSO d6): d = 7.90 (d, 3JHH = 5.3Hz, 1H,
H13), 7.68 (d, 3JHH = 4.1Hz, 1H, H5), 7.47-7.43 (m, 2H, H25), 7.43-7.38 (m,
2H, H19), 7.37-7.24 (m, 6H, H24, H26, H20, H21), 4.38 (dd, 2JHH = 11.7Hz,
3JHH = 5.9Hz, 1H, H12a), 4.32 (dd, 2JHH = 11.7Hz, 3JHH = 7.5Hz, 1H,
H12b), 4.00 (d, 2JHH = 13.4Hz, 1H, H17a), 3.93 (d, 2JHH = 13.4Hz, 1H,
H22a), 3.80 (d, 2JHH = 13.4Hz, 1H, H17b), 3.53 (d, 2JHH = 13.4Hz, 1H,
H22b), 3.53-3.45 (m, 1H, H14), 3.51 (dd, 3JHH = 7.1Hz, 3JHH = 5.9Hz,
1H, H10), 3.24-3.15 (m, 1H, H6), 3.16 (q, 3JHH = 7.1Hz, 1H, H2), 2.94
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(dd, 2JHH = 13.3Hz, 3JHH = 11.3Hz, 1H, H7a), 2.78 (dd, 2JHH = 13.1Hz,
3JHH = 11.3Hz, 1H, H15a), 2.48 (dd, 2JHH = 13.3Hz, 3JHH = 2.9Hz, 1H,
H7b), 2.29 (dd, 2JHH = 13.1Hz, 3JHH = 2.5Hz, 1H, H15b), 2.04 (s, 3H, H28),
1.18 (d, 3JHH = 6.5Hz, 3H, H16), 1.11 (d, 3JHH = 6.4Hz, 3H, H8), 1.04 (d,
3JHH = 7.1Hz, 3H, H4).
13C{H}-NMR (100.61MHz, 298K, DMSO d6): d = 172.17 (1C, C3),
170.21 (1C, C27), 169.31 (1C, C11), 139.04 (1C, C23), 138.99 (1C, C18),
129.21 (2C, C24), 129.14 (2C, C19), 128.23 (2C, C25), 128.18 (2C, C20),
127.24 (1C, C26), 127.17 (1C, C21), 63.22 (1C, C10), 60.38 (1C, C12), 59.18
(1C, C2), 58.32 (1C, C17), 56.45 (1C, C22), 55.14 (1C, C7), 54.80 (1C, C15),
44.13 (1C, C14), 43.99 (1C, C6), 20.79 (1C, C28), 17.65 (1C, C16), 17.59 (1
C, C8), 8.44 (1C, C4).
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( ( 2R ,5S ,8S ,11S ) -1 ,7 -D IBEN ZYL -5 ,8 ,11 -TR IMETHYL -1 ,4 ,7 ,10 -
TET RAAZACYCLODODECAN -2 -YL )METHANOL (119 ) .
((2S,5S,8S,11S)-1,7-dibenzyl-5,8,11-trimethyl-3,9-dioxo-1,4,7,10-tetraaza-
cyclododecan-2-yl)methyl acetate (111) (152mg, 307 µmol, 1.0 eq.) was
dissolved in dichloromethane (15mL) and cooled to 0-5  C. To this solution
trimethylchlorosilane (250 µL, 1.98mmol, 6.5 eq.) was added and stirred
for 30min under an argon atmosphere. To the reaction mixture lithium
aluminium hydride (2 M in tetrahydrofuran, 1.0mL, 2.01mmol, 6.5 eq.)
was added drop wise. After 3 h additional lithium aluminium hydride (2 M
in tetrahydrofuran, 1.0mL, 2.01mmol, 6.5 eq.) was added dropwise and
the reaction mixture was stirred at 20-25  C for 24 h. The excess of lithium
aluminium hydride was quenched with aqueous potassium hydroxide (1 M,
1.0mL). The suspension was dried with sodium sulphate, filtered and the
filter cake was washed with dichloromethane (3 x 20mL). The filtrate was
evaporated to dryness yielding a yellowish solid (123mg, 289 µmol, 94.1%).
HR-ESI-MS: calcd. for [119+H]+ C26H41N4O m/z= 425.3275, found m/z=
425.3279.
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Proton NMR showed very broad lines at 298K. Few HMBC correlations
could be obtained. Full assignment was not possible.
1H-NMR (600.13MHz, 298K, DMSO d6): d = 3.95 (d, 2JHH = 12.4Hz, 1
H), 3.82-3.73 (m, 1H), 3.43 (dd, 2JHH = 12.2Hz, 3JHH = 6.7Hz, 1H), 3.25
(d, 2JHH = 11.1Hz, 1H), 3.06 (bs, 1H), 3.01 (d, 2JHH = 11.2Hz, 1H), 2.93
(bs, 1H), 2.89-2.59 (m, 1H), 2.47 (bs, 1H), 2.41 (bs, 1H), 2.26 (bs, 1H),
2.13 (bs, 1H), 0.90 (d, 3JHH = 6.6Hz, 1H), 0.82 (bs, 1H).
13C{H}-NMR (150.9MHz, 298K, DMSO d6): d = 141.03 (1C, Carom.),
140.90 (1C, Carom.), 129.75 (Carom.), 129.49 (Carom.), 128.59 (Carom.), 128.58
(Carom.), 127.25 (Carom.), 60.06 (1C, CCH), 58.00 (1C, CCH2), 57.21 (1C,
CCH), 56.56 (1C, CCH2), 53.10 (1C, CCH2), 51.42 (1C, CCH2), 49.50 (1C,
CCH), 47.47 (1C, CCH2), 46.48 (1C, CCH), 46.36 (1C, CCH), 44.49 (1C,
CCH2), 18.09 (1C, CCH3), 17.98 (1C, CCH3), 9.91 (1C, CCH3).
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( ( 2R ,5S ,8S ,11S ) -5 ,8 ,11 -TR IMETHYL -1 ,4 ,7 ,10 -TET RA -AZACY-
CLODODECAN -2 -YL )METHANOL (108 ) .
((2R,5S,8S,11S)-1,7-dibenzyl-5,8,11-trimethyl-1,4,7,10-tetraazacyclodo-
decan-2-yl)methanol (119) (65.0mg, 153 µmol, 1.0 eq.) was dissolved in
methanol (2.0mL) and trifluoroacetic acid (100 µL). Palladium on activated
charcoal (moistened with water, 10% Pd, 100mg) was added and the
suspension was hydrogenated at room temperature and 90 bar hydrogen
pressure for 17 h. The suspension was filtered. The filtrate was evaporated to
dryness yielding an off-white solid (32.0mg, 131 µmol, 85.6%).
HR-ESI-MS: calcd. for [108+H]+ C12H29N4O m/z= 245.2336, found m/z=
245.2335.
The proton NMR spectrum is very crowded and shows the presence of
multiple species. Possibly conformations, different protonation states and
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remaining diastereoisomers.
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TR I -tert -BUTYL 2 ,2 0 ,2 0 0 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET RAMET -
HYL -1 ,4 ,7 ,10 -TETRAAZACYC LODODECANE -1 ,4 ,7 -TR I YL ) (2R ,
2 0R ,2 0 0R ) -TR I PROP IONATE (129 ) .
(2S,5S,8S,11S)-2,5,8,11-Tetramethyl-1,4,7,10-tetraazacyclododecane (22)
(137mg, 600 µmol, 1.0 eq.) and potassium carbonate (250mg, 1.80mmol,
3.0 eq.) were suspended in dichloromethane (20mL). tert-Butyl (S)-2-((-
(trifluoromethyl)sulfonyl)oxy)propanoate (500mg, 1.80mmol, 3.0 eq.) was
dissolved in dichloromethane (6.0mL) and was added to the reaction. The
mixture was stirred for 3 h. Acetonitrile (20mL) was added and the reaction
was left stirring at 20-25  C for 18 h. Excess tert-butyl (S)-2-(((trifluoro-
methyl)sulfonyl)oxy) was quenched with triethylamine (30.0 µL) and the
suspension was filtered and evaporated to dryness. The crude product was
purified by preparative HPLC (water / acetonitrile) yielding a white solid
(330mg, 538 µmol, 89.7%).
ESI-MS: calcd. for [129+H]+ C33H65N4O6m/z= 613.48, foundm/z= 613.70.
N HN
N N
O O
OO
O
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129
2 -METHYL -4 -( PHENYLSULFONYL )PYR ID INE (127 ) .
4-Bromo-2-methylpyridine (8.60 g, 50.3mmol, 1.0 eq.) was dissolved in
dimethylformamide (30mL). Potassium carbonate (8.42 g, 61.0mmol,
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1.2 eq.) and thiophenol (5.84 g, 53.1mmol, 1.1 eq.) were added. The mixture
was stirred at 90  C for 22 h. The Suspension was filtered trough celite.
The filtrate was split in half and one half was acidified with acetic acid
(5.0mL). Aqueous bleach (14% Cl2 basis, 90.0mL) was added and the
mixture was stirred at 20-25  C until full conversion. The pH of the mixture
was adjusted to 9 with aqueous sodium hydroxide and the product was
extracted with dichloromethane (2x 50mL). The combined organic layers
were evaporated to dryness yielding a white solid (4.50 g, 19.3mmol, 76.7%).
1H-NMR (500.13MHz, 298K, K): d = 7.98-7.93 (m, 2H, H8), 7.66-7.62 (m,
2H, H1, H10), 7.58-7.53 (m, (3H, H9, H4), 2.63 (s, 3H, H6).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 160.71 (1C, C2), 150.56
(1C, C3), 149.99 (1C, C5), 139.92 (1C, C7), 134.05 (1C, C10), 129.59 (2C,
C9), 128.10 (2C, C8), 120.04 (1C, C1), 117.71 (1C, C4), 24.68 (1C, C6).
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2 -(BROMOMETHYL ) -4 -( PHENYLSULF ONYL )PY R I D INE (128 ) .
2-Methyl-4-(phenylsulfonyl) pyridine (127) (1.04 g, 4.46mmol, 1.0 eq.) was
dissolved in tetrachloromethane (20mL) under an atmosphere of argon and
the solution was heated to reflux. N-bromosuccinimide (730mg, 4.01mmol,
0.9 eq.) and AIBN (cat. 20.0mg) were added in several portions over 10 h.
After 10 h the reaction mixture was filtered and evaporated to dryness. The
crude was purified by flash column chromatography (SiO2, ethyl acetate /
cyclohexane (1:9)) yielding a off-white solid (530mg, 1.70mmol, 38.0%).
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.76 (d, 3JHH = 5.1Hz, 1H, H3),
7.98 (m, 2H, H8), 7.90 (s, 1H, H1), 7.66 (m, 2H, H4, H10), 7.58 (m, 2H, H9),
4.58 (s, 2H, H6).
13C{H}-NMR (from HMQC, 150.95MHz, 298K, CDCl3): d = 151.16 (1C,
C3), 134.34 (1C, C10), 129.91 (2C, C9), 128.36 (2C, C8)), 120.49 (1C, C1),
120.06 (1C, C4), 32.48 (1C, C6).
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TR I -tert -BUTYL 2 ,2 0 ,2 0 0 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET RA-
METHYL -10 -( ( 4 -( PHENYLSULFONYL )PY R I D IN -2 -YL )METHYL ) -
-1 ,4 ,7 ,10 -TET RAAZACYC LODODECANE -1 ,4 ,7 -TR IYL ) (2R ,2 0R ,
2 0 0R ) -TR I PROP IONATE (131 ) .
Tri-tert-butyl 2,2’,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (129) (224mg,
365 µmol, 1.0 eq.) and potassium carbonate (100mg, 723 µmol, 2.0 eq.)
were suspended in acetonitrile (5.0mL). To this suspension 2-(Bromo-
methyl)-4-(phenylsulfonyl)pyridine (128) (340mg, 1.09mmol, 2.9 eq.) was
added and the mixture was stirred for 18 h at 20-25  C. The mixture was
filtered and evaporated to dryness. The residue was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (256mg, 303 µmol, 82.9%).
HR-ESI-MS: calcd. for [131+H]+ C45H74N5O8S m/z= 844.5264, found
m/z= 844.5253.
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(2R ,2 0R ,2 00R ) -2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TETRA-
METHYL -10 -( ( 4 -( PHENYLSULFONYL )PYR ID IN -2 -YL )METHYL ) -
-1 ,4 ,7 ,10 -TETRAAZACYCLODODECANE -1 ,4 ,7 -TR IYL )TR I PRO -
P ION IC AC ID (21 ) .
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((4-(phenyl-
sulfonyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)-
(2R,20R,200R)-tripropionate (131) (256mg, 303 µmol, 1.0 eq.) was dissolved
in acetonitrile (5.0mL) and hydrochloric acid (1 M, 10.0mL) was added. The
solution was stirred at 80  C for 4 h. The reaction mixture was concentrated
and purified by preparative HPLC (water , acetonitrile) yielding a white solid
(160mg, 237 µmol, 78.2%).
HR-ESI-MS: calcd. for [21+H]+ C33H50N5O8S m/z= 676.3375, found m/z=
676.3375.
NN
NN
OHO
O
HO
O OH
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LU -M7 -PY -SO2 -PHE -DOTA 132 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((4-(phenyl-
sulfonyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tri-
propionic acid (21) (40.0mg, 59.2 µmol, 1.0 eq.) was dissolved in aqueous
ammonium acetate (100mM, 5.0mL) and LuCl3 · 6H2O (92.2mg, 237 µmol,
4.0 eq.) was added. The reaction was heated to 80  C and stirred for 18 h
before purified by preparative HPLC (water, acetonitrile) yielding a white
solid (38.8mg, 45.7 µmol, 77.3%).
HR-ESI-MS: calcd. for [132+H]+ C33H47LuN5O8S m/z= 848.2555, found
m/z= 848.2548.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.65 (d, 3JHH = 5.8Hz, 1
H, H27), 8.03 (m, 2H, H29), 8.02 (d, 4JHH = 1.5Hz, 1H, H24), 7.99 (dd,
3JHH = 5.8Hz, 4JHH = 1.5Hz, 1H, H26), 7.80 (m, 1H, H31), 7.68 (m, 2H,
H30), 4.57 (d, 2JHH = 17.9Hz, 1H, H22a), 4.44 (d, 2JHH = 17.9Hz, 1H, H22b),
3.82 (q, 3JHH = 7.4Hz, 1H, H17), 3.79 (q, 3JHH = 7.4Hz, 1H, H20), 3.43
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(dd, 2JHH = 13.4Hz, 3JHH = 13.4Hz, 1H, H1ax), 3.14 (dq, 3JHH = 11.7Hz,
3JHH = 6.6Hz, 1H, H11), 3.08 (dq, 3JHH = 12.1Hz, 3JHH = 6.5Hz, 1
H, H8), 3.06 (dd, 2JHH = 15.0Hz, 3JHH = 11.7Hz, 1H, H10ax), 3.02 (dd,
2JHH = 14.6Hz, 3JHH = 13.4Hz, 1H, H7ax), 3.00 (dd, 2JHH = 13.4Hz,
3JHH = 13.4Hz, 1H, H4ax), 3.00 (dq, 3JHH = 13.4Hz, 3JHH = 6.1Hz, 1H,
H5), 2.84 (q, 3JHH = 7.4Hz, 1H, H14), 2.81 (d, 2JHH = 15.0Hz, 1H, H10eq),
2.71 (d, 2JHH = 14.6Hz, 1H, H7eq), 2.62 (dq, 3JHH = 13.4Hz, 3JHH = 6.4Hz,
1H, H2), 2.61 (d, 2JHH = 13.4Hz, 1H, H4eq), 2.59 (d, 2JHH = 13.4Hz, 1
H, H1eq), 1.46 (d, 3JHH = 7.5Hz, 3H, H16), 1.44 (d, 3JHH = 7.5Hz, 3H,
H19), 1.25 (d, 3JHH = 7.1Hz, 3H, H13), 1.19 (d, 3JHH = 6.6Hz, 3H, H12),
1.17 (d, 3JHH = 6.5Hz, 3H, H9), 1.16 (d, 3JHH = 6.1Hz, 3H, H6), 0.97 (d,
3JHH = 6.4Hz, 3H, H3).
13C{H}-NMR (150.92MHz, 298K, CDCl3): d = 183.31 (1C, C21), 183.16
(1C, C15), 183.10 (1C, C18), 161.87 (1C, C23), 151.73 (1C, C25), 149.93
(1C, C27), 136.84 (1C, C28), 135.58 (1C, C31), 130.13 (2C, C30), 128.30
(2C, C29), 121.29 (1C, C26), 119.07 (1C, C24), 67.33 (1C, C17), 67.23 (1
C, C20), 66.96 (1C, C14), 65.24 (1C, C22), 61.46 (1C, C11), 60.78 (1C, C2),
60.75 (1C, C8), 60.65 (1C, C5), 55.30 (1C, C1), 46.20 (1C, C7), 45.87 (1C,
C4), 45.27 (1C, C10), 13.41 (1C, C19), 13.24 (2C, C13, C16), 13.03 (1C, C6),
12.76 (1C, C9), 12.56 (1C, C3), 10.16 (1C, C12).
N N
N N
O O
OO
O
O Lu
N1
2
3
13
144
5
616
17
15
18
7
8
9
19
20
21
10
11
12
22
24
2523
26
27
S
28O
O
31
30
29
132
TM -M7 -PY -SO2 -PHE -DOTA 133 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((4-(phenyl-
sulfonyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tri-
propionic acid (21) (60.0mg, 88.8 µmol, 1.0 eq.) was dissolved in aqueous
ammonium acetate (100mM, 5.0mL) and Tm(OTf)3 (219mg, 355 µmol,
4.0 eq.) was added. The reaction was heated to 80  C and stirred for 18 h
before purified by preparative HPLC (water, acetonitrile) yielding a white
solid (55.3mg, 65.7 µmol, 74.0%).
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HR-ESI-MS: calcd. for [133+H]+ C33H47N5O8STm m/z= 842.2491, found
m/z= 842.2482.
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TB -M7 -PY -SO2 -PHE -DOTA 134 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((4-(phenyl-
sulfonyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tri-
propionic acid (21) (30.0mg, 44.4 µmol, 1.0 eq.) was dissolved in aqueous
ammonium acetate (100mM, 5.0mL) and TbCl3 · 6H2O (66.3mg, 178 µmol,
4.0 eq.) was added. The reaction was heated to 80  C and stirred for 18 h
before purified by preparative HPLC (water, acetonitrile) yielding a white
solid (31.3mg, 37.7 µmol, 84.8%).
HR-ESI-MS: calcd. for [134+H]+ C33H47N5O8STb m/z= 832.2395, found
m/z= 832.2393.
NN
NN
OO
O
O
O O
N
S
Tb
O
O
134
SM -M7 -PY -SO2 -PHE -DOTA 135 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((4-(phenyl-
sulfonyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tri-
propionic acid (21) (20.0mg, 29.6 µmol, 1.0 eq.) was dissolved in aqueous
ammonium acetate (100mM, 5.0mL) and SmCl3 · 6H2O (66.3mg, 178 µmol,
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4.0 eq.) was added. The reaction was heated to 80  C and stirred for 18 h
before purified by preparative HPLC (water, acetonitrile) yielding a white
solid (24.0mg, 29.2 µmol, 98.5%).
HR-ESI-MS: calcd. for [135+H]+ C33H47N5O8SSm m/z= 825.2337, found
m/z= 825.2332.
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4 -( ( 3 ,5 -B I S ( TR I FLUOROMETHYL)PHENYL )SULF ONYL ) -2 -
METHYLPYR I D INE (143 ) .
4-bromo-2-methylpyridine (710mg, 4.13mmol, 1.0 eq.), 3,5-Bis(trifluoro-
methyl) thiophenol (1.04 g, 4.13mmol, 1.0 eq.) and potassium carbonate
(680mg, 4.96mmol, 1.2 eq.) were suspended in dimethylformamide (10mL).
The mixture was stirred for 18 h at 80  C. The mixture was cooled to 40  C
and acidified with acetic acid (10.0mL). Bleach (10-15% chlorine basis,
10mL) was added and the mixture was stirred for 6 h. The pH was adjusted
to > 10 with aqueous sodium hydroxide (4 M) and the mixture was extracted
with dichloromethane (2x 15mL). The organic layer was dried with sodium
sulphate and evaporated to dryness yielding a brown oil. This brown oil
was redissolved in methanol (10mL), sodium tungstate dihydrate (608mg,
2.07mol, 0.5 eq.) and hydrogen peroxide (30 wt%, 2.0mL, 5.0 eq.) was
added. The mixture was stirred for 18 h at 20-25  C. The reaction mixture
was diluted with water (20mL) and methanol was removed under reduced
pressure. The product was extracted with dichloromethane (2x 20mL). The
organic layer was dried with sodium sulphate and evaporated to dryness. The
crude product was purified by flash column chromatography (ethyl acetate /
cyclohexane) yielding a yellowish solid (513mg, 1.39mmol, 33.6%).
HR-ESI-MS: calcd. for [143+H]+ C14H10F6NO2S m/z= 370.0331, found
m/z= 370.0337.
1H-NMR (400.13MHz, 298K, CDCl3): d = 8.77 (d, 3JHH = 5.3Hz, 1H, H3),
8.38 (bs, 2H, H8), 8.11 (bs, 1H, H11), 7.65 (d, 4JHH = 1.0Hz, 1H, H1), 7.59
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(dd, 3JHH = 5.3Hz, 4JHH = 1.0Hz, 1H, H4), 2.67 (s, 3H, H6).
13C{H}-NMR (100.6MHz, 298K, CDCl3): d = 161.52 (1C, C2), 151.27 (1
C, C3), 148.12 (1C, C5), 143.15 (1C, C7), 133.45 (q, 2JCF = 34.4Hz, 2C,
C9), 128.48 (2C, C8), 127.89 (1C, C11), 122.39 (q, 1JCF = 273.5Hz, 2C,
C10), 120.29 (1C, C1), 117.95 (1C, C4), 24.7 (1C, C6).
19F{H}-NMR (376.5MHz, 298K, CDCl3): d = −62.92 (6 F, F10).
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4 -( ( 3 ,5 -B I S ( TR I FLUOROMETHYL)PHENYL )SULF ONYL ) -2 --
(BROMOMETHYL ) PY R I D INE (140 ) .
4-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-2-methylpyridine (200mg,
542 µmol, 1.0 eq.) was dissolved in carbon tetrachloride (20.0mL) and
heated to reflux. During 2.5 h N-bromosuccinimide (289mg, 1.63mmol,
3.0 eq.) and AIBN (cat. 5.0mg) were added in small portions. The reaction
was refluxed for 18 h, filtered and evaporated to dryness under vacuum at
40  C. The crude reaction mixture was purified by flash column chromato-
graphy (pentane / methyl tert-butyl ether 7/3) yielding a slightly yellowish
solid (64.4mg, 117 µmol, 26.5%).
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.85 (d, 3JHH = 5.0Hz, 1H, H3),
8.41 (bs, 2H, H8), 8.15 (bs, 1H, H11), 7.97 (d, 4JHH = 1.7Hz, 1H, H1), 7.71
(dd, 3JHH = 5.0Hz, 4JHH = 1.7Hz, 1H, H4), 4.61 (s, 2H, H6).
13C{H}-NMR (150.9MHz, 298K, CDCl3): d = 159.89 (1C, C2), 151.68 (1
C, C3), 149.24 (1C, C5), 142.80 (1C, C7), 133.93 (q, 2JCF = 35.6Hz, 2C,
C9), 128.55 (q, 3JCF = 3.6Hz, 2C, C8), 128.12 (q, 3JCF = 3.6Hz, 1C, C11),
122.19 (q, 1JCF = 269.9Hz, 2C, C10), 120.68 (1C, C1), 120.18 (1C, C4),
32.24 (1C, C6).
19F{H}-NMR (564.6MHz, 298K, CDCl3): d = −62.91 (6 F, F10).
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TR I -tert -BUTYL 2 ,2 ’ ,2 ’ 0 - ( ( 2S ,5S ,8S ,11S ) -10 -( ( 4 -( ( 3 ,5 -B I S -
( TR I FLUOROMETHYL ) PHENYL )SULF ONYL )PY R I D IN -2 -YL ) -
METHYL ) -2 ,5 ,8 ,11 -TET RAMETHYL -1 ,4 ,7 ,10 -TET RAAZACY-
CLODODECANE -1 ,4 ,7 -TR I YL ) (2R ,2 0R ,2 0 0R ) -TR I PROP IONATE
(151 ) .
Tri-tert-butyl 2,2’,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (129) (50.0mg,
81.5 µmol, 1.0 eq.) and potassium carbonate (45.1mg, 326 µmol, 4.0 eq.)
were suspended in acetonitrile (6.0mL). To this suspension 4-((3,5-bis(tri-
fluoromethyl)phenyl)sulfonyl)-2-(bromomethyl)pyridine (140) (52.2mg,
116 µmol, 1.4 eq.) was added and the mixture was stirred for 18 h at 20-25  C.
The mixture was filtered and evaporated to dryness. The residue was purified
by preparative HPLC (water, acetonitrile) yielding a white solid (63.0mg,
64.3 µmol, 78.8%).
HR-ESI-MS: calcd. for [151+H]+ C47H72F6N5O8S m/z= 980.5000, found
m/z= 980.4989.
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(2R ,2 ’R ,2 ’ 0R ) -2 ,2 0 ,2 00 - ( ( 2 S ,5 S ,8 S ,11S ) -10 -( ( 4 -( ( 3 ,5 -B I S ( TR I -
FLUOROMETHYL ) PHENYL )SULF ONYL )PY R I D IN -2 -YL ) METH -
YL ) -2 ,5 ,8 ,11 -TET RAMETHYL -1 ,4 ,7 ,10 -TET RAAZACYCLODO -
DECANE -1 ,4 ,7 -TR I YL ) TR I PROP ION IC AC ID (152 ) .
Tri-tert-butyl 2,2’,2’0-((2S,5S,8S,11S)-10-((4-((3,5-bis (trifluoromethyl)-
phenyl)sulfonyl)pyridin-2-yl)methyl)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)(2R,2’R,2’0R)-tripropionate (151) (63.0mg,
64.3 µmol, 1.0 eq.) was dissolved in acetonitrile (2.0mL) and aqueous
hydrochloric acid (1 M, 5.0mL). The solution was stirred at 80  C for 4 h.
The solution was concentrated under reduced pressure at 50  C and the
residue was purified by preparative HPLC (water, acetonitrile) yielding a
white solid (42.0mg, 51.7 µmol 80.5%).
HR-ESI-MS: calcd. for [152+H]+ C35H48F6N5O8S m/z= 812.3122, found
m/z= 812.3112.
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LU -DOTA -M7 -PY -SO2 -B I S -CF3 -PHE 150 .
To a solution of (2R,2’R,2’0R)-2,20,200-((2S,5S,8S,11S)-10-((4-((3,5-bis(tri-
fluoromethyl)phenyl)sulfonyl)pyridin-2-yl)methyl)-2,5,8,11-tetramethyl-1,
4,7,10-tetraazacyclododecane-1,4,7-triyl) tripropionic acid (152) (20.0mg,
24.6 µmol, 1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was
added Lu(OTf)3 (61.2mg, 98.5 µmol, 4.0 eq.). The mixture was stirred at
80  C for 18 h before purified by preparative HPLC (water, acetonitrile)
yielding a white solid (17.2mg, 17.5 µmol, 71.1%).
HR-ESI-MS: calcd. for [150+H]+ C35H45F6LuN5O8S m/z= 984.2295, found
m/z= 984.2294.
1H-NMR (600.13MHz, 298K, CD3CN): d = 8.98 (bs, 1H, H26), 8.56 (bs,
2H, H29), 8.37 (bs, 1H, H31), 8.20 (bs, 1H, H27), 7.76 (bs, 1H, H24), 4.56
(d, 2JHH = 17.5Hz, 1H, H22a), 4.36 (d, 2JHH = 17.5Hz, 1H, H22b), 3.90
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(q, 3JHH = 7.2Hz, 1H, H17), 3.73 (q, 3JHH = 7.0Hz, 1H, H20), 3.32 (dd,
2JHH = 16.2Hz, 3JHH = 12.3Hz, 1H, H1ax), 3.28-3.16 (m, 2H, H11, H8),
3.11-2.90 (m, 5H, H14, H5, H7ax, H4ax, H10ax), 2.83 (d, 2JHH = 14.8Hz, 1H,
H10eq), 2.75-2.50 (m, 4H, H2, H1eq, H4eq, H7eq), 1.54 (d, 3JHH = 7.2Hz, 3H,
H16), 1.49 (d, 3JHH = 7.0Hz, 3H, H19), 1.26 (d, 3JHH = 6.8Hz, 3H, H12),
1.25 (d, 3JHH = 7.2Hz, 3H, H13), 1.18 (d, 3JHH = 6.3Hz, 3H, H9), 1.15 (d,
3JHH = 5.3Hz, 3H, H6), 0.98 (d, 3JHH = 6.3Hz, 3H, H3).
13C{H}-NMR (150.92MHz, 298K, CD3CN): d = 187.35 (1C, C18), 185.42
(1C, C15), 179.53 (1C, C21), 162.10 (1C, C23), 151.91 (1C, C25), 150.04 (1
C, C27), 142.34 (1C, C28), 133.65 (q, 2JCF = 34.3Hz, 2C, C30), 130.53 (2C,
C29), 129.88 (1C, C31), 125.41 (1C, C26), 123.66 (q, 1JCF = 274.0Hz, 2C,
C32), 120.41 (1C, C24), 68.93 (1C, C20), 67.57 (1C, C17), 66.73 (1C, C14),
66.52 (1C, C22), 63.00 (1C, C11), 62.47 (1C, C5), 61.52 (1C, C8), 61.47 (1
C, C2), 56.28 (1C, C1), 47.60 (1C, C7), 46.70 (1C, C4), 46.32 (1C, C10),
14.69 (1C, C16), 14.43 (1C, C6), 14.14 (1C, C19), 13.83 (1C, C9), 13.72 (1
C, C3), 13.66 (1C, C13), 11.60 (1C, C12).
19F{H}-NMR (564.6MHz, 298K, CD3CN): d = −63.07 (6 F, F32).
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150
TM -DOTA -M7 -PY -SO2 -B I S -CF3 -PHE 149 .
To a solution of (2R,2’R,2’0R)-2,20,200-((2S,5S,8S,11S)-10-((4-((3,5-bis(tri-
fluoromethyl)phenyl)sulfonyl)pyridin-2-yl)methyl)-2,5,8,11-tetramethyl-1,
4,7,10-tetraazacyclododecane-1,4,7-triyl) tripropionic acid (152) (20.0mg,
24.6 µmol, 1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was
added Tm(OTf)3 (60.6mg, 98.5 µmol, 4.0 eq.). The mixture was stirred at
80  C for 18 h before purified by preparative HPLC (water, acetonitrile)
yielding a white solid (13.4mg, 13.7 µmol, 52.3%).
HR-ESI-MS: calcd. for [149+H]+ C35H45F6N5O8STm m/z= 978.2230,
found m/z= 978.2225.
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2 -METHYL -4 -( ( 4 -( TR I FLUOROMETHYL)PHENYL )SULF ONYL )
PY R I D INE (142 ) .
4-bromo-2-methylpyridine (980mg, 5.67mmol, 1.0 eq.), 4-(trifluoromethyl)-
benzenethiol (1.00 g, 5.61mmol, 1.0 eq.) and potassium carbonate (930mg,
6.73mmol, 1.2 eq.) were suspended in acetonitrile (50mL) and stirred at
65  C for 18 h. The reaction mixture was filtered over celite and evaporated
to dryness. The residue was dissolved in methanol (40.0mL) and water
(5.0mL). Sodium tungstate dihydrate (930 g, 2.81mmol, 0.5 eq.) and aque-
ous hydrogen peroxide (30 wt%, 1.3mL, 11.2mmol, 2.0 eq.) were added.
The mixture was stirred at 20-25  C for 18 h. Water (50.0mL) was added and
methanol was removed under reduced pressure. The product was extracted
with dichloromethane (2x 50.0mL). The organic layers were combined,
dried with sodium sulphate and evaporated to dryness. The crude product
was purified by flash column chromatography (pentane / methyl tert-butyl
ether 5/5) yielding a yellowish solid (640mg, 2.15mmol, 37.9%).
HR-ESI-MS: calcd. for [142+H]+ C13H11F3NO2S m/z= 302.0457, found
m/z= 302.0453.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.73 (d, 3JHH = 5.1Hz, 1H, H3),
8.09 (d, 3JHH = 8.2Hz, 2H, H8), 7.82 (d, 3JHH = 8.2Hz, 2H, H9), 7.63 (d,
4JHH = 1.4Hz, 1H, H1), 7.57 (dd, 3JHH = 5.1Hz, 4JHH = 1.4Hz, 1H, H4),
2.66 (s, 3H, H6).
13C{H}-NMR (150.9MHz, 298K, CDCl3): d = 161.22 (1C, C2), 151.07
(1C, C3), 149.11 (1C, C5), 143.70 (1C, C7), 135.84 (q, 2JCF = 33.3Hz,
1C, C11), 128.82 (2C, C8), 126.89 (q, 3JCF = 3.7Hz, 2C, C9), 123.08 (q,
1JCF = 273.6Hz, 1C, C10), 120.29 (1C, C1), 117.92 (1C, C4), 24.86 (1C, C6).
19F{H}-NMR (564.6MHz, 298K, CDCl3): d = −63.29 (3 F, F10).
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2 -(BROMOMETHYL ) -4 -( ( 4 -( TR I FLUOROMETHYL)PHENYL ) -
SULF ONYL )PY R I D INE (139 ) .
2-methyl-4-((4-(trifluoromethyl)phenyl)sulfonyl)pyridine (142) (200mg,
664 µmol, 1.0 eq.) was dissolved in carbon tetrachloride (20mL) and heated
to reflux. During 5 h N-bromosuccinimide (380mg, 2.14mmol, 3.2 eq.) and
AIBN (cat. 5.0mg) were added in small portions. The reaction was refluxed
for 18 h, filtered and evaporated to dryness under vacuum at 40  C. The crude
reaction mixture was purified by flash chromatography (pentane / methyl
tert-butyl ether 7/3) yielding a yellowish wax (58.1mg, 153 µmol, 23.2%).
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.80 (dd, 3JHH = 5.1Hz,
5JHH = 0.7Hz, 1H, H3), 8.10 (d, 3JHH = 8.4Hz, 2H, H8), 7.94 (dd,
4JHH = 1.7Hz, 5JHH = 0.7Hz, 1H, H1), 7.84 (d, 3JHH = 8.4Hz, 2H, H9),
7.68 (dd, 3JHH = 5.1Hz, 4JHH = 1.7Hz, 1H, H4), 4.59 (s, 2H, H6).
13C{H}-NMR (150.9MHz, 298K, CDCl3): d = 159.47 (1C, C2), 151.38
(1C, C3), 150.14 (1C, C5), 143.34 (1C, C7), 136.11 (q, 2JCF = 33.1Hz,
1C, C11), 128.93 (2C, C8), 127.05 (q, 3JCF = 3.7Hz, 2C, C9), 123.07 (q,
1JCF = 274.4Hz, 1C, C10), 120.61 (1C, C1), 120.15 (1C, C4), 32.45 (1C, C6).
19F{H}-NMR (564.6MHz, 298K, CDCl3): d = −63.31 (3 F, F10).
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TR I -tert -BUTYL 2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET RA-
METHYL -10 -( ( 4 -( ( 4 -( TR I FLUOROMETHYL )PHENYL )SULF ON-
YL ) PY R I D IN -2 -YL )METHYL ) -1 ,4 ,7 ,10 -TET RAAZACYCLODO-
DECANE -1 ,4 ,7 -TR I YL ) (2R ,2 0R ,2 00R ) -TR I PROP IONATE (147 ) .
Tri-tert-butyl 2,2’,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (129) (100mg,
163 µmol, 1.0 eq.) and potassium carbonate (90.1mg, 651 µmol, 4.0 eq.) were
suspended in acetonitrile (5.0mL). To this suspension 2-(bromomethyl)-
-4-((4-(trifluoromethyl)phenyl)sulfonyl)pyridine (139) (74.4mg, 196 µmol,
1.2 eq.) was added and the mixture was stirred for 18 h at 20-25  C. The
mixture was filtered and evaporated to dryness. The residue was purified
by preparative HPLC (water, acetonitrile) yielding a white solid (70.0mg,
76.7 µmol, 47.1%).
HR-ESI-MS: calcd. for [147+H]+ C46H73F3N5O8S m/z= 912.5126, found
m/z= 912.5116.
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( 2R ,2 0R ,2 00R ) -2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TETRAMETH-
YL -10 -( ( 4 -( ( 4 -( TR I FLUOROMETHYL )PHENYL )SULFONYL )PY R I -
D IN -2 -YL )METHYL ) -1 ,4 ,7 ,10 -TETRAAZACYCLODODECANE -1 ,
4 ,7 -TR IYL )TR I PROP ION IC AC ID (148 ) .
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((4-((4-(triflu-
oromethyl)phenyl)sulfonyl)pyridin-2-yl)methyl)-1,4,7,10-tetraazacyclodo-
decane-1,4,7-triyl)(2R,20R,200R)-tripropionate (70.0mg, 76.7 µmol, 1.0 eq.)
was dissolved in acetontirile (2.0mL) and hydrochloric acid (1 M, 5.0mL).
The solution was stirred at 80  C for 4 h. The solution was concentrated under
reduced pressure at 50  C and the residue was purified by preparative HPLC
(water, acetonitrile) yielding a white solid (40.0mg, 53.7 µmol 70.1%).
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HR-ESI-MS: calcd. for [148+H]+ C34H49F3N5O8S m/z= 744.3248, found
m/z= 744.3243.
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LU -DOTA -M7 -PY -SO2 -MONO -CF3 -PHE 146 .
To a solution of (2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetrameth-
yl-10-((4-((4-(trifluoromethyl)phenyl)sulfonyl)pyridin-2-yl)methyl)-1,4,
7,10-tetraazacyclododecane-1,4,7-triyl)tripropionic acid (148) (20.0mg,
26.9 µmol, 1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was
added Lu(OTf)3 (66.9mg, 108 µmol, 4.0 eq.). The mixture was stirred at
80  C for 18 h before purified by preparative HPLC (water, acetonitrile)
yielding a white solid (17.2mg, 18.8 µmol, 71.1%).
HR-ESI-MS: calcd. for [146+H]+ C34H46F3LuN5O8S m/z= 916.2421, found
m/z= 916.2417.
1H-NMR (600.13MHz, 298K, CD3CN): d = 8.90 (bs, 1H, H26), 8.20
(d, 3JHH = 8.3Hz, 2H, H29), 8.17 (bs, 1H, H27), 7.53 (bs, 1H, H24), 7.96
(d, 3JHH = 8.3Hz, 2H, H30), 4.52 (d, 2JHH = 17.5Hz, 1H, H22a), 4.15
(d, 2JHH = 17.5Hz, 1H, H22b), 3.87 (q, 3JHH = 6.2Hz, 1H, H17), 3.76 (q,
3JHH = 7.0Hz, 1H, H20), 3.36 (dd, 2JHH = 15.8Hz, 3JHH = 12.3Hz, 1H,
H1ax), 3.28-3.16 (m, 2H, H11, H8), 3.12-2.88 (m, 5H, H14, H5, H7ax, H4ax,
H10ax), 2.83 (d, 2JHH = 14.5Hz, 1H, H10eq), 2.69-2.49 (m, 4H, H2, H1eq,
H4eq, H7eq), 1.54 (d, 3JHH = 6.2Hz, 6H, H19, H16), 1.25 (d, 3JHH = 6.1Hz, 3
H, H12), 1.24 (d, 3JHH = 6.1Hz, 3H, H13), 1.19 (d, 3JHH = 6.0Hz, 3H, H9),
1.15 (d, 3JHH = 6.3Hz, 3H, H6), 0.96 (d, 3JHH = 6.2Hz, 3H, H3).
13C{H}-NMR (150.92MHz, 298K, CD3CN): d = 187.36 (1C, C18), 185.48
(1C, C15), 179.71 (1C, C21), 161.60 (1C, C23), 152.61 (1C, C25), 150.10
(1C, C27), 143.25 (1C, C28), 136.12 (q, 2JCF = 33.3Hz, 1C, C31), 130.96
(2C, C29), 127.87 (q, 3JCF = 3.2Hz, 2C, C30), 125.37 (1C, C26), 124.49 (q,
1JCF = 273.0Hz, 1C, C32), 119.43 (1C, C24), 68.87 (1C, C20), 67.61 (1C,
C17), 66.49 (1C, C14), 66.43 (1C, C22), 63.20 (1C, C11), 62.45 (1C, C5),
61.58 (1C, C8), 61.21 (1C, C2), 56.23 (1C, C1), 47.64 (1C, C7), 46.79 (1
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C, C4), 46.44 (1C, C10), 14.65 (1C, C16), 14.49 (1C, C6), 14.31 (1C, C19),
13.86 (1C, C9), 13.72 (1C, C3), 13.60 (1C, C13), 11.68 (1C, C12).
19F{H}-NMR (564.6MHz, 298K, CD3CN): d = −63.40 (3 F, F32).
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TM -DOTA -M7 -PY -SO2 -MONO -CF3 -PHE 145 .
To a solution of (2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetrameth-
yl-10-((4-((4-(trifluoromethyl)phenyl)sulfonyl)pyridin-2-yl)methyl)-1,4,
7,10-tetraazacyclododecane-1,4,7-triyl)tripropionic acid (148) (20.0mg,
26.9 µmol, 1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was
added Tm(OTf)3 (66.3mg, 108 µmol, 4.0 eq.). The mixture was stirred at
80  C for 18 h before purified by preparative HPLC (water, acetonitrile)
yielding a white solid (14.9mg, 16.4 µmol, 60.9%).
HR-ESI-MS: calcd. for [145+H]+ C34H46F3N5O8STm m/z= 910.2356,
found m/z= 910.2363.
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5 -FLUORO -2 -METHYL -4 -( PHENYLSULF ONYL )PY R I D INE (156 ) .
Potassium carbonate (180mg, 1.33mmol, 1.2 eq.) was suspended in dimeth-
ylformamide (3.0mL) and 4-bromo-5-fluoro-2-methyl pyridine (211mg,
1.11mmol, 1.0 eq.) was added followed by thiophenol (103 µL, 1.00mmol,
0.9 eq.). The resulting white suspension was stirred at 70  C for 1 h. The
reaction mixture was concentrated under reduced pressure at 50  C to give
a white solid, which was dissolved in dichloromethane (10mL) and washed
with water (5.00mL). The organic layer was dried over sodium sulphate,
filtered and evaporated to dryness yielding a yellow oil (220mg, 93.0%
crude yield). The crude product was dissolved in methanol (5.0mL), sodium
tungstate dihydrate (82.5mg, 250 µmol, 0.3 eq.) and aqueous hydrogen per-
oxide (300 µL, 30%, 10.6mmol, 11 eq.) were added. The reaction mixture
was stirred at 20-25  C for 16 h. LC-MS showed incomplete conversion
therefore, additional sodium tungstate dihydrate (58.0mg, 175 µmol, 0.2 eq.)
and aqueous hydrogen peroxide (900 µL, 30%, 31.8mmol, 30 eq.) were
added. The mixture was left stirring at 20-25  C for another 24 h. After
completion, the reaction was diluted with water (5.0mL) and methanol
was removed under reduced pressure at 40  C. The aqueous heterogeneous
mixture was extracted with ethyl acetate (2x 15mL). The combined organic
layers were washed with water (10mL), brine (10mL), dried over sodium
sulphate, filtered and evaporated to dryness yielding a white solid (248mg,
998 µmol, 90.7%).
HR-ESI-MS: calcd. for [156+H]+ C12H10FNO2S m/z= 252.0489, found
m/z= 252.0492.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.42 (d, 3JHF = 1.0Hz, 1H,
H3), 8.03 (d, 3JHH = 8.5Hz, 2H, H8), 7.78 (d, 4JHF = 5.4Hz, 1H, H1),
7.68 (ddd, 3JHH = 8.5Hz, 3JHH = 7.4Hz, 4JHH = 1.7Hz, 2H, H9), 7.58
(ddd, 3JHH = 7.5Hz, 3JHH = 7.4Hz, 4JHH = 1.2Hz, 2H, H10), 2.64 (d,
4JHH = 1.0Hz, 3H, H6).
13C{H}-NMR (150.92MHz, 298K, CDCl3): d = 156.17 (1C, C1), 152.83
(1C, C4), 139.51 (1C, C7), 139.34 (1C, C5), 136.62 (1C, C3), 134.50 (1C,
C10), 129.44 (2C, C9), 128.56 (2C, C8), 121.16 (1C, C2), 23.91 (1C, C6).
19F{H}-NMR (564.6MHz, 298K, CDCl3): d = −129.49 (1 F, F4).
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2 -(BROMOMETHYL ) -5 -FLUORO -4 -( PHENYLSULF ONYL )PY R I -
D INE (154 ) .
5-Fluoro-2-methyl-4-(phenylsulfonyl) pyridine (156) (230mg, 91.7 µmol,
1.0 eq.) was dissolved in tetrachloromethane (20.0mL) under an atmosphere
of argon and the solution was refluxed. N-bromosuccinimide (330mg,
1.83mmol, 2.0 eq.) and AIBN (cat. 2.0mg) were added in five portions over
4 h. After 6 h the reaction mixture was filtered and evaporated to dryness. The
crude was immediately purified by flash column chromatography (SiO2, ethyl
acetate / cyclohexane (1:9)) yielding a colourless oil (82.5mg, 248 µmol,
27.0%).
HR-ESI-MS: calcd. for [154+H]+ C12H9BrFNO2S m/z= 329.9594, found
m/z= 329.9596.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.49 (d, 3JHF = 1.2Hz, 1H, H3),
8.07 (d, 4JHF = Hz, 2H, H1), 8.04 (d, 3JHH = 8.7Hz, 4JHH = 1.3Hz, 1H, H8),
7.70 (dddd, 3JHH = Hz, 3JHH = 7.1Hz, 4JHH = 2.2Hz, 4JHH = 1.0Hz, 1H,
H10), 7.60 (m, 2H, H9), 4.59 (s, 2H, H6).
13C{H}-NMR (150.92MHz, 298K, CDCl3): d = 154.74 (1C, C1), 153.93
(1C, C4), 140.30 (1C, C7), 139.28 (1C, C5), 137.76 (1C, C3), 134.96 (1C,
C10), 129.77 (2C, C9), 128.89 (2C, C8), 122.15 (1C, C2), 31.93 (1C, C6).
19F{H}-NMR (564.6MHz, 298K, CDCl3): d = −124.34 (1 F, F4).
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TR I -tert -BUTYL 2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -10 -( ( 5 -FLUORO -4 --
( PHENYLSULF ONYL )PY R I D IN -2 -YL )METHYL ) -2 ,5 ,8 ,11 -TET -
RAMETHYL -1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -1 ,4 ,7 -TR I -
YL ) (2R ,2 0R ,2 00R ) -TR I PROP IONATE (160 ) .
Tri-tert-butyl 2,2’,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (129) (100mg,
163 µmol, 1.0 eq.) and potassium carbonate (45.1mg, 326 µmol, 2.0 eq.) were
suspended in acetonitrile (3.0mL). To this suspension 2-(bromomethyl)-5-
fluoro-4-(phenylsulfonyl)pyridine (154) (56.5mg, 171 µmol, 1.1 eq.) was
added and the mixture was stirred at 20-25  C for 18 h. The mixture was
filtered, washed with acetonitrile (2.0mL) and evaporated to dryness. The
residue was purified by preparative HPLC (water, acetonitrile) yielding a
white solid (85.0mg, 98.5 µmol, 60.5%).
HR-ESI-MS: calcd. for [160+H]+ C45H73FN5O8S m/z= 862.5158, found
m/z= 862.5161.
NN
NN
OO
O
O
O O
N
S
F
O
O
160
( 2R ,2 0R ,2 00R ) -2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -10 -( ( 5 -FLUORO -4 --
( PHENYL SULF ONYL )PY R I D IN -2 -YL )METHYL ) -2 ,5 ,8 ,11 -TET -
RAMETHYL -1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -1 ,4 ,7 -TR I -
YL )TR I PROP ION IC AC ID (161 ) .
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-10-((5-fluoro-4-(phenylsulfonyl)pyri-
din-2-yl)methyl)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,
7-triyl) (2R,20R,200R)-tripropionate (160) (85.0mg, 98.5 µmol, 1.0 h) was
dissolved in acetonitrile (5.0mL) and hydrochloric acid (1 M, 10.0mL) was
added. The yellow solution was stirred at 65  C for 2 h. The reaction mixture
was concentrated and purified by preparative HPLC (water, acetonitrile)
yielding a white solid (51.0mg, 73.5 µmol, 74.6%).
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HR-ESI-MS: calcd. for [161+H]+ C33H49FN5O8S m/z= 694.3280, found
m/z= 694.3287.
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LU -M7 -FPY -SO2 -PHE -DOTA 159 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-10-((5-fluoro-4-(phenylsulfonyl)pyri-
din-2-yl)methyl)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,
7-triyl)tripropionic acid (161) (9.8mg, 14.1 µmol, 1.0 eq.) was dissolved
in aqueous ammonium acetate (100mM, 5.0mL) and Lu(OTf3) (17.9mg,
28.2 µmol, 2.0 eq.) was added. The reaction was heated to 80  C and stirred
for 18 h before purified by preparative HPLC (water, acetonitrile) yielding a
white solid (7.9mg, 9.12 µmol, 64.7%).
HR-ESI-MS: calcd. for [159+H]+ C33H45FLuN5O8S m/z= 866.2453, found
m/z= 866.2444.
1H-NMR (600.13MHz, 298K, D2O): d = 8.46 (d, 3JHF = 2.6Hz, 1H, H27),
8.15 (d, 4JHF = 5.5Hz, 1H, H24), 8.07 (d, 3JHH = 7.9Hz, 2H, H29), 7.85-7.81
(m, 1H, H31), 7.72-7.67 (m, 2H, H30), 4.65 (d, 2JHH = 17.9Hz, 1H, H22a),
4.45 (d, 2JHH = 17.9Hz, 1H, H22b), 3.81 (q, 3JHH = 7.2Hz, 1H, H17), 3.80
(q, 3JHH = 7.2Hz, 1H, H20), 3.45 (dd, 2JHH = 15.0Hz, 3JHH = 12.3Hz, 1
H, H1ax), 3.20-3.12 (m, 1H, H11), 3.12-2.99 (m, 5H, H5, H8, H4ax, H7ax,
H10ax), 2.97 (q, 3JHH = 7.2Hz, 1H, H14), 2.84 (d, 2JHH = 14.8Hz, 1H, H10eq),
2.73-2.68 (m, 1H, H2), 2.72 (d, 2JHH = 14.5Hz, 1H, H7eq), 2.66-2.60 (m, 2
H, H4eq, H1eq), 1.46 (d, 3JHH = 7.2Hz, 3H, H16), 1.45 (d, 3JHH = 7.2Hz, 3
H, H19), 1.29 (d, 3JHH = 7.0Hz, 3H, H13), 1.22 (d, 3JHH = 6.6Hz, 3H, H12),
1.19 (d, 3JHH = 6.6Hz, 3H, H9), 1.18 (d, 3JHH = 6.3Hz, 3H, H6), 1.02 (d,
3JHH = 6.4Hz, 3H, H3).
13C{H,F}-NMR (150.92MHz, 298K, D2O): d = 183.22 (1C, C21), 183.08
(1C, C15), 182.95 (1C, C18), 157.57 (1C, C23), 154.42 (1C, C26), 138.94 (1
C, C27), 138.88 (1C, C25), 136.64 (1C, C28), 135.94 (1C, C31), 129.96 (2C,
C30), 128.56 (2C, C29), 121.95 (1C, C24), 67.37 (1C, C20), 67.27 (1C, C17),
66.89 (1C, C14), 64.80 (1C, C22), 61.47 (1C, C11), 60.78 (1C, C2), 60.70
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(1 C, C8), 60.64 (1C, C5), 55.29 (1C, C1), 46.18 (1C, C7), 45.84 (1C, C4),
45.22 (1C, C10), 13.39 (1C, C19), 13.26 (1C, C13), 13.22 (1C, C16), 13.01 (1
C, C6), 12.74 (1C, C9), 12.54 (1C, C3), 10.18 (1C, C12).
19F{H}-NMR (564.76MHz, 298K, D2O): d = −122.72 (1 F, F26).
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TM -M7 -FPY -SO2 -PHE -DOTA 158 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-10-((5-fluoro-4-(phenylsulfonyl)pyri-
din-2-yl)methyl)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,
7-triyl)tripropionic acid (161) (50.0mg, 72.0 µmol, 1.0 eq.) was dissolved
in aqueous ammonium acetate (100mM, 8.0mL) and Tm(OTf3) (153.3mg,
86.4 µmol, 1.2 eq.) was added. The reaction was heated to 80  C and stirred
for 18 h before purified by preparative HPLC (water, acetonitrile) yielding a
white solid (51.0mg, 59.3 µmol, 82.3%).
HR-ESI-MS: calcd. for [158+H]+ C33H45FN5O8STm m/z= 860.2388, found
m/z= 860.2391.
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TM -M7 -FPY -S -C2H4 -TMS -DOTA 168 .
Tm-M7-FPy-SO2-Phe-DOTA 158 (50.0mg, 58.2 µmol, 1.0 eq.) was dissolved
in acetonitrile (5.0mL), 2-(tri|meth|ylsilyl)ethanethiol (18.4 µL, 116 µmol,
2.0 eq.) and potassium carbonate (32.2mg, 233 µmol, 4.0 eq.) were added.
The suspension was stirred at 20-25  C for 2 h. The mixture was filtered and
evaporated to dryness. The crude product was purified by preparative HPLC
(water, acetonitrile) yielding a white solid (43.2mg, 50.7 µmol, 87.1%).
HR-ESI-MS: calcd. for [168+H]+ C32H54FN5O6SSiTm m/z= 852.2885,
found m/z= 852.2882.
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TM -M7 -FPY -SO2 -C2H4 -TMS -DOTA 169 .
Tm-M7-FPy-S-C2H4-TMS-DOTA 168 (43.2mg, 50.7 µmol, 1.0 eq.) was dis-
solved in methanol (10mL). Sodium tungstate dihydrate (5.0mg, 15.1 µmol,
0.3 eq.) and aqueous hydrogen peroxide (300 µL, 30%, 2.94mmol, 60.0 eq.)
was added. The reaction mixture was stirred at 20-25  C for 18 h. After
completion the reaction mixture was concentrated to a final volume of
2-4mL. The remaining suspension was filtered and the filtrate was purified
by preparative HPLC (water, acetonitrile) yielding a white solid (32.3mg,
36.6 µmol, 71.7%).
HR-ESI-MS: calcd. for [169+H]+ C32H54FN5O8SSiTm m/z= 884.2783,
found m/z= 884.2781.
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TM -M7 -FPY -SO2NH2 -DOTA 170 .
Tm-M7-FPy-SO2-C2H4-TMS-DOTA (169) (15.0mg, 17.0 µmol, 1.0 eq.)
was dissolved in tetrahydrofuran (2.0mL) and acetonitirle (2.00mL).
Tetrabutylammonium fluoride (1 M in tetrahydrofuran, 34.0 µL, 34.0 µmol,
2.0 eq.) was added and the solution was stirred at 20-25  C for 30min. The
reaction mixture was evaporated to dryness and redissolved in water (5.0mL).
Sodium acetate (13.9mg, 170 µmol, 10.0 eq.) and hydroxylamine-o-sulfonic
acid (9.6mg, 85.0 µmol, 5.0 eq.) were added. The reaction was stirred at
20-25  C for 6 h before the solution was directly subjected to preparative
HPLC (water, acetonitrile) yielding a white solid (7.1mg, 8.89 µmol, 52.3%).
HR-ESI-MS: calcd. for [170+H]+ C27H43FN6O8STm m/z= 799.2184, found
m/z= 799.2187.
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TM -M7 -FPY -SH -DOTA 171 .
Tm-M7-FPy-SO2-C2H4-TMS-DOTA (169) (50.0mg, 58.7 µmol, 1.0 eq.)
was dissolved in tetrahydrofuran (5.00mL) and acetonitirle (5.00mL).
tetrabutylammonium fluoride (1 M in tetrahydrofuran, 120 µL, 120 µmol,
2.0 eq.) was added and the solution was stirred at 20-25  C for 30min. The
reaction mixture was evaporated to dryness and the residue was purified
by preparative HPLC (water, acetonitrile) yielding a white solid (32.2mg,
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42.8 µmol, 73.0%).
HR-ESI-MS: calcd. for [171+H]+ C27H42FN5O6STm m/z= 752.2176, found
m/z= 752.2166.
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TM -M7 -FPY -SME -DOTA 172 .
Tm-M7-FPy-SH-DOTA 171 (32.2mg, 42.8 µmol, 1.0 eq.) and potassium car-
bonate (11.0mg, 80.3mmol, 1.9 eq.) were suspended in acetonitrile (5.0mL).
Iodomethane (4.0 µL, 64.3 µmol, 1.5 eq.) was added and the mixture was
stirred at 20-25  C for 2 h. The mixture was filtered and evaporated to dryness
yielding a off-white solid (33.0mg, 43.4 µmol, quant.).
HR-ESI-MS: calcd. for [172+H]+ C28H44FN5O6STm m/z= 766.2333, found
m/z= 766.2337.
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TM -M7 -FPY -SO2ME -DOTA 173 .
Tm-M7-FPy-SMe-DOTA 172 (33.0mg, 43.4 µmol, 1.0 eq.) was dissolved in
methanol (5.0mL). Sodium tungstate dihydrate (6.6mg, 20.0 µmol, 0.5 eq.)
and aqueous hydrogen peroxide (30 wt%, 100 µL, 1.06mmol, 26.0 eq.)
were added. The reaction mixture was stirred at 20-25  C fro 18 h before
concentrated to a final volume of 2-4mL. The resulting suspension was
filtered and the filtrate was purified by preperative HPLC (water, acetonitrile)
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yielding a white solid (22.1mg, 27.7 µmol, 64.4%).
HR-ESI-MS: calcd. for [173+H]+ C28H44FN5O8STm m/z= 798.2231, found
m/z= 798.2236.
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4 -BROMO-2 -(BROMOMETHYL ) -5 -FLUOROPYR I D INE (232 ) .
4-bromo-5-fluoro-2-methylpyridine (75.1mg, 395 µmol, 1.0 eq.) was dis-
solved in tetrachloromethane (8.0mL) under an atmosphere of argon and
the solution was heated to 60  C. N-bromosuccinimide (211mg, 1.19mmol,
3.0 eq.) and AIBN (cat. 5.0mg) were added in five portions over 5 h. After 6 h
the reaction mixture was filtered and evaporated to dryness. The crude was
immediately purified by flash column chromatography (SiO2, ethyl acetate /
cyclohexane (1:9)) yielding a white solid (55.8mg, 207 µmol, 52.5%).
1H-NMR (400.13MHz, 298K, CDCl3): d = 8.39 (s, 1H, H3), 7.69 (d,
4JHF = 5.3Hz, 1H, H1), 4.49 (s, 2H, H6).
13C{H}-NMR (100.62MHz, 298K, CDCl3): d = 156.12 (d, 1JCF = 258.6Hz,
1C, C4), 153.75 (d, 4JCF = 5.4Hz, 1C, C2), 138.09 (d, 2JCF = 25.1Hz, 1C,
C3), 128.28 (1C, C1), 119.88 ((2JCF = 18.9Hz, 1C, C5), 31.82 (1C, C6).
19F{H}-NMR (376.46MHz, 298K, CDCl3): d = −122.97 (1 F, F4).
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TR I -tert -BUTYL 2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -10 -( ( 4 -BROMO-5 -
FLUORO PYR I D IN -2 -YL )METHYL ) -2 ,5 ,8 ,11 -TET RAMETHYL -
1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -1 ,4 ,7 -TR I YL ) (2R ,2 0R ,
2 00R ) -TR I PROP IONATE (233 ) .
Tri-tert-butyl 2,2’,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-te-
traazacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (129) (91.9mg,
150 µmol, 1.0 eq.) and potassium carbonate (82.9mg, 600 µmol, 4.0 eq.)
were suspended in acetonitrile (10mL). To this suspension 4-bromo-2--
(bromomethyl)-5-fluoropyridine (232) (40.3mg, 150 µmol, 1.0 eq.) was
added and the mixture was stirred for 18 h at 20-25  C. The mixture was
filtered and evaporated to dryness. The residue was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (107mg, 134 µmol, 89.1%).
HR-ESI-MS: calcd. for [233+H]+ C39H68BrFN5O6 m/z= 800.4332, found
m/z= 800.4330.
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( 2R ,2 ’R ,2 ’ 0R ) -2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -10 -( ( 4 -( ( 3 ,5 -B I S
( TR I FLUOROMETHYL ) PHENYL )SULF ONYL )PY R I D IN -2 -YL ) -
METHYL ) -2 ,5 ,8 ,11 -TET RAMETHYL -1 ,4 ,7 ,10 -TET RAAZACY-
CLODODECANE -1 ,4 ,7 -TR I YL ) TR I PROP ION IC AC ID (234 ) .
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-10-((4-bromo-5-fluoropyridin-2-yl)-
methyl)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)
(2R,20R,200R)-tripropionate (233) (107mg, 134 µmol, 1.0 eq.) was dissolved
in acetontirile (5.0mL) and hydrochloric acid (1 M, 10mL). The solution
was stirred at 80  C for 3 h. The solution was concentrated under reduced
pressure at 50  C and the residue was purified by preparative HPLC (water,
acetonitrile) yielding a white solid (67.5mg, 107 µmol, 79.6%).
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HR-ESI-MS: calcd. for [234+H]+ C27H44BrFN5O6 m/z= 632.2454, found
m/z= 632.2455.
NN
NN
OHO
O
HO
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TM -M7 -FPY -BR -DOTA (235 ) .
To a solution of (2R,2’R,2’0R)-2,20,200-((2S,5S,8S,11S)-10-((4-((3,5-bis(tri-
fluoromethyl)phenyl)sulfonyl)pyridin-2-yl) methyl)-2,5,8,11-tetramethyl-1,
4,7,10-tetraazacyclododecane-1,4,7-triyl) tripropionic acid (234) (20.0mg,
31.6 µmol, 1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was
added Tm(OTf)3 (48.7mg, 79.0 µmol, 2.5 eq.). The mixture was stirred at
80  C for 18 h before purified by preparative HPLC (water, acetonitrile)
yielding a white solid (19.0mg, 23.8 µmol 75.3%).
HR-ESI-MS: calcd. for [235+H]+ C27H41BrFN5O6Tm m/z= 798.1561,
found m/z= 798.1571.
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TM -M7 -FPY -S -B I PHENYL -SSPY -DOTA 224 .
Tm-M7-FPy-SO2-Phe-DOTA 158 (17.0mg, 19.8 µmol, 1.0 eq.) and po-
tassium carbonate were suspended in acetonitrile (3.0mL). 4,40-Bis(mercap-
tomethyl)biphenyl (48.8mg, 198 µmol, 10.0 eq.) was added and the reaction
was stirred for 2 h at 20-25  C. The suspension was filtered and the filtrate
was evaporated to dryness. The crude oil was purified by preparative HPLC
(water, acetonitrile). The isolated free thiol was immediately dissolved in
methanol (5.0mL) and acetic acid (1.0mL). 2,20-Dithiodipyridine (21.8mg,
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99.0 µmol, 5.0 eq.) was added and the reaction mixture was stirred for 2 h at
20-25  C before directly purified by preparative HPLC (water, acetonitrile)
yielding a white solid (5.0mg, 4.65 µmol, 23.5%).
HR-ESI-MS: calcd. for [224+H]+ C46H56FN6O6S3Tm m/z= 1073.2822,
found m/z= 1073.2820.
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2 -METHYL -3 -N ITROPYR ID IN -4 -OL (177 ) .
2-Methylpyridin-4-ol (877mg, 8.04mmol, 1.0 eq.) was dissolved in con-
centrated sulphuric acid (2.00mL) at 0-5  C. Fuming nitric acid (90%,
2.0mL) was added. The solution was stirred at 0-5  C for 3 h and afterwards
allowed to slowly warm up to 20-25  C overnight. The solution was poured
on ice (approx. 50 g), the precipitate was filtered off, washed with ice-cold
water (20mL) and dried under vacuum yielding an off white solid (463mg,
3.01mmol, 37.0%).
ESI-MS: calcd. for [177+H]+ C6H7N2O3 m/z= 155.05, found m/z= 155.20.
1H-NMR (500.13MHz, 298K, DMSO d6): d = 7.74 (d, 3JHH = 7.5Hz, 1H,
H6), 6.36 (d, 3JHH = 7.5Hz, 1H, H5), 2.30 (s, 3H, H1).
13C{H}-NMR (125.77MHz, 298K, DMSO d6): d = 168.01 (1C, C4),
143.62 (1C, C2/3), 142.08 (1C, C3/2), 138.06 (1C, C6), 117.88 (1C, C5),
15.35 (1C, C1).
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4 -BROMO-2 -METHYL -3 -N ITROPYR ID INE (177 ) .
2-Methyl-3-nitropyridin-4-ol (177) (495mg, 3.21mmol, 1.0 eq.) was sus-
pended in toluene (20mL) at 20-25  C. Phosphorous oxybromide (2.10 g,
7.31mmol, 2.3 eq.) was added and the suspension was heated to reflux. The
reaction mixture was refluxed for 19 h before cooled to 20-25  C. Aqueous
sodium hydroxide (1 M, 30mL) and ethyl acetate (50mL) were added. The
layers were separated and the organic layer was washed with water (2x
20mL) and dried over sodium sulphate. The crude brown oil was purified by
flash column chromatography (SiO2, pentane / tert-butyl methylether (7:3))
yielding a brownish solid (80.0mg, 370 µmol, 11.5%).
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.41 (d, 3JHH = 5.3Hz, 1H, H6),
7.50 (d, 3JHH = 5.3Hz, 1H, H5), 2.60 ( s, (3H, H1).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 151.67 (1C, Carom.), 150.35
(1C, C6), 148.42 (1C, Carom.), 126.16 (1C, C5), 123.64 (1C, Carom), 20.76 (1
C, C1).
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2 -METHYL -3 -N ITRO -4 -( PHENYLTH IO ) PYR ID INE (178 ) .
4-Bromo-2-methyl-3-nitropyridine (174) (69.0mg, 318 µmol, 1.0 eq.) was
dissolved in dimethylformamide (4.0mL). Then potassium carbonate
(94.0mg, 680 µmol, 2.1 eq.) and thiophenol (34.3mg, 312 µmol, 1.0 eq.)
were added. The solution was heated to 80  C for 70min. Afterwards the
solvent was evaporated. The residue was dissolved in ethyl acetate (5.0mL)
and water (5.00mL). The layers were separated and the aqueous layer was
washed with ethyl acetate (2x 20mL). The combined organic layers were
dried over sodium sulphate. The solvent was evaporated yielding a yellow
solid (80.0mg, 324 µmol, quant.) .
ESI-MS: calcd. for [178+H]+ C12H11N2O2S m/z= 247.06, found m/z=
247.45.
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.21 (d, 3JHH = 5.5Hz, 1H, H6),
7.59 (m, 5H, H8, H9, H10), 6.60 (d, 3JHH = 5.5Hz, 1H, H5), 2.66 (s, 3H, H1).
13C{H}-NMR (126.77MHz, 298K, CDCl3): d = 152.24 (Carom.), 149.63 (1
C, C6), 146.27 (Carom.), 144.36 (Carom.), 135.89 (Carom.), 130.75 (1C, C10),
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130.48 (Carom.), 128.71 (1C, C7), 120.14 (1C, C5), 22.19 (1C, C1).
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2 -METHYL -3 -N ITRO -4 -( PHENYLSULFONYL )PYR ID INE (179 ) .
2-Methyl-3-nitro-4-(phenylthio)pyridine ([178) (77.7mg, 315 µmol, 1.0 eq.)
was dissolved in methanol (5.0mL). Then sodium tungstate dihydrate
(102mg, 309 µmol, 1.0 eq.) and aqueous hydrogen peroxide (30%, 298 µL,
3.15mmol, 10 eq.) were added. The solution was stirred at 20-25  C for 4 h.
More sodium tungstate dihydrate (204mg, 618 µmol, 2.0 eq.) and aqueous
hydrogen peroxide (30%, 600 µL, 6.30mmol, 20 eq.) were added. The
solution was stirred at 20-25  C for further 72 h. Afterwards water (5.0mL)
was added and methanol was removed by distillation. The aqueous layer
was extracted with ethyl acetate (3x 10mL). The organic layer was dried
over sodium sulphate and the solvent was evaporated. The crude product
was purified by preparative HPLC (water, acetonitrile) yielding yellow solid
(35.0mg, 126 µmol, 40.0%).
HR-ESI-MS: calcd. for [179+H]+ C12H11N2O4S m/z= 279.05, found m/z=
279.45.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.84 (d, 3JHH = 5.1Hz, 1H, H6),
7.99-7.94 (m, 2H, H9/8), 7.86 (d, 3JHH = 5.1Hz, 1H, H5), 7.7-7.67 (m, 1H,
H10), 7.6-7.56 (m, 2H, H9/8), 2.59 (s, 3H, H1).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 152.48 (1C, Carom.), 151.64
(1C, C6), 142.71 (Carom.), 140.87 (Carom.), 129.63 (2C, C9/8), 128.62 (2C,
C9/8), 134.92 (1C, C10), 120.54 (1C, C5), 20.11 (1C, C1).
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2 -METHYL -4 -(METHYLTH IO ) -3 -N I TROPYR ID INE (180 ) .
2-Methyl-3-nitropyridin-4-ol (177) (250mg, 1.62mmol, 1.0 eq.) was sus-
pended in thionyl chloride (1.5mL). Dimethylformamide (20.0 µL) was
added and the reaction mixture was heated to 70  C for 18 h. The brownish
solution was evaporated to dryness yielding a yellow crude oil which was
dissolved in dimethylformamide (2.0mL). Potassium carbonate (448mg,
3.24mmol, 2.0 eq.) and sodium methanthiolate (136mg, 1.94mmol, 1.2 eq.)
were added and the reaction mixture was stirred for 2 h at 20-25  C. The
solution was evaporated and the crude product was purified by flash column
chromatopgraphy (SiO2, ethyl acetate / cyclohexane (5:5)) yielding a yellow
solid (110mg, 598 µmol, 36.9%).
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.43 (d, 3JHH = 5.5Hz, 1H, H6),
7.10 (d, 3JHH = 5.5Hz, 1H, H5), 2.62 (s, 3H, H1), 2.52 (s, 3H, H7).
13C{H}-NMR (150.95MHz, 298K, CDCl3): d = 151.77 (1C, C2), 149.57 (1
C, C6), 145.54 (1C, C4), 145.11 (1C, C3), 117.83 (1C, C5), 21.91 (1C, C1),
15.11 (1C, C7).
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2 -(BROMOMETHYL ) -4 -(METHYLTH IO ) -3 -N I TROPYR ID INE
(181 ) .
2-Methyl-4-(methylthio)-3-nitropyridine (180) (30.0mg, 163 µmol, 1.0 eq.),
was dissolved in tetrachloromethane (2.0mL) and refluxed. To this solution
over a period of 5 h NBS (580mg, 3.26mmol, 20.0 eq.) and AIBN (10mg)
were added in small portions. After 6 h the mixture was cooled to 20-25  C,
filtered and evaporated to dryness. The crude mixture was purified by flash
column chromatography (SiO2, ethyl acetate / cyclohexane (5:5)) yielding a
yellow oil (8.3mg, 32.0 µmol, 19.4%).
1H-NMR (250.13MHz, 298K, CDCl3): d = 8.59 (d, 3JHH = 5.5Hz, 1H, H6),
7.49 (d, 3JHH = 5.5Hz, 1H, H5), 4.80 (s, 2H, H1), 2.68 (s, 3H, H7).
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5 -METHYLTH IAZOLO[5 ,4 -B ] PY R I D INE -2 -TH IOL (186 ) .
2-Bromo-6-methylpyridin-3-amine (2.42 g, 12.9mmol, 1.0 eq.) and po-
tassium ethyl xanthogenate (4.55 g, 28.4mmol, 2.2 eq.) was dissolved in
dimethylformamide (5.0mL) and heated to 130  C for 16 h. The resulting
suspension was diluted with water (250mL) yielding a brownish solution.
The solution was acidified with hydrochloric acid (4 M, 5.0mL). The
precipitate was filtered and washed with water (50mL) yielding a brownish
solid (2.17 g, 11.9mmol, 92.3%).
HR-ESI-MS: calcd. for [186+H]+ C7H7N2S2 m/z= 183.0045, found m/z=
183.0044.
1H-NMR (400.13MHz, 298K, CDCl3): d = 11.08 (bs, 1H, H8), 7.42 (d,
3JHH = 8.2Hz, 1H, H4), 7.14 (d, 3JHH = 8.2Hz, 1H, H3), 2.59 (s, 3H, H1).
13C{H}-NMR (100.6MHz, 298K, CDCl3): d = 190.02 (1C, C7), 155.86 (1
C, C2), 151.68 (1C, C6), 132.73 (1C, C5), 121.45 (1C, C4), 118.55 (1C, C3),
23.99 (1C, C1).
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5 -METHYL -2 -(METHYLTH IO )TH IAZOLO[5 ,4 -B ] PY R I D INE
(187 ) .
5-Methylthiazolo[5,4-b]pyridine-2-thiol (186) (540mg, 2.96mmol, 1.0 eq.)
was dissolved in acetonitrile (60mL) and acetone (10mL). To this solution
potassium carbonate (818mg, 5.92mmol, 2.0 eq.) and iodomethane (221 µL,
3.55mmol, 1.2 eq.) were added. The suspension was stirred at 20-25  C
for 2 h. The solids were filtered off and the crude product was obtained by
evaporation of the solvent. The crude product was purified by flash column
chromatography (SiO2, ethyl acetate / cyclohexane (3:7)) yielding a off-white
solid (450mg, 2.29mmol, 77.4%).
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HR-ESI-MS: calcd. for [187+H]+ C8H9N2S2 m/z= 197.0202, found m/z=
197.0201.
1H-NMR (400.13MHz, 298K, CDCl3): d = 7.93 (d, 3JHH = 8.3Hz, 1H, H4),
7.18 (d, 3JHH = 8.3Hz, 1H, H3), 2.77 (s, 3H, H8), 2.62 (s, 3H, H1).
13C{H}-NMR (100.6MHz, 298K, CDCl3): d = 168.05 (1C, C7), 158.20 (1
C, C6), 155.07 (1C, C2), 144.60 (1C, C5), 128.09 (1C, C4), 121.29 (1C, C3),
24.31 (1C, C1), 15.48 (1C, C8).
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5 -METHYL -2 -(METHYLSULF ONYL )TH IAZOLO[5 ,4 -B ] PY R I D INE
(190 ) .
5-Methyl-2-(methylthio)thiazolo[5,4-b]pyridine (187) (271mg, 1.38mmol,
1.0 eq.), were dissolved in dichloromethane (5.0mL) and cooled to 0-5  C.
3-Chloroperoxybenzoic acid (680mg, 3.04mmol, 2.2 eq.) was added and the
reaction mixture was stirred at 0-5  C for 1 h before it was allowed to warm
up to 20-25  C. The reaction mixture was stirred another 1 h at 20-25  C.
The reaction mixture was extracted with aqueous sodium hydroxide (1 M,
3.0mL), dried with sodium sulphate and evaporated to dryness. The crude
product was purified by flash column chromatography (SiO2, ethyl acetate /
cyclohexane (1:1)) yielding a white solid (211mg, 925 µmol, 67.0%).
ESI-MS: calcd. for [190+H]+ C8H9N2O2S2 m/z= 229.00, found m/z=
228.95.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.31 (d, 3JHH = 8.4Hz, 1H, H4),
7.45 (d, 3JHH = 8.4Hz, 1H, H3), 3.39 (s, 3H, H8), 2.75 (s, 3H, H1).
13C{H}-NMR (150.9MHz, 298K, CDCl3): d = 166.01 (1C, C7), 160.70 (1
C, C2), 158.07 (1C, C6), 143.92 (1C, C5), 132.72 (1C, C4), 123.41 (1C, C3),
42.26 (1C, C8), 24.97 (1C, C1).
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5 -(BROMOMETHYL ) -2 -(METHYLSULF ONYL )TH IAZOLO[5 ,4 -B ]
PY R I D INE (182 ) .
5-Methyl-2-(methylsulfonyl)thiazolo[5,4-b]pyridine (190) (130mg,
569 µmol, 1.0 eq.) was dissolved in carbon tetrachloride (15mL) and
acetonitrile (5.0mL). The solution was heated to reflux. At reflux over a
period of 2.5 h N-bromosuccinimide (304mg, 1.71mmol, 3.0 eq.) and AIBN
(cat. 5.0mg) were added in small portions. The reaction was refluxed for
5 h, filtered and evaporated to dryness under vacuum at 40  C. The crude
product was purified by flash column chromatography (SiO2, ethyl acetate /
cyclohexane (1:1)) yielding a white solid (75.0mg, 244 µmol, 42.9%).
ESI-MS: calcd. for [182+H]+ C8H8BrN2O2S2 m/z= 306.91, found m/z=
306.85.
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.45 (d, 3JHH = 8.5Hz, 1H, H4),
7.74 (d, 3JHH = 8.5Hz, 1H, H3), 4.69 (s, 2H, H1), 3.41 (s, 3H, H8).
13C{H}-NMR (125.8MHz, 298K, CDCl3): d = 168.77 (1C, C7), 158.58 (1
C, C6), 158.31 (1C, C2), 145.14 (1C, C5), 133.71 (1C, C4), 123.32 (1C, C3),
42.19 (1C, C8), 32.75 (1C, C1).
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5 -(BROMOMETHYL ) -2 -(METHYLTH IO )TH IAZOLO[5 ,4 -B ] PYR I -
D INE (193 ) .
5-Methyl-2-(methylthio)thiazolo[5,4-b]pyridine (187) (210mg, 1.07mmol,
1.0 eq.) was dissolved in carbon tetrachloride (10.0mL). The solution was
heated to reflux. At reflux, over a period of 2 h N-bromosuccinimide (286mg,
1.71mmol, 1.5 eq.) and AIBN (cat.) were added in small portions. The reac-
tion was refluxed for 4 h, filtered and evaporated to dryness under vacuum
at 40  C. The crude product was purified by flash column chromatography
(SiO2, ethyl acetate / cyclohexane (3:7)) yielding a white solid (70.3mg,
256 µmol, 23.9%).
ESI-MS: calcd. for [193+H]+ C8H8BrN2S2 m/z= 274.9, found m/z= 274.85.
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.03 (d, 3JHH = 8.3Hz, 1H, H4),
7.48 (d, 3JHH = 8.3Hz, 1H, H3), 4.63 (s, 2H, H1), 2.80 (s, 3H, H1).
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13C{H}-NMR (125.8MHz, 298K, CDCl3): d = 170.07 (1C, C7), 158.55 (1
C, C6), 152.93 (1C, C2), 146.07 (1C, C5), 128.55 (1C, C4), 121.58 (1C, C3),
33.63 (1C, C1), 15.50 (1C, C8).
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TR I -tert -BUTYL 2 ,2 0 ,2 0 0 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET -
RAMETHYL -10 -( ( 2 -(METHYLSULF ONYL )TH IAZOLO[5 ,4 -B ] -
PY R I D IN -5 -YL )METHYL ) -1 ,4 ,7 ,10 -TET RAAZACYCLODODEC-
ANE -1 ,4 ,7 -TR I YL ) (2R ,2 0R ,2 0 0R ) -TR I PROP IONATE (191 ) .
Tri-tert-butyl 2,2’,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (129) (50.0mg,
81.6 µmol, 1.0 eq.) and potassium carbonate (45.1mg, 326 µmol, 4.0 eq.)
were suspended in acetonitrile (5.0mL). To this suspension 5-(bromometh-
yl)-2-(methylsulfonyl)thiazolo[5,4-b]pyridine (182) (25.1mg, 81.6 µmol,
1.0 eq.) was added and the mixture was stirred for 18 h at 20-25  C. The
mixture was filtered and evaporated to dryness. The residue was purified
by preparative HPLC (water, acetonitrile) yielding a white solid (55.0mg,
65.5 µmol, 80.3%).
HR-ESI-MS: calcd. for [191+H]+ C41H71N6O8S2 m/z= 839.4769, found
m/z= 839.4771.
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(2R ,2 0R ,2 00R) -2 ,2 0 ,2 00 - ( ( 2 S ,5 S ,8 S ,11S ) -2 ,5 ,8 ,11 -TET RAMETH-
YL -10 -( ( 2 -(METHYLSULF ONYL )TH IAZOLO[5 ,4 -B ] PY R I D IN -5 -
YL )METHYL ) -1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -1 ,4 ,7 -
TR I YL )TR I PROP ION IC AC ID (192 ) .
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((2-(meth-
ylsulfonyl)thiazolo [5,4-b]pyridin-5-yl)methyl)-1,4,7,10-tetraazacyclodo-
decane-1,4,7-triyl)(2R,20R,200R)-tripropionate (191) (55.0mg, 65.5 µmol,
1.0 eq.) was dissolved in acetonitrile (2.0mL) and aqueous hydrochloric acid
(1 M, 5.0mL). The solution was heated to 80  C for 7 h. The solution was
concentrated under reduced pressure at 50  C and the residue was purified
by preparative HPLC (water, acetonitrile) yielding a white solid (18.0mg,
26.8 µmol, 41.0%).
HR-ESI-MS: calcd. for [192+H]+ C29H47N6O8S2 m/z= 671.2891, found
m/z= 671.2895.
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LU -M7PYTH IAZOL -SO2ME -DOTA 188 .
To a solution of (2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetrameth-
yl-10-((2-(methylsulfonyl)thiazolo[5,4-b]pyridin-5-yl)methyl)-1,4,7,10-tet-
raazacyclododecane-1,4,7-triyl)tripropionic acid (192) (18.0mg, 26.8 µmol,
1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was added Lu(OTf)3
(33.3mg, 53.6 µmol , 2.0 eq.). The mixture was stirred at 80  C for 18 h before
purified by preparative HPLC (water, acetonitrile) yielding a white solid
(12.3mg, 14.6 µmol, 54.5%).
HR-ESI-MS: calcd. for [188+H]+ C29H44LuN6O8S2 m/z= 843.2064, found
m/z= 843.2067.
1H-NMR (600.13MHz, 298K, D2O): d = 8.76 (d, 3JHH = 8.7Hz, 1H,
H25), 7.83 (d, 3JHH = 8.7Hz, 1H, H24), 4.78 (d, 2JHH = 18.1Hz, 1H, H22a),
4.65 (d, 2JHH = 18.1Hz, 1H, H22b), 3.88 (q, 3JHH = 7.4Hz, 1H, H20), 3.84
(q, 3JHH = 7.4Hz, 1H, H17), 3.58 (s, 3H, H29), 3.53 (dd, 2JHH = 14.8Hz,
3JHH = 13.3Hz, 1H, H1ax), 3.28-3.21 (m, 1H, H11), 3.20-3.13 (m, 1H,
H8), 3.18-3.10 (m, 1H, H10ax), 3.12-3.07 (m, 1H, H4ax), 3.09-3.04 (m, 1
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H, H7ax), 3.05-2.99 (m, 1H, H5), 2.98-2.93 (m, 1H, H2), 2.93-2.85 (m, 1
H, H10eq), 2.89 (q, 3JHH = 7.2Hz, 1H, H14), 2.77 (dd, 2JHH = 15.3Hz,
3JHH = 1.6Hz, 1H, H7eq), 2.73 (dd, 2JHH = 14.8Hz, 3JHH = 2.8Hz, 1H,
H1eq), 2.69 (d, 2JHH = 14.2Hz, 1H, H4eq), 1.52 (d, 3JHH = 7.3Hz, 3H,
H16), 1.50 (d, 3JHH = 7.4Hz, 3H, H19), 1.27 (d, 3JHH = 6.7Hz, 3H, H12),
1.24 (d, 3JHH = 5.6Hz, 3H, H13), 1.23 (d, 3JHH = 5.4Hz, 3H, H9), 1.22 (d,
3JHH = 6.5Hz, 3H, H6), 1.09 (d, 3JHH = 6.5Hz, 3H, H3).
13C{H}-NMR (150.92MHz, 298K, D2O): d = 183.37 (1C, C21), 183.03 (1
C, C18), 182.71 (1C, C15), 167.90 (1C, C28), 161.98 (1C, C23), 156.30 (1C,
C27), 146.96 (1C, C26), 136.76 (1C, C25), 122.48 (1C, C24), 67.63 (1C, C17),
67.36 (1C, C20), 66.72 (1C, C14), 65.72 (1C, C22), 61.61 (1C, C11), 60.74
(1C, C8), 60.58 (1C, C5), 60.47 (1C, C2), 55.60 (1C, C1), 46.30 (1C, C7),
45.80 (1C, C4), 45.21 (1C, C10), 42.09 (1C, C29), 13.51 (1C, C19), 13.27 (1
C, C16), 13.21 (1C, C6), 12.77 (2C, C3, C9), 12.59 (1C, C13), 10.17 (1C, C12).
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TM -M7PYTH IAZOL -SO2ME -DOTA 189 .
To a solution of (2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetrameth-
yl-10-((2-(methylsulfonyl)thiazolo[5,4-b]pyridin-5-yl)methyl)-1,4,7,10-tet-
raazacyclododecane-1,4,7-triyl)tripropionic acid (192) (18.0mg, 26.8 µmol,
1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was added
Tm(OTf)3 (33.0mg, 53.6 µmol, 2.0 eq.). The mixture was stirred at 80  C
for 18 h before purified by preparative HPLC (water, acetonitrile) yielding a
yellowish solid (4.1mg, 4.77 µmol, 17.8%).
HR-ESI-MS: calcd. for [189+H]+ C29H44N6O8S2Tm m/z= 837.1999, found
m/z= 837.2003.
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TR I -TERT -BUTYL 2 ,2 0 ,2 0 0 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET RA-
METHYL -10 -( ( 2 -(METHYLTH IO )TH IAZOLO[5 ,4 -B ] PY R I D IN -5 -
YL )METHYL ) -1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -1 ,4 ,7 -
TR I YL ) (2R ,2 0R ,2 0 0R ) -TR I PROP IONATE (194 ) .
Tri-tert-butyl 2,2’,200-((2(S),5(S),8S,11(S))-2,5,8,11-tetramethyl-1,4,7,10-tet-
raazacyclododecane-1,4,7-triyl)(2R,20R,200R)-tri|prop|ion|ate (129) (50.0mg,
81.6 µmol, 1.0 eq.) and potassium carbonate (45.1mg, 326 µmol, 4.0 eq.)
were suspended in acetonitrile (5.0mL). To this suspension 5-(bromometh-
yl)-2-(methylthio)thiazolo[5,4-b]pyridine (193) (29.2mg, 106 µmol, 1.3 eq.)
was added and the mixture was stirred for 18 h at 20-25  C. The mixture was
filtered and evaporated to dryness. The residue was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (54.3mg, 67.2 µmol,
82.4%).
HR-ESI-MS: calcd. for [194+H]+ C41H71N6O6S2 m/z= 807.4871, found
m/z= 807.4870.
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( 2R ,2 0R ,2 00R ) -2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET RAMETH-
YL -10 -( ( 2 -(METHYLTH IO )TH IAZOLO[5 ,4 -B ] PYR I D IN -5 -YL )ME -
THYL ) -1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -1 ,4 ,7 -TR I YL ) -
TR I PROP ION IC AC ID (195 ) .
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-10-((2-(methyl-
thio)thiazolo[5,4-b]pyridin-5-yl)methyl)-1,4,7,10-tetraazacyclododecane-1,
4,7-triyl)(2(R),20(R),200(R))-tripropionate (194) (52.3mg, 64.8 µmol, 1.0 eq.)
was dissolved in dichloromethane (2.0mL) and trifluoroacetic acid (2.0mL)
and stirred at 20-25  C for 36 h. The solvent was removed and the residue
was purified by preparative HPLC (water, acetonitrile) yielding a white solid
(35.6mg mg, 55.7 µmol, 86.0%).
HR-ESI-MS: calcd. for [195+H]+ C29H47N6O6S2 m/z= 639.2993, found
m/z= 639.3002.
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TB -M7PYTH IAZOL -SME -DOTA (196 ) .
To a solution of (2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetrameth-
yl-10-((2-(methylthio)thiazolo[5,4-b]pyridin-5-yl)methyl)-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)tripropionic acid (195) (12.0mg, 18.8 µmol,
1.0 eq.) in aqueous ammonium acetate (100mM, 10mL) was added Tb(Cl)3
(14.0mg, 37.6 µmol, 2.0 eq.). The mixture was stirred at 80  C for 18 h before
purified by preparative HPLC (water, acetonitrile) yielding a white solid
(8.9mg, 11.2 µmol, 59.6%).
ESI-MS: calcd. for [196+H]+ C29H44N6O8S2Tb m/z= 795.19, found m/z=
795.25.
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DY -M7PYTH IAZOL -SME -DOTA (197 ) .
To a solution of (2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-
10-((2-(methylthio)thiazolo[5,4-b]pyridin-5-yl)methyl)-1,4,7,10-tetraazacy-
clododecane-1,4,7-triyl)tripropionic acid (195) (12.0mg, 18.8 µmol, 1.0 eq.)
in aqueous ammonium acetate (100mM, 10mL) was added Dy(OTf)3
(22.9mg, 37.6 µmol, 2.0 eq.). The mixture was stirred at 80  C for 18 h before
purified by preparative HPLC (water, acetonitrile) yielding a white solid
(9.8mg, 12.3 µmol, 65.3%).
ESI-MS: calcd. for [197+H]+ C29H44DyN6O8S2 m/z= 800.20, found m/z=
800.20.
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SM -M7PYTH IAZOL -SME -DOTA (198 ) .
To a solution of (2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-
10-((2-(methylthio)thiazolo[5,4-b]pyridin-5-yl)methyl)-1,4,7,10-tetraazacy-
clododecane-1,4,7-triyl)tripropionic acid (195) (30.0mg, 47.0 µmol, 1.0 eq.)
in aqueous ammonium acetate (100mM, 10mL) was added SmCl3 · 6H2O
(34.3mg, 94.0 µmol, 2.0 eq.). The mixture was stirred at 80  C for 18 h before
purified by preparative HPLC (water, acetonitrile) yielding a white solid
(29.0mg, 36.8 µmol, 78.4%).
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ESI-MS: calcd. for [198+H]+ C29H44N6O6S2Sm m/z= 788.20, found m/z=
788.20.
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TB -M7PYTH IAZOL -SO2ME -DOTA 199 .
To a solution of Tb-M7PyThiazol-SMe-DOTA 196 (8.0mg, 10.1 µmol,
1.0 eq.) in dichloromethane (5.0mL) was added 3-chloroperoxybenzoic acid
(>77%, 11.3mg, 50.5 µmol, 5.0 eq.). The mixture was stirred at 20-25  C for
18 h. The solvent was removed and the residue was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (6.3mg, 7.62 µmol, 75.4%).
HR-ESI-MS: calcd. for [199+H]+ C29H44N6O8S2Tb m/z= 827.1914, found
m/z= 827.1910.
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DY -M7PYTH IAZOL -SO2ME -DOTA 200 .
To a solution of Dy-M7PyThiazol-SMe-DOTA 197 (9.2mg, 11.5 µmol,
1.0 eq.) in dichloromethane (5.0mL) was added 3-chloroperoxybenzoic acid
(>77%, 25.8mg, 115 µmol, 10.0 eq.). The mixture was stirred at 20-25  C for
18 h. The solvent was removed and the residue was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (7.3mg, 8.79 µmol, 76.4%).
HR-ESI-MS: calcd. for [200+H]+ C29H44DyN6O8S2 m/z= 832.1951, found
m/z= 832.1955.
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SM -M7PYTH IAZOL -SO2ME -DOTA 201 .
To a solution of Sm-M7PyThiazol-SMe-DOTA 198 (29.0mg, 36.8mmol,
1.0 eq.) in dichloromethane (10.0mL) was added 3-chloroperoxybenzoic acid
(>77%, 82.5mg, 368 µmol, 10.0 eq.). The mixture was stirred at 20-25  C for
18 h. The solvent was removed and the residue was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (23.1mg, 28.2 µmol,
76.6%).
HR-ESI-MS: calcd. for [201+H]+ C29H44N6O8S2Sm m/z= 820.1852, found
m/z= 820.1852.
1H-NMR (600.13MHz, 298K, D2O): d = 8.41 (d, 3JHH = 8.7Hz, 1H, H25),
7.97 (d, 3JHH = 8.7Hz, 1H, H24), 7.91 (bs, 1H, H11), 7.49 (d, 2JHH = 15.9Hz,
1H, H22a), 7.02 (q, 3JHH = 6.9Hz, 1H, H20), 6.53 (q, 3JHH = 6.8Hz, 1
H, H14), 6.10 (q, 3JHH = 7.3Hz, 1H, H17), 5.56 (d, 2JHH = 15.9Hz, 1H,
H22b), 4.71 (bs, 1H, H5), 4.54 (bs, 1H, H2), 3.33 (s, 3H, H29), 2.76 (d,
3JHH = 6.9Hz, 3H, H19), 2.58 (d, 2JHH = 14.2Hz, 1H, H1eq), 2.45 (d,
3JHH = 6.8Hz, 3H, H13), 2.28 (d, 2JHH = 14.9Hz, 1H, H10eq), 1.86 (bs, 1H,
H8), 1.83 (d, 2JHH = 14.8Hz, 1H, H4eq), 1.68 (d, 3JHH = 7.3Hz, 3H, H16),
1.59 (d, 3JHH = 6.2Hz, 3H, H12), 1.05 (d, 3JHH = 6.7Hz, 3H, H3), 0.94 (dd,
2JHH = 14.2Hz, 3JHH = 13.3Hz, 1H, H1ax), 0.16 (d, 3JHH = 5.9Hz, 3H, H9),
0.13 (d, 3JHH = 6.3Hz, 3H, H6), −0.73 (d, 2JHH = 15.4Hz, 1H, H7eq), −1.78
(dd, 2JHH = 14.9Hz, 3JHH = 11.4Hz, 1H, H10ax), −2.46 (dd, 2JHH = 14.8Hz,
3JHH = 11.03Hz, 1H, H4ax), −3.96 (dd, 2JHH = 15.4Hz, 3JHH = 13.4Hz, 1H,
H7ax).
13C{H}-NMR (150.92MHz, 298K, D2O): d = 195.38 (1C, C21), 194.95 (1
C, C15), 187.76 (1C, C18), 167.05 (1C, C28), 163.41 (1C, C23), 154.83 (1C,
C27), 145.01 (1C, C26), 136.28 (1C, C25), 122.25 (1C, C24), 73.48 (1C, C14),
72.24 (1C, C20), 70.15 (1C, C22), 67.05 (1C, C17), 64.98 (1C, C11), 63.69
(1C, C2), 59.24 (1C, C5), 57.84 (1C, C8), 57.30 (1C, C1), 47.78 (1C, C29),
45.72 (1C, C10), 45.85 (1C, C4), 40.52 (1C, C7), 14.77 (1C, C19), 14.09 (1
C, C13), 12.09 (1C, C3), 11.79 (1C, C6), 11.68 (1C, C16), 10.76 (1C, C9),
9.37 (1C, C12).
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201
2 -(4 -(METHOXYCARBONYL)PHENOXY) -6 -METHYLN ICOT IN IC
AC ID (214 ) .
Sodium methoxide (490mg, 9.00mmol, 1.5 eq.) was dissolved in dry
methanol (5.00mL), followed by the addition of methyl-4-hydroxybenzoate
(4.56 g, 30.0mmol, 5.0 eq.) and 6-methyl-2-chloronicotinic acid (1.03 g,
6.00mmol, 1.0 eq.). Methanol was removed under reduced pressure and the
reaction was heated for 24 h at 125  C in a Kugelrohr oven. To the oil residue
water (20mL) and methyl tert-butyl ether (20.0mL) were added. The layers
were separated, and the aqueous layer was extracted with methyl tert-butyl
ether (2x 20mL). The combined organic layers were extracted with aqueous
saturated sodium hydrogen carbonate (30mL). The combined aqueous
layers were acidified with aqueous hydrochloric acid (37%). The resulting
suspension was filtered and washed with cold water (20mL) yielding an
off-white solid (1.41 g, 4.91mmol, 81.8%).
HR-ESI-MS: calcd. for [214+H]+ C15H14NO5 m/z= 288.0866, found m/z=
288.0868.
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.41 (d, 3JHH = 7.8Hz, 1H, H4),
8.15-8.11 (m, 2H, H11), 7.26-7.23 (m, 2H, H10), 7.08 (d, 3JHH = 7.8Hz, 1H,
H3), 3.93 (s, 3H, H14), 2.41 (s, 3H, H1).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 166.58 (1C, C13), 165.47
(1C, C7), 163.35 (1C, C2), 160.11 (1C, C6), 156.63 (1C, C9), 143.71 (1C,
C4), 131.48 (2C, C11), 127.32 (1C, C12), 121.49 (2C, C10), 119.79 (1C, C3),
110.75 (1C, C5), 52.37 (1C, C14), 24.49 (1C, C1).
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METHYL 2 -METHYL -5 -OXO -5H -CHROMENO[2 ,3 -B ] PYR ID INE -7 -
CARBOXYLATE (210 ) .
Polyphosphoric acid (70.0 g) was added to 2-(4-methoxycarbonylphenoxy)-
-6-methylnicotinic acid (214) (1.00 g, 3.48mmol, 1.0 eq.) and the reaction
mixture was stirred at 120  C for 18 h under argon. The resulting brown
liquid was cooled and methanol (50.0mL) was carefully added. The mixture
was stirred until a homogeneous solution was formed. The solution was
carefully adjusted to an apparent pH of approximately 7 by the addition of
aqueous potassium hydroxide (10%, 1.20 L). The mixture was extracted
with dichloromethane (3x 200mL) and the solvent was removed yielding
a yellow solid. The crude product was crystallized from ethyl acetate /
dichloromethane yielding a yellowish solid (530mg, 1.97mmol, 56.6%).
HR-ESI-MS: calcd. for [210+H]+ C15H12NO4 m/z= 270.0761, found m/z=
270.0759.
1H-NMR (500.13MHz, 298K, CDCl3): d = 8.99 (d, 4JHH = 2.2Hz, 1H, H13),
8.61 (d, 3JHH = 7.8Hz, 1H, H4), 8.41 (dd, 3JHH = 8.8Hz, 4JHH = 2.2Hz, 1
H, H11), 7.65 (d, 3JHH = 8.8Hz, 1H, H10), 7.34 (d, 3JHH = 7.8Hz, 1H, H3),
3.98 (s, 3H, H15), 2.73 (s, 3H, H1).
13C{H}-NMR (125.77MHz, 298K, CDCl3): d = 177.04 (1C, C7), 165.72
(1C, C14), 165.68 (1C, C2), 159.88 (1C, C6), 158.22 (1C, C9), 137.64 (1
C, C4), 136.13 (1C, C11), 129.30 (1C, C13), 129.07 (1C, C10), 126.74 (1C,
C12), 121.88 (1C, C3), 121.41 (1C, C8), 114.36 (1C, C5), 52.68 (1C, C15),
25.30 (1C, C1).
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METHYL 2 -(BROMOMETHYL ) -5 -OXO -5H -CHROMENO[2 ,3 -B ] -
PYR ID INE -7 -CARBOXYLATE (213 ) .
Methyl 2-methyl-5-oxo-5H-chromeno[2,3-b]pyridine-7-carboxylate (210)
(1.00 g, 3.71mmol, 1.0 eq.) was suspended in tetrachloromethane (100mL)
and degased with argon. The degassed suspension was heated to reflux under
an argon atmosphere. At reflux, acetonitrile (15.0mL) was added until a
solution was formed. N-bromosuccinimide (660mg, 3.71mmol, 1.0 eq.) and
AIBN (1.0mg) were added and a UV lamp was placed in front of the flask.
The reaction was refluxed for 4 d and 5 portions of N-bromosuccinimide
(660mg, 3.71mmol, 1.0 eq.) and AIBN (1.0mg) were added in portions
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ever 12-16 h. The reaction was stopped when the NMR showed a conversion
of about 70%. The crude reaction mixture was cooled to 0-5  C and the
participate was filtered off. The filtrate was evaporated to dryness and
the crude product was purified by flash chromatography (SiO2, dichloro-
methane / pentane (9 :1)) yielding a white solid (490mg , 1.41mmol, 37.9%).
HR-ESI-MS: calcd. for [213+H]+ C15H11BrNO4 m/z= 347.9866, found
m/z= 347.9866.
1H-NMR (600.13MHz, 298K, CDCl3): d = 8.99 (d, 4JHH = 2.2Hz, 1H, H13),
8.72 (d, 3JHH = 7.9Hz, 1H, H4), 8.43 (dd, 3JHH = 8.8Hz, 4JHH = 2.2Hz, 1
H, H11), 7.67 (d, 3JHH = 8.8Hz, 1H, H10), 7.62 (d, 3JHH = 7.9Hz, 1H, H3),
4.61 (s, 2H, H1), 3.98 (s, 3H, H15).
13C{H}-NMR (150.92MHz, 298K, CDCl3): d = 176.59 (1C, C7), 165.68
(1C, C14), 162.64 (1C, C2), 159.77 (1C, C6), 158.35 (1C, C9), 138.97 (1C,
C4), 136.47 (1C, C11), 129.35 (1C, C13), 127.22 (1C, C12), 121.48 (1C, C8),
121.46 (1C, C3), 119.10 (1C, C10), 116.13 (1C, C5), 52.70 (1C, C15), 32.14
(1C, C1).
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TETRA -tert -BUTYL 2 ,2 0 ,2 00 ,2 000 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET-
RAMETHYL -1 ,4 ,7 ,10 -TETRAAZACYCLODODECANE -1 ,4 ,7 ,10 -
TETRAYL ) (2R ,2 0R ,2 00R ,2 000R ) -TETRAPROP IONATE (207 ) .
(2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane (22)
(100mg, 43.8 µmol, 1.0 eq.) and potassium carbonate (363mg, 2.63mmol,
6.0 eq.) were suspended in acetonitrile (3.00mL). tert-Butyl (S)-2-(((tri-
fluoromethyl)sulfonyl)oxy)propanoate (731mg, 2.63mmol, 6.0 eq.) was
dissolved in acetonitrile (4.0mL). This solution was added to the reac-
tion and the mixture was stirred for 6 h. The suspension was filtered
and evaporated to dryness. The crude product was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (220mg, 297 µmol, 67.8%).
ESI-MS: calcd. for [207+H]+ C40H77N4O8m/z= 741.57, foundm/z= 741.60.
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( 2R ,2 0R ,2 0 0R ,2 0 0 0R ) -2 ,2 0 ,2 0 0 ,2 0 0 0 - ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET-
RAMETHYL -1 ,4 ,7 ,10 -TETRAAZACYCLODODECANE -1 ,4 ,7 ,10 -
TETRAYL )TETRAPROP ION IC AC ID (208 ) .
Tetra-tert-butyl 2,20,200,2000-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetrayl)(2R,20R,200R,2000R)-tetrapropionate
(207) (40.0mg, 54.0 µmol, 1 eq.) was dissolved in water (15mL) and
trifluoroacetic acid (500 µL) was added. The solution was heated in the
microwave to 120  C and stirred for 30min. After cooling to 20-25  C the
solution was evaporated to dryness and the crude product was purified by
preparative HPLC (water / acetonitrile) yielding a white solid (19.8mg,
38.0 µmol, 71.0%).
HR-ESI-MS: calcd. for [208+H]+ C24H45N4O8 m/z= 517.32, found m/z=
517.30.
N N
N N
O OH
O
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METHYL 5 -OXO -2 -( ( ( 2S ,5S ,8S ,11S ) -2 ,5 ,8 ,11 -TET RAMETHYL -
1 ,4 ,7 ,10 -TET RAAZACYC LODODECAN -1 -YL )METHYL ) -5H -CH -
ROMENO[2 ,3 -B ] PY R I D INE -7 -CARBOXYLATE (236 ) .
(2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyclododecane (22)
(295mg, 1.29mmol, 3.0 eq.) and methyl 2-(bromomethyl)-5-oxo-5H-chro-
meno[2,3-b]pyridine-7-carboxylate (150mg, 43.1 µmol, 1.0 eq.) were
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suspended in dichloromethane (15mL) and stirred at 20-25  C for 18 h.
The solvent was removed and the crude product was purified by preparative
HPLC (water, acetonitrile) yielding a white solid (120mg, 242 µmol, 56.2%).
HR-ESI-MS: calcd. for [236+H]+ C27H38N5O4 m/z= 496.2918, found m/z=
496.2922.
NH N
NH HN
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O
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TR I -tert -BUTYL 2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -10 -( ( 7 -(METHOXY-
CARBONYL ) -5 -OXO -5H -CHROMENO[2 ,3 -B ] PYR ID IN -2 -YL ) -
METHYL ) -2 ,5 ,8 ,11 -TETRAMETHYL -1 ,4 ,7 ,10 -TETRAAZACYC-
LODODECANE -1 ,4 ,7 -TR IYL ) (2R ,2 0R ,2 00R ) -TR I PROP IONATE
(215 ) .
Method A
Methyl 5-oxo-2-(((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetraazacyc-
lododecan-1-yl)methyl)-5H-chromeno[2,3-b]pyridine-7-carboxylate (236)
(40.0mg, 80.7 µmol, 1.0 eq.) and potassium carbonate (66.9mg, 484 µmol,
6.0 eq.) were suspended in acetonitrile (2.0mL). tert-Butyl (S)-2-(((trifluoro-
methyl)sulfonyl)oxy)propanoate (135mg, 484 µmol, 6.0 eq.) was dissolved
in acetonitrile (2.00mL) and added to the reaction mixture. The reaction was
stirred for 4 h. The solids were filtered off and the filtrate was evaporated
to dryness. The crude product was purified by preparative HPLC (water,
acetonitrile) yielding a white solid (68.2mg, 77.4 µmol, 88.4%).
Method B
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (129) (90.0mg,
147 µmol, 1.0 eq.), methyl 2-(bromomethyl)-5-oxo-5H-chromeno[2,3-b]-
pyridine-7-carboxylate (213) (56.2mg, 162 µmol, 1.1 eq.) and potassium
carbonate (60.9mg, 441 µmol, 3.0 eq.) were suspended in acetonitrile
(7.0mL) and stirred at 20-25  C for 18 h. The suspension was filtered and
the filtrate was evaporated to dryness. The crude product was purified by
preparative HPLC (water, acetonitrile) yielding a white solid (88.0mg,
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100 µmol, 68.1%).
ESI-MS: calcd. for [215+H]+ C48H74N5O10 m/z= 880.54, found m/z=
880.90.
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( 2R ,2 0R ,2 00R ) -2 ,2 0 ,2 00 - ( ( 2S ,5S ,8S ,11S ) -10 -( ( 7 -(METHOXYCAR-
BONYL ) -5 -OXO -5H -CHROMENO[2 ,3 -B ] PY R I D IN -2 -YL )METH-
YL ) -2 ,5 ,8 ,11 -TET RAMETHYL -1 ,4 ,7 ,10 -TET RAAZACYC LODO-
DECANE -1 ,4 ,7 -TR IYL )TR I PROP ION IC AC ID (216 ) .
Tri-tert-butyl 2,20,200-((2S,5S,8S,11S)-10-((7-(methoxycarbonyl)-5-oxo-
5H-chromeno[2,3-b]pyridin-2-yl)methyl)-2,5,8,11-tetramethyl-1,4,7,10-tet-
raazacyclododecane-1,4,7-triyl)(2R,20R,200R)-tripropionate (215) (30.0mg,
34.0 µmol, 1.0 eq.) was dissolved in a mixture of trifluoroacetic acid /
thioanisol / water 92:6:2 (4.0mL) and stirred at 20-25  C for 7 h. The solution
was evaporated to dryness and the crude product was purified by preparative
HPLC (water / acetonitrile) yielding a white solid (22.1mg, 31.0 µmol,
91.1%).
ESI-MS: calcd. for [216+H]+ C36H50N5O10 m/z= 712.35, found m/z=
712.60.
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EU -DOTA -M7 -AZAXANTHON 209 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-10-((7-(methoxycarbonyl)-5-oxo-5H-
chromeno[2,3-b]pyridin-2-yl)methyl)-2,5,8,11-tetramethyl-1,4,7,10-tetra-
azacyclododecane-1,4,7-triyl)tripropionic acid (216) (20.8mg, 29.2 µmol,
1.0 eq.) and Eu(OTf)3 (64.8mg, 108 µmol, 4.0 eq.) were dissolved in aqueous
ammonium acetate (100mM, 5.0mL) and stirred at 75  C for 18 h. The reac-
tion mixture was directly purified by preparative HPLC (water, acetonitrile)
yielding a white solid (12.9mg, 15.0 µmol, 55.4%).
HR-ESI-MS: calcd. for [209+H]+ C36H47EuN5O10 m/z= 862.25, found
m/z= 862.60.
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EU -DOTA -M8 202 .
Tetra-tert-butyl 2,20,200,2000-((2S,5S,8S,11S)-2,5,8,11-tetramethyl-1,4,7,10-tet-
raazacyclododecane-1,4,7,10-tetrayl)(2R,20R,200R,2000R)-tetrapropionate (207)
(40.0mg, 77.4 µmol, 1.0 eq.) and Eu(OTf)3 (57.5mg, 96.0 µmol, 1.2 eq.) were
dissolved in aqueous ammonium acetate (100mM, 5.0mL). The solution
was stirred at 70  C for 16 h. The reaction mixture was cooled to 20-25  C
and directly purified by preparative HPLC (water, acetonitrile) yielding a
white solid (22.4mg, 34.0 µmol, 43.5%).
HR-ESI-MS: calcd. for [202+2Na]+ C24H40EuN4Na2O8 m/z= 711.1850,
found m/z= 711.1834.
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EU -DOTA -M4 203 .
(2R,20R,200R,2000R)-2,20,200,2000-(1,4,7,10-tetraazacyclododecane-1,4,7,10-te-
trayl)tetrapropionic acid (20.0mg, 36.5 µmol, 1.0 eq.) was dissolved in
aqueous ammonium acetate (100mM, 4.00mL) and stirred at 70  C for
17 h. The reaction mixture was cooled to 20-25  C and directly purified
by preparative HPLC (water, acetonitrile) yielding a white solid (24.1mg,
quant.).
ESI-MS: calcd. for [203]- m/z= 609.14, found m/z= 609.40.
N N
N N
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EU -DOTA 204 .
2,20,200,2000-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid
(10.0mg, 24.0 µmol, 1.0 eq.) was dissolved in aqueous ammonium acetate
(100mM, 4.00mL) and stirred at 70  C for 17 h. The reaction mixture
was cooled to 20-25  C and directly purified by preparative HPLC (water,
acetonitrile) yielding a white solid (13.6mg, quant.).
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HR-ESI-MS: calcd. for [204]- C16H24EuN4O8 m/z= 553.08, found m/z=
553.30.
N N
N N
O O
O
O
OO
O
O Eu
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( 2R ,2 0R ,2 0 0R ) -2 ,2 0 ,2 0 0 - ( ( 2S ,5S ,8S ,11S ) -10 -( (R) -1 -( ( 6 -( ( 2 -( 4 --
(D IMETHYLAMINO)PHENYL )BENZO[D ]TH IAZOL -6 -YL )OXY)HE -
XYL )AM INO) -1 -OXO PROPAN -2 -YL ) -2 ,5 ,8 ,11 -TET RAMETHYL -
1 ,4 ,7 ,10 -TET RAAZACYCLODODECANE -1 ,4 ,7 -TR IYL )TR I PROP -
ION IC AC ID (237 ) .
4-(6-((6-aminohexyl)oxy)benzo[d]thiazol-2-yl)-N,N-dimethylaniline
(50.0mg, 135 µmol, 1.0 eq.) was dissolved in dimethylformamide (10.0mL).
N-Diisopropylamine (134 µL, 810 µmol, 6.0 eq.) and HATU (61.6mg,
162mmol, 1.2 eq.) were added. The solution was stirred at 20-25  C for 1 h.
The reaction mixture was evaporated to dryness yielding a yellow crude
product. The crude product was purified by flash column chromatography
(SiO2, ethyl acetate). The fractions containing the product were evaporated
to dryness and the residue was dissolved in hydrobromic acid solution (5%
in acetic acid, 2.0mL) and stirred at 40  C for 20min. The solution was
evaporated to dryness and the residue was purified by preparative HPLC
(water, acetonitrile) yielding a yellow solid (72.0mg, 82.9 µmol, 61.4%).
ESI-MS: calcd. for [237+2H]2+ C45H72N7O8S m/z= 434.75, found m/z=
434.64.
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GD -M8 -P I TSC6 -DOTA 238 .
(2R,20R,200R)-2,20,200-((2S,5S,8S,11S)-10-((R)-1-((6-((2-(4-(dimethylamino)-
phenyl)benzo[d]thiazol-6-yl)oxy)hexyl)amino)-1-oxopropan-2-yl)-2,5,8,11-
tetramethyl-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)tripropionic acid
(237) (72.0mg, 82.9 µmol, 1.0 eq.) was dissolved in dimethylformamide
(5.0mL) and Gd(OTf)3 (326mg, 540 µmol, 6.5 eq.) was added. The solution
was heated to 80  C for 16 h. The solvent was evaporated and the crude
product was purified by preparative HPLC (water, acetonitrile) yielding a
yellow solid (60.0mg, 58.7 µmol, 70.8%).
ESI-MS: calcd. for [238+2H]2+ C45H66GdN7O8S m/z= 512.20, found m/z=
512.09.
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Table A.1: In-vitro 1H-15N HSQC peak assignment in ppm of
GB1 E19C tagged with Lu, Tb and Tm loaded M7Py-DOTA at
298K.
Residue Lu Tm Tb
HN N HN N HN N
M1 - - - - - -
Q2 - - - - - -
Y3 124.2 9.10 - - - -
K4 122.9 9.26 - - - -
L5 126.8 8.75 126.3 7.49 125.8 7.83
I6 126.6 9.27 126.0 8.84 126.1 8.82
L7 126.0 8.86 125.4 8.00 125.7 8.74
N8 126.8 9.08 126.4 8.72 126.6 8.87
G9 110.0 8.09 109.7 7.68 109.7 7.96
K10 121.5 9.69 121.3 9.46 121.3 9.53
T11 108.8 8.98 108.6 8.71 108.6 8.84
L12 125.9 7.53 125.6 7.17 125.7 7.42
K13 124.2 8.28 123.6 7.69 124.0 8.23
G14 109.7 8.60 108.9 7.76 109.6 8.58
E15 119.1 8.58 117.6 7.03 119.0 8.70
T16 116.0 8.91 113.9 6.97 115.6 8.54
T17 112.0 8.24 - - - -
T18 114.3 9.11 - - - -
E19 - - - - - -
A20 126.4 9.35 - - - -
V21 116.2 8.72 - - - -
D22 115.7 7.49 - - 111.0 3.56
Continued on next page
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Table A.1 – continued from previous page
Residue Lu Tm Tb
HN N HN N HN N
A23 121.9 8.47 - - - -
A24 120.9 8.22 125.1 12.77 118.7 6.00
T25 116.7 8.44 - - 115.0 6.60
A26 124.1 7.34 - - - -
E27 117.1 8.48 119.7 11.69 115.2 6.51
K28 117.0 7.10 118.5 8.94 115.7 5.91
V29 121.0 7.49 121.9 8.76 119.9 6.34
F30 121.1 8.66 121.6 9.62 120.0 7.44
K31 123.3 9.25 123.7 9.94 122.5 8.42
Q32 120.0 7.59 120.1 7.93 119.3 7.04
Y33 121.4 8.40 121.1 8.25 120.8 8.00
A34 122.9 9.35 122.7 9.21 122.5 8.93
N35 118.0 8.42 117.9 8.38 117.6 8.08
D36 121.8 9.10 121.6 8.90 121.5 8.89
N37 115.8 7.55 115.5 7.21 115.6 7.35
G38 108.4 7.96 108.2 7.74 108.2 7.74
V39 121.4 8.26 121.2 8.08 121.1 8.00
D40 128.2 8.77 128.1 8.71 127.7 8.49
G41 107.5 7.90 107.6 8.00 107.1 7.56
E42 121.2 8.33 121.3 8.41 120.9 8.01
W43 128.8 9.50 129.3 9.86 128.3 9.02
T44 115.1 9.45 115.6 9.91 114.4 8.86
Y45 121.0 8.72 122.0 9.60 120.0 7.95
D46 128.8 7.79 129.9 9.02 127.7 6.73
D47 125.3 8.72 127.0 10.20 123.9 7.58
A48 120.2 8.48 121.4 9.41 119.0 7.58
T49 103.6 7.15 103.9 7.66 103.0 6.53
K50 123.5 8.01 125.9 10.24 121.8 6.40
T51 111.5 7.53 113.3 9.14 110.1 6.27
F52 131.3 10.52 132.4 11.45 130.0 9.31
T53 117.6 9.28 117.9 9.73 116.8 8.61
V54 123.7 8.32 123.8 8.19 123.1 7.93
T55 124.2 8.51 124.2 8.52 123.8 8.17
Continued on next page
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Table A.1 – continued from previous page
Residue Lu Tm Tb
HN N HN N HN N
E56 134.4 7.96 134.4 7.80 101.2 7.74
Table A.2: In-vitro 1H-15N HSQC peak assignment in ppm of
GB1 E42C tagged with Lu, Tb and Tm loaded M7Py-DOTA at
298K.
Residue Lu Tm Tb
HN N HN N HN N
Q2 123.8 8.42 124.0 8.70 123.6 8.32
Y3 125.0 9.27 125.1 9.45 124.7 8.95
K4 122.7 9.25 122.8 9.40 122.3 8.96
L5 126.8 8.76 126.8 8.79 126.1 8.18
I6 126.6 9.26 126.5 8.99 125.5 8.38
L7 126.1 8.87 125.9 8.76 124.8 7.67
N8 126.8 9.05 126.0 7.73 125.1 7.40
G9 110.1 8.11 109.0 7.30 109.0 7.04
K10 121.5 9.66 120.1 7.98 121.1 9.45
T11 108.8 8.99 108.1 8.04 108.5 8.74
L12 125.8 7.52 125.3 6.78 125.3 7.09
K13 124.1 8.28 123.9 8.15 123.2 7.55
G14 109.7 8.61 109.7 8.64 108.6 7.50
E15 119.1 8.57 119.2 8.66 118.2 7.81
T16 116.1 8.90 116.1 8.91 115.4 8.22
T17 112.2 8.23 112.2 8.25 111.6 7.79
T18 115.1 9.14 115.1 9.25 114.6 8.77
E19 126.4 8.10 126.5 8.19 126.1 7.79
A20 127.8 9.49 128.0 9.69 127.6 9.20
V21 116.1 8.64 116.4 8.89 115.8 8.34
D22 115.6 7.49 115.9 7.87 115.2 7.12
A23 121.8 8.44 122.5 9.17 121.3 8.02
A24 120.9 8.21 121.9 9.18 120.1 7.55
T25 116.7 8.43 117.3 9.06 116.1 7.88
A26 124.0 7.30 124.5 7.84 123.5 6.78
E27 117.0 8.50 117.7 9.31 116.2 7.73
Continued on next page
248 APPEND IX
Table A.2 – continued from previous page
Residue Lu Tm Tb
HN N HN N HN N
K28 116.9 7.10 117.4 7.64 116.2 6.42
V29 121.0 7.45 121.1 7.62 120.6 6.98
F30 121.0 8.67 121.0 8.76 120.5 8.13
K31 123.3 9.25 123.0 9.19 122.8 8.70
Q32 119.9 7.57 119.3 7.14 - -
Y33 121.3 8.38 120.7 7.89 121.0 8.12
A34 123.0 9.36 122.1 8.54 122.7 9.11
N35 118.1 8.45 116.8 7.23 118.2 8.55
D36 121.9 9.08 120.9 8.16 122.0 9.14
N37 115.8 7.55 115.0 6.60 115.8 7.52
G38 108.5 7.97 107.3 6.78 108.5 8.12
V39 121.3 8.26 119.5 6.61 121.4 8.40
D40 127.8 8.70 124.4 5.42 128.2 9.25
G41 106.7 8.06 100.3 1.99 107.4 9.02
E42 119.9 8.65 - - - -
W43 132.6 9.75 129.2 3.76 - -
T44 114.9 9.50 - - - -
Y45 120.9 8.75 - - 119.6 7.33
D46 128.8 7.75 128.0 7.16 131.0 9.33
D47 125.3 8.75 125.1 8.52 126.7 10.55
A48 120.3 8.50 120.1 8.07 121.2 9.93
T49 103.6 7.16 103.4 6.86 104.1 8.10
K50 123.6 8.01 123.6 8.00 123.9 8.51
T51 111.4 7.53 111.3 7.43 111.6 8.04
F52 131.5 10.54 131.4 10.50 131.4 10.27
T53 117.9 9.34 116.6 7.86 - -
V54 123.6 8.35 121.2 6.52 122.2 6.95
T55 123.8 8.52 117.6 0.78 - -
E56 134.8 8.03 - - 101.4 7.25
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Table A.3: In-vitro 1H-15N HSQC peak assignment in ppm of
GB1 K28C tagged with Lu, Tb and Tm loaded M7Py-DOTA at
298K.
Residue Lu Tm Tb
HN N HN N HN N
M1 - - - - - -
Q2 123.9 8.52 124.4 8.88 122.86 7.73
Y3 124.9 9.27 125.6 10.18 123.37 7.63
K4 122.7 9.26 123.4 9.82 - -
L5 126.8 8.77 127.3 9.36 126.01 8.02
I6 126.6 9.27 126.8 9.45 - -
L7 126.0 8.87 126.1 8.98 125.55 8.38
N8 126.9 9.08 126.7 8.88 126.71 9.04
G9 110.0 8.08 109.8 7.99 109.82 7.93
K10 121.5 9.69 121.3 9.49 121.35 9.68
T11 108.9 8.97 108.9 8.95 - -
L12 125.9 7.54 126.0 7.57 - -
K13 124.2 8.27 124.3 8.35 123.70 7.94
G14 109.7 8.59 109.8 8.68 109.19 8.19
E15 119.1 8.57 119.4 8.80 118.36 7.95
T16 116.2 8.91 116.6 9.38 115.04 7.87
T17 112.2 8.23 113.0 9.03 110.53 6.70
T18 115.0 9.14 116.5 10.38 - -
E19 126.4 8.11 128.1 10.03 125.52 7.50
A20 127.8 9.47 128.8 10.33 - -
V21 116.3 8.69 117.5 9.11 - -
D22 115.7 7.49 - - - -
A23 121.7 8.44 122.3 9.05 - -
A24 121.2 8.23 121.9 8.99 - -
T25 117.2 8.49 118.2 9.37 - -
A26 124.1 7.34 125.1 7.94 - -
E27 117.2 8.58 - - - -
K28 115.7 7.41 - - - -
V29 121.8 7.74 - - - -
F30 121.0 8.72 - - - -
K31 123.4 9.16 - - - -
Continued on next page
250 APPEND IX
Table A.3 – continued from previous page
Residue Lu Tm Tb
HN N HN N HN N
Q32 119.7 7.64 122.8 10.88 - -
Y33 121.5 8.36 - - - -
A34 123.0 9.38 123.5 10.40 - -
N35 117.9 8.34 - - - -
D36 121.7 9.02 - - - -
N37 115.7 7.53 - - - -
G38 108.5 7.94 109.4 9.17 107.39 6.71
V39 121.4 8.23 - - - -
D40 128.5 8.80 127.8 8.22 128.70 9.06
G41 107.6 7.90 105.7 5.81 109.08 9.91
E42 120.9 8.33 119.2 6.93 122.68 9.74
W43 128.8 9.50 127.1 7.43 131.11 12.39
T44 115.1 9.45 114.5 8.85 116.06 10.31
Y45 120.7 8.74 120.8 8.50 121.20 9.15
D46 128.8 7.79 128.9 7.91 128.47 7.51
D47 125.3 8.73 125.4 8.93 124.85 8.44
A48 120.2 8.49 120.4 8.68 119.74 8.16
T49 103.6 7.16 103.8 7.35 103.11 6.77
K50 123.5 8.02 123.8 8.29 122.84 7.47
T51 111.5 7.53 111.9 7.79 110.76 6.97
F52 131.3 10.53 131.5 10.88 130.59 9.71
T53 117.6 9.28 116.7 8.48 117.40 9.38
V54 123.8 8.32 123.4 8.09 123.90 8.35
T55 124.2 8.52 123.5 7.66 124.72 9.38
E56 134.3 7.96 133.6 7.45 - -
Table A.4: In-cell 1H-15N HSQC peak assignment in ppm of
GB1 E19C tagged with Lu and Tm loaded M7Py-DOTA at 298
K.
Residue Lu Tm
HN N HN N
M1 - - -
Q2 - - - -
Continued on next page
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Table A.4 – continued from previous page
Residue Lu Tm
HN N HN N
Y3 - - - -
K4 124.1 9.08 - -
L5 122.9 9.24 - -
I6 126.8 8.75 126.2 7.50
L7 126.6 9.26 125.9 8.81
N8 126.0 8.86 125.3 7.95
G9 126.8 9.07 126.3 8.66
K10 110.0 8.08 109.6 7.61
T11 121.5 9.68 121.2 9.38
L12 108.8 8.97 108.5 8.64
K13 125.8 7.51 125.5 7.10
G14 124.1 8.26 - -
E15 109.7 8.58 108.8 7.71
T16 119.1 8.57 117.6 7.00
T17 116.1 8.90 113.8 7.00
T18 112.0 8.24 - -
E19 114.2 9.10 - -
A20 126.0 9.27 - -
V21 116.3 8.73 - -
D22 115.7 7.48 - -
A23 121.9 8.48 - -
A24 120.9 8.22 - -
T25 116.8 8.43 - -
A26 124.1 7.34 - -
E27 117.0 8.46 - -
K28 117.0 7.09 - -
V29 121.0 7.49 121.7 8.68
F30 121.0 8.66 121.5 9.53
K31 122.9 9.24 -
Q32 119.9 7.59 120.1 7.86
Y33 121.3 8.38 121.0 8.16
A34 122.9 9.34 122.6 9.14
N35 118.0 8.41 117.8 8.31
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Table A.4 – continued from previous page
Residue Lu Tm
HN N HN N
D36 121.8 9.09 121.6 8.81
N37 115.8 7.53 - -
G38 108.4 7.95 108.0 7.68
V39 121.3 8.25 121.1 8.01
D40 128.2 8.78 128.1 8.65
G41 107.5 7.89 107.5 7.93
E42 121.2 8.33 121.2 8.34
W43 128.8 9.49 129.2 9.79
T44 115.0 9.44 115.5 9.83
Y45 121.0 8.70 121.9 9.51
D46 128.8 7.78 129.8 8.93
D47 125.2 8.72 126.9 10.13
A48 120.2 8.47 121.3 9.33
T49 103.5 7.15 103.8 7.58
K50 123.4 8.00 - -
T51 111.5 7.52 113.1 9.02
F52 131.3 10.51 132.3 11.40
T53 117.6 9.27 117.9 9.66
V54 123.7 8.31 123.8 8.12
T55 124.2 8.50 124.1 8.46
E56 134.3 7.96 134.3 7.73
Table A.5: In-cell 1H-15N HSQC peak assignment in ppm of
GB1 E42C tagged with Lu and Tm loaded M7Py-DOTA at 298
K.
Residue Lu Tm
HN N HN N
M1 - - - -
Q2 123.8 8.41 124.0 8.69
Y3 124.9 9.26 125.1 9.42
K4 122.7 9.24 122.8 9.37
L5 126.8 8.76 126.8 8.77
I6 126.6 9.25 126.5 8.97
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Table A.5 – continued from previous page
Residue Lu Tm
HN N HN N
L7 126.1 8.87 125.9 8.76
N8 126.8 9.04 126.0 7.72
G9 110.1 8.10 109.0 7.30
K10 121.5 9.65 120.1 7.96
T11 108.8 8.99 108.1 8.04
L12 125.8 7.51 125.2 6.77
K13 124.1 8.28 123.9 8.15
G14 109.7 8.60 109.7 8.65
E15 119.1 8.56 119.2 8.66
T16 116.1 8.90 116.1 8.90
T17 112.2 8.23 112.2 8.25
T18 115.0 9.13 115.0 9.24
E19 126.4 8.10 126.5 8.18
A20 127.8 9.48 128.0 9.67
V21 116.1 8.64 116.3 8.88
D22 115.6 7.48 115.9 7.85
A23 121.8 8.45 122.8 9.15
A24 120.9 8.21 121.8 9.15
T25 116.8 8.43 117.3 9.03
A26 124.0 7.30 124.5 7.81
E27 117.0 8.48 117.7 9.27
K28 116.9 7.09 117.3 7.61
V29 121.0 7.45 121.0 7.60
F30 121.0 8.66 121.0 8.73
K31 123.2 9.25 122.8 9.15
Q32 119.9 7.57 119.3 7.13
Y33 121.3 8.37 120.7 7.88
A34 123.0 9.35 122.1 8.53
N35 118.1 8.45 116.8 7.23
D36 121.9 9.07 120.9 8.15
N37 115.7 7.53 115.0 6.59
G38 108.5 7.96 107.3 6.79
V39 121.3 8.25 119.5 6.61
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Table A.5 – continued from previous page
Residue Lu Tm
HN N HN N
D40 127.8 8.70 - -
G41 106.7 8.05 100.3 2.03
E42 119.9 8.64 - -
W43 132.6 9.74 - -
T44 114.9 9.49 - -
Y45 120.9 8.74 - -
D46 128.8 7.73 127.9 7.08
D47 125.3 8.74 125.1 8.45
A48 120.2 8.49 120.1 8.03
T49 103.5 7.15 103.3 6.82
K50 123.6 8.00 123.5 7.97
T51 111.4 7.52 111.3 7.38
F52 131.5 10.53 131.4 10.45
T53 117.9 9.32 116.5 7.75
V54 123.7 8.35 121.1 6.47
T55 123.8 8.52 - -
E56 134.7 8.03 - -
Table A.6: In-cell 1H-15N HSQC peak assignment in ppm of
GB1 K28C tagged with Lu and Tm loaded M7Py-DOTA at 298
K.
Residue Lu Tm
HN N HN N
M1 - - - -
Q2 123.9 8.51 124.4 8.89
Y3 124.8 9.26 125.6 10.19
K4 122.8 9.26 123.4 9.84
L5 126.8 8.77 127.3 9.36
I6 126.6 9.27 126.9 9.45
L7 126.1 8.87 126.1 8.98
N8 126.8 9.08 126.7 8.87
G9 110.0 8.08 109.8 7.98
K10 121.5 9.68 121.3 9.49
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Table A.6 – continued from previous page
Residue Lu Tm
HN N HN N
T11 108.8 8.97 108.8 8.96
L12 125.9 7.53 125.9 7.56
K13 124.0 8.26 124.2 8.35
G14 109.7 8.59 109.8 8.67
E15 119.1 8.57 119.4 8.80
T16 116.2 8.91 116.6 9.39
T17 112.2 8.23 113.1 9.04
T18 115.0 9.14 116.5 10.38
E19 126.4 8.11 128.1 10.05
A20 127.7 9.47 128.8 10.32
V21 116.2 8.69 117.5 9.11
D22 115.7 7.48 - -
A23 121.7 8.44 122.3 9.06
A24 121.1 8.22 121.9 8.98
T25 117.2 8.49 118.2 9.35
A26 124.1 7.34 125.1 7.94
E27 117.2 8.57 - -
K28 115.7 7.40 - -
V29 121.7 7.75 - -
F30 121.0 8.72 - -
K31 123.3 9.15 - -
Q32 119.7 7.64 - -
Y33 121.4 8.35 - -
A34 123.0 9.38 123.5 10.36
N35 117.9 8.34 - -
D36 121.6 9.01 - -
N37 115.7 7.53 - -
G38 108.4 7.94 109.4 9.16
V39 121.4 8.22 - -
D40 128.5 8.81 127.8 8.21
G41 107.6 7.89 105.8 5.79
E42 121.0 8.33 119.2 6.93
W43 128.8 9.50 127.1 7.44
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Table A.6 – continued from previous page
Residue Lu Tm
HN N HN N
T44 115.1 9.44 114.4 8.84
Y45 120.7 8.74 120.8 8.51
D46 128.8 7.79 128.9 7.91
D47 125.3 8.73 125.4 8.93
A48 120.2 8.49 120.4 8.68
T49 103.6 7.16 103.7 7.35
K50 123.5 8.01 124.0 8.29
T51 111.5 7.53 111.9 7.79
F52 131.3 10.52 131.5 10.88
T53 117.6 9.27 116.7 8.47
V54 123.9 8.32 123.4 8.08
T55 124.2 8.51 123.5 7.66
E56 134.3 7.96 133.6 7.46
Table A.7: In-vitro and in-cell 1H-15N backbone amide RDC
in Hz of GB1 mutants tagged with Tm (paramagnetic) and Lu
(diamagnetic reference) loaded M7Py-DOTA at 293K and 600
MHz.
Residue in-vitro in-cell
E19C E42C K28C E19C E42C K28C
1 - - - - - -
2 - -3.9 4.9 - 1.0 5.4
3 - -10.6 1.8 - -14.5 -6.6
4 - -7.2 6.1 - -2.4 -
5 12.8 1.1 -2.3 23.5 1.6 1.8
6 14.0 2.6 4.3 11.6 0.7 7.2
7 22.0 7.1 -2.8 20.3 7.8 -1.9
8 14.2 5.4 3.7 23.8 5.0 3.5
9 15.5 5.4 -7.0 16.3 5.2 -4.9
10 7.1 1.3 -1.0 - 0.7 -
11 2.4 1.5 -0.3 3.8 2.2 -0.8
12 15.8 3.3 -1.1 15.1 6.0 -3.8
13 9.4 1.1 5.3 - 2.5 5.0
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Table A.7 – continued from previous page
Residue in-vitro in-cell
E19C E42C K28C E19C E42C K28C
14 11.4 0.4 1.5 14.5 1.3 -0.9
15 8.8 -1.0 1.8 - -0.5 0.0
16 5.4 -8.0 2.4 - -2.1 1.9
17 - -11.0 0.2 - -6.1 3.3
18 - -11.4 16.7 - -9.2 5.1
19 - -11.1 0.7 - -8.1 5.1
20 - -8.1 0.1 - -7.8 2.3
21 - -11.7 - - -8.1 -
22 - -7.4 - - -4.0 -
23 - -12.0 16.1 - -4.3 12.1
24 -7.8 6.4 5.0 - 2.2 9.3
25 - -0.1 13.3 - 0.3 10.4
26 - -4.0 - - -3.6 11.4
27 -5.2 -0.9 - - 0.2 -
28 -9.9 5.4 - - 2.9 -
29 -8.9 -1.5 - - -1.3 -
30 -6.1 -2.6 - - -0.9 -
31 -6.1 -6.0 - - 3.0 -
32 -7.8 5.2 - -4.0 3.6 -
33 -8.5 -0.9 - -16.5 -0.3 -
34 -4.4 -0.2 - -6.8 1.1 -
35 -7.5 -0.4 - -7.9 3.3 -
36 -8.5 3.1 - -15.0 2.0 -
37 -4.9 -1.9 - - -1.4 4.2
38 -6.4 0.8 2.4 - 0.1 -2.9
39 -9.4 -2.7 - -18.7 1.9 -7.7
40 -7.8 - -1.2 -0.8 - -1.5
41 -6.1 - 0.6 -1.0 2.1 -4.0
42 2.1 - 3.4 2.1 - -0.4
43 19.6 - - 17.5 6.4 3.7
44 13.7 2.9 12.9 - 1.6
45 7.8 - 1.8 10.5 - -0.8
46 3.1 -3.2 7.4 -3.8 -3.6 1.9
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Table A.7 – continued from previous page
Residue in-vitro in-cell
E19C E42C K28C E19C E42C K28C
47 11.6 -0.8 -8.8 12.5 1.2 -6.8
48 -0.4 2.1 -10.3 -1.8 3.2 -47.6
49 9.6 13.1 -12.8 - 6.4 -6.1
50 6.1 -3.3 - - -1.9 2.9
51 -3.3 -7.1 4.1 2.1 -7.5 2.6
52 7.5 -0.5 -9.7 2.3 -1.2 -3.5
53 16.5 10.8 -3.7 17.0 3.2 2.9
54 20.6 8.8 1.1 16.7 5.2 -0.8
55 15.8 - 2.6 16.2 4.5 3.2
56 21.2 - -2.1 19.0 - -1.7
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(a) E19C Tb (b) E19C Tm
(c) E42C Tb (d) E42C Tm
(e) K28C Tb (f) K28C Tm
Figure A.1: Correlation graphs between PCSs calculated from the X-ray structure
2QMT and the experimental in-vitro PCSs.
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(a) E19C Tm (b) E42C Tm
(c) K28C Tm
Figure A.2: Correlation graphs between PCSs calculated from the X-ray structure
2QMT and the experimental in-cell PCSs.
Table A.8: In-vitro 1H-15N HSQC peak assignment in ppm of
ubiqutin S57C tagged with Lu and Tm loaded M7FPy-DOTA
at 298K.
Residue Lu Tm
HN N HN N
M1 - - - -
Q2 8.87 123.2 8.64 122.9
I3 8.23 115.3 7.69 114.7
F4 8.53 118.6 7.79 117.9
V5 9.20 121.2 8.71 120.7
K6 8.86 128.0 8.33 127.5
T7 8.67 115.6 8.35 115.3
L8 9.05 121.3 8.76 121.1
T9 7.55 105.9 7.33 105.7
G10 7.74 109.3 7.52 109.1
K11 7.17 122.0 6.96 121.8
T12 8.56 120.7 8.34 120.5
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Table A.8 – continued from previous page
Residue Lu Tm
HN N HN N
I13 9.46 127.7 9.11 127.4
T14 8.66 121.6 8.40 121.3
L15 8.68 125.3 8.26 125.0
E16 8.03 122.6 7.85 122.4
V17 8.85 117.5 8.81 117.5
E18 8.59 119.9 8.95 120.6
P19 - - - -
S20 7.04 103.9 8.19 107.4
D21 7.93 123.5 7.19 122.4
T22 7.84 108.9 6.20 106.8
I23 8.42 121.3 5.81 119.0
E24 10.03 121.3 8.55 119.9
N25 7.87 121.5 6.68 120.5
V26 7.98 122.1 6.78 121.1
K27 8.45 118.9 7.51 118.0
A28 7.92 123.6 7.28 123.0
K29 7.77 120.3 7.26 119.8
I30 8.18 121.4 7.68 121.0
Q31 8.47 123.6 8.07 123.2
D32 7.92 119.8 7.65 119.5
K33 7.33 115.5 7.08 115.2
E34 8.64 114.5 8.39 114.2
G35 8.42 109.0 8.20 108.7
I36 6.06 120.3 5.79 120.1
P37 - - - -
P38 - - - -
D39 8.44 113.7 8.09 113.3
Q40 7.74 116.9 7.39 116.6
Q41 7.40 118.2 6.96 117.8
R42 8.41 123.2 7.92 122.7
L43 8.76 124.6 7.94 123.8
I44 9.03 122.3 8.22 121.5
F45 8.78 125.1 7.74 124.1
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Table A.8 – continued from previous page
Residue Lu Tm
HN N HN N
A46 8.90 100.2 8.12 132.3
G47 8.01 102.5 7.48 102.0
K48 7.89 122.1 7.20 121.5
Q49 8.56 123.2 7.98 122.5
L50 8.48 125.8 7.39 124.6
E51 8.27 123.1 6.63 121.7
D52 8.09 120.5 7.02 119.2
G53 - - - -
R54 7.38 119.3 - -
T55 8.92 109.1 1.42 102.7
L56 8.20 117.8 2.79 111.3
S57 8.26 117.0 - -
D58 7.93 121.9 - -
Y59 7.06 115.4 -3.00 106.1
N60 7.96 116.3 -2.76 104.4
I61 7.14 118.8 -1.04 112.3
Q62 7.52 124.8 - -
K63 8.47 120.8 6.72 119.1
E64 9.24 114.7 8.51 114.0
S65 7.58 115.0 6.51 114.2
T66 8.64 117.5 7.86 116.7
L67 9.33 127.8 8.49 126.9
H68 9.14 119.5 8.35 118.8
L69 8.19 123.9 7.69 123.4
V70 9.09 126.5 8.60 126.1
L71 8.02 123.0 7.71 122.7
R72 8.50 123.9 8.19 123.6
L73 8.28 124.7 8.04 124.5
R74 8.37 122.1 8.18 121.9
G75 8.41 111.2 8.25 111.1
G76 7.86 115.1 7.71 115.0
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Figure A.3: Correlation graphs between PCSs calculated from the X-ray structure
1UBI and the experimental in-vitro PCSs obtained for Tm loaded M7FPy-DOTA
Table A.9: In-vitro 1H-15N HSQC peak assignment in ppm of ubiquitin S57C
tagged with Lu, Tm, Tb and Dy loaded M7Pythiazol-DOTA at 298K.
Residue Lu Tm Tb Dy
HN N HN N HN N HN N
M1 - - - - - - - -
Q2 8.95 123.0 8.88 123.4 7.77 121.7 - -
I3 8.31 115.2 9.69 116.7 6.82 113.7 5.69 112.5
F4 8.62 118.6 10.08 120.0 7.31 117.3 6.46 116.5
V5 9.29 121.3 10.31 122.4 8.37 120.3 7.84 119.7
K6 8.95 128.0 9.99 128.9 8.08 127.2 7.67 126.8
T7 8.75 115.6 9.36 116.3 8.24 115.1 7.97 114.8
L8 9.13 121.3 9.69 121.9 8.65 120.9 8.43 120.7
T9 7.64 106.0 8.07 106.4 7.27 105.6 7.10 105.5
G10 7.83 109.3 8.25 109.7 7.49 109.0 7.33 108.9
K11 7.27 122.0 7.67 122.4 6.92 121.6 6.74 121.5
T12 8.64 120.7 9.02 121.2 8.30 120.3 8.09 120.1
I13 9.55 127.7 10.24 128.3 8.91 127.1 8.54 126.8
T14 8.74 121.7 9.25 122.3 8.15 120.9 7.75 120.5
L15 8.75 125.3 9.78 126.2 7.66 124.3 6.91 123.6
E16 8.12 122.5 9.05 123.6 7.12 121.4 6.31 120.7
V17 8.94 117.6 10.56 119.3 6.98 115.7 - -
E18 8.66 119.5 13.10 123.8 - - - -
P19 - - - - - - - -
S20 7.02 103.7 - - - - - -
D21 8.06 123.7 - - - - - -
T22 7.84 108.8 11.82 114.2 - - - -
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Table A.9 – continued from previous page
Residue Lu Tm Tb Dy
HN N HN N HN N HN N
I23 8.53 121.3 13.15 125.6 - - - -
E24 - - - - - - - -
N25 7.92 121.5 10.19 123.4 6.10 119.9 - -
V26 8.10 122.2 10.93 124.6 5.92 120.3 - -
K27 8.57 119.0 10.54 120.8 6.89 117.5 6.08 116.7
A28 7.98 123.6 9.21 124.7 6.84 122.5 6.26 121.9
K29 7.85 120.3 8.99 121.2 6.77 119.4 6.20 118.8
I30 8.29 121.4 9.42 122.4 7.23 120.4 6.68 119.9
Q31 8.56 123.7 9.34 124.4 7.79 122.9 7.39 122.5
D32 8.01 119.8 8.53 120.2 7.41 119.2 7.08 118.9
K33 7.42 115.5 7.93 115.9 6.85 115.0 6.52 114.7
E34 8.73 114.5 9.23 114.9 8.20 114.0 7.90 113.7
G35 8.50 109.0 8.91 109.4 8.05 108.5 7.80 108.2
I36 6.15 120.4 6.64 120.8 5.64 119.8 - -
P37 - - - - - - - -
P38 - - - - - - - -
D39 8.53 113.7 9.08 114.3 7.95 113.1 7.65 112.8
Q40 7.82 117.0 8.42 117.6 7.23 116.4 6.94 116.1
Q41 7.49 118.2 8.27 118.9 6.75 117.5 6.40 117.2
R42 8.50 123.2 9.47 124.2 7.64 122.2 7.27 121.9
L43 8.83 124.5 10.44 126.0 7.43 123.1 7.06 122.7
I44 9.11 122.4 10.76 124.1 7.71 120.8 7.15 120.2
F45 8.85 125.1 10.99 127.2 7.00 123.3 6.41 122.7
A46 8.98 132.9 10.58 101.7 7.80 131.7 7.51 131.4
G47 8.09 102.5 9.34 103.7 7.18 101.6 7.00 101.5
K48 7.98 122.2 9.62 123.6 6.64 121.0 6.40 120.6
Q49 8.64 123.2 10.08 124.8 7.42 121.9 7.07 121.5
L50 8.56 125.8 10.71 128.1 6.60 123.7 5.89 123.0
E51 8.41 123.2 11.26 125.7
D52 8.16 120.4 9.78 122.3 6.49 118.5 5.73 117.6
G53 - - - - - - - -
R54 7.46 119.4 10.66 122.7 - - - -
T55 8.95 109.2 - - - - - -
Continued on next page
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Table A.9 – continued from previous page
Residue Lu Tm Tb Dy
HN N HN N HN N HN N
L56 8.18 118.0 - - - - - -
S57 8.53 117.3 - - - - - -
D58 8.12 123.0 - - - - - -
Y59 7.19 115.5 - - - - - -
N60 8.18 116.6 - - - - - -
I61 7.27 119.0 - - - - - -
Q62 7.56 124.7 12.13 130.5 - - - -
K63 8.59 120.8 - - - - - -
E64 9.33 114.7 10.05 115.2 8.23 114.2 6.87 113.0
S65 7.64 115.0 9.13 116.2 6.26 114.0 - -
T66 8.72 117.5 10.03 118.9 7.82 116.5 7.38 115.9
L67 9.41 127.9 11.08 129.6 8.03 126.5 7.34 125.8
H68 9.22 119.6 10.82 121.0 7.92 118.4 7.40 117.9
L69 8.27 123.9 9.28 125.0 7.39 123.2 6.84 122.6
V70 9.18 126.6 10.17 127.5 8.33 125.8 7.98 125.5
L71 8.10 123.0 8.70 123.7 7.58 122.5 7.36 122.4
R72 8.59 123.9 9.19 124.5 8.06 123.4 7.82 123.2
L73 8.35 124.7 8.81 125.1 7.96 124.3 7.79 124.1
R74 8.45 122.1 8.80 122.5 8.14 121.8 8.00 121.7
G75 8.49 111.2 8.80 111.5 8.22 111.0 8.09 110.8
G76 7.94 115.2 8.23 115.4 7.69 114.9 7.58 114.8
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(a) S57C Tm (b) S57C Tb
(c) S57C Dy
Figure A.4: Correlation graphs between PCSs calculated from the X-ray structure
1UBI and the experimental in-vitro PCSs.
Table A.10: In-vitro 1H-15N HSQC peak assignment in ppm of ubiquitin
K48C tagged with Lu, Tm, Tb and Dy loaded M7Pythiazol-DOTA at 298K.
Residue Lu Tm Tb Dy
HN N HN N HN N HN N
M1 - - - - - - - -
Q2 8.95 122.9 8.37 122.2 8.26 122.2 8.74 122.7
I3 8.31 115.2 7.91 114.7 7.49 114.4 8.01 115.0
F4 8.62 118.6 8.72 118.8 7.09 117.6 7.87 118.3
V5 9.30 121.3 9.68 121.8 8.38 120.2 8.79 120.8
K6 8.96 128.0 10.17 129.1 7.47 126.7 7.99 127.3
T7 8.75 115.6 9.60 116.5 7.95 114.7 8.17 115.0
L8 9.13 121.3 10.14 122.4 8.59 120.7 8.66 120.8
T9 7.64 105.9 8.42 106.8 7.16 105.3 7.20 105.5
G10 7.83 109.3 8.66 110.1 7.13 108.6 7.27 108.8
K11 7.27 122.0 7.90 122.6 6.69 121.4 6.82 121.6
T12 8.64 120.7 9.06 121.2 8.06 120.0 8.31 120.1
Continued on next page
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Table A.10 – continued from previous page
Residue Lu Tm Dy Tb
HN N HN N HN N HN N
I13 9.55 127.7 9.97 128.0 8.89 127.2 9.14 127.5
T14 8.74 121.7 8.79 121.8 8.33 121.4 8.52 121.7
L15 8.74 125.2 8.55 125.0 8.15 125.0 8.52 125.3
E16 8.12 122.5 7.71 122.1 7.87 122.4 8.07 122.6
V17 8.94 117.6 8.20 116.8 8.42 117.2 8.84 117.6
E18 8.66 119.4 7.49 118.2 8.30 119.2 8.72 119.6
P19 - - - - - - - -
S20 7.03 103.5 5.49 101.6 6.08 102.4 6.79 103.3
D21 8.04 124.0 6.14 122.0 7.56 123.8 8.15 124.3
T22 7.88 109.0 5.81 106.6 8.98 110.3 8.75 110.1
I23 8.52 121.4 13.12 125.1 11.75 124.1
E24 - - - - - - - -
N25 7.92 121.6 6.01 120.0 10.14 123.8 9.43 123.2
V26 8.09 122.2 6.48 120.9 9.71 123.5 9.31 123.2
K27 8.55 119.0 7.36 118.2 10.42 120.5 9.81 120.1
A28 7.98 123.6 7.07 122.8 9.43 124.9 8.93 124.5
K29 7.86 120.3 7.18 119.8 8.64 121.0 8.41 120.8
I30 8.29 121.4 7.88 121.2 8.90 121.8 8.72 121.8
Q31 8.56 123.7 8.24 123.5 9.28 124.3 9.02 124.1
D32 8.01 119.8 7.70 119.5 8.51 120.3 8.24 120.3
K33 7.43 115.5 7.26 115.4 7.68 115.7 7.58 115.7
E34 8.73 114.5 8.69 114.5 9.00 114.6 8.88 114.5
G35 8.51 109.0 8.44 109.0 8.85 109.4 8.69 109.2
I36 6.16 120.4 6.16 120.3 6.64 120.9 6.40 120.7
P37 - - - - - - - -
P38 - - - - - - - -
D39 8.53 113.7 8.03 113.2 10.32 115.8 9.58 115.0
Q40 7.82 117.0 7.60 116.7 9.45 118.7 8.74 118.0
Q41 7.49 118.2 7.44 118.3 9.38 119.8 8.59 119.1
R42 8.51 123.2 9.42 123.9 9.71 124.8 9.15 123.9
L43 8.86 124.5 10.25 126.2 11.70 126.1 10.44 125.3
I44 9.12 122.2 12.77 126.7 7.39 120.9 7.84 121.3
F45 8.79 124.7 - - - - - -
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Table A.10 – continued from previous page
Residue Lu Tm Dy Tb
HN N HN N HN N HN N
A46 9.20 102.0 - - - - - -
G47 8.11 102.6 - - - - - -
K48 - - - - - - - -
Q49 - - - - - - - -
L50 8.58 126.3 - - - - - -
E51 8.35 123.2 - - - - - -
D52 8.15 120.7 3.14 115.1 - - - -
G53 - - - - - - - -
R54 7.48 119.2 - - - - - -
T55 8.73 108.7 0.90 101.7 - - - -
L56 8.13 118.1 - - 7.79 117.5 8.80 119.0
S57 8.44 113.3 3.93 109.5 5.93 110.0 8.07 112.9
D58 8.28 120.7 -0.47 111.3 - - - -
Y59 7.05 114.7 - - - - - -
N60 8.12 115.5 - - - - 6.88 114.1
I61 7.22 118.9 1.17 113.8 - - - -
Q62 7.64 125.1 - - - - 6.82 124.2
K63 8.50 120.7 7.06 119.4 7.32 119.3 8.28 120.4
E64 9.33 114.7 8.72 114.0 8.15 113.2 8.89 114.0
S65 7.67 115.1 7.08 114.7 5.80 113.0 6.89 114.1
T66 8.74 117.5 9.65 118.3 5.66 115.0 7.03 116.2
L67 9.43 128.0 10.52 129.4 7.11 125.0 8.11 126.3
H68 9.27 119.5 12.50 122.2 6.07 116.8 7.18 117.9
L69 8.28 123.9 9.93 125.8 7.09 122.8 7.42 123.1
V70 9.19 126.7 10.93 128.6 9.15 126.5 8.94 126.5
L71 8.10 123.1 9.44 124.0 8.26 123.4 8.00 123.1
R72 8.61 123.9 - - 9.79 124.7 9.14 124.4
L73 8.36 124.6 8.59 125.0 9.32 125.6 8.50 125.3
R74 8.45 122.1 - - 9.44 123.0 8.73 122.7
G75 8.49 111.2 - - - - - -
G76 7.95 115.2 - - - - - -
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(a) K48C Tm (b) K48C Tb
(c) K48C Dy
Figure A.5: Correlation graphs between PCSs calculated from the X-ray structure
1UBI and the experimental in-vitro PCSs.
Table A.11: In-vitro 1H-15N backbone amide RDC in Hz of
ubiquitin mutants tagged with Tm, Tb and Dy (paramagnetic)
and Lu (diamagnetic reference) loaded M7PyThiazol-DOTA at
298K and 600MHz.
Residue K48C S57C
Tm Dy Tb Tm Dy Tb
M1 - - - - - -
Q2 -14.9 - 18.1 -2.7 -4.8 -
I3 -14.3 - 16.4 -7.3 -0.4 1.0
F4 -10.5 15.2 11.5 -6.7 -0.2 -1.5
V5 -5.9 1.8 -5.4 3.1 4.9
K6 0.3 -3.5 -0.9 -5.5 0.0 -1.2
T7 -2.2 -12.9 -4.6 -4.8 2.5 3.8
L8 -2.3 - -2.0 -8.1 7.6 8.5
T9 5.4 - - -0.8 4.6 8.8
G10 - - - -2.4 4.8 6.7
K11 -11.1 9.9 8.2 -0.5 -1.9 -5.7
Continued on next page
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Table A.11 – continued from previous page
Residue K48C S57C
Tm Dy Tb Tm Dy Tb
T12 1.9 - -1.4 -7.5 4.2 0.4
I13 -6.4 -5.2 0.4 -5.2 3.1 4.0
T14 -4.7 - 6.3 -4.7 -1.8 -3.7
L15 -13.5 23.4 - -6.8 2.6 1.4
E16 -14.9 32.6 19.5 -1.0 -3.1 -2.2
V17 -15.2 21.7 13.3 -7.0 1.8 -
E18 -15.7 - 14.8 1.3 - -
P19 - - - - - -
S20 - -6.4 0.7 - - -
D21 -5.7 0.2 0.5 - - -
T22 - - - -6.4 - -
I23 - - - -3.6 - -
E24 - - - - - -
N25 5.5 10.6 6.7 0.0 -6.9 -
V26 -0.2 -2.4 0.5 -5.3 -0.5 -
K27 11.4 -17.5 -8.5 -3.3 -0.1 -0.4
A28 16.0 -6.5 -5.0 3.5 -6.1 -11.9
K29 -0.3 - 5.9 -3.9 -4.3 -7.3
I30 6.3 -8.2 -5.7 -4.8 -1.7 -1.4
Q31 18.4 -14.5 -10.5 2.2 -2.3 -6.9
D32 12.4 - -5.1 2.7 -7.7 -13.8
K33 0.3 1.8 2.6 -3.1 -2.5 -4.8
E34 14.3 -19.1 -9.1 -0.7 -1.6 -5.0
G35 15.7 -8.3 -7.0 13.7 -5.5 -6.8
I36 -9.6 21.5 - 4.9 -6.9 -
P37 - - - - - -
P38 - - - - - -
D39 -12.2 17.7 11.5 -7.9 3.6 -
Q40 -10.0 0.4 -1.6 0.4 5.5 3.2
Q41 -14.5 -24.8 - -3.2 8.2 9.4
R42 25.2 -7.7 -18.9 -9.0 1.6 15.9
L43 15.1 - -17.8 -4.7 1.6 8.0
I44 - - - -4.8 0.9 4.8
Continued on next page
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Table A.11 – continued from previous page
Residue K48C S57C
Tm Dy Tb Tm Dy Tb
F45 - - - -6.1 0.9 0.0
A46 - - - -7.8 - 5.0
G47 - - - -4.4 - -
K48 -83.9 - - 4.4 -1.5 -6.8
Q49 - - - -2.5 2.7 4.5
L50 - - - 0.1 -3.3 -4.1
E51 - - - 4.4 - -
D52 1.5 - - 12.2 -6.1 -12.9
G53 - - - - - -
R54 - - - 10.3 - -
T55 - - - - - -
L56 - - 7.0 - - -
S57 - 1.3 - - - -
D58 - - - - - -
Y59 - - - - - -
N60 - - -18.5 - - -
I61 1.8 - - - - -
Q62 - - -13.2 2.1 - -
K63 15.8 0.3 -2.9 - - -
E64 -12.5 - 8.6 -8.5 6.2 8.8
S65 18.6 -23.9 -18.0 1.0 6.3 -
T66 -14.7 20.7 11.8 -8.0 1.7 3.0
L67 -8.7 0.7 2.3 -5.6 3.8 8.3
H68 6.9 -11.0 -5.9 -4.8 -0.4 -1.9
L69 9.0 -20.8 -13.9 -4.3 3.8 8.9
V70 24.0 -28.2 -20.7 0.6 2.6 4.5
L71 22.1 - -15.8 -0.7 5.6 13.9
R72 - -26.3 -6.5 1.4 5.5 10.3
L73 -15.1 - 12.7 -3.0 2.2 2.7
R74 - - 20.9 -1.9 0.5 0.5
G75 - - - -0.2 0.1 -0.3
G76 - - - 0.3 0.3 0.7
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Table A.12: In-vitro RDC tensor parameters for ubiqutin S57C fitted
against the ubiqutin X-ray structure (PDB code: 1UBI).
Tm, 37 RDC Dy, 33 RDC Tb, 36 RDC
Dcax / 10 32m3 25.5 -36.0 -18.6
Dc rh / 10 32m3 3.6 -19.7 -8.2
x / Å 20.5 20.5 20.5
y / Å 15.1 15.1 15.1
z / Å 6.3 6.3 6.3
a / ° 169.2 20.0 23.6
b / ° 43.8 58.0 60.2
g / ° 70.5 35.3 37.0
Q-factor 0.38 0.43 0.41
Tensor parameters were calculated in FANTEN from the indicated num-
ber of selected RDC.138 All tensors are represented in the unique tensor
representation UTR.74 Only amino acids residing in a stable secondary
structure (2-7, 12-16, 23-34, 38-40, 41-45, 48-49, 56-59 and 66-71) were
used if present in the spectra.
Table A.13: In-vitro RDC tensor parameters for ubiqutin K48C fitted
against the ubiqutin X-ray structure (PDB code: 1UBI).
Tm, 32 RDC Dy, 25 RDC Tb, 31 RDC
Dcax / 10 32m3 45.5 62.5 -39.6
Dc rh / 10 32m3 12.2 35.0 -24.1
x / Å 19.0 19.0 19.0
y / Å 18.6 18.6 18.6
z / Å 22.8 22.8 22.8
a / ° 4.0 4.8 161.8
b / ° 83.4 67.8 83.2
g / ° 83.3 8.5 97.4
Q-factor 0.31 0.29 0.21
Tensor parameters were calculated in FANTEN from the indicated num-
ber of selected RDC.138 All tensors are represented in the unique tensor
representation UTR.74 Only amino acids residing in a stable secondary
structure (2-7, 12-16, 23-34, 38-40, 41-45, 48-49, 56-59 and 66-71) were
used if present in the spectra.
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Figure A.6: UV/Vis absorption and emission spectrum of Tb-M7PyThiazol-
DOTA 199 measured in acetonitrile at 20-25  C. lex=300 nm.
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